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Thesis abstract    
Background: Herpes zoster affects millions of people worldwide each year and many go on to 
suffer long-term pain, called postherpetic neuralgia (PHN). As zoster is common and PHN is difficult 
to treat, preventing zoster through vaccination is important. This thesis aims to better understand 
risk factors for zoster and PHN, in order to inform vaccination policy. 
Methods: Three large observational studies were carried out using primary care data from the UK 
Clinical Practice Research Datalink and linked secondary care data from the Hospital Episodes 
Statistics.  First, a matched case-control study quantified the effects of possible risk factors for 
zoster and explored whether their effects differed by age group.  Second, a descriptive study 
looked at antiviral prescription patterns and patient characteristics associated with antiviral receipt 
after zoster diagnosis.  Third, a cohort study assessed risk factors for PHN and investigated whether 
their effects were modified by antiviral use. 
Results: The case-control study of zoster risk factors included 144,959 zoster patients and 549,336 
controls and found an increased risk of zoster among patients with rheumatoid arthritis, systemic 
lupus erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, 
chronic kidney disease, depression and type 1 diabetes; odds ratios ranged from 1.14 to 1.72. In 
general, the relative effects of these risk factors on zoster decreased with increasing age. In the 
descriptive study of antiviral use, of 142,216 zoster cases, only 58.1% received an antiviral 
prescription at zoster diagnosis. Antivirals were even under-prescribed among the 
immunosuppressed and older individuals, for whom guidelines recommend routine treatment. The 
cohort study of PHN risk factors identified 119,413 zoster patients, 5.8% of whom developed PHN. 
An increased risk of PHN was found among patients with rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, 
depression, type 2 diabetes, lower socioeconomic status, smoking and under- or overweight; odds 
ratios ranged from 1.13-1.82.  Antiviral use was not associated with PHN risk overall. The zoster 
case-control and PHN cohort study showed that patients with severely immunosuppressive 
conditions were at greatest risk of both zoster and PHN. 
Conclusions: A number of patient characteristics and comorbidities were associated with increased 
zoster and PHN risks. Patients at highest risk of zoster and PHN are those of older age and those 
with immunosuppression; currently, patients with immunosuppression are not eligible for 
vaccination, highlighting a need for alternative risk reduction strategies in this group. Low antiviral 
use at zoster diagnosis suggests treatment guidelines be revised to encourage greater use, 
especially among the immunosuppressed and older individuals who are recommended, but not 
routinely given, antivirals.  Research on the cost-effectiveness of vaccinating patients with specific 
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Chapter 1:   Introduction  
 
In this introductory chapter, I present a brief overview of herpes zoster and postherpetic 
neuralgia (PHN), followed by details of the zoster vaccine. The aims and objectives of the 
research are then described and an outline of the thesis is given. 
1.1.   Introducing herpes zoster and postherpetic neuralgia 
 Herpes zoster 
1.1.1.1. Clinical presentation, diagnosis and treatment 
Herpes zoster, more commonly known as shingles, typically presents as a painful, vesicular 
rash with a dermatomal distribution, preceded by tingling, itching or pain, termed prodromal 
pain.  The rash usually abates within four weeks. Ophthalmic zoster occurs in approximately 
10% of cases and occurs when the rash appears in the dermatome supplied by the ophthalmic 
nerve.1  
 
Diagnosis of zoster is largely made clinically in primary care; hospitalization is rare, occurring in 
around 1 to 4% of cases.2 Antiviral therapy is recommended for patients deemed at risk of 
severe zoster, including all patients with immunosuppression and some immunocompetent 
patients.3   However, it is not known if these antiviral treatment guidelines are adhered to in 
the United Kingdom (UK). Antiviral therapy has been shown to limit the duration and severity 
of zoster and accelerates healing.4 
 
Zoster patients can experience a number of complications, the most common of which is PHN 
(see below). Other complications include; cranial and peripheral nerve palsies, encephalitis, 
and myelitis and, for ophthalmic zoster, chronic eye conditions and loss of vision;4 few data 
exist describing the frequency of these complications, however they are believed to be very 
rare. More recent research has also suggested that zoster may be associated with increased 
risk of stroke; ophthalmic zoster was associated with over three times the risk of stroke in the 
6 months after zoster onset.5,6  
 
1.1.1.2. Pathogenesis of zoster 
Primary varicella-zoster virus (VZV) infection manifests itself as varicella (chickenpox) infection, 
which is a highly infectious disease usually occurring before the age of ten in temperate 
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climates, after which the VZV lies dormant in sensory ganglia for many decades.4 Zoster arises 
from the reactivation of latent VZV in sensory nerve cells,7 whereupon the virus spreads along 
the nerve to the dermatome (an area of skin supplied by a single spinal or cranial nerve).  
 
Over fifty years ago Hope-Simpson proposed that immunity played a role in zoster 
reactivation.8 VZV-specific T cell-mediated immunity is understood to prevent reactivation of 
latent VZV and plays a greater role in suppressing reactivation than humoral immunity.9,10 The 
importance of cell-mediated immunity is supported by several lines of evidence, including: (1) 
the decline in VZV-specific cell-mediated immunity with age,11,12 correlating with the increased 
frequency of zoster in older individuals.  This contrasts to VZV-specific antibodies which remain 
relatively constant as people age;13 (2) immunocompetent individuals having lower VZV-
specific immunity at the start of their zoster episode, compared to non-zoster controls;14-16 (3) 
patients with immunosuppressive conditions affecting cell-mediated immunity being at greater 
risk of zoster;17,18 and finally, (4) that vaccination of adults with the live VZV vaccine reduces 
the incidence of zoster and PHN, suggesting that augmentation of the cellular immune 
response to VZV can reduce reactivation.19 
 
Cell-mediated immunity involves mostly T cells recognising VZV-infected cells and bringing 
about their destruction. No small-animal model replicates the signs and symptoms of varicella 
and zoster, therefore understanding of zoster pathogenesis is limited.9,12 VZV-specific CD8+ (or 
cytotoxic) T cells  have been detected, which recognise VZV antigens and destroy the infected 
cell.20  VZV-specific CD4+ (or helper) T cells, which recognize VZV antigens and release 
cytokines (predominantly interferon-γ12) to activate other immune responses, are also 
believed to play a role in suppressing VZV reactivation.12,21 
 
1.1.1.3. Epidemiology and risk factors 
In the pre-varicella vaccine era in North America, over 95% of adults (age>20 years) were 
seropositive for VZV22, putting the majority of these populations at risk of zoster. The lifetime 
risk of zoster is around 25%, increasing to around 50% for those reaching 80 years of age.23 The 
annual rate of zoster is around 3 to 4 cases per 1000 persons across all ages, and an estimated 
88,650 zoster cases occur each year in the UK among immunocompetent individuals aged over 
60.24 These numbers are expected to increase as the population ages.  
 
Waning cell-mediated immunity is understood to lead to viral reactivation; therefore 
increasing age, due to a general waning of cell-mediated immunity during life, and severe 
immunosuppression are well-established risk factors for zoster.23  However, these risk factors 
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do not explain the vast majority of zoster cases; over half of all zoster cases occur in people 
under 64 years of age,13,25 so zoster is not exclusively a disease affecting older individuals, and 
over 90% of zoster cases occur among immunocompetent patients.26 Despite this, predictors 
of zoster beyond age and severe immunosuppression are not fully understood. A full review of 
risk factors for zoster can be found in chapter 2. 
 
 
 Postherpetic neuralgia 
 
1.1.2.1. Clinical presentation, diagnosis and treatment  
PHN is a neuropathic pain syndrome which can develop after an episode of zoster.27 
Definitions of PHN vary, though the most commonly used classification is persistent pain 90 
days or longer following onset of zoster rash.27 Diagnosis of PHN is made clinically, on the basis 
of a patient’s history and a physical examination of sensory function.  The pain experienced by 
patients with PHN is described as a burning or stabbing pain, and can be accompanied by 
allodynia (pain triggered by contact with non-painful stimuli). This pain can last for months, 
years, or until death.27 The pain associated with PHN can thus have a significant effect upon a 
patient’s quality of life, physical functioning and mental health.28-30  
 
PHN is a challenging condition to treat and strategies focus on pain management rather than 
resolution.27 There are currently no therapies which can modify the course of the condition. 
Medications shown in randomized trials to reduce pain associated with PHN include topical 
lidocaine, anticonvulsant agents, opioids, tricyclic antidepressants and capsaicin.4 In clinical 
trials of available therapies, fewer than half of patients with PHN have a 50% or greater 
reduction in pain and adverse effects are common, particularly in older individuals.27 Some 
evidence exists suggesting antivirals administered during the acute zoster episode may reduce 
the risk of PHN, however the findings are inconclusive.31 
 
1.1.2.2. Pathogenesis of PHN 
Acute zoster infection undoubtedly results in nerve damage to both the peripheral and central 
nervous system, yet the nature of the damage and the specific mechanism resulting in 
persistent pain are not fully understood.32   There are two non-mutually exclusive hypotheses 
for the development of PHN; the first is that a persistence of the VZV following acute zoster, at 
higher levels than during latency, causes continued pain; and the second, after acute zoster 
infection there is increased neuronal excitability and an alteration of pain perception caused 
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by neural damage.33,34 A recent study showed that greater VZV cell-mediated immune 
responses in the first week after zoster onset was associated with less zoster morbidity and 
lower frequency of PHN.35  This finding suggests that among patients with a better cell-
mediated immune response, virus replication is limited and the underlying cell-mediated 
immune response plays an important part in PHN susceptibility. 
 
1.1.2.3. Epidemiology and risk factors of postherpetic neuralgia 
PHN is the most frequent complication of zoster, and the most common neuropathic pain 
following infection, developing in approximately 12.5% of patients with zoster aged over 50 
years.23   
 
The evidence regarding determinants of PHN is particularly limited. Increasing age is a clear 
risk factor for PHN4 and PHN is rarely seen among those below 50 years of age.  Certain 
features of the acute zoster episode, such as rash severity and prodromal pain,36,37 are also 
commonly cited risk factors, although the evidence has never been systematically reviewed.  A 
detailed systematic review and meta-analysis of risk factors for PHN can be found in chapter 6. 
 
 Preventing zoster and postherpetic neuralgia through vaccination  
The importance of zoster and PHN morbidity has led to large-scale vaccination programmes in 
the United States (US), the UK, Australia and elsewhere.38 A live-attenuated vaccine, called 
Zostavax, is currently used which works by boosting pre-existing cell-mediated immunity. 
Initially licensed in 2006 for patients aged 60 years and over, it is now approved for use in 
those 50 years and over.39 Due to concerns that the live vaccine may lead to a varicella-like or 
herpes zoster illness from the vaccine virus strain, the vaccine is contraindicated in patients 
with conditions, or undergoing therapy, associated with severe immunosuppression.40,41   
 
The vaccine demonstrated an efficacy of approximately 51% for zoster and 67% for PHN in a 
randomised controlled trial,19 later substantiated in vaccine effectiveness studies.42,43 Efficacy 
declines in older age groups and with time since vaccination.44  
 
Due to the high-cost of the zoster vaccine, its use is limited. In the UK it is available to patients 
aged 70, 78 and 79 years of age and as of December 2014 uptake was estimated at around 
60%.45 Uptake in the US, where individuals over 60 years are eligible, reached 27.9% in 2014,46 
having previously been very low;42 low uptake has in part been attributed to the high-cost of 
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the vaccine and difficulties around patient reimbursement, as well as low public awareness 
and logistic issues relating to vaccine supply.    
 
More recently a recombinant subunit vaccine (HZ/su) has been developed and shown in a 
large randomised placebo-controlled trial (n=15,411) among patients ≥50 years to have a 
vaccine efficacy of 97.2%.47 The HZ/su vaccine was equally as effective in patients ≥70 years, as 
patients <70 years. As opposed to the live Zostavax vaccine, the HZ/su vaccine may also be 
suitable for patients with immunosuppression, because the risk of disease resulting from 
replication of the vaccine virus is prevented. 
1.2.   Aim, rationale and research questions 
The overall aim of this research is to better understand risk factors for zoster and PHN to 
inform vaccination policy. Considerable research has been carried out demonstrating the 
effect of older age and severe immunosuppression on the risk of zoster, and to a lesser extent 
PHN, however evidence regarding other risk factors is limited.  Given the high frequency of 
zoster which is set to increase in the ageing population, and the intractability and lack of 
effective treatments for PHN, identifying groups who would benefit from the effective zoster 
vaccine could have important public health benefits (assuming the vaccine is safe, effective 
and sufficiently durable in these patients groups).  
 
Three observational studies using electronic health records (EHR) data were conducted to 
answer the following research questions. 
 What are the risk factors for herpes zoster? 
The first study of this thesis investigates the effects of possible risk factors for zoster. Many 
previous studies investigating risk factors for zoster have suffered from low power. 
Furthermore, few studies have evaluated multiple risk factors simultaneously, which has not 
enabled a consistent methodological approach to be applied to various factors.   
 
A population based matched case-control study was therefore conducted, using data from the 
Clinical Practice Research Datalink (CPRD) to assess risk factors for zoster, namely autoimmune 
conditions including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and 
inflammatory bowel disease (IBD), and other medical conditions such as diabetes mellitus, 
chronic obstructive pulmonary disorder (COPD), chronic kidney disease (CKD), asthma and 
depression. A case-control study was carried out as its design makes it convenient to look at 




 Who receives antiviral therapy following diagnosis of herpes zoster? 
The second study aims to analyse antiviral prescription patterns after a zoster diagnosis. As 
PHN risk may be modified by antiviral use, an understanding of how commonly antivirals are 
used within UK general practice is an important preliminary step, before assessing risk factors 
for PHN. Research on the proportion of zoster individuals prescribed antivirals is limited and 
previous studies have reported overall use, rather than use by specific risk groups. 
 
Therefore a descriptive study among zoster patients was carried out to calculate the 
proportion of zoster cases receiving antivirals. A risk factor analysis was also conducted to 
assess associations between patient characteristics and antiviral use. 
 
 What are the risk factors for postherpetic neuralgia? 
The final research question of the thesis is to identify risk factors for the most common 
complication of zoster, PHN. For this question, a systematic review of risk factors for PHN was 
carried out.  Following the review, a cohort study was conducted among previously identified 
zoster patients to identify those at higher risk of developing PHN.  A cohort study design was 
chosen as it allowed the estimation of the incidence of PHN following zoster. This approach 
also allowed inclusion of all zoster cases, thus maximising the power of the study and reducing 
the possibility of selection bias.  
 
1.3.   Outline of thesis 
The thesis follows the research paper style format, with articles incorporated into the 
chapters. Five articles have been written, four of which are published and one accepted, in 
peer-reviewed journals. Each chapter containing a research article is opened with a concise 
introduction describing the structure of the chapter. The original formatting of the journal 
articles has been kept. In some chapters the paper is followed by additional analyses and 
discussion, which could not be included in the published or submitted paper, due to length 
restrictions. There is some repetition in the thesis, as the chapters were written as separate 
publications. 
 
Below is an outline of the thesis, describing the content of each chapter:  
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Chapter 2 presents a published literature review of the epidemiology and prevention of zoster, 
with an in-depth discussion of risk factors for zoster.  
Chapter 3 provides a detailed account of the general methods which are relevant to the three 
key research questions.  Specifically, it initially describes the data sources utilised in the thesis. 
It goes on to outline how zoster and PHN were defined.  Finally, it outlines the definitions of 
other explanatory variables in the thesis.  
Chapter 4 incorporates the first research paper; a population-based case-control study of risk 
factors for zoster. 
The second research paper, a description of who is getting treated with antivirals in UK 
primary care, after a zoster diagnosis, is presented in chapter 5. 
Chapter 6 contains a systematic review and meta-analysis of risk factors for PHN.  
Chapter 7 presents the study investigating risk factors for PHN, nested within zoster patients. 
In Chapter 8 the findings from the thesis are summarised and discussed in the context of what 
was previously known on this topic.  The suitability of the data sources for answering the 
research questions are then discussed and the implications of the findings on future research 











 Zoster is a common dermatological condition caused by the reactivation of VZV, 
during periods of suppressed T cell-mediated immunity. It is more common in 
older and immunosuppressed individuals. 
 Zoster can cause a number of complications, the most common of which is PHN, 
a neuropathic pain which can last for months to years, and affects 
approximately 12.5% of zoster patients over 50 years of age. The pathogenesis 
and risk factors for PHN are poorly understood.  
 Zoster, and thereby PHN, can now be prevented through vaccination. However, 
the vaccines high-cost means its use is limited to older individuals, and because 
it is a live vaccine, it cannot be administered to immunosuppressed individuals. 




Chapter 2:    Epidemiology and 
prevention of herpes zoster: literature 
review 
 
2.1.   Introduction 
This chapter provides a general overview of the epidemiology and prevention of zoster, with a 
particular focus on describing risk factors for zoster.  Current Dermatology Reports invited a 
literature review on this topic, and it appears below.  As the review was carried out in 2011, 
evidence on zoster risk factors published between 2011 and 2016 has been gathered, and is 
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Abstract Herpes zoster is a common disease among older
individuals, affecting approximately 25% of people in their
lifetime and resulting in appreciable morbidity. The risk of
zoster increases sharply with age and immunosuppression, yet
relatively little is known about other risk factors for zoster. A
vaccine for zoster is now available that holds the potential to
reduce incidence of zoster and its complications. In this re-
view, the recent literature on zoster incidence and potential
risk factors for the disease are summarized. Current methods
of preventing zoster and its associated morbidity are dis-
cussed, including zoster vaccine and the use of antivirals.
Keywords Shingles . Herpes zoster . Epidemiology .
Incidence . Vaccine
Introduction
Herpes zoster is a common disease among older individuals,
with a lifetime risk of 10% to 30% that rises to 50% among
those living to ≥85 years [1•]. It is caused by the reactivation
of latent varicella zoster virus (VZV), which can lie dormant
for many decades after varicella (chickenpox) infection.
Reactivation is thought to result from waning cell-
mediated immunity. Zoster typically presents as a painful
unilateral vesicular dermatomal rash (Fig. 1) that causes
acute morbidity lasting between 2 weeks and 1 month [2].
The most common complication of zoster is post-herpetic
neuralgia (PHN), which develops in around 20% of
individuals aged ≥50 years [3]. PHN is often defined as pain
persisting for >90 days after the onset of the rash; the pain can
be very severe and remain for years [4]. Although zoster is
rarely fatal, the pain associated with the acute phase of the
disease and subsequent PHN significantly reduces quality of
life [5]. Other rarer complications of zoster, such as cranial and
peripheral nerve palsies [6], encephalitis and myelitis [7], and
stroke [8, 9], have been described but few data exist about the
frequency and severity of these complications.
There are two main reasons to present an update of the
epidemiology and prevention of zoster. Firstly, zoster pre-
dominantly affects older populations, and with an increas-
ingly aging population, it is likely to become increasingly
common. Secondly, a vaccine to prevent zoster has recently
been introduced for adult immunocompetent individuals in
the United States and Australia, so this is an exciting era for
zoster epidemiology and warrants increased research focus.
In this review, we summarize the literature on zoster, using
key articles and reviews up to 2003 with more detailed inves-
tigation of recent research. We cover incidence of zoster and
risk factors for the disease. Current methods for preventing
zoster and its associated morbidity are discussed, including
antivirals and the recently developed vaccine. Important un-
answered clinical questions identified during the review are
listed in Table 1.
Epidemiology
Incidence
Incidence in General Population
A systematic review published in 2004 found the overall
incidence of zoster among immunocompetent subjects
ranged from 1.2 to 4.8 per 1000 people per year [1•]; recent
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studies from the United States [10, 11] and France [12] have
also reported disease incidences within this range. The inci-
dence of zoster increases markedly with age, with estimated
incidences of up to 14.2 per 1000 people per year in those
aged ≥50 years in the United States [1•], the United King-
dom [3], Italy [13], and Germany [14].
Incidence Among Immunosuppressed
The incidence of zoster among people with a generalized loss
of cell-mediated immunity either from immunosuppressive
disorders, such as HIV and cancer, or from the use of immu-
nosuppressive therapies is much higher than in the general
population, with incidence rates ranging from 14.5 to 53.6 per
1000 person-years [15–20]. In a retrospective cohort study
using the Veteran Affairs administrative databases in the
United States, the rate of zoster following a solid organ
transplant was estimated at 22 per 1000 person-years
overall, with higher rates seen among African American
patients (37.6 per 1000 person-years) and heart trans-
plant patients (40 per 1000 person-years) [17].
The incidence of zoster among patients on biologic drugs
is of interest due to the increased use of these drugs and their
potential impact on cellular immunity. A retrospective co-
hort study in Israel among psoriasis patients found zoster
incidence was higher among patients treated with biologics
such as infliximab (19.1 per 1000-person-years) compared
to patients not on systemic therapy (4.6 per 1000 person-
years) [21], but the difference in incidence did not reach
statistical significance. Data from registries of patients with
rheumatic diseases treated with biological agents in Spain
[22], Germany [23], and France [24] suggest an increased
risk of zoster when these patients are treated with monoclo-
nal antibody–tumor necrosis factor (TNF) inhibitors. How-
ever residual confounding may contribute to these findings.
A longitudinal study from the United States of patients in
the National Data Bank for Rheumatic Diseases found bio-
logics were not a risk factor for zoster [25], whereas a
retrospective cohort study using an American administrative
data source of people with rheumatoid arthritis reported
those taking biologic therapy were at higher risk of zoster
(adjusted odds ratio [OR] 1.54; 95% CI, 1.04–2.29) com-
pared to patients not taking disease-modifying drugs or
corticosteroids (but those taking oral corticosteroids were
at even higher risk (adjusted OR 2.51; 95 CI, 2.05–3.06))
[26]. Disentangling risk associated with disease severity and
impact of therapy remain challenging.
Recurrent Incidence
It is widely believed that second episodes of zoster are very
uncommon, except among immunosuppressed individuals for
whom recurrent zoster is well described. Therefore, a surpris-
ing finding from a recent population-based, retrospective co-
hort study in Minnesota was that of 1530 individuals
diagnosed with zoster and deemed “immunocompetent” at
the time of diagnosis, a second zoster episode was recorded
in 5.7% in the subsequent 8 years [27]. Misclassification of
immune status is possible in this study: immune status was
determined only at the time of the first zoster episode and
individuals with HIV infection who had not yet developed
AIDS-defining illnesses and those taking low doses of sys-
temic corticosteroids (<5 mg/d) were deemed immunocom-
petent. Thus, the immunocompetent group may have included
some individuals with moderate immunosuppression at base-
line as well as some who became immunosuppressed during
follow-up [27, 28]. In addition, a small proportion of the
clinically diagnosed zoster cases could have had herpes sim-
plex rather than zoster. Research using larger datasets and
more detailed characterization of immune status over time
would be useful to confirm these findings. As expected in
Table 1 Unanswered questions
What is the risk of zoster among older patients with specific co-morbidities?
Can newer antiviral agents, such as famciclovir and valacyclovir, reduce the duration and severity of post-herpetic neuralgia?
What is the absolute risk of zoster directly related to treatment with biologic medications?
What approach should clinicians take regarding interruption of therapy in patients receiving biologics to administer the live zoster vaccine?
Fig. 1 Acute herpes zoster. (Courtesy of Professor Dr Thomas Diepgen,
Heidelberg, Germany)
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the Minnesota study, risk of recurrent zoster was almost three
times higher among the 139 immunosuppressed patients com-
pared to those classified as immunocompetent (hazard ratio
[HR] 2.80; 95% CI, 1.84–4.27).
Temporal Changes in Incidence
Despite an expectation that aging populations and in-
creasing use of immunosuppressive therapies during the
course of the 20th century could have caused an in-
crease in occurrence of zoster, reports of temporal
changes in zoster incidence are conflicting [1•]. Interest
in trends in zoster incidence over time heightened after
the introduction of the varicella vaccine because of
concerns that by removing exogenous boosting of
VZV immunity from varicella contacts [29], zoster inci-
dence could rise among older unvaccinated individuals
with latent VZV infection [30].
Varicella vaccine became available in the United States in
1995 for healthy children aged over 12 months, susceptible
adolescents, and adults. Vaccine uptake in the United States
was slow during the first 5 years but increased from 68% in
2000 to 89% in 2006 among 19- to 35- month-old children
[31]. Studies of the impact of introduction of the vari-
cella vaccine on zoster incidence have shown inconsis-
tent findings. Jumaan et al. [32] report no increase in
zoster incidence between 1993 and 2002 among patients
enrolled with a health insurance organization in Wash-
ington state [32]. In contrast, two further US studies
report increases in zoster incidence rates following var-
icella vaccination. A telephone survey in Massachusetts
found an increase in zoster incidence from 2.77 to 5.25
cases per 1000 people between 1999 and 2003 [33]. A
study using the Veterans Administration database
reported that between 2000 and 2007 (when vaccine
coverage was higher), zoster increased from 3.10 to
5.22 episodes per 1000 people aged ≥40 years, although
rates per year were not standardized for age [34]. Inter-
pretation of the impact of the vaccine on zoster also has
to consider background trends in zoster incidence. A
further US study described greater increases in zoster
incidence rates before varicella vaccine licensure com-
pared to post-licensure periods, although interpretation
was complicated by exclusion of Medicare enrollees (ie,
older individuals receiving Medicare health insurance)
from the earlier estimate [31]. As most older individuals
in the US are enrolled in Medicare and the majority of
zoster episodes occur in this age group, the true inci-
dence rates may be distorted. Increases in zoster inci-
dence prior to varicella vaccine introduction have also
been described in Canada [35], Australia [36], and
Spain [37]. Whether population-based varicella vaccina-
tion affects zoster incidence remains controversial.
Risk Factors for Herpes Zoster
Any factor impacting on VZV-specific or general cell-
mediated immunity may affect risk of zoster. However, be-
yond the two key risk factors of age and immunosuppression,
relatively little is known. Potential risk factors for zoster are
outlined below.
Factors Affecting General Cell-Mediated Immunity
Age
The most important risk factor for zoster is increasing age,
with incidence rates rising among older individuals (see
above). This is likely to be due to immunosenescence (the
generalized waning of cell-mediated immunity over the life
course), which puts individuals at greater risk of many
infections [38], as well as waning of VZV-specific immunity
with increasing time since primary infection.
Immunosuppression
As discussed in the section on zoster incidence, the inci-
dence of zoster among patients with immunosuppressive
diseases is far greater than among the general population.
Patients with HIV have up to 10 times the risk of developing
zoster compared to the general population [18], and in
specific young African populations, the positive predictive
value (PPV) for underlying HIV infection when zoster is
present is 85% to 90% [39, 40]. The PPV will vary depend-
ing on HIV prevalence in the population; reported PPVs of
zoster for HIV vary from 3.7% in Brazil to 91% in a
Ugandan study population [41, 42]. The risk of zoster is
also markedly increased among those with leukemia, lym-
phoma, and metastatic malignancies and among those with
selected autoimmune disorders, although disentangling im-
munosuppression related to disease pathology from immu-
nosuppressive therapies for these conditions (discussed
below) is challenging [15, 26, 43–47]. Recent studies have
indicated that diseases associated with less marked immune
suppression may also increase the risk of zoster. A retro-
spective hospital-based cohort study in Japan showed an
increased risk of zoster among diabetic patients (HR 2.38;
95% CI, 2.04–2.78) [48] as did a nested case–control study
from Israel (OR 1.53; 95% CI, 1.44–1.62) [49]. Chronic
obstructive pulmonary disorder (COPD) has also been
associated with increased risk of zoster, again possibly
reflecting the therapies used [50]. Although the magni-
tude of the risk is smaller than among patients with
severe immunosuppression, the high prevalence of com-
mon diseases means that the absolute number of people
affected may be significant.
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Increased zoster incidence is also reported in specific high-
risk groups with iatrogenic immunosuppression following
treatment with cytotoxic drugs or therapies affecting the im-
mune response. The increased risk of zoster identified among
individuals with COPD or with autoimmune disorders such as
rheumatoid arthritis, Wegener’s granulomatosis, or systemic
lupus erythematosus mentioned above may partly reflect use
of corticosteroids or disease-modifying drugs. Recent obser-
vational data from a German and Spanish biologics registry
has suggested additional increases in zoster incidence related
to use of monoclonal drugs inhibiting TNF-α in rheumatoid
arthritis treatment [22, 23], consistent with findings from
randomized controlled trials and observational studies in large
databases in the United Kingdom and United States. Findings
from psoriasis biologic registries are awaited to identify the
long-term effect of biologic therapies on zoster risk. Although
the relative risk among people with major immunosuppres-
sion from specific diseases and/or therapeutic interventions is
high, these individuals account for <10% of cases with zoster
in most population-based studies [10, 51] from Europe and
North America.
Gender
Thomas and Hall’s [1•] systematic review suggested that
female sex may be a risk factor for zoster. Subsequent studies
from the United States, United Kingdom, Italy, France, and
Germany have reported significantly higher incidence rates
among women [3, 10, 12–14]. It is unclear to what extent the
reported increased incidence rates in women reflect a bias due
to differences in health-seeking behavior as opposed to bio-
logical mechanisms affecting cell-mediated immunity that
could put women at higher risk [1•].
Diet, Smoking, and Alcohol Use
Diets low in micronutrients may increase zoster risk by
diminishing cell-mediated immunity and hastening
immunosenescence among older individuals. A UK
case–control study found no association between intake
of single micronutrients and risk of zoster; however,
among individuals aged ≥60 years, combined low mi-
cronutrient intake and low vegetable intake were asso-
ciated with increased risk of zoster, as was lower fruit
intake (at all ages) [52]. These results suggested that a
mixture of nutrients in the diet may be necessary to
maintain immune system health. Accurate measurement
of micronutrient and diet intake is notoriously difficult;
however, the study found strong dose–response associa-
tions that give credence to the findings.
Smoking and alcohol can affect cell-mediated immu-
nity [53, 54], although no studies have been specifically
designed to look at their effect on zoster risk. A cohort
study in North Carolina found smoking was associated
with a markedly lower risk of zoster [55], whereas
another study using routine data from UK general prac-
tices from 1991 to 92 found no association between
smoking and zoster risk [1•].
Stress
Stress may increase risk of zoster as it affects a number of
neuroendocrine functions that can affect cell-mediated im-
munity [56]. A case–control study in North Carolina found
stressful life events were more common in zoster cases
within the 6 months prior to rash onset than in age-
matched controls (2.64 vs 1.82 events; P00.008), although
recall bias may have contributed to this finding [57]. Anal-
yses of the same population using a cohort study design
found some evidence that negatively perceived life events
were weakly associated with risk of subsequent zoster (risk
ratio [RR] 1.38; 95% CI, 0.96–1.97), although the study
lacked power to detect a significant effect [55]. A retrospec-
tive cohort study in Taiwan found patients with a psychiatric
illness were more likely to have an episode of zoster (HR
1.29; 95% CI, 1.18–1.38) [58], which may reflect increased
stress among these patients.
Factors Affecting Varicella Zoster Virus-Specific Immunity
Age at Primary Infection
Individuals acquiring varicella later in life have been hy-
pothesized to be at lower risk of zoster as their immunity to
VZV may last to older ages. No published studies have
looked at this hypothesis directly, but country of birth has
been taken as a proxy for age at varicella infection. Typi-
cally, in temperate areas, varicella onset is during childhood,
whereas onset is often delayed until adolescence or even
adulthood in some tropical areas such as southern India, Sri
Lanka, and the Caribbean. Late varicella acquisition has
been suggested as the reason why people of black ethnicity
in a US study of older individuals had around one third the
risk of zoster compared with those of white ethnicity (OR
0.35; 95% CI, 0.24–0.51) [55].
There is also some evidence that very early acquisition of
varicella, in utero or in early infancy, may increase the risk
of zoster during childhood and adolescence, perhaps be-
cause the immune system is not able to establish VZV
immunity at such a young age [59].
Varicella Contacts
Hope-Simpson [29] hypothesized in 1965 that exposure to
individuals with varicella could naturally boost VZV-
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specific immunity in individuals with latent VZV infection
and thus could protect against zoster [29], leading to the
concern, as outlined in the section on zoster incidence, that
population-based varicella vaccination might lead to
changes in the incidence of zoster. Hope-Simpson’s theory
has been supported by a UK population-based case–control
study of incident zoster cases and age- and sex-matched
controls. The study found increasing protection against
zoster with increasing number of varicella contacts in the
10 years before zoster, and a similar association with child
contacts (used as proxies for unrecognized varicella con-
tacts) [1•]. In contrast, a recent US case–control study of
individuals interviewed 2 months to 5 years after zoster
diagnosis found no evidence that varicella contacts or child
contacts protected against zoster [60]. Even participants
with three or more varicella contacts over the past 10 years
were not associated with a significantly increased risk of
zoster compared with participants with no contacts (OR
1.37; 95% CI, 0.82–2.27). However the incidence of vari-
cella at the time of the US study was low in comparison to
that in the UK study, due to the US population-based vari-
cella vaccination program. Few participants in the US study
had more than two contacts with varicella in the previous
10 years (2% of controls compared with 17% of controls in
the UK study), and some of these contacts could have been
mild cases of breakthrough varicella in vaccinated children.
Thus, participants in the US study perhaps had insufficient
exposure to varicella to provide exogenous boosting.
Other Risk Factors
Genetics
The possibility of genetic susceptibility to zoster and its asso-
ciated morbidity has some support from genetic association
studies. Zoster cases in Finland and Korea were more likely to
carry certain polymorphisms of the interleukin-10 gene, an
immunomodulatory cytokine that suppresses cell-mediated
immunity, compared to healthy controls [61, 62]. A study in
Japanese zoster patients also found an association between
human leukocyte antigens (HLA) haplotypes and PHN cases
[63]. Two case–control studies using family history of zoster
as an indicator for genetic susceptibility to zoster found op-
posing results. Hicks et al. [64] reported finding a family
history of zoster more commonly among incident zoster cases
in the United States compared to controls with other skin
diseases, whereas Gatti et al. [65] found no difference in
family history of zoster between cases with PHN and controls
without a history of zoster presenting with hypertension in
Italy. Further research is needed to clarify whether there is
inherited susceptibility to zoster or to PHN among those who
develop zoster.
Mechanical Trauma
Mechanical trauma has long been thought to be a risk factor
for zoster, based largely on case reports. A case–control
study published in 2004 found that mechanical trauma in
the 6 months before rash onset was associated with an
eightfold increased risk of zoster at the site of the trauma
(OR 8.02; 95% CI, 2.24–28.69), and trauma within 1 month
before rash onset was associated with a 12-fold increased
risk (OR 12.07; 95% CI, 1.49–97.63) [66].
Immunotoxin Exposure
A cross-sectional study in the United States of people living
close to a pesticide dump site found those living closer to
the dump were more likely to report a history of zoster;
however, the sequence between zoster events and residence
near the dump was not ascertained [67].
Prevention
Vaccine
The zoster vaccine has been a significant breakthrough in this
field. The live-attenuated VZV vaccine works by boosting
pre-existing cell-mediated immunity, providing protection
against zoster and PHN. It was initially shown to be effica-
cious in the Shingles Prevention Study (SPS), a US-based
randomized, double-blind, placebo-controlled trial among
38,546 individuals aged 60 years and older, in which it re-
duced the incidence of zoster by 51% and PHN by 67% [68•].
Vaccine effectiveness was subsequently shown in a retrospec-
tive cohort study of 75,761 vaccinated individuals insured by
the Kaiser Permanente health plan in California, with each
matched to three unvaccinated controls; the incidence of
zoster was reduced by 55% among individuals over 60 years
of age [69•]. Using population-based data in Canada, the
estimated number of 65-year-old individuals needed to vacci-
nate to prevent a case of zoster and a case of PHN is 11 (90%
CI, 10–13) and 43 (90% CI, 33–53) [70].
The US Advisory Committee on Immunization Practices
(ACIP) recommends routine vaccination among all persons
over 60 years of age, excluding patients with major immu-
nosuppression or those with an allergy to any vaccine com-
ponents [71]. In the context of dermatology clinics, the
vaccine should not be given to individuals receiving high-
dose prednisolone and safety is unknown in relation to
biologic drugs, for which the ACIP recommends vaccinat-
ing those in target age groups at least 1 month prior to
commencement of treatment in the absence of contraindica-
tions. A US observational study assessing the use of zoster
vaccination in older individuals with inflammatory and
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*error: should read decreased
autoimmune diseases identified 32 patients taking biologic
drugs at the time of zoster vaccination; none developed
zoster in the subsequent month [72]. Research using Medi-
care data from 2006 to 2009, currently available in abstract
form only, report that among 387 biologic users there were
no cases of zoster in the 6 weeks following zoster vaccine
administration [73]. Further testing in a clinical trial is
required before acceptable safety margins for the use of
the live zoster vaccine in patients receiving biologics can
be given or specific recommendations on safe intervals for
temporary discontinuation of therapy prior to administra-
tion. The current literature does not provide clear answers
regarding safety in individuals taking other immunosuppres-
sants. The vaccine has also been introduced in Australia.
Although the vaccine has not yet been introduced in the
United Kingdom, the Joint Committee on Vaccinations and
Immunisations (JCVI) has recommended that the zoster
vaccine be introduced for immunocompetent individuals
aged 70 to 79 years [74].
Vaccine side effects were assessed in 97% of the study
participants in the SPS and the frequency of serious adverse
events within 42 days of inoculation was the same in vacci-
nated (1.4%) and placebo groups (1.4%) [68•]. A further
substudy of 6616 SPS participants (3345 vaccinated and
3271 placebo) gathered more detailed information on short-
term events and hospitalizations over the entire follow-up
period [75]. Local side effects at the inoculation site (eg,
erythema, pain, swelling, rash, and pruritus) were more fre-
quently reported in vaccinees (48%) than the unvaccinated
group (16%), and having ≥1 inoculation-site adverse event
was more common among those aged 60 to 69 years (56.6%)
compared to individuals aged ≥70 years (39.2%). However,
events were rarely long lasting or severe. Longer-term follow-
up showed rates of hospitalization and death did not differ
between the two groups [75].
Modelling work has suggested that zoster vaccine is cost-
effective. Using data from the SPS and population-based data
from Canada, Brisson et al. [76] suggested the most cost-
effective strategy was vaccinating adults aged 65 to 75 years,
with the main cost benefits being reduced PHN morbidity.
One of the main challenges in calculating cost-effectiveness is
uncertainty regarding duration of vaccine efficacy, due to the
short duration of the SPS trial (mean follow-up of SPS was
3.4 years) [76]. The US Food and Drug Administration have
also recently expanded the age range for the zoster vaccine to
individuals aged 50 to 59 years on the basis of a large unpub-
lished, multinational, randomized controlled trial showing
efficacy of 70% in terms of reduction of incident zoster;
further observational data of vaccine effectiveness are awaited
from this age group, and previously discussed ACIP recom-
mendations remain unchanged [77].
Despite the efficacy of the vaccine, its uptake in the US
target population has been disappointing. Data from a US
household survey from 2007 found 1.9% of adults aged
60 years and older were vaccinated against zoster, rising in
2008 to 6.7% [78]. In 2008, rates were lower among His-
panics (2.1%) and non-Hispanic blacks (2.5%) than non-
Hispanic whites (7.6%). Both patient and provider barriers
have been suggested as explanations for the low uptake of
the zoster vaccine, such as the high vaccine cost, complex
methods for reimbursement, and requirement for freezer
storage [79, 80].
Vaccination coverage levels could be higher if the
zoster vaccine was given at the same time as other
vaccines. In December 2009, the US Food and Drug
Administration stipulated that the zoster vaccine should
not be given concurrently with the pneumococcal vac-
cine, after results from a randomized, double-blind,
placebo-controlled trial by the manufacturer on 473
individuals aged ≥60 years found VZV antibody levels
were lower among patients receiving concomitant zoster
and pneumococcal vaccinations compared to those re-
ceiving the zoster vaccine 4 weeks after pneumococcal
vaccine (VSV geometric mean titers ratio [concomitant/
non-concomitant] 0.70; 95% CI, 0.61–0.80) [81]. A
retrospective cohort study in a US state compared inci-
dence rates of zoster, rather than antibody levels, over a
3-year period among individuals receiving both vaccines
either concomitantly (n07187) or with at least a 30-day
gap (n07179). The study found no difference in the
incidence of zoster between the groups (HR 1.19; 95%
CI, 0.81–1.74) [82]. The authors suggested that a thor-
ough assessment be undertaken before introducing rules
placing barriers on administration of the zoster vaccine,
especially considering its low uptake.
Antivirals
Antivirals are used to limit pain of an acute zoster episode, and
some evidence suggests they might also reduce the risk of
developing PHN. A recent Cochrane review of five trials
comparing acyclovir to placebo and one trial comparing fam-
ciclovir to placebo found little difference in prevalence of
PHN 6 months after rash onset; however, the meta-analysis
was limited to two of the acyclovir trials with the required data
(summary RR 1.05; 95% CI, 0.87–1.27) [83]. This finding
partly contrasted previous reviews in which different defini-
tions of PHN were used. These meta-analyses found some
evidence of an effect of acyclovir on reducing frequency of
PHN [84]. A randomized controlled trial of 419 adults showed
a significant reduction in median duration of PHN (although
no reduction in PHN incidence) when famciclovir was given
using a standard regime [85]. The authors of the Cochrane
review suggested further trials be conducted on famciclovir
and valacyclovir to clarify their role in reducing duration and
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severity of PHN [83]. These newer agents are, however,
significantly more expensive compared to acyclovir and are
currently infrequently prescribed.
Antivirals may also be effective in protecting against
incidence of zoster among severely immunosuppressed
patient groups. For example, a double-blind, placebo-
controlled trial of 77 patients undergoing allogenic he-
matopoietic cell transplant showed that 800 mg of acy-
clovir, given twice daily for 1 year after the procedure,
significantly reduced the risk of zoster (HR 0.16; 95%
CI, 0.04–0.74) [86]. With increasing numbers of people
becoming immunosuppressed from modern therapies,
antiviral use may be proven effective in reducing the
incidence of zoster and its associated morbidity in cer-
tain high-risk groups.
Conclusions
The lifetime risk of zoster is high and has important conse-
quences. The greatest breakthroughs in this field have argu-
ably been the development of a highly effective, safe zoster
vaccine that has the potential to significantly reduce incidence
and morbidity of zoster and PHN, as well as a vaccine to
prevent varicella, which could eventually lead to the appre-
ciable reduction of the burden of zoster. Further research
focusing on cost and logistics of the zoster vaccine needs
attention due to its current low uptake in the United States.
Despite the relatively high incidence of zoster in older indi-
viduals, relatively little is known about risk factors for zoster,
and recent questions have been raised about risks associated
with specific co-morbidities. Better understanding of the
determinants of zoster could be an important step in prevent-
ing herpes zoster episodes and identifying target groups for
the vaccine.
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2.3.   Risk factors for zoster: 2016 literature review update 
 
Research exploring risk factors for zoster appearing after the publication of the above article, 
“The Epidemiology and Prevention of Herpes Zoster” (and herein referred to as the “2011 
review”), are briefly summarised below. Table 2 below provides an overview of how literature 
published between 2011 and 2016 corroborates, challenges or extends the conclusions from 
the 2011 review. 
 
Briefly, the 2016 literature review update has substantiated the findings from the 2011 review 
regarding older age1,48 and severe immunosuppression48-51 as major risk factors for zoster. The 
increased risk of zoster associated with female sex,48,50-53 autoimmune conditions49,54-60  and 
mechanical trauma61,62  was similarly corroborated.   
 
Since the 2011 review, the effects of anti- tumour necrosis factor (TNF) drugs, have been 
further investigated. Evidence from a systematic review suggests anti-TNF drugs increase the 
risk of zoster among RA patients by 60% (compared to conventional disease modifying anti-
rheumatic drugs),63 with some evidence that monoclonal antibody anti-TNFs pose greatest 
risk. However, in the review there was significant statistical heterogeneity between studies 
(I²=80%) and one of the largest studies in the review concluded there was no evidence that 
new users of biologics were at greater risk of zoster, compared to new users of conventional 
DMARDs.64 The effect of anti-TNF drugs among patients with psoriasis and IBD is similarly 
inconsistent.58,64-66   
 
The 2011 review also suggested that more common medical conditions, associated with 
moderate immunosuppression, might increase the risk of zoster. The 2016 update found 
supporting evidence indicating that diabetes48,50,52,67 and COPD48,52 are associated with 
increased risks of zoster, of up to 45%. Additional research has suggested that other medical 
conditions may be risk factors for zoster including asthma,48,51,68 CKD,69-71 cancer,48,51,72 
cardiovascular disease48,51,52 and peptic ulcer disease.73  The risk of zoster was 5-80% greater for 
patients with these conditions, compared to the general population. However, a number of 
limitations were identified in these studies, including: 1) small study sizes; 2) inadequate 
adjustment for confounders; 3) lack of data on whether the associations were driven by the 
conditions themselves, or the use of immunosuppressive drugs; and 4) lack of data on how 





The 2016 update also identified two studies exploring recent negative life events as risk factors 
for zoster, in order to investigate the effects of stress. However, the effects of these life events 
were inconsistent between the studies.74,75 This finding demonstrates that the very commonly 
cited risk factor for zoster, psychological stress, has yet to be comprehensively demonstrated 
as a risk factor in the epidemiological literature.  The effect of varicella contact exposure,1,76 
age of primary varicella infection48,51 and genetics30,39 on zoster risk also remains unclear.  Black 
ethnicity was substantiated as a protective factor against developing zoster, reducing the risk 






Exposure Findings from main “2011 review” 2016 update: findings from papers published since 2011 
Factors affecting general cell-mediated immunity 
Age Increasing age is a risk factor for zoster with an estimated 
incidence of up to 14.2 per 1000 person years in those ≥50 
years old in North America and Europe. 
The effect of increasing age on risk of zoster was corroborated in a systematic 
review of zoster incidence studies, which confirmed a steep rise in zoster incidence 
after 50 years of age, with some suggestion that the incidence peaks around 75 
years of age, whereupon it starts to plateau or decline.1,48  
Gender Female sex may be a risk factor for zoster. Further studies support female sex as a risk factor for zoster; effect estimates 
ranged from 1.22 to 1.39.48,50-53 
Severely immunosuppressive 
conditions/therapies 
Zoster incidence in patients with severe immunosuppression 
is greater than in the general population; incidence rates 
range from 14.5 to 53.6 per 1000 person years. 
Further research supports findings from the “2011 review”.48-51 The incidence of 
zoster in HIV patients is reducing, perhaps due to modern antiretroviral drugs; the 
rate of zoster among HIV patients using French hospital data reduced from 2955 per 
100,000 person years in 1992-96 to 628 per 100,000 person years in 2009-
2011.17,77,78  
Autoimmune conditions The risk of zoster is markedly increased among patients with 
autoimmune disorders, specifically RA, Wegener’s 
granulomatosis, or SLE. 
Further evidence supports the increased zoster risk in autoimmune conditions, 
compared to the general population, including RA (risk 2 fold greater),57 IBD (risk 1.5 
times greater),58 SLE (risk 1.5 to 2.3 times greater),49,59,60 primary Sjögren’s 
syndrome,54 bullous pemphigoid,55 dermatomyositis and polymyositis.56 Anti-TNF 
drugs appear to increase zoster risk among RA patients,63 yet the effect in 
psoriasis64-66 and IBD patients58,64 is less clear.  
COPD One study suggested zoster risk was greater among patients 
with COPD, compared to the general population. 
Two studies demonstrated an increased risk of zoster associated with COPD of 
around 20 to 30%.48,52  
Diabetes Two studies indicated diabetes was associated with increased 
risk of zoster, with effect estimates ranging from 1.53 to 2.38.  
Four further studies found diabetes was associated with an increased risk of zoster, 
with effect estimates ranging from 1.04 to 1.45,48,50,52,67 and a further study 
distinguished between diabetes type and reported only type 2 diabetes was 
associated with zoster.79  





Exposure Findings from main “2011 review” 2016 update: findings from papers published since 2011 
Mental health problems  Negative life events and psychiatric disease were identified as 
risk factors for zoster in single studies.  
Two studies assessed the effect of negative life events on zoster risk; one reported 
these events increased the risk of zoster,74 whilst another found no evidence of 
increased risk.75 Two case-control studies found depression was associated with an 
increased risk of zoster, ranging from 1.5-4 times the odds,52,74 whilst an Australian 
cohort study found no association with depression or anxiety.51 
Asthma 
No evidence in 2011 review. 
Three studies have reported an increased risk of zoster associated with asthma, with 
effect estimates ranging from 1.12 to 1.70.48,51,68     
CKD 
No evidence in 2011 review. 
Recent studies indicate CKD is a risk factor for zoster,69 associated with 20 to 60% 
increased risk, with greater risk among CKD patients on dialysis.70,71 All studies used 
Taiwanese health records.   
Factors affecting general cell-mediated immunity (continued)  
Cancer 
No evidence in 2011 review. 
Non-haematological cancers were associated with over 10% increased risk of zoster 
in two studies,48,72 whilst an Australian cohort study assessed all cancers (excluding 
non-melanoma skin cancer) and found a 35% increased risk of zoster.51  
Cardiovascular disease 
No evidence in 2011 review. 
Since the review, studies have indicated a small but significantly increased risk of 
zoster associated with coronary heart disease48,51,52 (effect estimates range from 
1.09 to 1.24). 
Statins 
No evidence in 2011 review. 
Three studies reported a small but significantly increased risk of zoster with statin 
use, with effect estimates ranging from 1.13 to 1.28.80-82 
Peptic ulcer disease 
No evidence in 2011 review. 
One cohort study identified peptic ulcer disease as a risk factor for zoster, with 
almost 80% increased risk of zoster.73 
Liver disease No evidence in 2011 review. There is no evidence that patients with cirrhosis are at increased risk of zoster.83  
Diet, body mass index (BMI) 
smoking and alcohol use 
Diets low in micronutrients may increase zoster risk, smoking 
may be associated with lower risk of zoster and no studies 
have assessed alcohol use as a risk factor for zoster.   
An Australian cohort study51 found an 18% decreased risk of zoster in current 
compared to never smokers in line with previous research, along with a 6% 
increased risk of zoster among past smokers. This same cohort study found no 
association with alcohol use or BMI, and zoster. 
 
 
Table 2: (continued) 
 




Exposure Findings from main “2011 review” 2016 update: findings from papers published since 2011 
Factors affecting VZV-specific cell-mediated immunity 
Age at primary infection / 
ethnicity 
Later age of primary varicella infection may reduce the risk of 
zoster, potentially explaining the reduced risk of zoster in 
patients of black ethnicity originating from countries where 
varicella is contracted later in life. 
The reduced risk of zoster in patients of black ethnicity was corroborated, with 
protective effects ranging from 5 to 30%.51,53,72 A Spanish study reported a lower 
incidence of zoster in foreign born participants with those born in sub-Saharan 
Africa at 60% reduced risk,48 however in an Australian cohort study, participants 
born in countries where varicella onset is late were not at decreased risk of zoster in 
univariate analysis.51  
 
 
Varicella contacts Natural boosting of VZV-specific immunity through exposure 
to varicella contacts was partially supported by 
epidemiological evidence. 
A systematic review assessing exposure to varicella contacts and zoster risk found 
mixed results,76 whilst two systematic reviews concluded zoster incidence has not 
clearly increased following the introduction of the varicella vaccine.1,76  
Other risk factors 
Genetics Evidence regarding genetic susceptibility to zoster is scare 
and inconsistent.  
Two studies reported greater risk of zoster for patients with family history of 
zoster,74,84 however the effect of genetics on zoster susceptibility remains unclear. 
Mechanical Trauma A single case-control study found mechanical trauma six 
months pre-zoster was associated with eightfold increased 
risk of zoster, though the study may suffer from recall bias. 
Two studies using routinely collected data reported physical trauma was associated 
with over three times the risk of zoster.61,62  The effect appeared relatively 
immediate, specifically during the first week following trauma.  
Physical limitation 
No evidence in 2011 review. 
An Australian cohort study reported that patients with a severe physical limitation 
were 30% more likely to develop zoster.51  
Health-seeking behaviour 
No evidence in 2011 review. 
An Australian cohort study found patients attending cancer screening programmes 
and taking supplements were up to 17% more likely to develop zoster, and patients 
living in regional areas, rather than cities, were less likely to develop zoster.51 










Epidemiology and prevention of herpes zoster 
 A review of the epidemiology and prevention of zoster was carried out in 2011, 
and evidence regarding zoster risk factors was updated in 2016.  
 The lifetime risk of zoster is high and it can have significant consequences. 
 The greatest breakthrough in this field has been the development of an 
effective, safe zoster vaccine, which has the potential to significantly reduce the 
incidence and morbidity of zoster and PHN.  
 Well demonstrated risk factors for zoster include age, severe 
immunosuppression and mechanical trauma. Newer evidence indicates biologics 
may increase the risk zoster.  
 Various common conditions, including diabetes, asthma, COPD, CKD, 
cardiovascular disease, cancer and peptic ulcer disease, have been indicated as 
zoster risk factors. However, a number of limitations were identified and the 
effect of these risk factors on zoster remains unclear.  
 Better understanding of the determinants of zoster could be an important step 





Chapter 3:   Data sources and variable 
definitions 
This chapter summarises the data sources utilised in this thesis and outlines how the main 
outcomes of interest (zoster and PHN) and the explanatory variables were defined.  
 
3.1.   Data sources 
This study will utilise data from two EHR databases: the UK CPRD and the Hospital Episode 
Statistics (HES) database.  
 
 The Clinical Practice Research Datalink   
3.1.1.1. Overview 
CPRD is a large computerised database of anonymised patient records from UK primary care. 
At the time this research project was carried out, over 600 general practices contributed data 
from over 12 million patients and over 5 million currently registered patients. Approximately 
7% of the UK population were represented, making it one of the largest sources of electronic 
primary care data in the world for research. Enrolled practices use a specific information 
technology (IT) system, called Vision, which uses coded and free text data to record 
information. Practices agree to participate, however individual patients may opt out upon 
request. Over 98% of the UK population are registered at a general practice and studies have 
shown that patients in CPRD are broadly representative of the UK population in terms of age, 
sex and ethnicity.85  
 
The general practitioner (GP) in the UK acts as the gatekeeper of primary care and specialist 
referrals, therefore the majority of patients will seek care initially from their GP for health-
related issues.  This system results in a rich source of patient-level health data, including all 
consultations, diagnoses, prescriptions, tests, immunizations, referral to hospitals and 
hospitalizations. Unlike many administrative databases, particularly those collected for 
insurance purposes, CPRD also contains some lifestyle and anthropometric data, such as 





3.1.1.2. Data structure and coding 
CPRD release new database builds on a monthly basis. For this thesis the January 2012 build 
was used, except for the descriptive study of antiviral use (chapter 5) in which the June 2011 
build was used. The data are split into several files and Table 1 below describes the main file 
types in CPRD used for this study, along with their contents.  The patient-level files can be 
linked using a unique patient identifier, present in each file. The last three characters of this 
identifier also constitute a unique practice identifier, for linkage to the practice-level data.  
 
Table 1: Description and contents of files types available and utilised in this thesis 
File type File contents 
Patient Patient level demographic details including; year of birth, gender, registration 
status (acceptable/unacceptable), death date, transfer out date. 
  
Practice Practice level data including; geographical region, 'Up to standard' date (date 
CPRD have classed the practice data sufficient quality for research), last data 
collection date (for the practice). 
  
Consultation Patient level data on consultations with GP; date of consultation, type of 
consultation and duration of consultation. 
  
Clinical Patient level data on clinical events including; date of clinical event, diagnosis 




Additional detail regarding clinical events, such as number of cigarettes smoked 
per day and test results. The file is split into entity type, which relates to a 
specific type of data. There are a total of 460 different entity types.  For 
example, entity “type one” records information on blood pressure.  
  
Referral Patient level data on referrals to specialist services including; date of referral, 
diagnosis given, method of referral, referral specialty, urgency of referral. 
  
Therapy Patient level data on drug prescriptions and apparatus including; date of 
prescription, CPRD product code for the prescription. 
 
 
GPs in the UK record medical and non-medical events using the hierarchical Read code 
classification system.86 This system covers a range of areas including symptoms, diagnoses and 
administrative processes. The Read code hierarchy is organised into chapters and subchapters, 
with initial values representing high-level categories and following values specifying further 
detail on the event. Therapy prescriptions are recorded using the Multilex product dictionary, 
and include pharmaceuticals, drug appliances or devices. CPRD have translated these Read and 
Multilex codes into medical and product codes respectively, and created dictionaries that can 
be easily searched.  For this thesis the dictionary versions 1.3.2 were used. 
41 
 
Defining follow-up for individual patients 
Although records go back many years, CPRD recommend restricting the start of follow-up 
period to be the latest of practice ‘up to standard’ date or the date the patient first registered 
at the practice.  They also recommend ending follow-up at the earliest of the following; when 
the patient died, transferred out of the practice, or when data were last collected on that 
practice.  
 
3.1.1.3. Data Quality and Validity of Information 
CPRD data undergoes some checks to ensure the data meet certain standards before release.87  
These checks occur at the practice and patient level. Practices are assessed and labelled ‘up to 
standard’ when the practice is considered to have continuous high quality data, fit for 
research. The practice must meet various criteria, such as a minimum referral rate per 100 
patients. Patient level data are marked as “acceptable” for research, where certain criteria are 
met, such as: 1) age at end of follow-up is below 115 years; and 2) year of birth is recorded. 
 
Guidance documents for practices contributing to CPRD ask GPs to record various aspects of a 
patients’ medical details including; all significant clinical events from a patients history at 
registration and as they occur, indications for therapy prescriptions, all known hospitalisations 
and cause of death. However, data completeness may vary substantially over time, by 
population or type of data. 
 
Recording of certain data types has been improved by the introduction of the Quality and 
Outcomes Framework (QoF), which encourages recording of key data items through an 
incentivised payment programme for GPs.88 QoF was introduced in 2004 and sets out a series 
of data fields for collection, such as the BMI status of diabetes patients and the delivery of 
services to patients with severe mental health conditions.  The completeness of data for 
factors included in QoF increased following the introduction of this programme. 
 
Diagnostic validity in the CPRD is generally considered to be an advantage of the database. A 
systematic review of studies validating a variety of disease diagnoses found the median 
proportion of CPRD-defined cases with a confirmed diagnosis was 89%89 (positive predictive 
value (PPV) of a recorded diagnosis). However, the PPVs ranged from 24 to 100% for individual 
diseases and the review acknowledged that validation studies were limited due to their size 
and frequently restricted to specific populations. Furthermore, the same systematic review 
noted that negative predictive values (NPV) are very rarely assessed in CPRD validation studies, 
42 
 
due to the financial implications of sampling a vast number of patients without the diagnostic 
codes of interest.  The lack of information on the NPV is an acknowledged weakness of CPRD 
data.  
 
 Linked Hospital Episodes Statistics  
3.1.2.1. Overview 
A subset of English CPRD practices participate in a linkage scheme, where related datasets are 
linked to CPRD. One of these datasets is HES, a secondary care database of hospital admissions 
from all National Health Service (NHS) trusts throughout England. Patients in CPRD are linked 
to HES data using deterministic matching (where all or some identifiers are required to match 
exactly) on a combination of the patient’s NHS number, gender, and partial date of birth. The 
research in this thesis uses hospitalisation data from April 1997 to March 2012, during which 
time 375/497 (75%) of English practices participated in the linkage scheme. Linked HES data 
contains information on inpatient admissions only (limited outpatient data did not become 
available until September 2014). HES contains comprehensive diagnostic information, however 
prescription data are not currently available.  
 
3.1.2.2. Data structure and coding 
The structure of HES data are demonstrated in Figure 1 below.  HES data are divided into 
“hospitalisations”, which relate to a stay in hospital. For each hospitalisation there may be one 
to many “episodes”, an episode being a time period for which a patient is under the care of a 
particular consultant.  Within an episode, a patient has a primary diagnosis and up to 20 
further secondary diagnoses; the primary diagnosis field usually relates to the reason the 
patient was admitted.  The data are provided to researchers as files relating to hospitalisations 
or episodes. 
 
Clinical diagnoses in HES data are coded using the International Classification of Disease, tenth 
revision (ICD-10) system, developed by the World Health Organisation (WHO). It is organised 
into chapters, themed on particular medical areas, covering diagnoses and procedures. ICD-10 
codes are made up of 6 or 7 digits; the first three digits indicate the medical category, the next 
three give information on the location, severity or aetiology and the 7th digit is optional, 




Figure 1: HES data structure 
 
Note: “hospitalisations” relate to a stay in hospital and “episodes” relate to a time period for which a 
patient is under the care of a particular consultant. 
 
 
3.1.2.3. Data quality 
HES data are collected during a patient’s hospital stay, and are processed to allow hospitals to 
be paid for the care they deliver. HES data are also designed to enable secondary use, that is 
use for non-clinical purposes, such as research. Trained clinical coders input ICD-10 codes from 
unstructured, hand-written clinical notes.  Data input by clinical coders are then sent to a data 
warehouse. At pre-arranged time-points in a year, HES then extracts a copy of the data, and 
carry out validation and data cleaning. Each variable undergoes a set of cleaning rules, for 
example each patients date of birth must lie between 1/1/1885 and the last day of the period 
being processed, and where invalid codes appear, they are overwritten with the code for 
“Unknown”.90  
 
Errors and omissions within HES data are acknowledged to occur;91,92 in 2013/14 an audit of 
8,990 episodes of care from 50 NHS trusts compared case notes to clinical codes, and 
estimated the error rate of clinical codes in admitted patient care data at 10.8%.93  The errors 
may be entirely incorrect codes, or codes lacking detail of the clinical event.94  The main 
reasons for errors are thought to be incomplete paper records and the lack of involvement 
from front-line clinicians in the coding process.91  The impact of this level of coding inaccuracy 
on epidemiological research is difficult to quantify and is likely to vary according to the hospital 
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1° diagnosis field  
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specialty and the study question. Despite this, data quality is improving over time and is 
considered sufficiently robust for health research.95,96  
3.2.   Creating code lists 
To identify patient characteristics in CPRD and HES, such as diagnoses or therapies, code lists 
are created.  A code list refers to a list of all codes indicating the patient characteristic or drug 
of interest. Code lists can be merged with the raw data to identify all patients with the 
characteristic or all patients prescribed the drug.  
 
For this project, a systematic approach was used when creating diagnosis and product code 
lists.  The relevant dictionaries of codes were searched using a STATA do file, such that all 
decisions on inclusion and exclusion criteria were recorded and were easily replicated. 
 
The approach to creating a diagnosis code list was as follows: 
 All possible codes were identified by creating a set of search terms (synonyms of the 
medical event) and looking for these in the entire Read or ICD-10 dictionary, within the 
Read term data field or ICD-10 Terms field. The Read code or ICD-10 hierarchy was 
additionally utilised to identify all codes within relevant chapters or sub-chapters.  
Codes not meeting the search criteria were dropped. 
 Final diagnosis codes were selected by reviewing the possible codes with a clinician (in 
the majority of cases Dr Sinéad Langan, dermatologist) and collating a list of exclusion 
terms, which were then applied. Remaining codes were then compared to any 
available pre-existing code lists (for example if a code list for the medical condition had 
been created for a previous study) and discrepancies were assessed.  
 
The approach to creating a product code list was as follows: 
 All possible codes were identified by creating a set of search terms and looking for 
them within the entire product code dictionary, within the following data fields: 
product name, British National Formulary (BNF) header, drug substance and route of 
administration.  Most codes were identified from the product name search, however if 
this data field was missing, searching the other data fields picked up extra terms. The 
hierarchical structure of the BNF dictionary was utilised by searching for codes within 
BNF chapters (using the BNF code data field).  Product codes not meeting the search 
criteria were dropped. 
 Final therapy codes were selected by reviewing the possible codes with a clinician (in 
the majority of cases Dr Sinéad Langan, dermatologist) and compiling a list of exclusion 
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terms, which were then applied. Remaining codes were compared to existing code lists 
where possible and discrepancies assessed.  
 
All medical and product code lists can be found in appendix V. 
3.3.   Outcome definitions 
 Definition of zoster in CPRD and HES 
Zoster diagnoses were identified in CPRD by Read codes in the clinical and referral files and in 
HES data by ICD-10 codes (listed in appendix V).   
 
Patients were required to be ≥18 years of age at zoster diagnosis, as zoster among children is 
very rare. The zoster diagnosis had to occur within the patient’s follow-up period (see section 
3.1.1.3). It was also necessary to identify patients with a first ever episode of zoster, as 
recurrent zoster is rare and its aetiology and clinical course is believed to be different to the 
majority of zoster episodes. 
  
It was important for the thesis’ objectives to identify incident rather than prevalent cases of 
zoster, to ensure the optimal accuracy of diagnosis date. In order to ensure this, patients were 
required to have 12 months registration in CPRD without a zoster diagnosis. This 12-month 
threshold is in line with research by Lewis et al,97  which reported that in routinely collected 
data, recording of prevalent cases is more likely shortly after registration at a general practice, 
therefore it is common practice not to include diagnoses recorded shortly after registration.  
 
Incident zoster cases in HES data were identified by ICD-10 codes (B02, B02.0, B02.1, B02.31, 
B02.7, B02.8, B02.9, G53.0).  Although the majority of zoster cases do not require in-patient 
care, a small proportion of cases require hospitalisation.26 Identifying hospitalisations due to 
zoster is challenging, as it is not easy to determine whether zoster triggered the admission, 
occurred during hospitalisation or was associated with admission for another reason. HES data 
contain up to 20 diagnoses per episode, however hospitalisations were only considered to be 
related to zoster if the zoster diagnosis was recorded in the primary field of any episode during 
a hospitalisation (see Figure 1: HES data structure). This is because it is not possible to identify 
whether records in any of the secondary fields are incident zoster, history of zoster or 
misdiagnosis of zoster. For zoster cases identified in HES the date of hospital admission was 









 Postherpetic neuralgia 
 
This section describes some of the challenges of defining PHN in EHR data, as well as a 
summary of how researchers have identified PHN in previous studies.  The method used to 
identify PHN patients in CPRD is then outlined in greater detail.  
 
Background information on the management of PHN in UK primary care 
The UK Clinical Knowledge Summary on the management of PHN (last revised February 2014)98 
suggests patients with zoster-associated pain are treated as follows: initially, with paracetamol 
in combination with codeine if necessary; where this proves ineffective, tricyclic 
antidepressants or anticonvulsants are recommended for 4-6 weeks. Clinicians are also 
encouraged to consider using capsaicin cream 0.075% and lidocaine 5% medicated plasters on 
the affected areas to relieve pain. For patients awaiting referral to pain specialists, if the above 
treatments have failed, GPs are recommended to consider prescribing a short course of 
tramadol. The chosen treatment depends on patient characteristics (such as their age, 
comorbidity and frailty), the phase of the illness (acute or established PHN), local prescribing 
preferences and physician preferences. The pharmacological management of PHN patients 
may therefore be heterogeneous. 
 
Challenges in defining PHN using EHR data:  
There are two main avenues for identifying PHN from CPRD records namely (1) looking for 
clinical records indicating a PHN diagnosis or continuous post-zoster pain that would meet the 
criteria for PHN, and (2) looking for prescriptions for treatments that are given for PHN. 
 
Long-term pain due to PHN is difficult to capture in EHR databases such as CPRD, for a variety 
of reasons: 
 There is no single definition of PHN. The definition of PHN varies in the literature, primarily 
in terms of when zoster-associated pain becomes classified as PHN.  The most accepted 
definition of PHN is pain persisting beyond 90 days of rash onset, however some GPs and 
researchers may diagnose PHN 30 days following zoster. 
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 PHN treatments have various clinical indications, therefore prescriptions for PHN 
medications may not be sufficient to confirm PHN. PHN drug treatments such as codeine or 
anticonvulsants are not exclusively given for PHN. As clinicians in the UK are not required 
to record the indication for every prescription, it cannot be confirmed whether a 
prescription was given for PHN. 
 PHN pain codes are not always specific. The pain codes available and used by some GPs to 
diagnose PHN are often non-specific (such as “neuralgia” or “neuropathic pain”), so again 
it is difficult to be certain the pain is due to PHN. 
 Patients may be referred to secondary care for pain management. The UK Clinical 
Knowledge Summaries suggest that if pain is not controlled, despite medical advice and 
trials of two drug treatments (normally about 8–12 weeks [56-84 days] after starting 
treatment), or adverse effects limit treatment, doctors should consider referral to a pain 
clinic or seek specialist advice.98 Therefore some PHN patients may be missed in CPRD if 
treatment is provided in secondary care.  However, these patients would typically be 
referred back to primary care for ongoing treatment. 
 Patients may not attend primary care for pain-management. Patients may not seek care 
from their GP for a number of reasons: (i) they may establish stable pain regimens before 
90 days that no longer require repeated physician visits (many painkillers used in PHN pain 
management can be obtained over-the-counter); (ii) they may seek second opinions and 
alternative therapies outside the primary practice; (iii) they may resign themselves to pain 
as PHN is often refractory to treatment; (iv) or they may develop new health concerns that 
displace PHN pain as the focus of their visits. The implications of the above factors are that 
there is likely to be decreasing sensitivity of capturing PHN in EHR data with increasing 
time since zoster.  
 
How researchers currently deal with PHN in EHR data 
Researchers have used a variety of techniques to ascertain PHN patients in EHR data (see Table 
2 below for some examples). Most researchers use evidence within a certain time-frame 
following zoster to define their PHN cases.  The presence of PHN diagnosis codes (if available) 
and/or zoster plus neuropathic pain codes are widely used.  Hall et al identified patients with a 
PHN code (without a requirement for previous zoster) or a code for neuropathy or neuropathic 
pain 3 to 6 months following an acute zoster code in CPRD. They validated their definition in a 
sample of 108 patients with PHN diagnosed between 2006 and 2010.99  Questionnaires were 
sent to GPs to confirm PHN.  The response rate was 86.8% and the PPV for PHN was 91%.  This 
finding appears to suggest using PHN codes and zoster with a later nerve pain code is effective 
at identifying PHN patients in CPRD.  However, this algorithm may not be reliable; it could be 
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argued that in CPRD, the majority of PHN codes may not indicate PHN itself, but zoster-
associated pain shortly after zoster. Figure 2 below shows the distribution of time from zoster 
diagnosis to PHN code in patients with a first ever zoster code in CPRD.  This figure suggests 
almost 70% of the codes occur within 90 days of zoster; as the most accepted definition of 
PHN is pain after 90 days, none of these codes alone would meet the criteria for PHN.  
 












Any evidence of pain or analgesic prescription in patients’ 




CPRD, UK Diagnostic code for PHN; or 
Neuropathic pain medication (topical analgesics, tricyclic 
antidepressants, anticonvulsants and tramadol) >1 to >12 
months and >3 to <12 months post-zoster diagnosis. 
Assessed PHN severity from prescribed medications. 
Diabetic 
neuropathy, 









major regions in 
Italy 2003-05.  
ICD9-CM code for zoster and a prescription for any drug 
commonly prescribed for PHN (tramadol, anti-epileptics, 
tricyclic antidepressants capsaicin cream or lidocaine) 3-12 
months and 1-12 months after zoster diagnosis; or 





CPRD, UK PHN code; or 
Code for neuropathy or neuropathic pain code 3-6 months 




Medicare, USA Zoster code 90 days following incident zoster, with a 
prescription of analgesia, anticonvulsant, antidepressant on 
the same day; or 
Non-specific neuralgia/neurological complications code 90 






Figure 2: Distribution of time from zoster diagnosis to PHN code appearing, in CPRD 
patients with first ever zoster 
 
 
Some researchers have additionally used medications prescribed within a time frame following 
zoster to identify PHN cases. The use of relevant medications following zoster to identify PHN 
has not been validated in CPRD, however a US study by Klompas et al, developed an algorithm 
to identify PHN patients using administrative data, incorporating medication history into their 
final definition.102  They used the Harvard Vanguard Medical Associates database, an 
ambulatory practice group that provides primary and specialty care to more than 550,000 
patients in eastern Massachusetts. This database uses ICD version 9 (ICD-9), which has no code 
for PHN. Patients included were aged 20 years or older, with an ICD-9 code for zoster, in the 
calendar year 2008. 
 
Klompas et al focused on identifying persistent pain 30 days following zoster and developed an 
algorithm with a sensitivity of 86% and PPV of 78%. In the algorithm, they required two or 
more visits with an ICD-9 code for zoster 21 days or more apart and a new prescription for an 
analgesic, antidepressant or anticonvulsant; or an ICD-9 code for zoster with nervous system 
complications; or an ICD-9 for neuralgia within 180 days of a visit for zoster. This validation 
study was carried out in an administrative data source, which differs from CPRD in so far as 
rule out codes are more commonly used and certain diagnoses may be under-reported if there 
are no financial incentives to record them.  However, some high-level elements of this 
algorithm were used to help identify patients with PHN in CPRD; specifically, using a 
combination of diagnostic and “new” prescription codes within specified time periods 























Strategy to identify PHN patients in CPRD 
Methods previously used to define PHN were considered and an approach was developed to 
identify patients with PHN in the study. The approach was motivated by the specific study 
objective; that is to identify risk factors for PHN. A definition which prioritised high specificity 
(correctly identifying those without the disease) rather than high sensitivity (correctly 
identifying those with the disease) was required to reduce the chance of type I error (incorrect 
rejection of a true null hypothesis);103 in other words, reporting spurious associations by 
rejecting the null hypothesis when it is actually true.  
 
Underlying definition of PHN 
The underlying definition of PHN on which the algorithm was based was pain persisting for at 
least 90 days following zoster. Patients were assumed to have PHN at 90 days following zoster, 
even where evidence of PHN was, say, 180 days after zoster. 
 
Exclusions 
As anticonvulsant prescriptions were to form part of the PHN algorithm (described in detail 
below), patients with other indications for anticonvulsants (e.g. epilepsy) recorded pre-zoster 
were excluded. Also excluded were patients without 365 days follow-up after zoster diagnosis; 
as the definition would use data within 365 days from zoster diagnosis, it would not be 
possible to know whether individuals censored before 365 days without PHN met the PHN 
definition. 
 
Identifying zoster patients with and without PHN 
The case definition of PHN was categorised into three groups; diagnosed, probable and 
possible. 
 Diagnosed PHN: a PHN code 90-365 days following zoster within either; a) the clinical 
or referral files in CPRD or b) a primary diagnosis field within any episode of HES for 
linked patients.  
 Probable PHN: a first ever non-specific neuralgia code 90-365 days following zoster in 
CPRD; or an additional zoster code 90-365 days following zoster with a drug 
prescription for an anticonvulsant, tricyclic antidepressant, capsaicin cream or 
lidocaine patch (see Table 3 below for drug descriptions) on the same day in CPRD.  
 
Due to an unrealistically low number of PHN cases being ascertained using the above criteria 
(n=3110/119,413; 2.6% of zoster patients) drug prescription data were utilized further. As GPs 
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in UK primary care are not required to record the indication for every prescription, it is 
plausible patients are prescribed medications for PHN, without the diagnosis being recorded.  
The PHN medications searched for and their indications are described in Table 3. To increase 
the likelihood of the medication being prescribed for PHN, “new” prescriptions were searched 
for, defined as no previous prescriptions of the same medication type 12 months to two weeks 
prior to zoster (medications may have been prescribed for pain management two weeks prior 





Table 3. Medications used to treat PHN 
Medication type Specific drugs Indications¹ 
Mild Painkillers Paracetamol Mild to moderate pain 
 Ibuprofen 
 Aspirin 
   
Strong painkillers Codeine Mild to moderate pain, diarrhoea, cough 
suppression.  Dihydrocodeine  
 Dextropropoxyphene 
 Tramadol tablets or injection Moderate to severe pain 
   
Tricyclic antidepressants Amitriptyline Depressive illness, neuropathic pain, chronic 




   
Anticonvulsants Pregabalin Seizures, peripheral neuropathic pain and 






   
Other Lidocaine patches No other indications 
 Capsaicin cream 0.075% No other indications 
¹According to BNF 2014 
Note on selection of medications: Mild painkillers included paracetamol as indicated for PHN in the Clinical Knowledge 
Summaries, and other commonly used painkillers ibuprofen and aspirin were additionally included. Stronger painkillers included 
codeine and tramadol, as indicated in the Clinical Knowledge Summaries, as well as dihydrocodeine and dextropropoxyphene 
which are indicated for treatment of neuropathic pain in the UK. Although other painkillers such as morphine and oxycodone can 
be used for neuropathic pain treatment, their use is not recommended for treating neuropathic pain in primary care98.  
Amitriptyline is clinically the most widely used tricyclic antidepressant for treatment of PHN yet nortriptyline, protriptyline, 
imipramine, desipramine were also included as they are occasionally used. Pregabalin and gabapentin are the most commonly 
used anticonvulsants in PHN treatment, yet others also indicated for PHN were included.  Finally capsaicin cream 0.075% and 
lidocaine patch 5% were included, given specifically for PHN. 
 
Medications appearing 90-180 days (rather than 90-365 days) were considered to further 
reduce misclassification of PHN. To get a sense of whether a PHN-medication was likely to 
have been given for PHN, or another condition, the expected number of “new” PHN-related 
prescriptions in similar patients without recent zoster was estimated. This was achieved by 
comparing the prescription patterns among the study cohort with age, sex and practice 
matched patients without zoster (using controls from the case-control study described in 
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Chapter 4 assessing risk factors for zoster). After applying the same exclusion criteria to the 
non-zoster controls as with the zoster cases (at least 365 days follow-up from their index date, 
no neuropathic pain syndromes or epilepsy prior to index date) and randomly selecting 1 
control per zoster patient (see Table 4).  
 
Table 4: Proportion of patients within the zoster cohort, and a similar non-zoster population, 
receiving a “new” PHN medication 90-180 days following zoster diagnosis 
PHN medication % of zoster study cohort 
(N= 117,815) 
% of similar non-zoster sample 
(N= 117,815) 
Anticonvulsants 1.65 0.25 
Tricyclic antidepressants 2.84 0.69 
Lidocaine patches  0.09 0.01 
Capsaicin cream  0.25  <0.01 
Strong painkillers 4.42 2.98 
Mild Painkillers 2.51 2.05 
Note: 1,598 patients from the study cohort had no matched control after exclusion criteria were applied 
 
Table 4 demonstrates that “new” anticonvulsants, antidepressants, lidocaine patches and 
capsaicin creams were much more common among the zoster cohort than amongst controls. 
Patients with zoster had a slightly higher use of strong painkillers.  On the basis of this 
evidence strong painkillers were not included in the definition of probable PHN, but instead 
possible PHN. Due to the comparable use of mild painkillers within the zoster and non-zoster 
samples, these medications were not used to identify further PHN patients.   On browsing the 
clinical and therapeutic records of a selection of patients, two further criteria were added: 
 
 Further probable PHN; patients with a “new” PHN drug prescription for an 
anticonvulsant, capsaicin cream or lidocaine patch 90-180 days following zoster; 
patients with a ”new” tricyclic antidepressant 90-180 days following zoster with two 
additional criteria (to reduce misclassification of PHN, particularly with depression): 
firstly, no clinical diagnoses suggesting non-PHN indications on the same day as the 
tricyclic prescription [that is, any Read codes suggesting depressive diagnosis 
(symptoms of depression, such as “Crying all the time” or life-events with the potential 
to precipitate depression, such as divorce), a pain that may be chronic, or a need for 
migraine prophylaxis], as well as additional evidence of the drug being prescribed for 
zoster or PHN previously (in other words, a tricyclic antidepressant prescription 0-89 





To capture other “possible” PHN patients, these criteria were added; 
 
 Possible PHN: patients with a “new” tricyclic antidepressant prescription 90-180 days 
following zoster with no clinical diagnoses suggesting non-PHN indications on the same 
day as the tricyclic prescription (without additional evidence of the drug being 
prescribed for zoster or PHN 0-89 days after zoster); patients with a “new” strong 
painkiller 90-180 days following zoster with no clinical diagnoses suggesting non-PHN 
indications on the same day as the strong painkiller prescription (that is, any Read 
codes suggesting the presence of pain, diarrhoea, or cough) as well as additional 
evidence of the drug being prescribed for zoster or PHN previously (a strong pain killer 
prescription 0-89 days following zoster, with a zoster/PHN code on the same day); or 
patients with a neuropathic pain code 90-365 days following zoster.  
 
The use of pain and symptom codes to diagnose PHN (e.g. “Chest pain”, “Burning pain” or “Has 
tingling sensation”) as well as referrals to pain clinics/specialists was considered; however their 
lack of specificity may have led to a number of false positive PHN cases. Finally, utilising 
information on the dosage of tricyclic antidepressant prescriptions was explored; when these 
drugs are given for neuropathic pain, patients are started on a low dose and graduated to a 
higher dose (compared to their use in patients with depression, who are more typically started 
on a high dose).  Unfortunately the dosage information in the CPRD doesn’t sufficiently 
capture information on graduated dose; therefore it was not possible to incorporate this into 
the definition.  
 





Table 5: PHN definition used in this thesis 
PHN classification 
Diagnosed PHN PHN code* (90-365 days post-zoster) 
  
Probable PHN Zoster code and prescription consistent with PHN• on same day (90-365 days post-
zoster) 
 Non-specific neuralgia code (90-365 days post-zoster) 
 NEW anticonvulsant or capsaicin cream or lidocaine patch prescription  (90-180 days 
post-zoster) 
 NEW tricyclic antidepressants 90-180 days post-zoster with no other indication on the 
day of the prescription, plus evidence of the drug being prescribed for zoster or PHN 
previously† 
  
Possible PHN NEW tricyclic antidepressants 90-180 days post-zoster with no other indication on the 
day of the prescription 
 NEW strong painkiller 90-180 days following zoster with no other indication on the day 
of the prescription, plus evidence of the drug being prescribed for zoster or PHN 
previously† 
 Non-specific neuropathic pain code (90-365 days post-zoster) 
PHN: Postherpetic neuralgia.*Read code for PHN in CPRD or (for those with linked data) an ICD10 PHN code in the primary 
diagnosis field within any episode of linked HES. •Prescriptions included anticonvulsants, tricyclic antidepressants, capsaicin cream 
or lidocaine patch.  
NEW prescriptions were defined as no previous prescriptions of the same medication type 12 months to two weeks prior to 
zoster, to increase the likelihood of the medication being prescribed for PHN (medications may have been prescribed for pain 
management two weeks pre-zoster, if zoster initially presented without a rash). †Here, previously is defined as a prescription 0-89 
days following zoster.  
Medications indicative of zoster were only considered in the 90-180 day period after zoster diagnosis (rather than 90-365 days) to 




3.4.   Potential explanatory variables 
 
Various other potential explanatory variables were defined for this thesis, including severe 
immunosuppressive conditions, autoimmune conditions, other comorbidities, demographic 
characteristics, lifestyle data and finally characteristics of the zoster episode. Below are 
detailed notes on how these variables were identified in CPRD records. HES data were not 
utilised to identify the medical conditions, as they are chronic, rather than acute conditions, 
and were thus assumed to be recorded in primary care records.  All code lists are given in 
appendix V. 
 
 Severely immunosuppressive conditions 
Severely immunosuppressive conditions were determined by the zoster vaccine 
contraindications set out by the Advisory Committee on Immunization Practices (ACIP), a 
group of medical and public health experts that develop recommendations on how to use 
vaccines in the US.104  As the currently available zoster vaccine is a live vaccine, patients with 
primary or acquired immunodeficiency are assumed to be at risk of developing a varicella-like 
or zoster illness from the vaccine virus strain, if vaccinated. Therefore the contraindications 
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provide a list of conditions considered to result in severe immunosuppression.  These 
contraindications are very similar to those set out in the UK’s counterpart vaccine guidelines, 
the Green Book.41  
 
The definition of severely immunosuppressive conditions used throughout this thesis therefore 
included a recent history (less than two years before the zoster diagnosis) of leukaemia or 
lymphoma, or any history of HIV, hematopoietic stem cell transplantation, myeloma or ‘other 
unspecified cellular immune deficiencies’ (e.g. pancytopenia). These diagnoses were all 
identified through the presence of Read codes in CPRDs clinical and referral files. 
 
 Immunosuppressive therapies 
3.4.2.1. Corticosteroids 
Definition 
Two definitions of oral corticosteroid exposure were used: 1) a high-dose (≥20 milligrams 
(mg)/day), 14-day or longer course, in the month prior to zoster diagnosis (in keeping with the 
ACIP guidelines for zoster vaccine contraindications104); and 2) any dose of oral corticosteroids 
in three months prior to zoster diagnosis.  
 
To identify high-dose prescriptions of 14 days or more in CPRD required some data cleaning. 
Below is some background information on how prescription data are collected in CPRD, how 
these data were cleaned, how prescription duration and prescription dose were calculated and 
finally, how missing data were handled. 
 
Background on prescription data in CPRD 
CPRD does not provide researchers with duration and dose for individual prescriptions. 
Instead, these must be generated using information from other variables.  
 
Prescribing GPs select the drug, enter information on the prescription and can also enter free 
text.  The drug name itself contains the dose in milligrams per tablet and the GP enters the 
total number of tablets to be prescribed, within in a field called quantity. The free text field 
contains the actual prescribing information; in other words how many tablets the patient 
should take each day, known as the numeric daily dose. Examples include, “take one daily” and 
“take one twice a day”. To utilize this information, CPRD developed an algorithm to derive 




Data cleaning on oral corticosteroid prescriptions 
A series of data-checking and data-cleaning tasks were carried out on oral corticosteroid 
prescriptions, including;  
 Checking commonly occurring free texts; 500 of the most commonly used free texts 
were compared to the numeric daily dose for accuracy and 150 of the most commonly 
occurring free texts where numeric daily dose equalled zero were checked for 
accuracy. This approach captured over 90% of all prescriptions. Very few errors were 
found when checking the most commonly used free text against the numeric daily 
dose. 
 The clinical and referral records for 20 randomly selected patients were browsed to 
verify that the duration and dose of the prescriptions were consistent with the 
diagnoses. For a single patient, consistency checks took on average 30 minutes, and 20 
patients records were selected for review. This analysis demonstrated that patients 
prescribed short-term high-dose courses of oral corticosteroids tended to have codes 
consistent with an acute illness, such as an exacerbation of COPD or asthma.  Longer 
term, lower doses were less easy to assign a reason for use.  
 Tapering dose; the possibility of identifying tapering doses of oral corticosteroid 
prescriptions was explored by searching for words in the free text implying tapering 
doses, specifically, “*reduc*”, *then*, *3*2*1*, *stop*. In total, 36 phrases were 
identified. However very few records had information about the actual reducing dose, 
therefore it was concluded that tapering doses could not be accurately identified. 
 Unlikely values for quantity and numeric daily dose were excluded; for oral 
corticosteroids, individual prescription quantities of >1000 tablets and numeric daily 
dose’s >40 were changed to missing. 
 
Dealing with missing data 
Although 99% of oral corticosteroid prescriptions had the quantity of tablets, as well as the 
dose of the tablets, data on numeric daily dose (required to calculate daily dose and duration 
of prescription) was missing for more than 30% of oral corticosteroid prescriptions. Steps were 
therefore taken to impute missing data for numeric daily dose. 
 
Where numeric daily dose was missing for oral corticosteroids, the majority of the texts were 
“as directed”. This suggests the dose may be uncommon.  Alternatively, it may be the same as 
58 
 
a previously prescribed dose. It was agreed that clinically the best predictor of numeric daily 
dose was likely to be a person’s previous prescriptions.  
 
Several approaches were considered to handle missing numeric daily dose data: 
1) Using the mode or median numeric daily dose: Most previous CPRD studies have used 
the mode or median numeric daily dose for oral corticosteroids where numeric daily 
dose is missing,106,107 however this approach does not fully utilise the information 
available in the data. 
2) Multiple imputation of numeric daily dose: This technique replaces each missing value 
with values representing the conditional distribution of the variable, based on 
observed data. These multiply imputed data sets are then individually analysed and 
the results are combined. In this instance, there were repeated measurements (i.e. 
several prescriptions), clustered within individual participants. This meant the data 
structure was multi-level.108 Dealing with clusters would be statistically complex and is 
not handled by standard multiple imputation software commands, therefore this 
technique was not pursued.  
3) An alternative multiple imputation approach was considered, whereby a single-
variable summary of "numeric daily dose at other times" could be generated, perhaps 
using “last numeric daily dose” or “closest numeric daily dose”. In this approach the 
data are no longer multi-level, therefore can be handled easily in STATA. The approach 
was taken in a recent paper by Fardet et al to impute daily dose.109  However, use of 
this technique would not predict numeric daily dose for patients who only had a single 
prescription with missing numeric daily dose. 
 
Another, computationally simpler, imputation approach called “Hot Decking” was instead used 
to address missing numeric daily dose. Hot Decking involves replacing missing data with 
observed data from a similar unit, or strata, for example patients of the same age and gender. 
The median numeric daily dose of the observed data, within the chosen strata, was used to 
replace missing numeric daily dose within that same strata. An algorithm was developed which 
reviewed each oral corticosteroid therapy record and imputed missing values, first where the 
strata were based on data within- persons, then where the strata were based on data from 
groups of patients.  See Figure 3 for specific details. 
 
Calculating duration and dose of oral corticosteroid prescriptions 
Having cleaned the relevant variables and imputed missing data using the “hot decking” 
approach (see Figure 3), first the duration and dose of individual prescriptions were identified, 
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then, if patients had a series of prescriptions within a certain timeframe, continuous periods of 
use were defined. 
 
The duration and daily dose of oral corticosteroid prescriptions were calculated as follows:  
Duration = quantity ÷ numeric daily dose 
  Daily dose = dose per tablet x numeric daily dose 
 
 
3.4.2.2. Inhaled corticosteroids 
Definition 
Inhaled corticosteroid (ICS) use 3 months prior to zoster diagnosis was identified.  Prescriptions 
of any dose were included, as discrepancies are likely between the prescription and actual 
adherence, potentially making any calculated dose unreliable. 
 
Background and data cleaning 
Numeric daily dose for ICS represents the number of puffs a patient is directed to take on the 
inhaler per day. The variable “pack type” largely provided the number of puffs per inhaler, and 
the quantity variable represented the number of inhalers.  Implausible values for ICS were 
identified; quantities > 4 (99% of ICS prescriptions had a quantity 1-4) were changed to the 
median value of one and numeric daily doses >40 (in other words, more than 40 puffs per day, 
as this was deemed a clinically plausible upper threshold) were changed to missing. 
 
Missing data 
Missing data for ICS were dealt with as follows; 
- Missing pack type: the most common pack type for the quantity and dose of each 
prescription, or if not available the median pack type value for all prescriptions of 200 
was used. 
- Missing numeric daily dose: the median value of 4 puffs per day was used. 
- Missing quantity: the median value of 1 was used. 
 
Calculating duration of inhaled corticosteroid prescriptions 
Duration of individual inhaled corticosteroid prescriptions were calculated as follows:  




Figure 3: Flow chart describing the “hot decking” imputation method used to impute missing 
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3.4.2.3. Other immunosuppressive therapies 
In addition to corticosteroids, there are a number of other drugs which can cause 
immunosuppression, including: chemotherapy drugs such as antimetabolites, anthracyclines 




The primary definition of these “other immunosuppressive therapies” was any use in the 
month prior to zoster diagnosis. An alternative definition was also coded; which comprised any 
use in the three months prior to zoster diagnosis.  
 
Data cleaning and imputing missing data 
Where the variable quantity (total number of tablets prescribed) had a value of >1000 tablets, 
quantity was coded to missing. As with oral corticosteroid prescriptions, quantity was 99% 
complete and numeric daily dose had around 30% missing data. The hot-deck method was 
used to impute missing numeric daily dose, in the exact same way as for imputing numeric 
daily dose for oral corticosteroids (see Figure 3); the only difference being the binary quantity 
variable that was created used the median value 36 tablets (rather than 42 tablets).  
 
Calculating duration of other immunosuppressive therapies 
Duration was calculated as follows:  
Quantity ÷ numeric daily dose 
 
 Autoimmune conditions 
Three autoimmune conditions were defined: RA, SLE, and IBD.  These disorders were defined 
through the presence of a Read code in CPRD any time prior to the zoster diagnosis.  
 
 Other clinical conditions 
3.4.4.1. Diabetes 
The diabetes definition required either: a definite diabetes diagnosis identified by Read codes 
in the CPRD clinical or referral files; or a possible diabetes Read code [e.g. self- monitoring of 
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blood glucose] with a subsequent diabetes-specific prescription [insulin or oral anti-diabetics]; 
or ≥2 diabetes drug prescriptions prior to the zoster diagnosis. Gestational diabetes and drug-
induced diabetes were excluded as these are usually temporary, rather than chronic 
conditions.  
 
Patients were categorised as type 1 or type 2 diabetes where possible. Distinguishing between 
type 1 and type 2 diabetes is not always possible using diabetes codes as patients are 
frequently given a non-specific code. Furthermore, where type of diabetes is assigned within a 
Read code, it has been found to be unreliable.111 Therefore Read code data for type 1 and type 
2 diabetes were not used, but instead age at first diagnosis, age at first treatment and, finally, 
treatment received was used to classify diabetes type, as in previous CPRD studies.112,113  
 
Type 1 diabetes was assigned where: 
- age at first diagnosis was ≤35 years and treatment ever was exclusively insulin; or  
- patients received at least two insulin prescriptions ≤35 years, but had no diabetes 
diagnosis. 
 
Type 2 diabetes was assigned where:  
- age at first diabetes diagnosis was >35; or 
- patients received exclusively oral anti-diabetics after 35 years of age. 
 
Patients with age at diagnoses >35, but treated exclusively with insulin or any others not fitting 
into these categories were assigned as “Unknown type”.  
 
 
3.4.4.2. Chronic obstructive pulmonary disorder 
COPD patients were defined as anyone with a Read code for COPD prior to zoster diagnosis 
and aged ≥35 years at the time of diagnosis. Diagnostic READ codes used to identify COPD 
included chronic bronchitis, emphysema, chronic obstructive airways disease and chronic 
airflow limitation.114  
 
Previous studies of COPD patients in UK primary care databases have used diagnostic codes or 
diagnostic codes115-118 along with prescription data, for example having a minimum number of 
treatments following COPD diagnosis.119  In this study, prescription data were not included 
because: 1) patients with mild COPD may not receive treatment (despite guidelines suggesting 
all COPD patients are given bronchodilators); 2) patients may be receiving treatment in 
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secondary care; 3) treatment is non-specific to COPD; prednisolone, the oral corticosteroid 
most commonly used in COPD treatment, is also used in other inflammatory and allergic 
disorders such as RA, asthma and IBD; bronchodilators and ICS are used in asthma treatment 
and other respiratory diseases; and finally 4) a recent validation study in CPRD of COPD 
diagnoses, concluded that use of COPD Read codes alone is sufficient to identify COPD 
patients.120 Using medication in the definition of COPD does not appreciably improve the 
accuracy of the diagnoses.  
 
The use of spirometry data were also considered, however, the above mentioned validation 




Although asthma can be chronic, patients may not continuously experience symptoms. 
Therefore it was decided to identify patients who were likely to have “active” asthma at the 
time of zoster diagnosis. Patients were considered to have “active” asthma if they had an 
asthma diagnosis prior to zoster diagnosis and additionally an asthma-related prescription 
within the 12 months prior to the zoster diagnosis.  This definition matches the criteria 
required to be on the asthma register in the UK.121 Patients with a COPD diagnosis ever in their 
medical history were also unable to be defined as asthma patients; differentiating between 
these two conditions is challenging and this criteria helped exclude COPD patients 
misdiagnosed as asthma. Asthma related prescriptions included the following respiratory 
drugs; short and long-acting beta-2 agonists and short and long-acting antimuscarinics, ICS, 
cromoglycates and nedocromil, theophyllines, leukotriene receptor agonists and omalizumab.  
 
3.4.4.4. Chronic Kidney Disease 
CKD was defined as any patient with a clinical diagnosis of mild, moderate or severe CKD, or 
evidence of having received kidney dialysis, any time prior to zoster diagnosis. CKD diagnosis is 
mostly based on serum creatinine tests which can be used to obtain the glomerular filtration 
rate (how much blood passes through the kidneys each minute), and estimate the stage of 
kidney disease.  However, these tests were not included in the definition of CKD as certain 
groups, such as elderly patients with diabetes, may be more likely to be tested, potentially 





As depression tends to occur in episodes, the aim was to identify recent depression.  In this 
study, depression was defined as any patient with a Read code within one year prior to the 
zoster diagnosis for new onset or current symptomatic depression. Read codes for both 
diagnoses and symptoms were included. Symptoms were included, in addition to diagnoses, 
due to the trend post-2004 of using symptom, rather than diagnosis codes, in UK primary 
care.122  Antidepressants were not used in the definition of depression as these drugs are used 
in a wide range of other disorders, including the management of chronic pain and stroke 
recovery.  
 
 Demographic factors 
 
3.4.5.1. Age 
All “acceptable” patients in CPRD have a year of birth, and some patients born after 1990 have 
a month of birth.  Where month of birth was missing, July was used, and all patients were 
allocated a birth date of the 1st of the month, as day of birth is not available.  
 
3.4.5.2. Gender 
Gender is provided in CPRD and there was no missing information for gender.  Patients with 
indeterminate gender were excluded (in the January 2012 CPRD build, 0.0001% were 
indeterminate gender).  
 
3.4.5.3. Socioeconomic status 
Socioeconomic status (SES) was analysed using quintiles of the Index of Multiple Deprivation 
(IMD) score. The IMD combines a number of indicators, chosen to cover a range of economic, 
social and housing issues, into a single deprivation score.123,124 IMD is available at the practice 
and patient level.  The practice postcode or patient's home postcode is mapped at the lower 
level super output level to the corresponding IMD score; a low quintile represents the least 
deprived, while a higher quintile the most deprived. Patient level IMD data are available for 
patients registered at English practices agreeing to link medical records with other databases 
and who have a valid and linkable postcode in their medical records. The papers on zoster risk 
factors (chapter 4) and antiviral use (chapter 5) used the IMD dataset released in 2007, whilst 
the paper on PHN risk factors (chapter 7) used the IMD dataset released in 2010. Practice level 
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IMD was available for all practices within the IMD 2010 dataset, whereas only for English 
patients in the IMD 2007 dataset.  
 
 Lifestyle data 
 
3.4.6.1. Smoking status 
Smoking was defined at zoster diagnosis using three categories; non-smoker, current smoker 
and ex-smoker. Data were derived from: 1) medical Read codes such as “tobacco dependence 
in remission” and “stopped smoking”; and 2) data from structured data fields in the additional 
details file, specifically entity type number four records information on smoking, including the 
patients smoking “status” (yes, no or ex) and the “number of cigarettes per day” smoked. 
These data were extracted for each patient along with the date the status was assigned.   
 
Smoking status was then classified by the algorithm shown in Figure 4. 
 






3.4.6.2. BMI category 
BMI is a metric used to classify people as under- or overweight. It is derived from patients 
weight in kilograms / (height in meters)². In this study BMI was defined at zoster diagnosis, 
according to adult BMI cut-offs defined by the WHO, as underweight (BMI <18.5), healthy 
weight (BMI 18.5-24.9), overweight (BMI 25+) or obese (BMI ≥30).   
 
Height and weight are recorded opportunistically in UK primary care and are contained in the 
CPRD additional details files, in entity types 104 and 140. Data cleaning was based on that 
described in the paper by Bhaskaran et al on BMI recordings in CPRD.125 Any records taken 












First choice Second choice Third choiceThird choice Fourth choice 
Fourth choice Third choice 
Note: the nearest record to the index date from the first choice period was taken if available, otherwise from 
the second choice period and so on. If patients had any evidence of smoking or alcohol prior to zoster diagnosis, 




Implausible values were excluded, specifically height records <4 and >7 foot were dropped, 
and weight records <20 kilograms were dropped. For each weight record, a BMI was calculated 
using first, height recorded on that day, otherwise, last observation of height, or if no previous 
height records were available, then first future height.  
 
BMI status was then classified by the algorithm shown in Figure 4. 
 
Read codes exist classifying patients by BMI category, however they are very rarely used 
(around 3% of patients have a clinical code that would enable classification into WHO BMI 
categories),125 therefore Read codes were not incorporated into the definition of BMI.  
 
3.4.6.3. Alcohol use 
Alcohol use was defined at zoster diagnosis and classified as non-drinker, ex-drinker, or current 
drinker using: 1) medical Read codes, such as “alcohol problem drinking”; and 2) data from 
structured data fields in the additional details file, specifically entity type 5 records data on 
alcohol use, including the patients alcohol “status” (yes, no or ex) and the number of alcohol 
“units per week” consumed.  
 
Alcohol status was then classified by the algorithm shown in Figure 4. 
  
 Characteristics of the acute zoster episode 
 
3.4.7.1. Antiviral use during acute zoster episode 
Antiviral medications are recommended for all immunosuppressed and some 
immunocompetent patients following zoster diagnosis. Guidelines specify they must be given 
within seven days of a zoster diagnosis.126 Therefore antiviral medications given up to a week 
following zoster diagnosis were identified from CPRD therapy records.  Three different 
antivirals were searched for; aciclovir, famciclovir and valaciclovir.3 If zoster patients had two 
different antivirals prescribed on the same day, this was recorded.  
 
3.4.7.2. Site of zoster 
The site of zoster is not routinely recorded in CPRD or HES.  However, some Read and ICD 
codes which identify zoster also contain the location of zoster, for example, “Herpes zoster 
with ophthalmic complication”. The level of detail contained in the diagnostic codes allowed 
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zoster patients to be categorised as, “ophthalmic zoster”, “non-truncal zoster” or “site 
unspecified”.  
 
As patients may have more than one interaction with their GP or hospital regarding their 
zoster episode, particularly for complicated zoster involving the eye, all zoster codes in the 
year following the first zoster diagnosis were extracted from CPRD and HES, and their site 
determined. Site was then assigned in order of priority; ophthalmic, non-truncal and finally site 
unspecified.   
 
In the study of PHN risk factors (described in chapter 7) ophthalmic zoster was identified 
through a revised algorithm, to improve identification of ophthalmic zoster. In a US study of an 
administrative data source (specifically, all adult residents of Olmsted County, Minnesota, aged 
≥22 years seeking medical care for zoster between 1996 and 2001) just 10% of patients whose 
full medical records reported zoster affecting the eye, also had an ICD-9 code indicating an 
ophthalmic complication.  In the study described in chapter 7, ophthalmic zoster was therefore 
additionally defined as patients with non-specific zoster, plus a diagnosis of, or treatment for, 
acute eye infection (such as keratitis or conjunctivitis) within 2 weeks of zoster onset or from 
records of first-ever specific chronic eye conditions known to be associated with zoster (such 
as, conjunctival scarring or episcleritis), within 3 months after zoster onset. This was in line 









Data sources and variable definitions 
 This study utilises data from a UK primary care database called CPRD, which 
holds data on over 12 million patients and is largely representative of the UK 
population. The study also uses a linked secondary care database called HES, 
which holds data on all hospital admissions throughout England. 
 Zoster was defined through the presence of Read codes in CPRD and ICD-10 
codes in HES. 
 PHN was defined as pain for at least 90 days following zoster diagnosis, and 
identified through the presence of diagnosis codes in CPRD and HES, along 
with prescription data in CPRD.  
 The other explanatory variables utilised in this thesis were identified from data 
in CPRD, and included: severely immunosuppressive conditions, 
immunosuppressive therapies, autoimmune conditions (RA, SLE and IBD), 
other clinical conditions (diabetes, COPD, asthma, CKD and depression), 
demographic factors (age, gender and SES), lifestyle data (BMI category, 
smoking and alcohol use) and characteristics of the acute zoster episode 





Chapter 4:   Quantification of risk 
factors for zoster: population based 
case-control study 
 
4.1.   Introduction 
Understanding the risk factors for zoster is important when planning vaccination campaigns.  A 
large case-control study was therefore carried out to quantify the effects of various proposed 
risk factors for zoster and explore whether their effects differed by age group. Such 
investigations may help to identify any groups of patients at high risk of zoster, who are not 
currently targeted for vaccination.  
 
This research, which was published in the British Medical Journal, is presented below, along 
with its published appendices which were too detailed for the main paper.  The paper is 
followed with some additional information on: 1) how controls were selected in this study; 2) 
the relative risk of zoster according to smoking, BMI and alcohol status; and 3) additional 
biological evidence indicating impaired cell-mediated immunity, associated with the risk 
factors of interest. 
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\RXQJHU DJH JURXSV &XUUHQW YDFFLQHV DUH FRQWUDLQGLFDWHG LQ SHRSOH DW
WKH JUHDWHVW ULVN RI ]RVWHU KLJKOLJKWLQJ WKH QHHG IRU DOWHUQDWLYH ULVN
UHGXFWLRQ VWUDWHJLHV LQ WKHVH JURXSV
Introduction
+HUSHV ]RVWHU FRPPRQO\ NQRZQ DV VKLQJOHV LV FDXVHG E\ WKH
UHDFWLYDWLRQ RI ODWHQW YDULFHOOD ]RVWHU YLUXV ZKHQ VSHFLILF FHOO
PHGLDWHG LPPXQLW\ EHFRPHV FRPSURPLVHG ,W LV D FRPPRQ
GLVHDVH LQ ROGHU SHRSOH ZLWK D OLIHWLPH ULVN RI XS WR  ULVLQJ
WR  DPRQJ WKRVH OLYLQJ WR  \HDUV =RVWHU W\SLFDOO\ SUHVHQWV
DV D SDLQIXO XQLODWHUDO YHVLFXODU GHUPDWRPDO UDVK WKDW FDXVHV
DFXWH PRUELGLW\ ODVWLQJ WZR WR IRXU ZHHNV $ VHYHUH
FRPSOLFDWLRQ࣓SRVWKHUSHWLF QHXUDOJLD࣓DOWKRXJK XQFRPPRQ
LQ SDWLHQWV DJHG XQGHU  GHYHORSV LQ  RI ]RVWHU SDWLHQWV
DJHG  \HDUV RU RYHU  LW FDXVHV LQWHQVH SDLQ WKDW FDQ ODVW IURP
PRQWKV WR \HDUV DQG LV DVVRFLDWHG ZLWK FRQVLGHUDEOH LPSDLUPHQW
RI TXDOLW\ RI OLIH
$ OLYH YDFFLQH WKDW UHGXFHV WKH ULVN RI ]RVWHU DQG SRVWKHUSHWLF
QHXUDOJLD KDV UHFHQWO\ EHHQ GHYHORSHG 7KH YDFFLQH LV OLFHQVHG
LQ SHRRSOH DJHG RYHU  \HDUV ,Q WKH 8QLWHG 6WDWHV DQG
$XVWUDOLD LW LV UHFRPPHQGHG LQ SHRSOH DJHG  \HDUV RU RYHU
,Q WKH 8QLWHG .LQJGRP LW LV URXWLQHO\ DYDLODEOH IRU SDWLHQWV
DJHG  ZLWK D FDWFKXS FDPSDLJQ IRU  \HDU ROGV RQ WKH
EDVLV RI FRVW HIIHFWLYHQHVV VWXGLHV WKH FXUUHQW FDWFKXS FRKRUW
LV WKRVH DJHG  7DEOH দ VKRZV VRPH H[DPSOHV RI
UHFRPPHGDWLRQV RQ YDFFLQDWLRQ LQPDMRU FRXQWULHV $V WKH ]RVWHU
YDFFLQH LV H[SHQVLYH WDUJHWLQJ YDFFLQDWLRQ WRZDUGV JURXSV DW
KLJK ULVN RI ]RVWHU LV QHFHVVDU\ $JH LV WKH PRVW LPSRUWDQW ULVN
IDFWRU IRU ]RVWHU DQG SRVWKHUSHWLF QHXUDOJLD VR LW GULYHV
YDFFLQDWLRQ SROLFLHV 7KH LQFLGHQFH RI ]RVWHU ULVHV IURP  SHU
 SHUVRQ \HDUV DPRQJ  \HDU ROGV WR  SHU  SHUVRQ
\HDUV DPRQJ  \HDU ROGV LQ WKH 8. +RZHYHU ZKHWKHU
SHRSOH ZLWK RWKHU ULVN IDFWRUV SDUWLFXDUO\ LQ \RXQJHU DJH JURXSV
PLJKW DOVR EHQHILW IURP YDFFLQDWLRQ LV QRW FOHDU
6HYHUDO FOLQLFDO FRQGLWLRQV QRW OLVWHG DV FRQWUDLQGLFDWLRQV IRU
WKH ]RVWHU YDFFLQH KDYH EHHQ DVVRFLDWHG LQ VRPH VWXGLHV ZLWK
DQ LQFUHDVHG ULVN RI ]RVWHU WKHVH LQFOXGH DXWRLPPXQH FRQGLWLRQV
VXFK DV UKHXPDWRLG DUWKULWLV V\VWHPLF OXSXV HU\WKHPDWRVXV
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DQG LQIODPPDWRU\ ERZHO GLVHDVH DQG FKURQLF FRQGLWLRQV VXFK
DV GLDEHWHV PHOOLWXV  FKURQLF REVWUXFWLYH SXOPRQDU\
GLVHDVH  FKURQLF NLGQH\ GLVHDVH DVWKPD DQG
GHSUHVVLRQ  /DUJH DGHTXDWHO\ SRZHUHG VWXGLHV LQYHVWLJDWLQJ
WKH DVVRFLDWLRQ RI WKHVH FRQGLWLRQV ZLWK ]RVWHU DUH ODFNLQJ
7KLV VWXG\ WKHUHIRUH DLPHG WR TXDQWLI\ WKH HIIHFWV RI YDULRXV
SURSRVHG ULVN IDFWRUV IRU ]RVWHU DQG H[SORUH ZKHWKHU WKHLU HIIHFWV
GLIIHU E\ DJH JURXS WR KHOS WR LGHQWLI\ DQ\ JURXSV RI SDWLHQWV
DW KLJK ULVN ZKR DUH QRW FXUUHQWO\ WDUJHWHG IRU YDFFLQDWLRQ :H
DLPHG WR DGG WR WKH H[LVWLQJ OLWHUDWXUH E\ XVLQJ D YHU\ ODUJH GDWD
VRXUFH DQG D FRQVLVWHQW PHWKRGRORJLFDO DSSURDFK WR KHOS
FRPSDULVRQ EHWZHHQ YDULRXV ULVN IDFWRUV
Methods
:H GLG D PDWFKHG FDVHFRQWURO VWXG\ WR TXDQWLI\ WKH HIIHFWV RI
D UDQJH RI LQGLYLGXDO OHYHO IDFWRUV RQ WKH ULVN RI ]RVWHU LQ D
JHQHUDO SRSXODWLRQ
Data source
7KLV VWXG\ XVHG GDWD IURP WKH 8. &OLQLFDO 3UDFWLFH 5HVHDUFK
'DWDOLQN D SULPDU\ FDUH GDWDEDVH RI DQRQ\PLVHG SDWLHQWVࣕ
UHFRUGV FRQWDLQLQJ FRPSOHWH SUHVFULELQJ DQG GLDJQRVWLF
LQIRUPDWLRQ DQG IHHGEDFN IURP KRVSLWDO UHIHUUDOV &OLQLFDO
GLDJQRVHV DUH FRGHG LQ WKH &OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN
ZLWK 5HDG FRGHV ,W LV RQH RI WKH ODUJHVW VRXUFHV RI FRQWLQXRXV
SDWLHQWVࣕ UHFRUGV LQ WKH ZRUOG FRQWDLQLQJ GDWD RQ DSSUR[LPDWHO\
 RI WKH 8. SRSXODWLRQ DQG LV EURDGO\ UHSUHVHQWDWLYH RI
SDWLHQWVࣕ DQG SUDFWLFHVࣕ FKDUDFWHULVWLFV LQ WKH 8. 6L[W\ SHU
FHQW RI SDWLHQWV LQ WKH &OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN KDYH
GDWD DYDLODEOH LQ WKH +RVSLWDO (SLVRGH 6WDWLVWLFV GDWDEDVH ZKLFK
LV D OLQNHG FRPSXWHULVHG GDWDEDVH RI KRVSLWDO DWWHQGDQFHV LQ
(QJODQG IURP 
Selection of cases
7KH EDVH VWXG\ SRSXODWLRQ FRQVLVWHG RI DOO SDWLHQWV DJHG  \HDUV
RU RYHU XQGHU IROORZXS EHWZHHQ  -DQXDU\  DQG 
'HFHPEHU  ZLWK QR HYLGHQFH RI SUHYLRXV ]RVWHU QR FRGHV
IRU ]RVWHU RU SRVWKHUSHWLF QHXUDOJLD EHIRUH WKH VWDUW RI IROORZXS
:H LGHQWLILHG ]RVWHU FDVHV E\ XVLQJ WKH &OLQLFDO 3UDFWLFH
5HVHDUFK 'DWDOLQN DQG +RVSLWDO (SLVRGHV 6WDWLVWLFV &DVHV LQ
WKH &OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN ZHUH WKRVH ZLWK D ]RVWHU
5HDG FRGH DQG DW OHDVW  PRQWKVࣕ IROORZXS EHIRUH D ILUVW
GLDJQRVLV RI ]RVWHU WR H[FOXGH SDVW FDVHV RI ]RVWHU UHFRUGHG
UHWURVSHFWLYHO\ DIWHU UHJLVWUDWLRQ DW D JHQHUDO SUDFWLFH ,QFLGHQW
]RVWHU LQ +RVSLWDO (SLVRGHV 6WDWLVWLFV ZDV LGHQWLILHG E\ ,&'
LQWHUQDWLRQDO FODVVLILFDWLRQ RI GLVHDVHV WK UHYLVLRQ FRGHV
% % % % % % % * WKDW
DSSHDUHG LQ WKH SULPDU\ GLDJQRVLV ILHOG ZH H[FOXGHG SDWLHQWV
ZLWK WKHVH FRGHV UHFRUGHG LQ VHFRQGDU\ GLDJQRVLV ILHOGV DV WKLV
FRXOG UHIOHFW HLWKHU LQFLGHQW ]RVWHU RU VHTXHODH RI SDVW ]RVWHU
)RU FDVHV LGHQWLILHG LQ +RVSLWDO (SLVRGHV 6WDWLVWLFV ZH WRRN WKH
GDWH RI KRVSLWDO DGPLVVLRQ DV WKH LQGH[ GDWH ,I ]RVWHU ZDV
LGHQWLILHG LQ ERWK +RVSLWDO (SLVRGHV 6WDWLVWLFV DQG WKH &OLQLFDO
3UDFWLFH 5HVHDUFK 'DWDOLQN ZH WRRN WKH HDUOLHVW UHFRUGHG ]RVWHU
GLDJQRVLV DV WKH LQGH[ GDWH
Selection of controls
:H LGHQWLILHG DOO SRWHQWLDO FRQWUROV IRU HDFK FDVH DQG XVHG
LQFLGHQFH GHQVLW\ VDPSOLQJ WR VHOHFW XS WR IRXU FRQWUROV SHU FDVH
DW UDQGRP &RQWUROV ZHUH UHJLVWHUHG ZLWK WKH SUDFWLFH DW WKH
LQGH[ GDWH RI WKH FDVH DQG IRU DW OHDVW  PRQWKV EHIRUH DQG
ZHUH PDWFKHG WR FDVHV E\ SUDFWLFH VH[ DQG DJH ZLWKLQ  \HDU
:H VHOHFWHG FRQWUROV EHIRUH WKHLU H[SRVXUH VWDWXV IRU RWKHU ULVN
IDFWRUV ZDV NQRZQ %\ PDWFKLQJ RQ SUDFWLFH ZH FRQWUROOHG IRU
SUDFWLFH OHYHO VRFLRHFRQRPLF VWDWXV &RQWUROV WRRN WKH LQGH[
GDWH RI WKHLU PDWFKHG FDVH &RQWUROV KDG QR KLVWRU\ RI ]RVWHU RU
SRVWKHUSHWLF QHXUDOJLD DW WKH LQGH[ GDWH EXW WKH\ FRXOG JR RQ
WR KDYH ]RVWHU DQG WKHUHIRUH DOVR EH LQFOXGHG DV D FDVH &RQWUROV
ZLWK QR FRQWDFW ZLWK WKHLU SUDFWLFH WKDW LV QR FRQVXOWDWLRQ UHFRUG
RI DQ\ NLQG LQFOXGLQJ UHSHDW SUHVFULSWLRQV DQG IDFH WR IDFH RU
WHOHSKRQH FRQVXOWDWLRQV DQ\ WLPH IURP VL[ PRQWKV EHIRUH WR 
PRQWKV DIWHU WKH LQGH[ GDWH ZHUH DVVXPHG LQDFWLYH LQ WKH
GDWDEDVH DQG H[FOXGHG
Risk factors
,QIRUPDWLRQ RQ ULVN IDFWRUV ZDV EDVHG RQ UHFRUGV HQWHUHG LQ WKH
&OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN DQ\ WLPH EHIRUH WKH LQGH[
GDWH )RU HDFK ULVN IDFWRU ZH GHYHORSHG D GHILQLWLRQ DQG D OLVW
RI UHOHYDQW 5HDG FRGHV $ FOLQLFLDQ UHYLHZHG DOO FRGH OLVWV DQG
WKHVH DUH DYDLODEOH RQ UHTXHVW 3DWLHQWV ZLWKRXW 5HDG FRGHV IRU
D FOLQLFDO FRQGLWLRQ ZHUH DVVXPHG QRW WR KDYH WKH FRQGLWLRQ
Key risk factors of interest
2XU NH\ ULVN IDFWRUV RI LQWHUHVW ZHUH UKHXPDWRLG DUWKULWLV
V\VWHPLF OXSXV HU\WKHPDWRVXV LQIODPPDWRU\ ERZHO GLVHDVH
FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH DVWKPD FKURQLF NLGQH\
GLVHDVH GHSUHVVLRQ DQG GLDEHWHV RYHUDOO DQG E\ W\SH VHH
DSSHQGL[ VHFWLRQ $ IRU D IXOO GHVFULSWLRQV RI KRZ WKHVH ULVN
IDFWRUV ZHUH LGHQWLILHG
Severe immunosuppression
2XU PRGHOV LQFOXGHG VHYHUHO\ LPPXQRVXSSUHVVLYH FRQGLWLRQV
GHWHUPLQHG E\ WKH $GYLVRU\ &RPPLWWHH RQ ,PPXQL]DWLRQ
3UDFWLFHV WR EH FRQWUDLQGLFDWLRQV WR YDFFLQDWLRQ࣓QDPHO\ UHFHQW
KLVWRU\ OHVV WKDQ WZR \HDUV EHIRUH LQGH[ GDWH RI OHXNDHPLD
O\PSKRPD RU ERQH PDUURZ WUDQVSODQW RU DQ\ KLVWRU\ RI +,9
KDHPDWRSRLHWLF VWHP FHOO WUDQVSODQWDWLRQ P\HORPD RU ࣘRWKHU
XQVSHFLILHG FHOOXODU LPPXQH GHILFLHQFLHVࣙ IRU H[DPSOH
SDQF\WRSHQLD :H DOVR LQFOXGHG XVH RI LPPXQRVXSSUHVVLYH
WUHDWPHQW ZH H[WUDFWHG DOO UHOHYDQW SUHVFULSWLRQV EHIRUH WKH
LQGH[ GDWH DQG FDOFXODWHG GXUDWLRQ RI SUHVFULSWLRQ XVLQJ GDWD
RQ TXDQWLW\ RI WDEOHWV SUHVFULEHG DQG QXPHULF GDLO\ GRVH :H
GHILQHG RUDO FRUWLFRVWHURLG H[SRVXUH DV D  GD\ FRXUVH RI KLJK
GRVH ਅ PJGD\ RUDO FRUWLFRVWHURLGV LQ WKH PRQWK EHIRUH WKH
LQGH[ GDWH :H LQFOXGHG H[SRVXUH WR RWKHU LPPXQRVXSSUHVVLYH
WUHDWPHQWV LQ WKH PRQWK EHIRUH WKH LQGH[ GDWH DV DQ DGGLWLRQDO
FRYDULDWH VHH DSSHQGL[ VHFWLRQ $ IRU IXUWKHU GHWDLOV
Other characteristics
2WKHU FKDUDFWHULVWLFV RI SDWLHQWV LQFOXGHG VPRNLQJ H[VPRNHU
FXUUHQW VPRNHU QRQVPRNHU DOFRKRO FRQVXPSWLRQ QRQGULQNHU
FXUUHQW GULQNHU H[GULQNHU DQG ERG\ PDVV LQGH[ XQGHUZHLJKW
 QRUPDO ZHLJKW  RYHUZHLJKW ਅ REHVH
ਅ VHH DSSHQGL[ VHFWLRQ $ IRU IXUWKHU GHWDLOV :H FDSWXUHG
H[SRVXUH WR LQKDOHG FRUWLFRVWHURLGV ZLWKLQ WKUHH PRQWKV EHIRUH
WKH LQGH[ GDWH VHH DSSHQGL[ VHFWLRQ $ IRU IXUWKHU GHWDLOV DV
VRPH HYLGHQFH VXJJHVWV WKDW WKH\ PD\ LQFUHDVH WKH ULVN RI
]RVWHU :H FRPSDUHG IROORZXS WLPH LQ \HDUV IRU FDVHV DQG
FRQWUROV WR FKHFN WKDW WKH RSSRUWXQLW\ WR UHFRUG WKH H[SRVXUHV
RI LQWHUHVW LQ WKH WZR JURXSV ZDV HTXDO
7R H[SORUH ZKHWKHU WKH DVVRFLDWLRQ EHWZHHQ RXU ULVN IDFWRUV RI
LQWHUHVW DQG ]RVWHU FRXOG EH DIIHFWHG E\ DVFHUWDLQPHQW ELDV WKDW
LV YLVLWLQJ D JHQHUDO SUDFWLFH IRU WKH ULVN IDFWRU PD\ LQFUHDVH
WKH OLNHOLKRRG RI UHFHLYLQJ D GLDJQRVLV RI ]RVWHU ZH LQYHVWLJDWHG
WKH DVVRFLDWLRQ EHWZHHQ ]RVWHU DQG WUHDWHG HSLOHSV\ DQ HSLOHSV\
5HDG FRGH EHIRUH LQGH[ GDWH DQG DQ HSLOHSV\ WUHDWPHQW British
National Formulary FKDSWHU   PRQWKV EHIRUH WKH LQGH[
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GDWH (SLOHSV\ LV D FKURQLF FRQGLWLRQ UHTXLULQJ KLJK OHYHO
KHDOWKFDUH XVH LW LV QRW WKRXJKW WR EH DVVRFLDWHG ZLWK ]RVWHU
Statistical analysis
:H GHVFULEHG WKH FKDUDFWHULVWLFV RI WKH VWXG\ SRSXODWLRQ E\
FDVHFRQWURO VWDWXV 7KH DQDO\VLV DFFRXQWHG IRU WKH PDWFKHG
GHVLJQ E\ XVLQJ FRQGLWLRQDO ORJLVWLF UHJUHVVLRQ VR DOO RGGV UDWLRV
DFFRXQWHG IRU WKH PDWFKLQJ IDFWRUV RI DJH ZLWKLQ  \HDU VH[
SUDFWLFH DQG FDOHQGDU WLPH ,QLWLDOO\ ZH FDOFXODWHG XQLYDULDEOH
RGGV UDWLRV WR HVWLPDWH WKH VWUHQJWK RI DVVRFLDWLRQ RI HDFK
SRWHQWLDO ULVN IDFWRU ZLWK ]RVWHU  FRQILGHQFH LQWHUYDOV ZHUH
JHQHUDWHG WR DFFRXQW IRU PXOWLSOH WHVWLQJ DQG UHGXFH WKH FKDQFH
RI SLFNLQJ XS VPDOO DQG FOLQLFDOO\ XQLPSRUWDQW DVVRFLDWLRQV :H
WKHQ GLG PXOWLYDULDEOH DQDO\VHV RQ SDWLHQWV ZLWK FRPSOHWH GDWD
IRU DOO YDULDEOHV VHH DOVR EHORZ IRU DSSURDFK WR PLVVLQJ GDWD
:H LQYHVWLJDWHG D SRWHQWLDOO\ HIIHFW PRGLI\LQJ UROH RI DJH DW
GLDJQRVLV LQGH[ GDWH E\ FDOFXODWLQJ VWUDWXP VSHFLILF RGGV UDWLRV
IRU HDFK YDULDEOH LQ WKH PXOWLYDULDEOH PRGHO E\ DJH JURXSV !
\HDUV  \HDUV  \HDUV DQG ਅ \HDUV :H DGGHG
LQWHUDFWLRQ WHUPV EHWZHHQ DJH DQG RWKHU ULVN IDFWRUV RQH DW D
WLPH LQWR WKH PXOWLYDULDEOH UHJUHVVLRQPRGHO DQG XVHG OLNHOLKRRG
UDWLR WHVWV WR LQYHVWLJDWH LQWHUDFWLRQV
7R TXDQWLI\ WKH HIIHFW RI RXU DVVHVVHG ULVN IDFWRUV ZH HVWLPDWHG
WKH DJH VSHFLILF DEVROXWH UDWH RI ]RVWHU IRU HDFK IDFWRU E\
PXOWLSO\LQJ WKH DJH VSHFLILF HIIHFW HVWLPDWHV E\ WKH DJH VSHFLILF
UDWH RI ]RVWHU LQ WKH JHQHUDO SRSXODWLRQ LQ  :H HVWLPDWHG
WKH DJH VSHFLILF JHQHUDO SRSXODWLRQ UDWHV ZLWKLQ WKH &OLQLFDO
3UDFWLFH 5HVHDUFK 'DWDOLQN E\ GLYLGLQJ WKH QXPEHU RI LQFLGHQW
FDVHV RI ]RVWHU LQ  E\ WKH WRWDO SHUVRQ WLPH FRQWULEXWLRQ RI
WKH SRSXODWLRQ DW ULVN LQ WKDW \HDU ZKLFK LQFOXGHG DOO SDWLHQWV
LQ WKH &OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN ZLWK DW OHDVW RQH \HDU
RI IROORZXS DQG QR KLVWRU\ RI ]RVWHU
:H WKHQ HYDOXDWHG WR ZKDW H[WHQW FRPELQDWLRQV RI ULVN IDFWRUV
FRXOG OHDG WR D KLJK ULVN RI ]RVWHU VSHFLILFDOO\ ZLWKLQ DJH JURXSV
QRW WDUJHWHG IRU YDFFLQDWLRQ :H FDOFXODWHG WKH SUHGLFWHG ULVN
RI ]RVWHU IRU HDFK SHUVRQ E\ VXPPLQJ WKH FRHIILFLHQWV IRU WKHLU
ULVN IDFWRUV IURP WKH ILQDO PRGHO DQG PXOWLSO\LQJ WKHLU SUHGLFWHG
RGGV UDWLR E\ WKH DJH VSHFLILF UDWH RI ]RVWHU LQ WKH JHQHUDO
SRSXODWLRQ:H ZHUH WKXV DEOH WR GHWHUPLQH WKH QXPEHU RI FDVHV
DJHG XQGHU  EXW ZLWK D SUHGLFWHG ULVN RI ]RVWHU HTXDO WR RU
KLJKHU WKDQ WKDW RI WKH JHQHUDO SRSXODWLRQ DJHG DW OHDVW  \HDUV
YDFFLQDWLRQ LV FXUUHQWO\ RIIHUHG WR  DQG  \HDU ROGV LQ WKH
8. :H UHSHDWHG WKLV DQDO\VLV ZLWK D  \HDUV DJH FXWRII WR
UHIOHFW YDFFLQDWLRQ SROLF\ IURP GLIIHUHQW FRXQWULHV:H UHVWULFWHG
WKHVH FDOFXODWLRQV WR SHRSOHZLWKRXW VHYHUHO\ LPPXQRVXSSUHVVLYH
FRQGLWLRQV
6HQVLWLYLW\ DQDO\VHV LQFOXGHG XVH RI D ZLGHU GHILQLWLRQ RI
H[SRVXUH WR RUDO FRUWLFRVWHURLGV DQG RWKHU LPPXQRVXSSUHVVLYH
WUHDWPHQW DQ\RQH H[SRVHG WKUHH PRQWKV EHIRUH WKH LQGH[ GDWH
:H XVHG PXOWLSOH LPSXWDWLRQ E\ FKDLQHG HTXDWLRQV WR DFFRXQW
IRU PLVVLQJ GDWD  RI SDWLHQWV KDG PLVVLQJ GDWD IRU DOFRKRO
RU VPRNLQJ 7KH LPSXWDWLRQ PRGHO LQFOXGHG DOO FRYDULDWHV
IURP WKH PDLQ RXWFRPHPRGHO WRJHWKHU ZLWK PDWFKLQJ YDULDEOHV
RI DJH DQG VH[ DQG H[WUD FRPRUELGLWLHV DV DGGLWLRQDO PDUNHUV
RI DOFRKRO RU VPRNLQJ UHODWHG GLVHDVHV:H FUHDWHG ILYH LPSXWHG
GDWDVHWV DQG FRPELQHG WKHP IRU DQDO\VLV :H IXUWKHU DGMXVWHG
IRU SDWLHQW OHYHO VRFLRHFRQRPLF VWDWXV LQ WKH VXEJURXS RI SDWLHQWV
UHJLVWHUHG DW (QJOLVK SUDFWLFHV IRU ZKRP WKHVH GDWD ZHUH
DYDLODEOH VHH DSSHQGL[ VHFWLRQV %' IRU IXUWKHU GHWDLOV :H
DSSOLHG WZR GLIIHUHQW GHILQLWLRQV RI DQ ࣘDFWLYHࣙ FRQWURO )LUVWO\
ZH FRQVLGHUHG FRQWUROV WR EH LQDFWLYH LI WKH\ KDG QR FRQWDFW ZLWK
WKHLU JHQHUDO SUDFWLFH GXULQJ DQ\ WLPH IURP RQH \HDU EHIRUH WR
WZR \HDUV DIWHU WKH LQGH[ GDWH 6HFRQGO\ ZH FRQVLGHUHG FRQWUROV
WR EH LQDFWLYH LI WKH\ KDG QRW FRQVXOWHG WKHLU JHQHUDO SUDFWLFH LQ
WKH SUHYLRXV WKUHH \HDUV )LQDOO\ ZH FDOFXODWHG WKH PHDQ \HDUO\
FRQVXOWDWLRQ UDWH EHIRUH WKH LQGH[ GDWH E\ GLYLGLQJ WKH WRWDO
QXPEHU RI IDFH WR IDFH RU WHOHSKRQH FRQVXOWDWLRQV GXULQJ
IROORZXS E\ WKH WRWDO \HDUV RI IROORZXS EHIRUH WKH LQGH[ GDWH
DPRQJ SDWLHQWV ZLWK RXU ULVN IDFWRUV RI LQWHUHVW DQG DPRQJ
SDWLHQWV ZLWK HSLOHSV\
Results
:H LGHQWLILHG D WRWDO RI   LQFLGHQW FDVHV RI ]RVWHU $IWHU
PDWFKLQJ ZH UHPRYHG LQDFWLYH FRQWUROV Q    RI DOO
  PDWFKHG FRQWUROV :H H[FOXGHG D VPDOO QXPEHU RI
FDVHV DV WKH\ KDG QR HOLJLEOH FRQWUROV Q   ODUJHO\
RZLQJ WR DGYDQFHG DJH OHDYLQJ   FDVHV
7DEOH দ VKRZV GHVFULSWLYH GHWDLOV RI WKH FDVHV DQG FRQWUROV
 RI FDVHV DQG  RI FRQWUROV ZHUH IHPDOH WKH KLJKHU
SURSRUWLRQ DPRQJ FRQWUROV ZDV GXH WR WKH YDULDEOH QXPEHU RI
FRQWUROV SHU FDVH 7KH PHGLDQ DJH DW GLDJQRVLV RI ]RVWHU ZDV
 LQWHUTXDUWLOH UDQJH  \HDUV IRU FDVHV DQG  
\HDUV IRU FRQWUROV $SSUR[LPDWHO\  RI ]RVWHU FDVHV RFFXUUHG
LQ SDWLHQWV XQGHU  \HDUV DQG  LQ WKRVH XQGHU  \HDUV
5HJLVWHUHG IROORZXS WLPH EHIRUH WKH LQGH[ GDWH ZDV HTXLYDOHQW
LQ FDVHV DQG FRQWUROV   \HDUV
7DEOH দ VKRZV WKH SURSRUWLRQ RI FDVHV DQG FRQWUROV ZLWK RXU
NH\ ULVN IDFWRUV RI LQWHUHVW DQG RWKHU FRYDULDWHV 7KH VWURQJHVW
ULVN IDFWRUV IRU ]RVWHU ZHUH WKH VHYHUHO\ LPPXQRVXSSUHVVLYH
FRQGLWLRQV DOWKRXJK WKHLU RYHUDOO SUHYDOHQFH ZDV ORZ࣓
RI FDVHV DQG  RI FRQWUROV WDEOH দ 2GGV UDWLRV YDULHG
IURP  WR  DOWKRXJK WKH ODWWHU HVWLPDWH IRU
KDHPDWRSRLHWLF VWHP FHOO WUDQVSODQWDWLRQ KDG D SDUWLFXODUO\ ZLGH
 FRQILGHQFH LQWHUYDO DV LW ZDV EDVHG RQ RQO\  H[SRVHG
SDWLHQWV
$PRQJ RXU NH\ ULVN IDFWRUV RI LQWHUHVW V\VWHPLF OXSXV
HU\WKHPDWRVXV KDG WKH VWURQJHVW UHODWLYH ULVN RI ]RVWHU DGMXVWHG
RGGV UDWLR   FRQILGHQFH LQWHUYDO  WR  WDEOH
দ EXW WKH FRQGLWLRQ ZDV YHU\ UDUH  RI FDVHV DQG 
RI FRQWUROV 7KH ULVN RI ]RVWHU ZDV LQFUHDVHG E\PRUH WKDQ 
DPRQJ SDWLHQWV ZLWK UKHXPDWRLG DUWKULWLV DGMXVWHG RGGV UDWLR
  WR  DQG FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH
  WR  $VWKPD FKURQLF NLGQH\ GLVHDVH DQG
GHSUHVVLRQ ZHUH DVVRFLDWHG ZLWK D JUHDWHU WKDQ  LQFUHDVHG
ULVN RI ]RVWHU $OWKRXJK QR DVVRFLDWLRQ H[LVWHG EHWZHHQ ]RVWHU
DQG GLDEHWHV RYHUDOO DGMXVWHG RGGV UDWLR   WR  ZH
IRXQG VWURQJ HYLGHQFH WKDW SDWLHQWV FODVVLILHG DV KDYLQJ W\SH 
GLDEHWHV ZHUH DW LQFUHDVHG ULVN RI ]RVWHU   WR 
7R DVVHVV ZKHWKHU VRPH RI WKH RYHUDOO HIIHFW RI WKHVH FRQGLWLRQV
ZDV PHGLDWHG E\ WKHLU WUHDWPHQWV ZH DGGLWLRQDOO\ DGMXVWHG IRU
LPPXQRVXSSUHVVLYH WUHDWPHQWV DQG LQKDOHG FRUWLFRVWHURLGV WDEOH
দ ILQDO FROXPQ 7KH DVVRFLDWLRQV EHWZHHQ ]RVWHU DQG
UKHXPDWRLG DUWKULWLV V\VWHPLF OXSXV HU\WKHPDWRVXV
LQIODPPDWRU\ ERZHO GLVHDVH FKURQLF REVWUXFWLYH SXOPRQDU\
GLVRUGHU DQG DVWKPD ZHUH DWWHQXDWHG DIWHU DGMXVWPHQW EXW GLG
QRW GLVDSSHDU $PRQJ FRQGLWLRQV QRW FRPPRQO\ WUHDWHG ZLWK
WKHVH GUXJV FKURQLF NLGQH\ GLVHDVH GHSUHVVLRQ DQG GLDEHWHV
WKH DVVRFLDWLRQ GLG QRW YDU\ DIWHU WKLV DGGLWLRQDO DGMXVWPHQW
7UHDWHG HSLOHSV\ QRW H[SHFWHG WR EH DVVRFLDWHG ZLWK ]RVWHU ZDV
PDUJLQDOO\ PRUH FRPPRQ DPRQJ FDVHV WKDQ FRQWUROV 
 v  :H IRXQG OLWWOH HYLGHQFH RI DVVRFLDWLRQ
ZLWK ]RVWHU LQ FUXGH RGGV UDWLR   WR  RU DGMXVWHG
DQDO\VHV   WR  VXJJHVWLQJ WKDW RWKHU DVVRFLDWLRQV
REVHUYHG LQ WKLV VWXG\ DUH XQOLNHO\ WR EH H[SODLQHG E\
DVFHUWDLQPHQW ELDV
:H H[SORUHG KRZ WKH HIIHFW RI RXU ULVN IDFWRUV YDULHG E\ DJH
WDEOHV দ DQG দ :H IRXQG VRPH HYLGHQFH RI DJH LQWHUDFWLRQ
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,Q JHQHUDO WKH UHODWLYH HIIHFWV RI WKHVH ULVN IDFWRUV RQ ]RVWHU
GHFUHDVHG ZLWK LQFUHDVLQJ DJH )RU H[DPSOH DPRQJ SDWLHQWV
ZLWK FKURQLF NLGQH\ GLVHDVH WKH RGGV UDWLR SRLQW HVWLPDWH ZDV
  DQG  DPRQJ SDWLHQWV DJHG   DQG
 \HDUV UHVSHFWLYHO\
7R TXDQWLI\ WKH HIIHFW RI RXU NH\ ULVN IDFWRUV RI LQWHUHVW
SDUWLFXODUO\ DPRQJ DJH JURXSV QRW WDUJHWHG IRU YDFFLQDWLRQ ZH
HVWLPDWHG DEVROXWH UDWHV RI ]RVWHU WDEOH দ 7KH UDWHV UHPDLQHG
ORZ DPRQJ SDWLHQWV DJHG  \HDUV IRU H[DPSOH IRU WKRVH
ZLWK UKHXPDWRLG DUWKULWLV   FRQILGHQFH LQWHUYDO 
WR  SHU  SHUVRQ \HDUV GHVSLWH WKH KLJK UHODWLYH ULVNV
LQ WKLV DJH JURXS 7KH DEVROXWH UDWHV RI ]RVWHU DPRQJ SDWLHQWV
DJHG  \HDUV ZHUH UHODWLYHO\ KLJK SDUWLFXODUO\ IRU WKRVH
ZLWK FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH DQG UKHXPDWRLG
DUWKULWLV
:H FDOFXODWHG WKH SUHGLFWHG ULVN RI ]RVWHU DPRQJ   ]RVWHU
FDVHV KDYLQJ H[FOXGHG  SDWLHQWV ZLWK VHYHUHO\
LPPXQRVXSSUHVVLYH FRQGLWLRQV RQ WKH EDVLV RI WKHLU ULVN IDFWRU
SURILOH $PRQJ WKHVH FDVHV    KDG DW OHDVW RQH
ULVN IDFWRU RI LQWHUHVW 2I   ]RVWHU FDVHV DJHG XQGHU 
\HDUV   KDG D SUHGLFWHG ULVN DV KLJK DV WKDW IRU WKH
JHQHUDO SRSXODWLRQ DJHG  RU RYHU   RI  
SDWLHQWV XQGHU  \HDUV KDG D SUHGLFWHG ULVN DV KLJK DV WKRVH
DJHG  \HDUV
6HQVLWLYLW\ DQDO\VHV LPSXWLQJ PLVVLQJ GDWD IRU VPRNLQJ DQG
DOFRKRO VHH DSSHQGL[ VHFWLRQ % XVLQJ GLIIHUHQW GHILQLWLRQV IRU
LPPXQRVXSSUHVVLYH WUHDWPHQW VHH DSSHQGL[ VHFWLRQ &
DGMXVWLQJ IRU SDWLHQW OHYHO VRFLRHFRQRPLF VWDWXV VHH DSSHQGL[
VHFWLRQ ' DQG DSSO\LQJ GLIIHUHQW GHILQLWLRQV RI DQ DFWLYH FRQWURO
VHH DSSHQGL[ VHFWLRQ ( GLG QRW FKDQJH WKH VWXG\ ILQGLQJV 7KH
FRQVXOWDWLRQ UDWH ZDV VLPLODU DPRQJ SDWLHQWV ZLWK HSLOHSV\ DQG
WKRVH ZLWK RXU ULVN IDFWRUV RI LQWHUHVW VHH DSSHQGL[ VHFWLRQ )
Discussion
,Q WKLV ODUJH PDWFKHG FDVHFRQWURO VWXG\ D UDQJH RI FRQGLWLRQV
ZHUH DVVRFLDWHG ZLWK LQFUHDVHG ULVN RI ]RVWHU LQFOXGLQJ
UKHXPDWRLG DUWKULWLV V\VWHPLF OXSXV HU\WKHPDWRVXV
LQIODPPDWRU\ ERZHO GLVHDVH FKURQLF REVWUXFWLYH SXOPRQDU\
GLVHDVH DVWKPD FKURQLF NLGQH\ GLVHDVH W\SH  GLDEHWHV DQG
GHSUHVVLRQ 7KH UHODWLYH HIIHFWV RI PDQ\ RI WKHVH ULVN IDFWRUV
ZHUH ODUJHU DPRQJ \RXQJHU SDWLHQWV 7KLV UDLVHV WKH TXHVWLRQ
RI ZKHWKHU YDFFLQDWLRQ RI FHUWDLQ \RXQJHU KLJK ULVN JURXSV PD\
EH EHQHILFLDO FRVW HIIHFWLYHQHVV VWXGLHV DOVR FRQVLGHULQJ WKH
ULVN RI SRVWKHUSHWLF QHXUDOJLD ZRXOG EH QHHGHG WR DQVZHU WKLV
TXHVWLRQ $PRQJ D ZLGH UDQJH RI ULVN IDFWRUV SHRSOH ZLWK
FRQWUDLQGLFDWLRQV WR FXUUHQWO\ DYDLODEOH YDFFLQHV ZHUH DW WKH
KLJKHVW ULVN RI ]RVWHU KLJKOLJKWLQJ WKH QHHG WR LGHQWLI\ VWUDWHJLHV
WR UHGXFH WKH ULVN RI ]RVWHU DPRQJ WKHVH JURXSV
Strengths and limitations of study
7KLV ODUJH VWXG\ LQFOXGHG DOO LQFLGHQW FDVHV RI ]RVWHU LQ WKH
&OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN RYHU DQ  \HDU SHULRG
SURYLGLQJ KLJK SRZHU WR GHWHFW VPDOO HIIHFWV H[FHSW IRU UDUH
SRWHQWLDO ULVN IDFWRUV :H DVVHVVHG D ZLGH UDQJH RI IDFWRUV
DOORZLQJ DGMXVWPHQW IRU PDQ\ RI WKH NQRZQ DV ZHOO DV SRWHQWLDO
FRQIRXQGHUV LQ DGGLWLRQ WR H[SORULQJ LQWHUDFWLRQV ZLWK DJH
ZKLFK LV RI NH\ SXEOLF KHDOWK UHOHYDQFH LQ WHUPV RI YDFFLQDWLRQ
SROLF\
7KH VWXG\ PD\ EH VXEMHFW WR DVFHUWDLQPHQW ELDV UHJXODU JHQHUDO
SUDFWLFH YLVLWV IRU D FKURQLF FRQGLWLRQ VXFK DV GLDEHWHV PD\
LQFUHDVH WKH OLNHOLKRRG RI UHFHLYLQJ D ]RVWHU GLDJQRVLV +RZHYHU
ZH EHOLHYH WKDW PRVW ]RVWHU FDVHV ZRXOG SUHVHQW WR WKHLU JHQHUDO
SUDFWLFH RZLQJ WR WKH H[WHQVLYH UDVK DQG FRQVLGHUDEOH SDLQ
DVVRFLDWHG ZLWK ]RVWHU DQG IUHH JHQHUDO SUDFWLFH DWWHQGDQFH LQ
WKH 8. $ VXUYH\ DERXW LPPXQLVDWLRQ SUDFWLFHV LQ WKH 8QLWHG
6WDWHV DPRQJ SHRSOH DJHG  DQG RYHU IRXQG WKDW  RI WKRVH
ZKR NQHZ WKH\ KDG ]RVWHU VRXJKW FDUH )XUWKHUPRUH ZH IRXQG
OLWWOH HYLGHQFH WR VXJJHVW WKDW SDWLHQWV ZLWK HSLOHSV\ ZKR ZHUH
YLVLWLQJ WKHLU JHQHUDO SUDFWLFH DV IUHTXHQWO\ DV SDWLHQWV ZLWK RXU
ULVN IDFWRUV RI LQWHUHVW ZHUH DW LQFUHDVHG ULVN RI ]RVWHU
$V ZLWK DQ\ REVHUYDWLRQDO VWXG\ UHVLGXDO FRQIRXQGLQJ PD\ EH
SUHVHQW )RU H[DPSOH H[SRVXUH WR YDULFHOOD FRQWDFWV
K\SRWKHVLVHG WR QDWXUDOO\ ERRVW YDULFHOOD ]RVWHU YLUXV VSHFLILF
LPPXQLW\ LQ SHRSOH ZLWK ODWHQW YDULFHOOD ]RVWHU YLUXV LQIHFWLRQ
DQG WKXV SURWHFW DJDLQVW ]RVWHU ZDV QRW DYDLODEOH
6RPH PLVFODVVLILFDWLRQ RI ]RVWHU LV SRVVLEOH ,Q 8. SULPDU\
FDUH GLDJQRVLV RI ]RVWHU LV FOLQLFDOO\ EDVHG ZLWK QR ODERUDWRU\
WHVWLQJ 9DOLGDWLRQ RI ]RVWHU GLDJQRVHV LQ SULPDU\ FDUH LQ WKH
1HWKHUODQGV IRXQG WKDW  RI FDVHV KDG UDLVHG DQWLERGLHV
LQGLFDWLQJ UHFHQW ]RVWHU LQIHFWLRQ VXJJHVWLQJ WKDW GLDJQRVLV RI
]RVWHU KDV D KLJK SRVLWLYH SUHGLFWLYH YDOXH 7KH IUHTXHQF\ ZLWK
ZKLFK JHQHUDO SUDFWLWLRQHUV ZURQJO\ UHMHFW WKH GLDJQRVLV RI
]RVWHU KDV QRW KRZHYHU EHHQ LQYHVWLJDWHG WKLV PD\ EH PRUH
FRPPRQ DPRQJ \RXQJHU SDWLHQWV LQ ZKRP ]RVWHU LV XQFRPPRQ
+RZHYHU WKH PRVW FRPPRQ PLVFODVVLILFDWLRQ RI ]RVWHU LV DV
UHFXUUHQW KHUSHV VLPSOH[ ZKLFK YHU\ UDUHO\ SUHVHQWV LQ D
GHUPDWRPDO GLVWULEXWLRQ =RVWHU LV W\SLFDOO\ D VWUDLJKWIRUZDUG
FOLQLFDO GLDJQRVLV VR WKH H[WHQW RI PLVFODVVLILFDWLRQ LV OLNHO\ WR
EHPLQLPDO $Q\PLVFODVVLILFDWLRQ LV OLNHO\ WR EH QRQGLIIHUHQWLDO
ZLWK UHVSHFW WR H[SRVXUH VWDWXV WKXV OHDGLQJ WR DQ
XQGHUHVWLPDWLRQ RI DVVRFLDWLRQV
)LQDOO\ H[FOXGLQJ ࣘLQDFWLYHࣙ FRQWUROV WR UHPRYH SDWLHQWV ZKR
ZRXOG QRW DWWHQG WKHLU JHQHUDO SUDFWLFH LI WKH\ GLG GHYHORS ]RVWHU
PD\ KDYH UHVXOWHG LQ KHDOWKLHU FRQWUROV QRW EHLQJ LQFOXGHG DQG
OHG WR DQ XQGHUHVWLPDWLRQ RI WKH RGGV UDWLRV
Comparison with other studies
7KH VWUHQJWK RI DVVRFLDWLRQ EHWZHHQ WKH DXWRLPPXQH FRQGLWLRQV
LQ WKLV VWXG\ DQG ULVN RI ]RVWHU LV EURDGO\ LQ OLQH ZLWK SUHYLRXV
VWXGLHV  7KH LQFUHDVHG ULVN DVVRFLDWHG ZLWK WKHVH FRQGLWLRQV
PD\ SDUWO\ UHIOHFW H[SRVXUH WR LPPXQRVXSSUHVVLYH GUXJV DV
ZHOO DV WKH FRQGLWLRQV WKHPVHOYHV :KHQ ZH DGMXVWHG IRU
LPPXQRVXSSUHVVLYH WUHDWPHQWV WKH LQFUHDVHG ULVN RI ]RVWHU ZDV
DWWHQXDWHG VXJJHVWLQJ WKDW WKHVH GUXJV FRQWULEXWH WR WKH RYHUDOO
LQFUHDVHG ULVN RI ]RVWHU LQ WKHVH SDWLHQWV
7KH HIIHFW RI FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH LV DOVR
FRQVLVWHQW ZLWK SUHYLRXV VWXGLHV  $IWHU DGMXVWPHQW IRU RUDO
DQG LQKDOHG FRUWLFRVWHURLGV FRPPRQO\ XVHG WR WUHDW FKURQLF
REVWUXFWLYH SXOPRQDU\ GLVHDVH WKH DVVRFLDWLRQ UHGXFHG LQ WKHVH
SDWLHQWV DJDLQ VXJJHVWLQJ WKDW WKHVH WUHDWPHQWV DGG WR WKHLU
RYHUDOO ULVN RI ]RVWHU /DUJHU DVVRFLDWLRQV EHWZHHQ ]RVWHU DQG
GHSUHVVLRQ KDYH EHHQ UHSRUWHG   1R FRQVHQVXV H[LVWV RQ
KRZ WR FDSWXUH GHSUHVVLRQ LQ HOHFWURQLF UHFRUGV SUHYLRXV VWXGLHV
XVHG GLIIHUHQW GHILQLWLRQV ZKLFK PD\ FRQWULEXWH WR WKH YDULHG
ILQGLQJV )RU H[DPSOH D PDWFKHG FDVHFRQWURO VWXG\ XVLQJ
FRPPHUFLDO FODLPV DQG HQFRXQWHUV GDWD LQ WKH 8QLWHG 6WDWHV
IRXQG D KLJKHU ULVN RI ]RVWHU DPRQJ SDWLHQWV DJHG RYHU  ZLWK
GHSUHVVLRQ RGGV UDWLR   FRQILGHQFH LQWHUYDO  WR
 EXW RQO\ LQFOXGHG YHU\ VHYHUH FDVHV GHSUHVVLYH GLVRUGHU
FKURQLF GHSUHVVLYH SHUVRQDOLW\ GLVRUGHU RU G\VWK\PLF GLVRUGHU
7KH DVVRFLDWLRQ RI ]RVWHU ZLWK FKURQLF NLGQH\ GLVHDVH ZDV DOVR
VPDOOHU WKDQ SUHYLRXV VWXGLHV KDYH VXJJHVWHG
7KH ULVNV RI ]RVWHU DUH UHSRUWHGO\ LQFUHDVHG LQ SDWLHQWV ZLWK
GLDEHWHV RI XQVSHFLILHG W\SH    :H IRXQG VRPH HYLGHQFH
WKDW W\SH  EXW QRW W\SH  GLDEHWHV ZDV DVVRFLDWHG ZLWK DQ
LQFUHDVHG ULVN RI ]RVWHU DOWKRXJK GLIIHUHQWLDWLQJ EHWZHHQ W\SH
ZDV QRW EDVHG RQ GLDJQRVWLF FRGHV VR PLVFODVVLILFDWLRQ LV
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SRVVLEOH 3DWLHQWV ZLWK W\SH  GLDEHWHV PD\ EH DW KLJKHU ULVN RI
]RVWHU RZLQJ WR WKH LPPXQH G\VUHJXODWLRQ UHVXOWLQJ IURP
DXWRLPPXQH SDWKRJHQHVLV 7KH ODFN RI HIIHFW IRXQG ZLWK W\SH
 GLDEHWHV PXVW EH LQWHUSUHWHG FDXWLRXVO\ DV QHJDWLYH
FRQIRXQGLQJ E\ HWKQLF JURXS LV SRVVLEOH WKH W\SH  GLDEHWHV
SRSXODWLRQ PD\ KDYH LQFOXGHG 6RXWK $VLDQ SDWLHQWV NQRZQ WR
EH DW ORZHU ULVN RI ]RVWHU  DQG KLJKHU ULVN RI GLDEHWHV
(WKQLFLW\ LV SRRUO\ UHFRUGHG IRU ROGHU SDWLHQWV QRW UHFHQWO\
UHJLVWHUHG LQ WKH &OLQLFDO 3UDFWLFH 5HVHDUFK 'DWDOLQN VR ZH
FRXOG QRW FDSWXUH WKLV FKDUDFWHULVWLF
7KH REVHUYHG LQFUHDVHG ULVNV RI ]RVWHU VXJJHVW WKDW DOO WKHVH
FRQGLWLRQV DUH DVVRFLDWHG ZLWK VRPH FHOO PHGLDWHG
LPPXQRVXSSUHVVLRQ 'LVHDVH LQGXFHG LPPXQRVXSSUHVVLRQ KDV
EHHQ SURSRVHG LQ FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH DQG
DVWKPD SDWLHQWV DOWKRXJK ORQJ WHUP H[SRVXUH WR
FRUWLFRVWHURLGV LQ WKHVH SDWLHQWV LV DOVR OLNHO\ WR FRQWULEXWH WR
LPPXQRVXSSUHVVLRQ 3DWLHQWV ZLWK FKURQLF NLGQH\ GLVHDVH DUH
NQRZQ WR KDYH LPPXQH G\VIXQFWLRQ SDUWLFXODUO\ ZKHQ WKH
GLVHDVH UHDFKHV HQG VWDJH )RU GHSUHVVLRQ VWUHVV PD\ LQFUHDVH
WKH ULVN RI ]RVWHU DV LW DIIHFWV VHYHUDO QHXURHQGRFULQH IXQFWLRQV
WKDW FDQ DIIHFW FHOO PHGLDWHG LPPXQLW\ DQG GHSUHVVLRQ LWVHOI
KDV EHHQ DVVRFLDWHG ZLWK SRRUHU ]RVWHU LPPXQLW\ 
Conclusions and policy implications
6HYHUH LPPXQRVXSSUHVVLRQ LV NQRZQ WR EH DVVRFLDWHG ZLWK DQ
LQFUHDVHG ULVN RI ]RVWHU  :KDW WKLV VWXG\ KDV KLJKOLJKWHG
KRZHYHU LV WKDW WKH VWURQJHVW FOLQLFDO ULVN IDFWRUV IRU ]RVWHU DUH
FRQWUDLQGLFDWLRQV WR LWV YDFFLQH WKH SHRSOH DUJXDEO\ LQ PRVW
QHHG RI SURWHFWLRQ DJDLQVW ]RVWHU FDQQRW FXUUHQWO\ EHQHILW IURP
YDFFLQDWLRQ $OWHUQDWLYH ULVN UHGXFWLRQ VWUDWHJLHV LQ WKHVH SDWLHQWV
ZRXOG KHOS WKRVH DW JUHDWHVW ULVN RI WKLV GLVHDVH DQG LWV
FRPSOLFDWLRQV
$QRWKHU LPSRUWDQW FRQVLGHUDWLRQ UHJDUGLQJ YDFFLQDWLRQ SROLF\
LV ZKHWKHU WKH ULVN IDFWRUV IRU ]RVWHU DUH DOVR ULVN IDFWRUV IRU
]RVWHUࣕV PDLQ PRUELGLW\ SRVWKHUSHWLF QHXUDOJLD 7R GDWH YHU\
IHZ VWXGLHV KDYH ORRNHG DW WKLV UHVHDUFK TXHVWLRQ DQG PRVW KDYH
EHHQ XQGHUSRZHUHG 7KH UROH RI VHYHUH LPPXQRVXSSUHVVLRQ DV
D ULVN IDFWRU IRU SRVWKHUSHWLF QHXUDOJLD LV LQFRQFOXVLYH WKUHH
VWXGLHV IRXQG WKDW ࣘJHQHUDOࣙ LPPXQRVXSSUHVVLRQ ZDV D ULVN
IDFWRU IRU SRVWKHUSHWLF QHXUDOJLD   ZKHUHDV DQRWKHU VWXG\
IRXQG QR DVVRFLDWLRQ $XWRLPPXQH FRQGLWLRQV KDYH VFDUFHO\
EHHQ DVVHVVHG RQH ODUJH FRKRUW VWXG\ LQ   ]RVWHU SDWLHQWV
LGHQWLILHG LQ 7DLZDQHVH KHDOWK LQVXUDQFH UHFRUGV IRXQG WKDW
WKRVH ZLWK V\VWHPLF OXSXV HU\WKHPDWRVXV ZHUH DW JUHDWHU ULVN
RI SRVWKHUSHWLF QHXUDOJLD 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What is already known on this topic
$ QHZ KHUSHV ]RVWHU YDFFLQDWLRQ FDPSDLJQ LQWURGXFHG LQ WKH 8QLWHG .LQJGRP LQ 6HSWHPEHU  LV IRFXVHG RQ ROGHU SHRSOH RQO\
5HFHQW OLWHUDWXUH KDV VXJJHVWHG WKDW D UDQJH RI FOLQLFDO FRQGLWLRQV DUH DVVRFLDWHG ZLWK DQ LQFUHDVHG ULVN RI ]RVWHU UDLVLQJ WKH SRVVLELOLW\
WKDW VRPH \RXQJHU SHRSOH PD\ EH DW KLJK ULVN
+RZHYHU ODUJH KLJKO\ SRZHUHG VWXGLHV LQYHVWLJDWLQJ WKH DVVRFLDWLRQ RI WKHVH FOLQLFDO FRQGLWLRQV ZLWK ]RVWHU DUH ODFNLQJ
What this study adds
&RQGLWLRQV DVVRFLDWHG ZLWK LQFUHDVHG ULVN RI ]RVWHU LQFOXGHG UKHXPDWRLG DUWKULWLV V\VWHPLF OXSXV HU\WKHPDWRVXV LQIODPPDWRU\ ERZHO
GLVHDVH FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH DVWKPD FKURQLF NLGQH\ GLVHDVH W\SH  GLDEHWHV DQG GHSUHVVLRQ
7KH LQFUHDVHG ULVNV ZHUH JHQHUDOO\ JUHDWHU DPRQJ \RXQJHU DJH JURXSV
7KH VWURQJHVW ULVN IDFWRUV DUH FRQWUDLQGLFDWLRQV WR YDFFLQDWLRQ HPSKDVLVLQJ WKH QHHG IRU DOWHUQDWLYH ULVN UHGXFWLRQ VWUDWHJLHV DPRQJ
WKHVH JURXSV
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Tables
Table 1| Vaccine recommendations in United Kingdom, United States, Canada, Australia, and Sweden
ContraindicationsGroups recommended to receive vaccineCountry
3HRSOH ZLWK SULPDU\ RU DFTXLUHG LPPXQRGHILFLHQF\ VWDWH DFWLYH XQWUHDWHG WXEHUFXORVLV
LQIHFWLRQ FRQILUPHG DQDSK\ODFWLF UHDFWLRQ WR SUHYLRXV GRVH RI YDULFHOOD YDFFLQH RU DQ\
FRPSRQHQW RI YDFFLQH SUHJQDQW ZRPHQ SHRSOH UHFHLYLQJ LPPXQRVXSSUHVVLYH WUHDWPHQW
LQFOXGLQJ KLJK GRVH FRUWLFRVWHURLGV
3HRSOH DJHG  \HDUV ZLWK FDWFKXS FDPSDLJQ IRU
 \HDU ROGV FXUUHQW FDWFKXS FRKRUW LV  \HDU
ROGV
8QLWHG .LQJGRP
3HRSOH ZLWK KLVWRU\ RI DQDSK\ODFWLFDQDSK\ODFWRLG UHDFWLRQ WR DQ\ FRPSRQHQW RI YDFFLQH
KLVWRU\ RI SULPDU\ RU DFTXLUHG LPPXQRGHILFLHQF\ VWDWH SHRSOH UHFHLYLQJ LPPXQRVXSSUHVVLYH
WUHDWPHQW LQFOXGLQJ KLJK GRVH FRUWLFRVWHURLGV ZRPHQ ZKR DUH RU PD\ EH SUHJQDQW
5HFRPPHQGHG IRU SHRSOH DJHG ݱ \HDUV8QLWHG 6WDWHV
3HRSOH ZLWK DQDSK\ODFWLF K\SHUVHQVLWLYLW\ WR DQ\ RI YDFFLQHۍV FRPSRQHQHWV FRQJHQLWDO RU
DFTXLUHG LPPXQH GHILFLHQF\ DFWLYH XQWUHDWHG WXEHUFXORVLV XVH RI LPPXQH VXSSUHVVLYH
GUXJV SUHJQDQW ZRPHQ SHRSOH ZLWK FHUWDLQ DFXWH LOOQHVVHV
5HFRPPHQGHG IRU SHRSOH DJHG ݱ \HDUV DOVR
DYDLODEOH IRU WKRVH DJHG  \HDUV
&DQDGD
3HRSOH ZLWK DQDSK\ODFWLF K\SHUVHQVLWLYLW\ WR DQ\ RI YDFFLQHۍV FRPSRQHQHWV WKRVH UHFHLYLQJ
KLJK GRVH V\VWHPLF LPPXQRVXSSUHVVLYH WUHDWPHQW VXFK DV FKHPRWKHUDS\ UDGLDWLRQ WKHUDS\
RU RUDO FRUWLFRVWHURLGV SHRSOH ZLWK PDOLJQDQW FRQGLWLRQV RI UHWLFXORHQGRWKHOLDO V\VWHP DQ\
SHUVRQ ZLWK VLPLODU LPPXQRVXSSUHVVLRQ GXH WR GLVHDVH RU WUHDWPHQW
5HFRPPHQGHG IRU SHRSOH DJHG ݱ \HDUV DOVR
DYDLODEOH IRU WKRVH DJHG  \HDUV
$XVWUDOLD
3HRSOH ZLWK ZHDNHQHG LPPXQH V\VWHPV GXH WR GUXJ WUHDWPHQW RU RWKHU KHDOWK FRQGLWLRQV
DOOHUJ\ WR JHODWLQ RU QHRP\FLQ PRGHUDWH RU VHYHUH LOOQHVV ZRPHQ ZKR DUH RU PD\ EH
SUHJQDQW
5HFRPPHQGHG IRU SHRSOH DJHG ݱ \HDUV6ZHGHQ
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Table 2| Description of cases and controls. Values are numbers (percentages) unless stated otherwise
Controls (n=549 336)Cases (n=144 959)
Matching factors
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Table 3| Relative risk of zoster in patients with key risk factors of interest and other covariates
Odds ratio (99% CI)No (%)
Model 3‡Model 2†Model 1*
Controls
(n=549 336)Cases (n=144 959)
Key risk factors of interest
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۔$GMXVWHG IRU +,9 OHXNDHPLD O\PSKRPD P\HORPD KDHPDWRSRLHWLF VWHP FHOO WUDQVSODQWDWLRQ RWKHU XQVSHFLILHG FHOOXODU LPPXQH GHILFLHQFLHV UKHXPDWRLG DUWKULWLV
V\VWHPLF OXSXV HU\WKHPDWRVXV LQIODPPDWRU\ ERZHO GLVHDVH FKURQLF REVWUXFWLYH SXOPRQDU\ GLVHDVH DVWKPD FKURQLF NLGQH\ GLVHDVH GHSUHVVLRQ GLDEHWHV VPRNLQJ
DQG DOFRKRO
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Table 4| Numbers of cases and controls with various risk factors, stratified by age
≥70 years60-69 years50-59 years<50 years
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Table 5| Association of various risk factors with herpes zoster, stratified by age
P value †
Adjusted odds ratio (99% CI)*Key risk factors of
interest ≥70 years60-69 years50-59 years<50 years
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Table 6| Estimated rate of zoster in patients with various risk factors, by age group
Rate of zoster/1000 person years (99% CI)
Key risk factors of interest ≥70 years60-69 years50-59 years<50 years
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Appendix (as published) 
 
A: Further detail on defining risk factors  
B: Dealing with missing data 
C: Different definition of exposure to oral corticosteroids and immunosuppressive 
conditions 
D: Association of various risk factors with zoster, after additionally adjusting for 
patient-level socioeconomic status 
E: Different definitions of “active” controls 
F: Consultation rate among patients with risk factors of interest 
 
 
A: Further detail on defining risk factors 
 
This information has been removed, as all risk factor definitions have been described in 
chapter 3, “Data sources and variable definitions”.  For transparency, the information can be 









B: Dealing with missing data 
 
We used multiple imputation to account for missing data. Missing data was present for alcohol 
and smoking. In total, 89% of patients had complete data for all variables. To maximise the use 
of the data while properly incorporating the extra uncertainty arising due to missing data, 
multiple imputation by chained equations127 was used to impute missing values for alcohol and 
smoking from multinomial models. The imputation model included all covariates from the 
main outcome model, together with the matching variables age and sex. We also included 
extra comorbidities, identified using medical Read codes, to look for additional markers of 
alcohol or smoking related diseases. These included: stroke, peripheral artery disease, angina 
(stable and unstable), acute coronary syndrome, congestive heart failure, myocardial 
infarction, hypertension and alcoholic liver disease (including portal hypertension) and 
pancreatitis. Five imputed datasets were created and combined for analysis. Distributions of 
imputed values were visually checked for comparability with the observed data. 
 
Table B1: Relative risk of zoster in patients with various risk factors, using a multiply imputed 
dataset 
  Adjusted OR (99% CI)* 
Clinical conditions  
Rheumatoid Arthritis 1.47 (1.39 to 1.56) 
Systemic Lupus Erythematosis 1.71 (1.46 to 2.01) 
Inflammatory Bowel Disease 1.35 (1.26 to 1.45) 
COPD 1.34 (1.29 to 1.40) 
Asthma 1.23 (1.20 to 1.27) 
Chronic Kidney Disease 1.16 (1.12 to 1.20) 
Depression 1.17 (1.13 to 1.22) 
Diabetes 1.04 (1.01 to 1.07) 
Diabetes Type  
No diabetes 1 
Type 1 1.33 (1.14 to 1.56) 
Type 2 1.02 (0.99 to 1.05) 
Unknown 1.15 (1.03 to 1.29) 
OR, odds ratio. CI, confidence interval. *Adjusted for HIV, Leukaemia, Lymphoma, Myeloma, HSCT, 




C: Different definition of exposure to oral corticosteroids and immunosuppressive 
conditions 
Rationale 
The definition of exposure to oral corticosteroids and other immunosuppressive therapy in the 
main analysis was derived from guidelines on zoster vaccine contraindications (a 14-day course 
of high-dose oral corticosteroids or other immunosuppressive therapies, within the month 
prior to index date).  The vaccine contraindications suggest patients remain 
immunosuppressed for one month following the end of their prescription. However we 
acknowledge this definition may not capture all patients with immunosuppression due to 
these medications.   
 
Our sensitivity analysis therefore defined exposure as anyone taking an oral corticosteroid or 
other immunosuppressant within 3 months prior to the index date, and placed no restrictions 
on duration or dose of prescription.  
 
Results 
A much higher number of patients were defined as exposed to immunosuppressive therapy 
using this broader criterion (table C1).  The overall effect of oral corticosteroids and 
immunosuppressive therapies was slightly lower when using the 3-month definition compared 
to the vaccine contraindication definition, however the confidence intervals overlapped (table 
C1).  There were no major differences in the effect of our main risk factors after adjusting for 
the broader definition of exposure to immunosuppressive drugs, compared to the main 




Table C1: Relative risk of zoster in patients taking immunosuppressive therapy, defined as 
exposure in the previous 3 months.  






Adjusted OR (99% CI) 






4151 (0.76) 2.21 (2.07 to 2.36) 1.71 (1.57 to 1.86) 
OR, odds ratio. CI, confidence interval. *Adjusted for HIV, Leukaemia, Lymphoma, Myeloma, HSCT, Other Immune deficiencies, 
Oral corticosteroids (previous 3 months), Other Immunosuppressive  (previous 3 months), ICS, RA, SLE, IBD, COPD, Asthma, CKD, 
Depression, Diabetes, Smoking and Alcohol. 








Table C2: Relative risk of zoster in patients with various risk factors  
 Adjusted OR (99% CI)* 
Clinical conditions  
Rheumatoid Arthritis 1.17 (1.10 to 1.25) 
Systemic Lupus Erythematosis 1.52 (1.27 to 1.82) 
Inflammatory Bowel Disease 1.26 (1.17 to 1.37) 
COPD 1.20 (1.14 to 1.26) 
Asthma 1.11 (1.06 to 1.16) 
Chronic Kidney Disease 1.11 (1.07 to 1.16) 
Depression 1.15 (1.10 to 1.20) 
Diabetes 1.01 (0.98 to 1.05) 
Diabetes Type  
No diabetes 1 
Type 1 1.25 (1.05 to 1.48) 
Type 2 1.00 (0.97 to 1.03) 
Unknown 1.11 (0.98 to 1.26) 
OR, odds ratio. CI, confidence interval. *Adjusted for HIV, Leukaemia, Lymphoma, Myeloma, HSCT, 
Other Immune deficiencies, Oral corticosteroids (previous 3 months), Other Immunosuppressive  
(previous 3 months), ICS, RA, SLE, IBD, COPD, Asthma, CKD, Depression, Diabetes,  






D: Association of various risk factors with zoster, after additionally adjusting for 





In the main analyses patients were matched on practice and thereby the analyses controlled 
for practice-level socioeconomic status.  For patients registered at English practices and 
agreeing to their medical records being linked to other dataset, a patient level socioeconomic 
status score is available. Socioeconomic status (at the patient and practice level) is captured 
using quintiles of the Index of Multiple Deprivation score. At the patient level, the patient's 
home postcode is mapped at the lower level super output level to the corresponding 2007 
IMD score; a low quintile represents the least deprived.  
 
Results 
In total, 427,689 (61.6%) patients had a patient-level socioeconomic status score. The results 
from our sensitivity analysis which additionally adjusts for patient-level socioeconomic status 
are shown in Table D1.  There were no major differences compared to the main analyses.   
 
Table D1: Relative risk of zoster in patients with various risk factors 
 Adjusted OR (99% CI)* 
  
Clinical conditions  
Rheumatoid Arthritis 1.54 (1.42 to 1.65) 
Systemic Lupus Erythematosis 1.82 (1.46 to 2.27) 
Inflammatory Bowel Disease 1.39 (1.26 to 1.54) 
COPD 1.33 (1.26 to 1.40) 
Asthma 1.21 (1.16 to 1.26) 
Chronic Kidney Disease 1.13 (1.08 to 1.19) 
Depression 1.16 (1.10 to 1.22) 
Diabetes 1.01 (0.98 to 1.06) 
Diabetes Type  
No diabetes 1 
Type 1 1.30 (1.05 to 1.61) 
Type 2 1.01 (0.96 to 1.05) 
Unknown 1.09 (0.93 to 1.27) 
OR, odds ratio. CI, confidence interval. *Adjusted for HIV, Leukaemia, Lymphoma, Myeloma, HSCT, 
Other Immune deficiencies, RA, SLE, IBD, COPD, Asthma, CKD, Depression, Diabetes, Smoking and 








In the main analyses we only included “active” controls, by ensuring controls had at least one 
consultation anytime within an 18 month period around the index date.  In these sensitivity 
analyses, we applied different definitions of “active” controls. First we ensured controls had a 
consultation anytime from 1 year prior, to 2 years following the index date. Second, we 
required controls to have a consultation in the three years prior to index date.  
 
Results 
In the first analysis, 12,891 controls and 35 cases were excluded (compared to 27,928 controls 
and 88 cases in the main analysis). This meant 145,012 cases of zoster and 564,373 controls 
were included. In the second sensitivity analysis (where controls were required to have contact 
3 years prior to index date), 31,551 controls and 303 cases were excluded; this left 144,744 
cases of zoster and 545,713 controls in the analysis. There were no differences in the study 
findings compared to the main analyses (Table E1).   
 
Table E1: Relative risk of zoster in patients with various risk factors 
 
Adjusted OR (99% 
CI)*once excluding 
controls without contact 
anytime from 1 year prior, 
to 2 years following the 
index date 
Adjusted OR (99% CI)* 
once excluding controls 
without contact 3 years 
prior to index 
   
Clinical conditions   
Rheumatoid Arthritis 1.47 (1.39 to 1.56) 1.45 (1.37 to 1.54) 
Systemic Lupus 
Erythematosis 1.72 (1.46 to 2.04) 1.70 (1.43 to 2.01) 
Inflammatory Bowel Disease 1.37 (1.28 to 1.48) 1.35 (1.26 to 1.46) 
COPD 1.33 (1.27 to 1.38) 1.31 (1.26 to 1.36) 
Asthma 1.23 (1.20 to 1.28) 1.21 (1.17 to 1.25) 
Chronic Kidney Disease 1.14 (1.10 to 1.19) 1.13 (1.09 to 1.07) 
Depression 1.17 (1.12 to 1.22) 1.15 (1.10 to 1.19) 
Diabetes 1.03 (1.00 to 1.06) 1.02 (0.99 to 1.05) 
Diabetes Type   
No diabetes 1 1 
Type 1 1.32 (1.11 to 1.55) 1.29 (1.09 to 1.52) 
Type 2 1.02 (0.98 to 1.05) 1.00 (0.97 to 1.04) 
Unknown 1.15 (1.02 to 1.30) 1.13 (1.00 to 1.28) 
OR, odds ratio. CI, confidence interval. *Adjusted for HIV, Leukaemia, Lymphoma, Myeloma, HSCT, Other Immune  














We explored how frequently patients consulted the general practitioner as this may introduce 
ascertainment bias (i.e. patients visiting their general practitioner more frequently may be 
more likely to receive a zoster diagnosis). We calculated the mean yearly consultation rate 
prior to index date (by dividing the total number of face-to-face or telephone consultations 
during follow-up, by the total years of follow-up prior to index date) among patients with our 
risk factors of interest. We compared this to the mean consultation rate for epilepsy, to assess 
whether epilepsy patients had a similar likelihood of being diagnosed with zoster.  
 
Results 
The results are shown in Table F1.  The consultation rates among patients with our risk factors 
of interest were very similar. The mean number of consultations per year among epilepsy 
patients was 10.2, suggesting these patients consult with similar frequency as patients with 
our risk factors of interest. 
 
Table F1: Mean consultation rate prior to index date 
 
Mean number of consultations per year prior 
to index date 
  
Clinical conditions  
Rheumatoid Arthritis 11.7 
Systemic Lupus Erythematosis 10.9 
Inflammatory Bowel Disease 9.7 
COPD 11.7 
Asthma 9.5 









4.4.   Additional methods: selecting controls 
Appropriate control selection in case-control studies is key to generating valid results.   
 Sampling controls 
There are three methods for sampling controls in case-control studies (represented pictorially 
in Figure 1).128 
 Cumulative sampling: Traditionally employed by case-control studies, where non-cases 
are selected at the end of follow-up from “survivors” or those who are disease free.  
 Case-cohort sampling: Where controls are selected from the entire cohort at baseline, 
in other words the base population. This method is also known as case-base sampling 
and is the least common method. 
 Incidence density sampling: where controls are selected from the “risk set” of persons 
at risk at the time that each case occurs. Also called concurrent sampling. 
 
 


















Note: the horizontal lines represents individual patients and their follow-up ends when the line 
stops.129 
 
The matched case-control study in this chapter utilises incidence density sampling to match 
cases to controls; so for each case, controls were selected from all those “at risk” of zoster on 
the day the zoster case was diagnosed.  It can be shown that when this method of control 























Case: patient diagnosed with zoster 
Potential control: Non-zoster patient lost to 
follow-up 
Time point at which controls are selected 
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Please note that although this method does provide rate ratio estimates, ORs were reported in 
the paper, as this is still technically correct and reporting rate ratios may have led to confusion.  
 
In incidence density sampling, a single control could be matched to more than one case.131 In 
other words, even after being selected as a control, individuals should remain eligible to be 
controls for other cases. Furthermore, cases can be controls prior to their zoster diagnosis.131 
These features ensure that the resulting OR will provide an unbiased estimate of the 
underlying rate ratio, by sampling controls from all those at risk of zoster at the time of 
sampling.  
 
This sampling method was chosen as it is seen as the gold-standard sampling method for case-
control studies and provides usefully interpretable effect estimates. The key disadvantages of 
cumulative sampling are: 1) cases cannot be in the control group, therefore the control group 
will not truly represent the entire base population at risk; and 2) by sampling controls at the 
end of follow-up, factors influencing loss to follow-up will influence the selection of controls. 
Finally, time-window bias, where the observation time during which exposures could have 
been recorded differs between cases and controls, is less of a problem if incidence density 
sampling is used.132  By selecting controls from the all person-moments instead of the end of 
follow-up (as in cumulative sampling), the resulting exposure measurement for controls and 
cases are based on a more similar time span. 
 
 Matching cases and controls  
Individual-level matching in case-control studies is the process of selecting a specified number 
of controls for each case, who are similar in terms of certain pre-specified characteristics, in 
order to reduce the confounding effects of those characteristics.131 If the matching 
characteristic is a very strong confounder, then matching increases the efficiency of the study. 
Without matching, adjusting for these confounders could lead to multiple strata with few data. 
Forcing the cases and controls to have a similar distribution of the matching variables results in 
gains in precision and narrower confidence intervals (CIs).133 Matching may also control for 
unmeasured confounders.  
 
4.4.2.1. Matching factors  
The matching factors were; age (within 1 year), gender and general practice.  Calendar time is 
matched on by default when using incidence density sampling, as the controls have to be 




Age is a very strong risk factor for zoster, therefore an important confounder to control for as 
tightly as possible.  Gender is another well-reported risk factor for zoster, and associated with 
a number of the potential risk factors. Matching on practice controlled for practice level SES 
helping to account for some unmeasured socioeconomic differences as well as allow 
heterogeneity between patterns of prescribing or recording to be accounted for.     
 
 
4.4.2.2. Ratio of cases to controls 
Cases were matched to up to four controls, as any more controls is not deemed to increase 
efficiency.134  
 
 Matching programme 
With the help of a statistician, an algorithm was developed to individually match cases to 
controls, as follows: 
1. All potential controls for each case were identified: as cases were eligible to be 
controls up until their zoster diagnosis, they were included in the pool of potential 
controls, with their end date redefined as their zoster date, minus one day.  
2. Up to four controls were randomly selected for each case at random without 
replacement. Priority was given to potential controls closest in age to the case. 
 






4.5.   Additional results: body mass index, smoking and alcohol 
status 
 
BMI category, smoking status and alcohol use were investigated as potential confounders in 
the published zoster case-control study (section 4.2). As these factors were not pre-specified 
exposures of interest, their effect on zoster risk was not reported in the published paper.  
Table 7 below describes the relative risk of zoster by BMI, smoking and alcohol status.  Please 
note BMI was not included in the fully adjusted models.   
 
Table 7: Relative risk of zoster by BMI category, smoking status and alcohol use 
 No (%)  OR (95% CI) 




 Model 1* Model 2† Model 3‡ 
Risk factor       
BMI category       
Underweight 2,776  (2.1)    10,549 (2.2)  0.98 (0.92-1.04) - - 
Normal 
weight 
50,530 (38.6)      188,060 (38.7)      1.00 - - 
Overweight 47,886 (36.6)      177,603 (36.6)      1.00 (0.99-1.02) - - 
Obese 29,581 (22.6) 109,440 (22.5)  1.01 (0.99-1.04) - - 
Smoking       
  Non-smoker 54,751 (38.2)      208,436 (38.8)      1.00 1.00 1.00 
  Current 
smoker 
36,107 (25.2)      141,826 (26.4)   0.95 (0.93-0.97) 0.93 (0.91-0.95) 0.93 (0.91-0.95) 
  Ex-smoker 52,353 (36.6) 186,373 (34.7)  1.10 (1.08-1.12) 1.06 (1.04-1.08) 1.06 (1.04-1.09) 
Alcohol use       
  Non-drinker 14,481 (11.1)     56,774 (11.7)     1.00 1.00 1.00 
  Current 
drinker 
103,113 
(79.1)      
383,976 (79.0)       1.05 (1.02-1.08) 1.05 (1.02-1.08) 1.05 (1.02-1.08) 
  Ex-drinker 12,786 (9.8) 45,242 (9.3)  1.13 (1.09-1.17) 1.11 (1.07-1.15) 1.11 (1.07-1.15) 
*Adjusted for matching factors only. 
†Adjusted for HIV, leukaemia, lymphoma, myeloma, haematopoietic stem cell transplantation, other unspecified 
cellular immune deficiencies, RA, SLE, IBD, COPD, asthma, CKD, depression, diabetes, smoking, and alcohol. 
‡Additionally adjusted for oral corticosteroids, other immunosuppressive treatment, and ICS. 
 
 
BMI: results and interpretation 
There appeared to be no evidence that BMI category was associated with zoster risk, after 
adjusting for matching factors (age within one year, gender and practice). BMI category was 
therefore not included in the fully adjusted models (that is, model 2 and model 3 in table 7 
above).  This null association is in line with a previous Australian cohort study.51 
 
Smoking: results and interpretation 
From table 7 there is good evidence that current smokers have a small but significant 
reduction in the risk of zoster (Model 3: OR:0.93, 95%CI 0.91-0.95), compared to non-smokers.  
By contrast, ex-smokers have 1.06 times the odds of zoster than non-smokers (Model 3, 
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OR:1.06, 95%CI 1.04-1.09). These findings are in line with previous research, suggesting that 
current smoking may be protective against zoster and previous smoking may be a risk factor 
for zoster.51,135 
 
Alcohol: results and interpretation 
Being both a current and an ex-drinker was associated with 5% and 11% increased risk of 
zoster respectively. This is the first known study to report an association, albeit small, between 







4.6.   Additional biological evidence indicating impaired cell-
mediated immunity associated with the exposures of interest 
As described in the introduction, zoster reactivation occurs due to a waning of VZV-specific T 
cell-mediated immunity.  Below is some biological evidence suggesting that the exposures of 
interest (specifically, RA, SLE, IBD, asthma, COPD, depression, diabetes, and CKD) investigated 
as risk factors for zoster in this thesis, are associated with impaired cell-mediated immune 
function.  
 
 Autoimmune conditions 
Autoimmune conditions are associated with increased risk of infections,136 indicating poor 
immune function. Cell-mediated immunity may be suppressed in patients with autoimmune 
conditions, due to the routine use of immunosuppressive medications, or the underlying 
disease itself.136 RA patients have been shown to experience accelerated immune senescence 
of T cells and reduced T cell diversity.137 A study of 38 SLE patients and 51 healthy controls, 
found decreased cellular immune responses and VZV-specific immunity in the SLE patients 
compared to healthy controls, and this was not influenced by immunosuppressive medication 
use.138 This finding suggests that SLE, as a disease, may be driving impaired cell-mediated 
immune function.  The other autoimmune condition assessed in this thesis is IBD.  Little 
research exists exploring VZV-specific immunity among IBD patients, however IBD is reported 
to be associated with abnormalities in cell-mediated immunity.58,139 
 
 Asthma and chronic obstructive pulmonary disorder 
Authors have suggested that asthma might play a role in waning cell-mediated immunity, as 
evidenced by reduced immune response to measles, mumps and rubella vaccination in 
asthmatic compared to non-asthmatic children.140 It is currently unclear whether COPD as a 
disease itself alters cell-mediated immunity; however, some authors have suggested that 
COPD leads to systemic immune disturbances.141 As asthma and COPD are both treated with 
corticosteroids,  patients may experience drug-induced alterations in cell-mediated immunity 
from use of ICS142-146 and oral corticosteroids.104  
 
 Depression 
Depression may also lead to poorer cell-mediated immune function. Recent virology studies 
indirectly support the hypothesis that depression may lead to an increased risk of zoster. A 
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study demonstrated that 52 patients with major depressive disorder had lower VZV-specific 
cell-mediated immunity, compared to 52 age and sex-matched patients without depression, 
and the level of the immune response correlated negatively with the severity of depression.147 
Another study showed that depressed individuals had reduced VZV cell-mediated immune 
responses when administered the zoster vaccine.148  
 
There is also evidence that stress, common in patients with depression, may also affect cell-
mediated immunity. The central nervous, endocrine and immune system interact with each 
other, such that a dysregulation in one system can have an effect on the other systems. Stress 
can affect a number of neuroendocrine functions, including activating the hypothalamic–
pituitary–adrenal axis which can thereby in turn affect cell-mediated immunity.149,150 
Additionally, patients experiencing stress are likely to have habits, such as reduced sleep, 
which may indirectly affect immune function. Virological evidence that astronauts have 
experienced sub-clinical VZV reactivation during space travel, suggests stress may trigger a 
reduced cell-meditated immune response.151,152 Finally, evidence of a randomised controlled 
trial of a stress-reducing behavioural intervention, Tai Chi, found the Tai Chi group showed 
higher levels of VZV cell-mediated immunity than the control group (who received some health 
education) after 25 weeks.153 
 
 Chronic Kidney Disease 
Researchers have suggested that a decline in renal function can result in reduced cell-
mediated immunity.  VZV-specific cell-mediated immunity has not been assessed in patients 
with kidney disease.  However, patients with CKD demonstrate an increased susceptibility to 
infections (the second most common cause of death in dialysis patients is infection) and 
decreased serological response to vaccination, such as Hepatitis B and influenza, which points 
to an impaired cellular immune response.154,155 There is also some evidence that CKD causes a 
diminished activation of T cells.156 The causes of immune dysfunction in CKD are not fully 
understood, however uraemia (a raised level of waste products in the blood, usually 
eliminated by the kidneys), is thought to be the mediating factor.157 
 
 Diabetes 
Patients with diabetes have more infections than patients without diabetes158 and 
hyperglycaemia (too much blood sugar in the bloodstream) is believed to lead to immune 
suppression159,160 and T-cell dysregulation.161 Furthermore, a virological study found VZV-
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4.7.   Chapter summary 
 
  
Quantification of risk factors for herpes zoster 
 Current zoster vaccination campaigns focus on older people only. 
 Recent literature has suggested that a range of clinical conditions are 
associated with an increased risk of zoster, raising the possibility that some 
younger people may be at high risk. However, large, highly powered studies 
investigating the association of these clinical conditions with zoster are lacking. 
 A case-control study was carried out in CPRD with 144,959 zoster cases and 
549,336 age, sex and practice-matched controls, and the associations between 
a range of potential risk factors and zoster were investigated. 
 Conditions associated with increased risk of zoster included RA, SLE, IBD, 
COPD, asthma, CKD, type 1 diabetes and depression. 
 The increased risks were generally greater among younger age groups. 
 Those at highest risk of zoster remain those who have severely weakened 
immune systems and the current vaccine is contraindicated for these 
individuals. This emphasises that alternative strategies (which could include 
non-live vaccines and antiviral prophylaxis) are needed to reduce the risk of 
shingles among these patient groups. 
 Further information about the risk of complications, particularly PHN, is 




Chapter 5:   Prescription of antiviral 
therapy after herpes zoster: who 
receives therapy?  
5.1.   Introduction 
Antiviral medication is given to certain patients following zoster, to accelerate rash healing 
during an acute zoster episode and to limit the severity and duration of pain.  Their 
effectiveness in preventing PHN is disputed. Understanding which patients receive antivirals in 
routine practice will be important to: 1) assess whether prescriptions guidelines are adhered to 
in UK general practice; and 2) inform the analysis in chapter 7, which evaluates the effect of 
antiviral use on the risk of PHN among zoster patients.  
 
This research on the prescription of antiviral therapy following zoster was published in the 
British Journal of General Practice and is presented below.  Please note at the time of 









Herpes zoster presents as a painful unilateral 
vesicular dermatomal rash1 resulting from 
reactivation of latent varicella zoster virus 
infection. Reactivation is thought to result 
from waning cell-mediated immunity. 
Zoster is common among older people with 
a lifetime risk of 10–30%, rising to 50% 
among those living to 85 years.2 Post-
herpetic neuralgia develops in around 20% 
of individuals aged 50 years3 and causes 
persistent severe pain for months to years 
after rash onset.4
Antivirals have been demonstrated in 
multiple clinical trials to accelerate rash 
healing and limit the severity and duration 
of pain during an acute zoster episode.4 
There is also some evidence suggesting 
they may reduce the risk of post-herpetic 
neuralgia,5–7 possibly by reducing neural 
damage which may contribute to its 
development.4 Treatment options for post-
herpetic neuralgia are limited, therefore the 
potential use of antivirals to prevent post-
herpetic neuralgia is particularly important. 
Current UK guidelines advise GPs 
to prescribe oral antiviral drugs within 
72 hours of rash onset for: people aged 
50 years, ophthalmic zoster, other non-
truncal disease, immunosuppression, or 
individuals with moderate to severe pain 
or rash.8 Guidelines further recommend 
treatment up to 1 week after rash onset, 
particularly when characteristics for severe 
zoster or complications are present, such 
as continued vesicle formation, older age, 
immunosuppression, or severe pain.8 
Research on the proportion of zoster 
individuals prescribed antivirals is limited3 
and previous studies have reported overall 
use, rather than by specific risk groups. 
Zoster incidence is likely to increase in the 
UK, due to population ageing and increasing 
use of immunosuppressive therapies, 
and it is important to understand current 
prescribing patterns.
This study aims to analyse antiviral 
prescription patterns by patient 
characteristics after a zoster diagnosis in 
UK general practice. 
METHOD
This is a descriptive and risk factor analysis 
of UK electronic healthcare records over a 
study period from 1 January 2000 to 13 June 
2011.
Data source
This study utilised data from the UK General 
Practice Research Database (GPRD), a large 
computerised database of anonymised 
patient records that contains complete 
prescribing and diagnostic information in 
primary care and feedback from hospital 
referrals. It is one of the largest sources 
of continuous patient records in the UK, 
containing data on approximately 7% of the 
UK population and is broadly representative 
of patient and practice characteristics in 
the UK. 
Selecting incident zoster cases
An incident zoster case was anyone aged 
18 years with a diagnostic code for zoster 
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Antivirals can accelerate rash healing during an 
acute zoster episode and can limit the severity 
and duration of pain. Their use within 7 days of 
rash onset is recommended among specific 
patient groups.
Aim
To describe antiviral prescription patterns and 
patient characteristics associated with antiviral 
receipt after zoster diagnosis.
Design and setting
Descriptive study and risk factor analysis using 
electronic healthcare records from UK general 
practice.
Method
Incident adult zoster cases occurring between 
2000 and 2011 were identified in the General 
Practice Research Database. Therapy records 
were searched for antiviral prescriptions of 
aciclovir, famciclovir, or valaciclovir within 
7 days of zoster diagnosis. The proportion of 
incident zoster cases receiving antivirals was 
calculated and multivariable logistic regression 
used to assess associations between patient 
characteristics and antiviral use.
Results
Of 142 216 incident zoster cases 58.1% received 
an antiviral prescription. The majority (69.0%) 
were aciclovir. The proportion receiving antiviral 
prescriptions increased with age up to 65 years, 
then declined to 56.8% among patients 
aged 85 years. Being female and of higher 
socioeconomic status were associated with 
higher antiviral receipt. Antivirals were more 
commonly prescribed to immunosuppressed 
patients with herpes zoster (odds ratio 1.27; 
95% CI = 1.22 to 1.33), however they were not 
given routinely to this patient group. 
Conclusion
Antiviral therapies for zoster are under-
prescribed in UK general practice even among 
groups, such as immunosuppressed and older 
individuals, for whom guidelines recommend 
treatment. Patients may present too late to 
receive treatment or physicians may decide 
that antivirals are not essential treatment. 
Consideration could be given to reviewing the 
guidelines.
Keywords
antivirals; database; epidemiology; general 
practice; GPRD; herpes zoster; shingles; United 
Kingdom.
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in GPRD during the study period, without any 
consultations for zoster during the previous 
year. For patients with recurrent zoster 
episodes during the study period only the 
first episode was included. Those with zoster 
episodes occurring within 1 year of the start 
date were excluded, to remove potentially 
incorrectly dated prevalent cases.9 Patients 
diagnosed with zoster encephalitis, zoster 
meningitis, or with another central nervous 
system complication within 7 days of the 
first zoster record were also excluded 
(n = 113) as they would typically be treated in 
secondary care. Read Codes indicating the 
anatomical site of zoster were searched for 
in all records within a zoster episode, defined 
as 1 year following first zoster record. Site 
of zoster was categorised into ophthalmic, 
other non-truncal and unspecified site; there 
is no existing Read Code for truncal zoster.
Sociodemographic characteristics of 
zoster cases
Age, sex, and geographical health region 
were obtained from the extracted GPRD data. 
Age was categorised as 18–49, 50–64, 65–74, 
75–84, or 85 years. Socioeconomic status 
was analysed using quintiles of the Index of 
Multiple Deprivation (IMD) score, available 
for patients registered at English practices 
agreeing to link medical records with other 
databases. The patient’s home postcode is 
mapped at the lower level super output level 
to the corresponding 2007 IMD score; a low 
quintile represents the least deprived. As 
patient-level IMD score was not available for 
patients from unlinked practices in England, 
a sensitivity analysis was run using practice-
level IMD quintile when patient-level IMD 
quintile was unavailable.10
Identifying comorbidities at zoster 
diagnosis
As NHS guidelines recommend antiviral 
prescription for all immunosuppressed 
individuals, prescribing patterns were 
explored in this group. Patients were 
considered severely immunosuppressed 
if they had a diagnosis within 2 years 
preceding their zoster episode of leukaemia, 
lymphoma, or a bone marrow transplant 
or if they had ever had a diagnosis of HIV, 
a splenectomy, an organ/tissue transplant, 
myeloma diagnosis, or ‘other immune 
deficiencies’ (for example, immunodeficiency 
with predominantly antibody defects such 
as selective IgA immune deficiency and 
agammaglobulinemia, aplastic anaemias, 
and non-specific diagnoses of immune 
disorder). Patients prescribed at least one 
immunosuppressive medication, including 
oral corticosteroids, 3 months before 
their zoster episode were also considered 
severely immunosuppressed. 
To explore antiviral prescribing 
patterns among patients with moderate 
immunosuppression, the following 
autoimmune conditions were flagged: 
diabetes, rheumatoid arthritis, inflammatory 
bowel disease, and systemic lupus 
erythematosus. 
Antiviral use
Antiviral prescriptions including aciclovir, 
famciclovir, or valaciclovir within 7 days of a 
zoster diagnosis were identified from GPRD 
therapy records. 
Data analysis
Data were analysed using STATA/MP (version 
11.2). The proportion of incident zoster cases 
receiving antivirals was determined, and 
described by various patient characteristics. 
The association between antiviral use and 
patient characteristics was assessed using 
multivariable logistic regression adjusting 
for age, sex, region, year, zoster site, and 
immunosuppression status. Socioeconomic 
status was not adjusted for as it was only 
available for selected English practices. 
RESULTS
Between 2000 and 2011 142 216 incident 
zoster cases were identified. Of these 82 656 
(58.1%) received an antiviral prescription 
within 7 days of diagnosis in GPRD. Of those 
prescribed antivirals 80 751 (97.7%) were 
given on the day of the zoster diagnosis. 
The most commonly prescribed antiviral 
was aciclovir (69.0%), followed by famciclovir 
(27.8%) and valaciclovir (3.5%). A small 
number (n =  224) of cases had two different 
antivirals prescribed on the same day and 
were included in both antiviral groups 
(therefore totals do not add up to 100%).
The proportion of patients prescribed 
antivirals increased with age up to 
How this fits in
This article is the first to describe who 
receives antiviral therapy following a zoster 
diagnosis within the UK. It highlights 
that antivirals are under-prescribed in 
UK primary care, including among those 
particularly recommended for treatment, 
such as older individuals and those with 
immunosuppressive conditions. Although 
patients may present too late to receive 
therapy, under-treatment may reflect 
poor adherence to treatment guidelines.  
Consideration could be given to reviewing 
the guidelines. 
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65–74 years, when the percentage plateaued 
and then reduced to 56.8% among patients 
aged 85 years (Table 1). Females were 
more likely to be prescribed antivirals 
compared to males (adjusted odds ratio 
[AOR] 1.11, 95% confidence interval [CI] = 
1.09 to 1.13). However, the sex difference 
disappeared among patients aged 75 years 
(Figure 1) (in 2 tests P>0.2). 
Patients with an ophthalmic zoster 
diagnosis were less likely to receive 
antivirals compared to patients with zoster 
at an unspecified site (AOR 0.66, 95% CI = 
0.61 to 0.72) (Table 1). Similarly, patients with 
other non-truncal zoster were less likely to 
be prescribed antivirals (AOR 0.34, 95% CI = 
0.30 to 0.40) (Table 1).
The percentage of patients receiving 
antivirals increased every year between 
2000 and 2010, from 45.7% to 65.3% and 
this trend remained after adjusting for 
confounders (Table 1). Antiviral use varied 
by UK region. The lowest use of antivirals 
was in the north-east regions of England, 
specifically Yorkshire and Humber (51.9%) 
and the North East (52.8%). The highest 
use was in Northern Ireland (67.7%), where 
patients were 89% more likely to receive 
antivirals compared to patients in Yorkshire 
and Humber (AOR 1.89, 95% CI = 1.75 to 2.04). 
IMD score was available for 78 718/112 482 
patients (70.0%) in England. The percentage 
of patients prescribed antivirals reduced 
with increasing IMD quintile, with 58.4% of 
patients in quintile zero and 54.6% in quintile 
four (most deprived) having received antiviral 
therapy (Table 1). Using practice-level IMD 
score for cases in England missing patient-
level IMD, the results did not change (data 
not shown).
Zoster patients with immunosuppression 
were 27% more likely to receive 
antivirals compared to patients without 
immunosuppression (AOR 1.27, 95% CI 
= 1.22 to 1.33) (Table 2). Some evidence 
for greater antiviral use was found for all 
patients with severe immunosuppression, 
excluding myeloma (AOR 1.03, 95% CI = 0.85 
to 1.24) (Table 2).
Of the selected autoimmune 
conditions considered to cause moderate 
immunosuppression, there was strong 
evidence that patients with rheumatoid 
arthritis were more likely to receive antiviral 
therapy, compared to patients without 
rheumatoid arthritis (Table 2). This effect 
was seen both among rheumatoid arthritis 
patients not taking immunosuppressive 
therapies (AOR 1.17, 95% CI = 1.05 to 
1.29), and among rheumatoid arthritis 
patients on immunosuppressive therapy 
(AOR 1.28, 95% CI = 1.14 to 1.42). A similar 
pattern was seen among systemic lupus 
erythematosus patients (Table 2). Patients 
with inflammatory bowel disease were only 
more likely to receive therapy if they were 
on immunosuppressants (AOR 1.52, 95% CI 
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Table 1. Proportion of patients prescribed antiviral medication, by 
patient characteristics  
  % Unadjusted OR Adjusted OR 
Patient characteristic n Treated  (95% CI) (95% CI)a P-value
Age group, years      
  18–49 38 665 52.2 1.00 1.00   
  50–64 42 631 58.6 1.30 (1.26 to 1.34) 1.29 (1.26 to 1.33)  
  65–74 29 203 62.6 1.53 (1.49 to 1.58) 1.53 (1.49 to 1.58)  
  75–84 23 341 62.0 1.50 (1.45 to 1.55) 1.49 (1.44 to 1.54)  
  85 8376 56.8 1.21 (1.15 to 1.26) 1.17 (1.12 to 1.23) <0.01
Zoster site      
  Site unspecified 139 214 58.4 1.00 1.00   
  Non-truncal zoster 873 30.9 0.32 (0.28 to 0.37) 0.34 (0.30–0.40) 
    (excluding ophthalmic)   
  Ophthalmic zoster 2129 49.4 0.69 (0.64 to 0.76) 0.66 (0.61 to 0.72) <0.01
Sex      
  Male 57 096 56.5 1.00 1.00   
  Female 85 120 59.2 1.12 (1.09 to 1.14) 1.11(1.09 to 1.13) <0.01
Year diagnosed      
  2000 8638 45.7 1.00 1.00  
  2001 10 202 48.5 1.12 (1.06 to 1.18) 1.12 (1.06 to 1.19)  
  2002 11 114 50.7 1.22 (1.16 to 1.29) 1.22 (1.15 to 1.29)  
  2003 12 130 54.3 1.41 (1.33 to 1.49) 1.40 (1.32 to 1.48)  
  2004 13 080 56.7 1.56 (1.47 to 1.65) 1.55 (1.46 to 1.63)  
  2005 13 663 58.7 1.69 (1.60 to 1.78) 1.68 (1.59 to 1.77)  
  2006 13 933 59.4 1.74 (1.65 to 1.84) 1.72 (1.63 to 1.81)  
  2007 13 897 61.9 1.93 (1.83 to 2.04) 1.90 (1.80 to 2.01)  
  2008 13 997 63.1 2.03 (1.93 to 2.15) 2.01 (1.90 to 2.13)  
  2009 14 021 64.0 2.11 (2.00 to 2.23) 2.08 (1.97 to 2.20)  
  2010 13 518 65.3 2.24 (2.12 to 2.37) 2.21 (2.09 to 2.33)  
  2011 4023 64.2 2.13 (1.97 to 2.30) 2.07 (1.91 to 2.24) <0.01
Region      
  Yorkshire and Humber 6682 51.9 1.00 1.00       
  North West 18 808 59.1 1.34 (1.27 to 1.42) 1.30 (1.23 to 1.37)  
  North East 3076 52.8 1.04 (0.95 to 1.13) 1.00 (0.92 to 1.09)  
  East Midlands 5789 54.6 1.11 (1.04 to 1.20) 1.10 (1.03 to 1.18)  
  West Midlands 13 664 55.4 1.15 (1.09 to 1.22) 1.12 (1.06 to 1.19)  
  East of England 13 274 58.2 1.29 (1.22 to 1.37) 1.25 (1.18 to 1.33)  
  South West 12 056 59.4 1.36 (1.28 to 1.44) 1.29 (1.21 to 1.37)  
  South Central 15 632 57.2 1.24 (1.17 to 1.31) 1.19 (1.12 to 1.26)  
  London 11 551 55.4 1.15 (1.09 to 1.23) 1.10 (1.04 to 1.17)  
  South East Coast 11 950 59.2 1.34 (1.27 to 1.43) 1.26 (1.19 to 1.34)  
  Northern Ireland 5114 67.7 1.94 (1.80 to 2.09) 1.89 (1.75 to 2.04)  
  Scotland 11 475 63.1 1.59 (1.49 to 1.69) 1.48 (1.39 to 1.57)  
  Wales 13 145 58.8 1.32 (1.25 to 1.40) 1.23 (1.16 to 1.31) <0.01
IMD quintilec      
  (Least deprived) 0 19 762 58.4 1.00 1.00   
  1 19 650 57.9 0.98 (0.94 to 1.02) 0.97 (0.93 to 1.01)  
  2 16 050 57.4 0.96 (0.92 to 1.00) 0.95 (0.91 to 0.99)  
  3 13 892 56.2 0.91 (0.87 to 0.95) 0.91 (0.87 to 0.95)  
  (Most deprived) 4 9364 54.6 0.86 (0.81 to 0.90) 0.85 (0.81 to 0.90) <0.01b
AV = antivirals. aAdjusted for age, sex, region, year, zoster site and immunosuppression status, based on severe 
immunosuppression. bTest for trend. cAnalysis restricted to patients registered at English practices with IMD 
score available.
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= 1.24 to 1.85). Patients with diabetes were 




In the UK between 2000 and 2011, the overall 
proportion of patients prescribed antivirals 
within 7 days of a zoster diagnosis was low 
(58.1%) though a clear increase was seen 
over time. Aciclovir was the most common 
antiviral prescribed. Antiviral prescriptions 
increased with age; however this trend 
stopped after age 65 years and prescriptions 
declined among patients 85 years. 
Being female, of higher socioeconomic 
status, and registered at a GP in Northern 
Ireland or Scotland was associated with 
higher antiviral receipt. Although antivirals 
were more commonly prescribed to 
immunosuppressed patients with herpes 
zoster, they were not given routinely in 
general practice to this patient group. 
Why are antiviral prescriptions for zoster 
low? The finding that a low proportion of 
patients are prescribed antivirals for an 
acute episode of zoster correlates with a 
previous study of GPRD data reporting that 
56.3% of 27 225 immunocompetent patients 
with herpes zoster aged 50 years received 
antivirals between 2000 and 2006.3 These 
findings could suggest a lack of adherence 
to guidelines. Antivirals are generally safe, 
well tolerated,4 and aciclovir is inexpensive, 
therefore neither adverse effects nor cost 
implications can explain their low use 
following zoster diagnosis. It is possible 
that antivirals are not seen as essential 
treatment, as they do not provide a cure, 
rather they can reduce duration of the rash 
and the severity of pain during the episode. 
Although antivirals are suggested to reduce 
the risk of post-herpetic neuralgia, evidence 
is inconclusive,5–7 which may again deter 
physicians from prescribing them. This may 
be especially pertinent to mild cases of 
zoster.
An alternative explanation is patients are 
presenting too late to receive treatment; 
more than 72 hours after rash onset. 
This 72-hour cut-off reflects an arbitrary 
criterion used in clinical trials of antiviral 
therapy in patients with herpes zoster.4 
This may be an unrealistic time frame for 
patients to secure an appointment with their 
GP.4 Therefore guidelines encourage GPs to 
‘consider’ use of antivirals within 7 days of 
rash onset for older or immunosuppressed 
patients. The guidelines for treating patients 
presenting after 72 hours from rash onset 
lack clarity, and furthermore, are based on 
limited evidence11–12 both of which may deter 
prescribing. 
Patients may also present following the 
7-day window when it is too late to receive 
antiviral therapy. Although data on time 
from actual rash onset to presentation to 
the GP is not available in this data set, 
two previous UK studies suggest patients 
present soon after rash onset: Scott et 
al reported that 50–60% of patients aged 
>50 years presented to GPs within 72 hours 
of rash onset,13 and analyses of data from 
Thomas et al shows that 65% of adult 
patients with herpes zoster presented by 
72 hours, with less than 7% presenting after 
7 days.14
Additionally, a small proportion of 
immunosuppressed patients who get 
disseminated zoster will be referred, as per 
guidelines, to secondary care for systemic 
therapy and their antiviral use not recorded 
here. However this would not explain the low 
prescribing rates for the majority of patients 
in this study.
Why are there age, sex, regional, and 
socioeconomic differences? As expected 
the proportion of patients with herpes zoster 
prescribed antivirals increases with age. 
Explanations for why this trend plateaus 
at age 65 years and subsequently declines 
among the oldest may include; older patients 
being in nursing homes and presenting to 
GPs later, or reluctance to prescribe to older 
patients nearing the end of their life. Patients 
in Scotland and Northern Ireland were more 





























50–64 65–74 75–84 ≥85
Female
Figure 1. Percentage of patients receiving 
antiviral therapy, by age and sex (error bars 
represent 95% CIs).
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reflect patients accessing GP services more 
quickly or different prescribing cultures 
among physicians. Reasons why males and 
people of lower socioeconomic status were 
less likely to receive antivirals may include 
differences in when these groups access 
care or physicians differentially prescribing 
antivirals among these groups.
Antiviral use among patients with 
immunosuppression. It is recommended 
antivirals be given routinely to patients 
with immunosuppression; however the 
proportion receiving treatment ranged 
between 62–68%. This may again be 
explained by delay in consulting GPs, 
some patients with severe underlying 
comorbidities accessing antiviral therapy 
through secondary care or physicians not 
seeing antiviral treatment as a necessity. 
Antiviral use by zoster site. Ophthalmic 
and other non-truncal zoster cases were 
less commonly prescribed antivirals than 
zoster cases where site was unspecified, 
even after adjusting for age, sex, region, 
year, and immunosuppression status. This 
is a surprising finding considering guidelines 
suggest these groups routinely be given 
antiviral therapy. Patients with Ramsay 
Hunt Syndrome, the most common other 
non-truncal diagnosis, may present initially 
without an obvious rash and delayed 
diagnosis might contribute to lower 
prescription rates in this group. Ophthalmic 
zoster patients may be immediately referred 
to secondary care for treatment, resulting in 
lower prescribing rates among this group. 
However, misclassification of zoster site is 
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Table 2. Proportion of patients prescribed antiviral medication, by 
comorbidities   
  %  Unadjusted Adjusted 
Patient characteristic n Treated OR (95% CI) OR (95% CI)a P-value
Conditions causing severe immunosuppressionb
Severe immunosuppression 8924 64.9 1.36 (1.30 to 1.42) 1.27 (1.22 to 1.33) <0.01 
  HIV 132 64.4 1.30 (0.91 to 1.86) 1.51 (1.06 to 2.17) 0.02 
  Leukaemiac 203 64.0 1.28 (0.96 to 1.71) 1.31 (0.98 to 1.76) 0.07 
  Lymphomac 441 62.4 1.19 (0.98 to 1.45) 1.17 (0.96 to 1.43) 0.11 
  Myeloma 479 61.8 1.17 (0.97 to 1.40) 1.03 (0.85 to 1.24) 0.78 
  Organ/tissue transplantd 341 63.3 1.25 (1.00 to 1.55) 1.30 (1.04 to 1.62) 0.02 
  Splenectomy 263 63.9 1.27 (0.99 to 1.64) 1.25 (0.97 to 1.62) 0.08 
  Other immune deficiencies 144 67.4 1.49 (1.05 to 2.11) 1.42 (1.00 to 2.03) 0.05 
  Immunosuppressive therapye  2174 66.8 1.46 (1.33 to 1.60) 1.37 (1.25 to 1.50) <0.01 
  Oral corticosteroid therapy 6149 65.1 1.36 (1.29 to 1.44) 1.27 (1.21 to 1.34) <0.01
Autoimmune diseases 
Diabetes 11 015 61.3 1.15 (1.11 to 1.20) 1.03 (0.99 to 1.07) 0.21 
Rheumatoid Arthritis (RA)      
  No RA 139 113 58.0 1.00 1.00  
  RA without 1639 63.6 1.27 (1.14 to 1.40) 1.17 (1.05 to 1.29) <0.01 
    immunosuppressive therapy  
  RA with 1464 66.2 1.42 (1.27 to 1.58) 1.28 (1.14 to 1.42) <0.01 
    immunosuppressive therapy  
Systemic lupus erythematosus (SLE)      
  No SLE 141 824 58.1 1.00 1.00  
  SLE without 223 63.2 1.24 (0.94 to 1.63) 1.20 (0.91 to 1.58) 0.20 
    immunosuppressive therapy  
  SLE with 169 72.8 1.93 (1.37 to 2.71) 2.11 (1.49 to 2.97) <0.01 
    immunosuppressive therapy  
Inflammatory bowel disease (IBD)      
  No IBD 140 665 58.1 1.00 1.00  
  IBD without 1083 60.4 1.10 (0.97 to 1.24) 1.05 (0.93 to 1.19) 0.43 
    immunosuppressive therapy  
  IBD with 468 68.4 1.56 (1.28 to 1.90)  1.52 (1.24 to 1.85) <0.01 
    immunosuppressive therapy 
aAdjusted for age, sex, region, year, zoster site. bCompared to population without specified diagnosis. cDiagnoses 
<2 years before zoster episode. dBone marrow transplants included if <2years before zoster episode. eExcluding 
oral corticosteroids. Other immune deficiencies: for example immunodeficiency with predominantly antibody 
defects such as selective IgA immune deficiency and agammaglobulinemia, aplastic anaemias such as 
pancytopenia, and non-specific diagnoses of immune disorder.
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likely as the zoster site was seldom recorded. 
Despite this, it is surprising that less than 
50% of cases with a definite diagnosis of 
ophthalmic or other non-truncal zoster 
received antivirals. 
Strengths and limitations
The GPRD is one of the largest databases 
of healthcare records and has excellent 
capture of primary care prescriptions. 
However, these data may not fully capture 
prescriptions in secondary care. A minority 
of patients, particularly those with severe 
underlying comorbidities, may obtain antiviral 
prescriptions in secondary or tertiary care. 
Therefore this study may underestimate the 
prescription of antivirals following an acute 
zoster episode. However, as these patients 
received a zoster diagnosis in primary care, 
it is likely that most would have received any 
subsequent antiviral prescription from their 
GP. Finally, there may be misclassification 
of immunosuppression status as newer 
biologic therapies are poorly recorded in 
GPRD and some patients on long-term 
immunosuppressive therapies may be given 
prescriptions 6-monthly and would not have 
been detected; it is unclear whether receipt 
of antivirals among such individuals would 
differ from that among those identified as 
immunosuppressed in this study. 
Comparison with existing literature
Studies from the US, Italy, and Australia 
report higher proportions of patients 
with herpes zoster receiving antiviral 
prescriptions. A retrospective study of 
healthcare records in Italy between 2003 and 
2005 found 78% of 3260 immunocompetent 
patients with herpes zoster aged 50 years 
received antivirals.15 In Australia analysis 
of healthcare records between 2000–
2006 showed that 73.5% of 379 incident 
zoster cases aged 50 years received 
antivirals16 and a similarly high proportion 
was found in the US where 71.3% of 8741 
newly diagnosed zoster adults (aged 19) 
received antivirals;17 both studies included 
immunosuppressed and immunocompetent 
individuals. In contrast, data from a large 
database of general practice records in the 
Netherlands in 2001 found 22.5% of 1129 
patients with herpes zoster aged 44 years 
received antivirals.18 Observed variation in 
prescribing patterns between countries may 
reflect differences in healthcare systems or 
distribution of patients with characteristics 
more/less likely to get antivirals in study 
populations, or to variations in data quality. 
Implications for research and practice
The proportion of patients in the UK 
receiving antivirals following a diagnosis of 
zoster in primary care is low. This research 
highlights the problem of under-prescribing 
of antivirals for zoster in UK general practice 
even for groups where clear guidelines 
recommend treatment.
Further research is required to understand 
the basis for the low proportions given 
antivirals. This is particularly pertinent for 
older and immunocompromised patients. 
Controlled trials assessing the benefits of 
antivirals prescribed >72 hours after rash 
onset would enable more detailed guidance 
for physicians and may increase antiviral 
prescribing if delay in presenting to GPs is 
a factor contributing to low antiviral use. 
Treatment guidelines could be reviewed to 
clarify which patients should be treated with 
antivirals when it is not possible to initiate 
treatment within 72 hours of rash onset. 
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5.3.   Update of antiviral prescribing guidelines and literature: 
 
The prescribing guidelines for use of antivirals during acute zoster have not changed since 
2012, when the study was carried out and the paper published.   
 
Regarding other literature on the use of antivirals during acute zoster in primary care, two 
relevant studies have been published since. Both studies are in accordance with previous 
literature, demonstrating that outside of the UK, a higher proportion of acute zoster patients 
receive antiviral prescriptions. A study within a large general practice in New Zealand between 
2004 and 2009, found that of 278 incident zoster patients (≥18 years), 82% received antiviral 
treatment; treatment was higher among ophthalmic zoster patients (97% received antivirals) 
and patients presenting within 3 days of symptom onset (96%).163 Another prospective study 
within 108 general practices in Italy between 2009 and 2010, found higher use of antivirals in 
immunocompetent patients aged ≥50 years;164 of 413 patients, 91.5% of patients received 














Antiviral use following first episode of zoster 
 This chapter describes who receives antiviral therapy following a zoster diagnosis 
within the UK.  
 A descriptive study was carried out in CPRD among 142,216 zoster patients to 
calculate the proportion receiving antivirals within seven days of zoster diagnosis.    
 Antivirals are under-prescribed in UK primary care; 58.1% of zoster cases 
received an antiviral prescription within seven days of diagnosis. Even in those 
where guidelines recommend the use of antivirals, specifically older individuals 
and those with immunosuppressive conditions, treatment was not always 
received.  
 Although patients may present too late to receive therapy, under-treatment may 
reflect poor adherence to treatment guidelines.   
 Consideration could be given to reviewing the guidelines. 
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Chapter 6:   Systematic review and 
meta-analysis of risk factors for 
postherpetic neuralgia 
6.1.   Introduction 
As well as exploring risk factors for zoster, this thesis aimed to explore risk factors for PHN.  
Prior to conducting an original research study in CPRD, a systematic review and meta-analysis 
was carried out collating and presenting evidence regarding risk factors for PHN within zoster 
patients.  
 
The article, published in the journal Pain, is presented below. This is followed up with the 
article’s appendices, containing work and details that were too extensive for the main paper, 
specifically: further data extraction details, risk of bias assessment details and letters to 
authors (requesting further study details).  
 
Following the paper and its appendices, there is an additional, shorter review of articles 
investigating risk factors for PHN within general population samples. The published review only 
included articles set within cohorts of zoster patients.  In terms of vaccination policy, it is also 
informative to know who, within the general population, is at high risk of PHN, because such 
individuals could potentially be targeted for vaccination before developing zoster, therefore it 









A systematic review and meta-analysis of risk
factors for postherpetic neuralgia
Harriet J. Forbes*, Sara L. Thomas, Liam Smeeth, Tim Clayton, Ruth Farmer, Krishnan Bhaskaran,
Sine´ad M. Langan
Abstract
Patients with herpes zoster can develop persistent pain after rash healing, a complication known as postherpetic neuralgia. By
preventing zoster through vaccination, the risk of this common complication is reduced. We searched MEDLINE and Embase for
studies assessing risk factors for postherpetic neuralgia, with a view to informing vaccination policy. Nineteen prospective studies were
identified.Meta-analysis showed significant increases in the risk of postherpetic neuralgia with clinical features of acute zoster including
prodromal pain (summary rate ratio 2.29, 95% confidence interval: 1.42-3.69), severe acute pain (2.23, 1.71-2.92), severe rash (2.63,
1.89-3.66), and ophthalmic involvement (2.51, 1.29-4.86). Older age was significantly associated with postherpetic neuralgia; for
individual studies, relative risk estimates per 10-year increase ranged from 1.22 to 3.11. Evidence for differences by gender was
conflicting,with considerable between-study heterogeneity. A proportion of studies reported an increased risk of postherpetic neuralgia
with severe immunosuppression (studies, n5 3/5) and diabetesmellitus (n5 1/4). Systemic lupus erythematosus, recent trauma, and
personality disorder symptoms were associated with postherpetic neuralgia in single studies. No evidence of higher postherpetic
neuralgia risk was foundwith depression (n5 4) or cancer (n5 5). Our review confirms a number of clinical features of acute zoster are
risk factors for postherpetic neuralgia. It has also identified a range of possible vaccine-targetable risk factors for postherpetic neuralgia;
yet aside from age-associated risks, evidence regarding risk factors to inform zoster vaccination policy is currently limited.
Keywords: Herpes zoster, Postherpetic neuralgia, Epidemiology, Risk factors
1. Introduction
Postherpetic neuralgia (PHN) is pain after an acute episode of
herpes zoster (commonly known as shingles) continuing beyond
rash healing.16 The pain has been described as a constant
burning or stabbing sensation, and some individuals experience
allodynia (pain triggered from light contact with nonpainful
stimuli).47 Symptoms can persist for months or even years, and
the condition can profoundly affect a patient’s quality of life.12,24
PHN is the most common complication of zoster; an estimated
12.5% of patients with zoster aged $50 years have PHN 3
months after zoster onset, and the proportion affected increases
sharply with age.
Postherpetic neuralgia is often refractory to treatment.10,20,40
Despite decades of research, evidence for the efficacy of
administering antivirals at first appearance of the rash in reducing
PHN incidence is unconvincing.7 However, an effective live-
attenuated vaccine is now available providing protection against
zoster and might be used to protect those most likely to develop
PHNand other complications of zoster.30,36 Apart from age, other
often reported risk factors for PHN relate largely to characteristics
of the acute zoster episode, particularly, the severity of acute pain
and rash at initial zoster presentation; however, the evidence has
not been systematically reviewed.14,31,32,42,48 Furthermore, as
these are not vaccine-targetable, there is interest in identifying
risk factors for PHN, which can be identified before the zoster
episode, to inform zoster vaccination policy.
This article aims to systematically collate and summarise the
epidemiological literature on risk factors for PHN including clinical





We searched all published journal articles in MEDLINE and
Embase between 1950 and February 3, 2014. We searched for
articles containing PHN terms and risk factor analysis terms
(Box 1 for full details). The search strategy used both subject
heading and text word searches. Initial search terms were
updated after searching the reference lists of relevant articles.
To capture relevant grey literature, the New York Academy of
Medicine Grey Literature Report (www.greylit.org), the Elec-
tronic Theses Online Service through the British Library (http://
ethos.bl.uk), and the ISI Conference Proceedings Citation Index
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(http://isknowledge.com) were searched for the terms: “PHN”
or “postherpetic neuralgia” or “postherpetic neuralgia,” within




[ { (“Postherpetic neuralgia”[exploded MeSH] OR PHN[Title or abstract] OR
“postherpetic neuralgia”[Title or abstract] OR “post herpetic neuralgia”[Title or
abstract] OR post-herpetic neuralgia[Title or abstract] OR “postherpetic
pain”[Title or abstract] OR “post herpetic pain”[Title or abstract] OR post-
herpetic pain [Title or abstract] OR ((“Neuralgia”[exploded MeSH] OR
“Pain”[exploded MeSH] OR neuralgia [Title or abstract] OR pain [Title or
abstract]) AND (“Herpes zoster”[exploded MeSH] OR zoster[Title or abstract]
OR shingles[Title or abstract] OR zona[Title or abstract] OR VZV[Title or
abstract]))
AND (“Risk factors”[exploded MeSH] OR “Epidemiologic studies”[exploded
MeSH] OR “Odds ratio”[exploded MeSH] OR “Multivariate analysis”[exploded
MeSH] OR “Logistic Models”[exploded MeSH] OR “Prevalence”[exploded
MeSH] OR “Incidence”[exploded MeSH] OR “odds ratio”[Title or abstract] OR
“risk ratio”[Title or abstract] OR “relative risk”[Title or abstract] OR “risk
factor”[Title or abstract] OR risk[Title or abstract] OR predict*[Title or abstract]
OR correlat*[Title or abstract] OR etiol*[Title or abstract] OR aetiol*[Title or
abstract] OR prevalence[Title or abstract] OR incidence[Title or abstract] OR
rate*[Title or abstract]) }
OR “Postherpetic neuralgia/etiology”[exploded MeSH]
OR ((“Neuralgia/etiology”[MeSH] OR “Pain/etiology”[MeSH]) AND (herpes
zoster[exploded MeSH] OR “zoster”[Title or abstract] OR “shingles”[Title or
abstract] OR “zona”[Title or abstract] OR “VZV”[Title or abstract])) ]
AND “Humans”[MeSH]; limited to articles in language: ENGLISH
Embase:
[ { (“Postherpetic neuralgia”[exploded subject heading] OR “PHN”[Title or
abstract] OR “postherpetic neuralgia”[Title or abstract] OR “post herpetic
neuralgia”[Title or abstract] OR “post-herpetic neuralgia”[Title or abstract] OR
“postherpetic pain”[Title or abstract] OR “post herpetic pain”[Title or abstract]
OR post-herpetic pain [Title or abstract] OR ((“Neuralgia”[exploded subject
heading] OR “Pain”[exploded subject heading] OR “neuralgia” [Title or
abstract] OR “pain” [Title or abstract]) AND (herpes zoster[exploded subject
heading] OR “zoster”[Title or abstract] OR “shingles”[Title or abstract] OR
“zona”[Title or abstract] OR “VZV”[Title or abstract]))
AND (“Risk factor”[exploded subject heading] OR “Epidemiology”[exploded
subject heading] OR “Odds ratio”[exploded subject heading] OR “Multivariate
analysis”[exploded subject heading] OR “Statistical model”[exploded subject
heading] OR “Prevalence”[exploded subject heading] OR “Incidence”[ex-
ploded subject heading] OR “odds ratio” OR “risk ratio” OR “relative risk” OR
“risk factor” OR “risk” [Title or abstract] OR “risk factor”[Title or abstract] OR
“predict*”[Title or abstract] OR “correlat*”[Title or abstract] OR “etiol*”[Title or
abstract] OR “aetiol*”[Title or abstract] OR “prevalence”[Title or abstract] OR
“incidence”[Title or abstract] OR “rate*”[Title or abstract]) }
OR “Postherpetic neuralgia/etiology”[exploded subject heading]
OR ((“Neuralgia/etiology”[subject heading] OR “Pain/etiology”[subject head-
ing]) OR (herpes zoster[exploded subject heading] OR “zoster”[Title or
abstract] OR “shingles”[Title or abstract] OR “zona”[Title or abstract] OR
“VZV”[Title or abstract])) ]
AND “Humans”[subject heading]; limited to language: ENGLISH
Grey literature:
New York Academy of Medicine Grey Literature Report: PHNOR postherpetic
neuralgia OR title:(postherpetic AND neuralgia) OR title:PHN
ISI Conference Proceedings Citation Index: [ {TS5(PHN or “postherpetic
neuralgia” or “post herpetic neuralgia”) AND TS5(risk or epidem* or “odds
ratio” or rate)} OR {TI5(PHN or “postherpetic neuralgia” or “post herpetic
neuralgia”)}] AND TI5(risk or epidem* or “odds ratio” or rate) AND LANGUAGE:
(English).
Note: In both databases the subject heading terms are arranged in a hierarchy
with more specific linked subheadings arranged beneath wider terms. Exploding
a subject heading indicates that the search includes all results below that
heading.
2.2. Inclusion and exclusion criteria
Criteria were developed in an iterative process after preliminary
searches. We included studies based on original data from
analytical epidemiological studies, among adults (18 years1) with
zoster. Postherpetic neuralgia had to be a study outcome and an
age-adjusted effect estimate was required. We included risk
factors, which were either (1) clinical features of the acute zoster
episode or (2) vaccine-targetable, defined as risk factors identifi-
able before the onset of the zoster rash. Studies assessing only
age as a risk factor were required to treat age as a continuous
exposure (ie, linear on a log scale) such that its effects on PHN risk
could be reported per 10-year increase. Studies assessing genes
as risk factors for PHNwere not required to have an age-adjusted
effect measure, because allele frequencies are not typically
associated with age.
We omitted studies assessing antiviral therapy as a de-
terminant of PHN as they have been recently summarised in
a Cochrane Systematic Review7; we also omitted studies
assessing other PHN treatments (such as acupuncture and
corticosteroids). We excluded studies examining risk factors for
PHN within a general population sample (where patients with
PHN were compared with non-zoster controls) because the risk
of PHN in the general population comprises 2 parts; first, the risk
of zoster and second, the risk of developing PHN among those
with zoster. In these studies, it is impossible to disentangle
whether any identified risk factors are simply predictive of zoster
itself, or whether they are specifically risk factors for getting
PHN. We also excluded studies restricted to specific clinical
subgroups of patients with zoster, such as individuals with HIV,
because their risk factors for PHN may differ. We restricted to
English articles only; however, we did not place any restriction
on study location or publication status.
2.3. Selecting studies
The titles and abstracts of all identified articles were assessed. If
a study was deemed to potentially fulfil the inclusion criteria, full-
text versions were retrieved and assessed. Reference lists of all
retrieved articles were searched. To assess how reliably the study
eligibility criteria were applied, a second author (R.F.) applied the
inclusion criteria to a random 10% sample of all articles, and
agreement between the primary allocation and the sample
allocation was tested using Cohen’s kappa statistic.29 A kappa
score of 1 denotes full agreement, and kappa values greater than
0.75 indicate excellent agreement.44
2.4. Data extraction
Extraction tables were piloted by S. L. Thomas and H. J.
Forbes and then applied to remaining studies. Data (listed in
Appendix, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132) were extracted by H. J.
Forbes for each study. Authors were contacted for missing
information (see appendix for template e-mail to correspond-
ing authors, available online as Supplemental Digital Content
at http://links.lww.com/PAIN/A132). When individual studies
used multiple definitions of PHN, results classifying PHN as
pain at 3 months after zoster onset (or that closest to 3
months) were extracted for the main analysis, as this is the
most widely used definition of PHN.12,17,30,36,45 Results from
other PHN definitions were extracted for the Appendix
(available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
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2.5. Assessing risk of bias
The risk of bias assessment was based on the Cochrane
Collaboration approach, in which each study is assessed
separately for prespecified bias domains (see Appendix for
further details available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
We also considered the validity of each study based on the
sampling of patients with zoster, numbers declining to participate,
and their characteristics, particularly the percentage develop-
ing PHN.
2.6. Data analysis
When at least 2 studies were deemed to be capturing the same
risk factor within similar populations, we assessed between-
study heterogeneity using the Cochrane Q statistic and the I2
statistic, with I2 . 50% used as a threshold indicating moderate
heterogeneity. In the absence of heterogeneity, we planned to
combine the estimates and produce a summary relative risk using
fixed effects meta-analysis. However, for some risk factors, there
was significant between-study statistical heterogeneity; there-
fore, we performed posthoc analysis to help ascertain the
possible reasons for heterogeneity. This included rerunning the
meta-analysis removing studies at high risk of bias and
comparing I2 values between clinical and methodological
subgroups to evaluate potential sources of heterogeneity.22 For
this latter analysis, summary estimates from subgroups were
formally compared using meta-regression; we compared sub-
groups according to (1) mean age of the study population ($60
years vs ,60 years), (2) definition of PHN (pain at 4 months vs
pain at 3 months), (3) ascertainment of PHN (self-reported vs
ascertained from medical records), (4) whether immunosuppres-
sive patients were included or excluded, and (5) sources of study
population (primary care vs other).
We also created a funnel plot to determine the risk of
publication bias; gender was the only risk factor assessed in
sufficient studies to be suitable for assessment (age effects were
reported in different units making it unsuitable). The odds ratios
(OR), representing the effect estimate of gender on PHN, were
plotted against the standard error of the log odds,41 representing
the precision of the estimate, and symmetry was assessed
visually (as there were too few studies to perform a formal test).43
Statistical analyses were performed in STATA (version 13.1).
3. Results
The initial search identified 3614 articles. After removing
duplicates, 2559 titles and abstracts were screened. Of these,
116 full-text articles were retrieved, 19 of which were included in
the review (Fig. 1). Excluded studies are listed in the Appendix
(Table A1), available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132.
Agreement between reviewers over the application of the
inclusion criteria was very good (kappa score, 0.88). From the
10% sample of articles double screened, 1 study was not agreed
on; the second reviewer initially selected this study11 for inclusion;
however, both reviewers subsequently agreed this extra article
replicated a study already selected.13
3.1. Study characteristics and findings
Study characteristics are described in Table 1. There were 18
cohort studies and 1 case-base study (a modified case–control
study, where the risk ratio is estimated by sampling controls from
those at risk at the start of follow-up).39 Study sizes ranged from
55 to 34,280, and 17/19 studies had less than 1000 participants
at baseline. Zoster diagnoses were predominantly based on
clinical opinion. Definitions of PHN were presence of pain 3
months after rash onset in 10 studies, although other definitions
from 1 to 6 months were used. The percentage of patients with
zoster developing PHN ranged from 2.6% to 67.3%.Mean age of
study participants (available in 9 studies) ranged from52.3 to 67.7
years. Studies were all from high-income countries.
Study findings are summarised in Table 2 and Figures 2 and 3.
Data were collected on clinical features of the acute episode
including pain (15), rash extent and location (14), rash duration (9),
sensory dysfunction (3), and other clinical features (11), and also
vaccine-targetable risk factors including age and gender (18
studies), severe immunosuppression (5), other physical comorbid-
ities such as autoimmune conditions (4), diabetes (6), cancer (5),
recent physical trauma (1), psychological comorbidities (4), and
other risk factors (9).
3.2. Clinical features of acute zoster episode as risk factors
3.2.1. Pain
3.2.1.1. Prodrome
Eleven cohort studies and the case-base study collected data on
prodromal pain, ie, pain appearingbefore rashonset. Seven included
prodromal pain in the final age-adjustedmodel and 5 reported effect
estimates, with each giving a point estimate above 1. We obtained
apooled effect estimate of 2.29, 95%confidence interval (CI): 1.42 to
3.69 (Pheterogeneity50.716; I
250.0%) in fixed effectmeta-analysis. A
cohort study among 533 immunocompetent patients reported
a shorter prodrome (#3days) before rash onsetwas associatedwith
reduced risk of PHN (adjOR: 0.49, 95% CI: 0.24-0.99).
3.2.1.2. Severe acute pain during zoster
Twelve cohort studies investigated severe acute pain as a risk
factor for PHN. Although definitions of severe acute pain varied
among studies, eg, pain scoring $4 using the Neuropathic Pain
Questionnaire5 and pain scoring $5 on the Visual Analogue
Scale,9 8 reported it as a binary variable enabling us to pool
estimates; there was good evidence that severe acute pain was
associated with increased risk of PHN (rate ratio [RR]: 2.23,
95% CI: 1.71-2.92, Pheterogeneity 5 0.649; I
2 5 0.0%).
3.2.1.3. Allodynia
Allodynia was investigated in 3 cohort studies. One study
reported a greater than 4-fold increased risk of PHN with brush
(adjOR: 5.89, 95% CI: 1.50-23.1) and stretch-evoked allodynia
(adjOR: 4.13, 95% CI: 0.98-17.50)19; however, small numbers
(N5 93) led to wide CIs. A study among hospital patients treated
in a pain clinic found no effect of allodynia (definition unclear;
adjOR: 0.82, 95% CI: 0.24-2.81), whereas a final cohort study
similarly reported no evidence of effect.5,26 A summary estimate
was not calculated because of the varying definitions of allodynia.
3.2.1.4. Pain interferes with daily functioning
Pain interfering with daily functioning at zoster onset was assessed
in 3 cohort studies. The first, among 1358 individuals, reported
a 1-unit increase in zoster brief pain inventory interference score
was associated with 18% increase in PHN risk (adjOR: 1.18, 95%
CI: 1.05-1.31).13 Two other cohort studies reported binary (yes or
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¹ The Cochrane Collaboration have tools for assessing bias in randomized trials (Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's 
tool for assessing risk of bias in randomised trials. BMJ 2011: 343: d5928) and non-randomised studies (Sterne JAC HJ, Reeves BC. On behalf of the 
development group for ACROBAT-NRSI. A Cochrane risk of bias assessment tool: for non-randomized studies of interventions (ACROBAT-NRSI).  2014 
Available from: www.riskofbias.info.).  Both tools pre-specify bias domains, within which there may be more than one item.  Each item is assigned a 
judgment of risk along with a supporting comment for the judgement.   
¹
no) data on pain interference. One found over 2-fold increased
risk,27 whereas the other found no evidence of association; the
summary estimate of these 2 studies suggested there was strong
evidence that pain interfering with daily functioning was associated
with PHN (summary RR: 2.10, 95% CI: 1.27-3.48).
3.2.2. Rash severity and location
3.2.2.1. Severe rash
Rash severity data were collected in 8 studies. Five included it in
their final age-adjusted model (although one did not report an
OR); when combined in meta-analysis, severe rash was strongly
associatedwith PHN risk (summary RR: 2.63, 95%CI: 1.89-3.66,
Pheterogeneity 5 0.892; I
2 5 0.0%).
3.2.2.2. Ophthalmic involvement
A total of 13 studies recorded information on zoster location. Only
3 studies reported an effect estimate for ophthalmic involvement.
Each of these 3 studies reported a point estimate above 1, yet the
CIs crossed 1. When combining in a meta-analysis, there was
evidence that ophthalmic zoster was associated with over twice
the risk of PHN, compared with nonophthalmic zoster (summary
RR: 2.51, 95% CI: 1.29-4.86, Pheterogeneity 5 0.782; I
2 5 0.0%).
3.2.3. Rash duration at presentation
Longer rash duration at presentation of zoster showed some
evidence of being associated with reduced risk of PHN. A study
on 598 immunocompetent patients showed for everyday the rash
was present since presentation in primary care; there was over
20% reduced risk of PHN (adjOR: 0.78, 95% CI: 0.64-0.97).35
Three other cohort studies estimated the risk of PHN for everyday
from onset to diagnosis; point estimates were all below 1 (yet CIs
were wide).9,25,27 The summary estimate from meta-analysis
showed a small reduction in PHN risk with everyday since rash
onset (0.93, 95% CI: 0.86-0.99).
3.2.4. Other
One study assessed pinprick hypaesthesia (or numbness) as
a risk factor for PHN: it was associatedwith a 7-fold increased risk
of PHN (adjOR: 7.72, 95% CI: 2.00-29.90).
3.3. Vaccine-targetable risk factors
3.3.1. Age
Eighteen studies assessing the effects of age showed an
increased risk of PHN with greater age. When possible, we
summarised the effect of a 10-year increase in age on PHN risk
(n 5 9). The point estimates ranged from 1.22 to 3.11 per 10
years; the meta-analysis showed strong evidence of between-
study heterogeneity (Pheterogeneity 5 0.029; I
2 5 55.1%). A small
study (N5 249) showing an increased risk of PHN with a 10-year
increase in age (adjRR: 1.22, 95% CI: 1.00-1.48) was excluded
from themeta-analysis as the effect was reported as a risk ratio. In
posthoc analysis, there was some weak evidence that the effect
of age was associated with age of the study population (P value
from meta-regression 5 0.08; specifically the effect of age on
PHN risk seemed higher in studies where the mean age was$60
Figure 1. Flow diagram describing study selection.
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years) (Appendix Table A2, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A132). There was
no evidence that the effect of age on PHN risk varied by definition
of PHN (P 5 0.52), ascertainment of PHN (P 5 0.14),
immunosuppression status (P 5 0.23), or sources of study
population (P 5 0.18).
3.3.2. Gender
Of 9 studies reporting the age-adjusted association between
gender andPHN, somesuggested an increased riskof PHNamong
females,9,25,38 others a decreased risk,2,5 whereas others found no
evidence of an association.2,6,8,23,33,37 These conflicting results
were supported by strong evidence of between-study heteroge-
neity (Pheterogeneity , 0.001; I
2 5 73.9%). In posthoc analysis, the
effect of female gender seemed protective in studies in which the
mean age was $60 years, compared with among studies with
mean age,60 years, for which female gender increased the risk of
PHN; heterogeneity was reduced within these subgroups (,1% in
both) (Appendix Table A2, available online as Supplemental Digital
Content at http://links.lww.com/PAIN/A132). There was no ev-
idence that the effect of gender on PHN risk varied by definition
of PHN (P 5 0.45), ascertainment of PHN (P 5 0.83),
immunosuppression status (P50.25), or sourcesof studypopulation
(P 5 0.97). These analyses were limited by 4/7 studies in meta-
analysis of gender having at least 1 bias domain assigned high-risk.
3.3.3. Severe immunosuppression
A cohort study among patients with zoster$18 years found
immunosuppression (including HIV, currently treated for cancer, or
exposed to high-dose corticosteroids) was more common in
patients with PHN (15%, n 5 3/20) than without (7.3%, n 5 6/82);
but the sample sizewas too small to be conclusive.27 Another cohort
study among patients $50 years of age reintroduced 12 patients
with immunosuppression excluded from the main analysis (defined
as using high-dose oral corticosteroids/other immunosuppressive
drugs, having invasive cancer or HIV/AIDS); these patients had an
increased risk of PHNafter adjustment for confounders (adjRR: 1.98,
95% CI: 1.14-3.45).13 Finally, the case-base study in the United
States found connective tissue disease, HIV, or organ allograft was
associated with 10-fold increased risk of PHN, although the CI was
wide (adjOR: 9.5, 95% CI: 2.0-45.0).8 Two studies specifically
assessed HIV: one excluded HIV from the final multivariable
analyses,38 whereas another found over 50% decreased risk of
PHN among patients with HIV (antiretroviral treatment status not
reported) (adjRR: 0.48, 95% CI: 0.26-0.86).23 The latter study also
reported strong evidence of an increased risk of PHN with
lymphoma/leukaemia (adjRR: 1.74, 95% CI: 1.32-2.28).
3.3.4. Other physical comorbidities
3.3.4.1. Overall physical health
One study measured overall health status at zoster presentation
using the physical component summary score and found
a decreased risk of PHN with better physical health.5 The second
study summed total number of reported medical conditions and
found no evidence of association with PHN.27
3.3.4.2. Autoimmune conditions
A large cohort study among 34,280 patients with zoster identified
in Taiwanese electronic health insurance records identified 284
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more than twice as likely to develop PHN (adjRR: 2.27, 95% CI:
1.75-2.94).23 Another smaller study (N 5 837) using electronic
medical records from the Netherlands collected data on lupus
and rheumatoid arthritis; however, they were not included in the
final model (numbers not reported).33
3.3.4.3. Diabetes
Three cohort studies reported point estimates for the association
between diabetes and PHN $1 in multivariable analyses;
however, there was insufficient evidence to confirm an associ-
ation.8,26,33 A larger cohort study among 34,280 patients with
zoster did find evidence of an increased risk (adjRR: 1.35, 95%CI:
1.25-1.47).23 There was no evidence of between-study hetero-
geneity for studies reporting age-adjusted diabetes effects
(Pheterogeneity 5 0.564; I
2 5 0.0%); the pooled effect estimate
was 1.36 (95% CI: 1.25-1.47) in the fixed effect meta-analysis;
however, the large study (N 5 34,280) dominated the pooled
relative risk (contributing 99.1% to the model).
3.3.4.4. Cancer
Five studies investigated cancer and its relationship with PHN; 3
excluded it from the final model.26,28,38 Breast and liver cancer were
investigated in a single study, but were not associated with PHN in
the final adjusted model.23 The case-base study found 13.5% of
PHN cases and 4.7% of non-PHN controls had a cancer diagnosis
180 days before zoster8; after adjustment, cancer was associated
with a reduced risk of PHN (adjOR: 0.1, 95%CI: 0.02-0.9); however,
the CIs were wide. A meta-analysis for cancer effect estimates was
not conducted as they involved different cancer sites.
3.3.4.5. Recent physical trauma
The only study to investigate this risk factor reported over 2-fold
increased risk of PHN associated with experiencing trauma at the
zoster site (contusions, burnings, wounds, and multiple traumas)
within 6 months before study enrolment.38
3.3.4.6. Other
Other physical conditions investigated aspredictors of PHN, but not
included in the age-adjusted models included surgical interven-
tion,38 hepatitis-C virus infection,38 hypertension,26,38 neurological
disorders,38 allergy,38 family history of coronary heart disease,38
angina,26 and chronic obstructive pulmonary disorder.33
3.3.5. Psychological comorbidities
These were assessed as risk factors for PHN in 4 studies. Two
cohort studies assessed a range of psychological comorbidities;
only personality disorder symptoms (adjOR: 1.09, 95% CI: 1.01-
1.18),27 and lower levels of trust in health care (adjOR: 1.01, 95%
CI: 1.00-1.03)35 showed a small association with PHN in
multivariable analyses. Neither depression nor anxiety was
included in multivariable analyses.5,27,35,38
3.3.6. Other risk factors
A cohort study found alipoprotein E-e3 was more common and
alipoprotein E-e4 less common among female patients with
zoster and PHN, suggesting that this host genetic factor may
influence the risk of PHN.50 One study found evidence that
current/former smoking was associated with greater risk of PHN
(adjOR: 2.08, 95%CI: 1.22-3.55)38 whereas another included it in
their final model, but did not report the association.2 One study
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Figure 2. Summary of associations between postherpetic neuralgia and clinical features of acute zoster. 1Composite score ranges from 0-100 numerical pain
ratings andMcGill Pain Questionnaire Present Pain 2Intensity ratings of average andworst shingles pain. Intensity of pain using the Short Italian questionnaire, from
0-10. 3Temperature differences are between normal and affected skin. 4Percentage of body surface area thermal asymmetry ($3 vs ,3%). †Risk factors too
varied to combine inmeta-analyses. •Not included in summary RR (either because study has already contributed tometa-analysis, or exposure definition is not in-
keeping with other studies). *Studies reporting RR (rather thanOR) are not included inmeta-analysis. CI, confidence interval; DN4, Neuropathic pain questionnaire
with 4 questions; NPSI, Neuropathic pain symptom inventory score; OR, odds ratio; RR, rate ratio; SF-12, short-form 12; VAS, visual analogue scale ranging from
0 (non pain) to 100 (worst pain ever experienced); VZV, varicella zoster virus; ZBPI, Zoster brief pain inventory interference score.
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Figure 3. Summary of associations between postherpetic neuralgia and vaccine-targetable risk factors from identified studies. *Only 10/20 studies reported age such
that the effect estimate could be converted into 10-year increases. Of the remaining 10 studies; 8 reported an increased risk of PHN with greater age, 1 showed no
effect all, and 1 did not report an age-effect. **Studies reporting RRs rather than ORs not included in meta-analysis as RR can underestimate OR when outcome
becomes common. ***Effect estimate from study may be erroneous therefore the study is not included in the meta-analysis: Parruti 2010 CIs are too narrow, and
Opstelten 2002 confidence also too narrow. 1Using high-dose oral corticosteroids or other immunosuppressive drugs, having invasive cancer or HIV/AIDS.
2Undefined, however included HIV or currently being treated for cancer. 3Connective tissue disease, HIV infection or organ allograft. 4Better health: measured using
continuous physical component summary score (higher scorer score reflects worse health). 5Poorer health: measured using continuous variable of total number of
medical conditions. †Risk factors too varied to combine inmeta-analyses. ‡The large study by Jih et al. (N5 34,280) dominated the pooled relative risk contributing to
99·1%of themodel. Other risk factors investigated as predictors of PHN, but not included in the final model, included; surgical intervention, hepatitis-C virus infection,
hypertension, neurological disorders, allergy, family history of CHD, angina, chronic obstructive pulmonary disorder, education, alcohol abuse, familial status, years of
education and race. APOE, alipoprotien E; CI, confidence interval; OR, odds ratio; RA, rheumatoid arthritis; RR, rate ratio; SLE, systemic lupus erythematosus.
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cell-mediated immunity, evidenced from reduced response to
VZV skin-test, was associated with greater risk of PHN.2 Studies
investigating education,13,27,38,46 race,27 being married,5,27,38
being in work,13 consultation rate,8,33 or alcohol abuse38 did not
select these risk factors in their final model.
Nine of the 19 studies had 2 or more definitions of PHN. Briefly,
studies additionally defined PHN as pain at 16,8,13,21,33,35,38 (n5 7)
and 6 months9,21,28 (n5 3) after zoster onset; there were no major
differences in study findings using these alternative definitions,
except older age was a stronger risk factor for pain persisting 6
months, compared with 2 or 3 months, after zoster (Appendix
Table A3, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132), indicating older age may be
a risk factor for long-term PHN.
3.4. Assessment of bias
Our assessment of bias found 8/19 studies with at least 1
prespecified domainwith a high risk of bias, 8 studieswith at least 1
domain of medium risk, and 3 studies with only low or unclear risk
of bias. Residual confounding by age was the most common
source of potential bias, affecting 7/19 studies requiring age-
adjustment (Table 3). Studies using electronic health care records
were at greatest risk of reporting bias; specifically ascertainment
bias, where outcome ascertainment relies on patients returning to
their GP and higher general practice (GP) attendance could have
increased the chance of PHN diagnosis.8,23,26,33 Of the cohort
studies, 5 experienced loss to follow-up of greater than 10%
(Table 3). See Appendix Table A4 for detailed note on the bias
assessment (available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A132).
The funnel plot gave a relatively symmetric pattern, suggesting
that there was little indication of publication bias (Fig. 4). The
distribution did not suggest that more extreme findings were
being selectively published.
The sampling methods and patient characteristics of some
studies suggest their external validitymay be limited; characteristics
of included patients indicate a nonrepresentative sample in some
studies (Coen et al. reported that 20% of the study population was
immunosuppressed8 and in 3 studies over 30% of the cohort
developed PHN28,46,50); 1 study used convenience sampling,6 thus
not all population members had an equal probability of being
selected; and the number or characteristics of eligible patients
refusing to participate were unclear in most studies.
4. Discussion
4.1. Summary of evidence
Our systematic review identified 19 prospective studies in-
vestigating risk factors for PHN. There was good evidence that
clinical features of acute zoster including prodromal pain, severe
Table 3
Assessment of bias for individual studies ( ).














Asada et al.2 ? ¤




Coen et al.9 ¤ ? ? ?
Drolet et al.12 ? n
Haanpaa et al.19 n n ? ?
Helgason et al.21 ?
Jih et al.23 ¤ ? ? ¤ ¤ ?
Jung et al.25 n ?
Kanbayashi et al.26 ¤ ¤ ? ¤
Katz et al.27 n n ?
Kotani et al.28 ? ? ? ?
Opstelten et al.33 ¤ ¤ ¤ n
Opstelten35 ? n
Park et al.37 ¤ ? ? ? ?
Parruti et al.38 ? n
Volpi et al.46 ¤ ¤ ? n
Wozniak et al.50 ? ? ?
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Figure 4. Assessment of publication bias for gender as a risk factor for
postherpetic neuralgia. Funnel plot of the log odds ratio plotted against the
standard error of the log odds ratio for seven studies reporting the effect of female
gender on PHN risk (dotted line represents pseudo 95% confidence limits).
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acute pain, severe rash, and ophthalmic involvement were
associated with increased risk of PHN. Rash duration at zoster
presentation was less strongly associated with PHN. Regarding
vaccine-targetable risk factors, older age was consistently
associated with PHN. The evidence for gender as a risk factor
was conflicting. Immunosuppression and diabetes were signifi-
cantly associated with PHN in a few, but not all studies. Systemic
lupus erythematosus, recent trauma, and personality disorder
symptoms were associated with PHN; however, evidence came
from single studies only. No studies found evidence suggesting
that depression or cancer was associated with increased risk of
PHN. Most studies had small sample sizes reducing their power
to detect associations. Our review highlights that we have a good
understanding of which clinical features of zoster predict PHN,
yet there is a need for better evidence on common and potentially
easily vaccine-targetable risk factors for PHN prevention.
4.2. Interpreting the findings
It is believed that several pathophysiological mechanisms may
contribute to the development of PHN. Acute zoster infection
undoubtedly results in nerve damage to both the peripheral and
central nervous system, yet the nature of the damage and specific
mechanism resulting in persistent pain are not fully understood.4
There are 2 (nonmutually exclusive) hypotheses for its development;
the first is that persistence of VZV after acute zoster, at higher levels
than during latency, causes continued pain; and the second, that
after acute zoster infection, there is increased neuronal excitability
and alteration of pain perception caused by neural damage.1,20
The variety of possible risk factors for PHN identified in the review
may reflect these different mechanisms.3 The finding that greater
rash severity and greater acute pain are associated with increased
risk of PHN supports the notion that greater neural damage caused
bymore severe infection contributes to the development of PHN.15
That longer rash durationwas associated with reduced risk of PHN
initially seems inconsistent with the finding that more severe zoster
rash is associated with PHN. However, late presentation might
indicate patients had milder zoster not immediately demanding
medical attention. Either way, this finding is unlikely to be due to the
duration of the rash itself. Patients with ophthalmic zoster seem at
greater risk of PHN, although it is not clear whether concerns about
eye complications cause them to react differently, rather than the
increased risk being driven by a biological mechanism.20 Ageing
undoubtedly causes a waning of cell-mediated immunity and may
cause increased levels of the virus after zoster reactivation,
potentially causing PHN. Other risk factors for PHN identified here
are also associated with reduced cell-mediated immunity, in-
cluding severe immunosuppression, systemic lupus erythemato-
sus, and smoking. Trauma at the site of the rash may induce local
changes facilitating reactivation of herpes zoster (HZ) and greater
nerve damage leading to increased risk of PHN. However, the
aetiological mechanism(s) by which these risk factors affect the
development of PHN remains largely unknown.
4.3. Limitations of the selected studies
The included studies had some limitations. Many had small
sample sizes, and we were unable to combine some results in
a meta-analysis. Furthermore, many tested a number of risk
factors; the associations observed may occur by chance due to
testing multiple exposures. Most studies based zoster diagnosis
on clinical opinion rather than serological or virological testing; this
may have led tomisclassification of patients with zoster; however,
clinical diagnosis is typically reliable.34
Some studies may have been affected by specific biases. Age is
a very strong predictor of PHN and yet 7/18 studies assessing age
adjusted for it as a binary or categorical variable with wide age
intervals, potentially causing residual confounding by age. Loss to
follow-up affected 5/19 studies, and if loss to follow-up is
associated with both PHN and the risk factor, bias could have
been introduced.18 Patients with PHNmay be more likely to return
for follow-up as they require continued care, and patients with
particular risk factors may also return to their GP more commonly,
making bias due to loss to follow-up likely. Ascertainment biasmay
have affected studies using routinely collected health care data.
Here, spurious associations between PHN andmedical conditions
requiring regular contact with health care professionals may arise.
One such study adjusted for health care utilisation8 and still found
a positive association with PHN and certain immunosuppressive
disorders, suggesting the effect cannot be driven solely by
ascertainment bias. Finally, not all studies adjusted for clinical
features of the acute zoster episode,2,21,23 and results may be
subject to residual confounding.
4.4. Strengths and limitations of the review
This is the first study to systematically review the literature on risk
factors for PHN; although clinical features of acute zoster have
been acknowledged as risk factors for PHN, this is the first to
summarise age-adjusted results and pool them in a meta-
analysis. We undertook a comprehensive search of several
databases using multiple keywords and indexed subject head-
ings. The reliability of study selection criteria was confirmed by
double screening of 10% of the articles.
There are some important limitations to this review. There is no
consensus over the exact definition of PHN; in this review, PHN
definitions ranged frompainpersisting1 to6months after rashonset,
with some studies assessing any pain, whereas others required
severe pain. A full assessment of risk factors by different PHN
classifications was not possible here because of too few studies.
Between-study variability prevented us frompooling the effects
of age and gender on PHN; there was some evidence that age of
the study population contributed to the observed heterogeneity.
However, these analyses were limited by the small number of
studies and may have reduced our power to detect associations.
Variability may be due to different adjustment for confounders or
some studies reporting biased effect estimates, eg, due to PHN
measurement error or loss to follow-up. Studies also used
different definitions for certain clinical features of acute zoster,
such as severe acute pain and severe rash, potentially giving
some heterogeneity to the results.
Our search strategy may have missed some studies; however,
we used multiple databases (including grey literature) and
searched reference lists of selected articles, to minimise this
issue. As with any literature review, studies finding no effects may
have gone unpublished. Our funnel plot did not demonstrate any
evidence of publication bias with respect to assessing gender as
a risk factor for PHN. However, publication bias may affect other
risk factors differently, and there were not enough studies per risk
factor to assess this for other exposures. Finally, non–English-
language articles were excluded because of resource limitations;
however, the authors believe it is unlikely to have led to the
omission of any major articles in the area.
4.5. Implications
Zoster vaccination offers a way of preventing this debilitating
complication by preventing zoster itself, but is currently
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expensive; therefore, targeting the vaccine toward groups at
high-risk of PHN may be beneficial. The vaccine is currently
licensed in certain countries in the European Union, United
States, and Australia.49 It is targeted at older age groups and
contraindicated in patients with severe immunosuppression. As
older age is the only indisputable risk factor that vaccination
policies can use, this approach seems reasonable. If patients with
severe immunosuppression are at increased risk of PHN as
suggested by this review, in addition to being at greater risk of
zoster itself, there is even more need to identify alternative
strategies to prevent zoster in these groups.
This review has highlighted our lack of understanding of
vaccine-targetable risk factors for PHN, and the need to perform
studies exploring suggested associations. Such studies would
need to be generalizable to a wide group, by recruiting patients
aged 18 and over and including immunosuppressed patients, to
examine the risk of PHN by age and immunosuppression status.
Other desirable features would include recruiting a large number
of individuals to achieve greater power to help detect small
effects, collecting data on all known and possible risk factors for
PHN, actively following up patients with zoster to allow persistent
pain to be identified for the entire cohort at the same time and
reducing loss to follow-up to avoid differential ascertainment of
PHN. Finally, at the analysis stage, detailed adjustment for age
using either a continuous or finely categorised age variable would
reduce residual confounding by age.
5. Conclusions
This study confirms that features of the acute zoster episode,
including prodromal pain, severe rash, severe acute pain, and
ophthalmic involvement are risk factors for PHN. Our current
understanding of vaccine-targetable risk factors for PHN is
however limited. There are some suggestions that immunosup-
pression, systemic lupus erythematosus, diabetes, and recent
trauma may be associated with greater risk of PHN. Increasing
age is the only established risk factor for PHN that has been
quantified with sufficient rigour as to usefully inform vaccine
policy. Larger studies with greater power to detect associations,
and studies addressing the limitations of previous research, may
elucidate some of the unknown risk factors for PHN.
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6.3.   Published appendices  
145 
 
Data extraction details 
 
The following data were extracted for the selected studies by HF; study characteristics 
including, study design, country and year(s) of study, study size, study population (including 
mean age and range), definition and method of ascertaining zoster cases, risk factors assessed 
and how they were ascertained, definition and method of ascertaining PHN, % with PHN,  and 
statistical analysis. We extracted all study results from the final age-adjusted model, including 
the multivariable effect estimates when available (e.g. adjusted relative risks (RR), or odds 
ratios (OR) with 95% confidence intervals (CI)) and any other relevant analysis (such as sub-
group analysis or investigation of effect modification).   
 
Risk of bias assessment details 
The risk of bias was assessed separately for each study using the following pre-specified 
domains; residual confounding by age, selection bias, exposure and outcome information bias 
and bias due to missing data. We formulated our assessment based on the Cochrane 
Collaborations approach, where domains are categorised as having; “High risk” (bias may alter 
the results seriously), “Medium risk” (bias may alter the results moderately), “Low/No risk” 
(bias, if present, is unlikely to alter the results seriously) or “Unclear risk” (a risk of bias that 
raises some doubt about the results). Support for each judgement of risk is provided in the 




Letter to authors 
 
Dear [author name] 
 
I am carrying out a systematic review of studies investigating risk factors for postherpetic 
neuralgia (PHN). This is part of my PhD on zoster epidemiology, and we also aim to publish the 
review as a paper. I have identified the studies to be included in the review, one of which is the 
following study in which you are listed as corresponding author: 
[Reference] 
 
I am now extracting data from study reports to summarise in the review. I would be most 
grateful if you could clarify a few points (listed below) regarding your methods and results?  
[Specific questions] 
 
Your help would be greatly appreciated as I am keen to summarise your study as accurately 
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   No. of studies  Summary RR (95% CI)  Pheterogeneity; I²  P‐value from meta‐regression (univariate) 
Age      
All studies  8  ‐  P=0.029; 55.1%  ‐ 
      
Mean age of study population      
≥60 years  3 2.39 (1.81‐3.16) P=0.533;  0.0%
<60 years  3 1.46 (1.24‐1.73) P=0.242; 29.4% 0.08
Definition of PHN    
Pain at 4 months 3 1.45 (1.21‐1.73) P=0.195; 38.9%
Pain at 3 months 3 1.80 (1.48‐2.20) P=0.305; 15.8% 0.52
Ascertainment of PHN    
Self‐reported  6 1.63 (1.44‐1.85) P=0.079; 49.3%
Medical records  1 3.11 (1.82‐5.31) ‐  0.14
Excluded immunosuppressed     
Yes  2 1.41 (1.18‐1.68) P=0.235; 29.1%
No  4 1.96 (1.62‐2.37) P=0.126; 47.6% 0.23
Source population from primary care     
Yes  5 1.97 (1.67‐2.33) P=0.188; 35.0%
No  2 1.39 (1.15‐1.68) P=0.186; 42.8% 0.18
      
Gender     
All studies  7  ‐  P=0.01; 73.9%  ‐ 
      
Mean age of study population      
≥60 years  2 0.62 (0.40‐0.95) P=0.335;  0.0%
<60 years  3 1.65 (1.19‐2.30) P=0.364;  1.0% 0.04
Definition of PHN    
Pain at 4 months 1 2.01 (1.28‐3.16) ‐ 
Pain at 3 months 3 0.68 (0.47‐0.99) P=0.013; 77.0% 0.45
Ascertainment of PHN    
Self‐reported  6 1.13 (0.88‐1.44) P=0.000; 78.1%
Medical records  1 0.90 (0.38‐2.16) ‐  0.83
Excluded immunosuppressed     
Yes  1 2.01 (1.28‐3.16) ‐ 
No  6 0.88 (0.66‐1.16) P=0.018; 63.5% 0.25
Source population from primary care     
Yes  3 0.78 (0.53‐1.15) P=0.020; 74.5%




















































































































‐  ‐  ‐  ‐ 
  1m  1.87 (1.56 to 2.23)  Not in final model: 
No association in 
univariate analyses
‐  ‐  ‐  ‐ 
  6m  2.45 (1.50‐4.01)  Not in final model: 
No association in 
univariate analyses
‐  ‐  ‐  ‐ 
  12m  2.33 (1.48‐3.69  Not in final model: 
No association in 
univariate analyses
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6.4.   Review of studies assessing risk factors for postherpetic 
neuralgia within general population samples   
 
 Introduction 
The risk of PHN in the general population is made up of two parts; first, the risk of zoster and 
second, the risk of PHN, once you have zoster. In general population based studies, it is not 
immediately clear whether any identified risk factors are simply predictive of zoster itself, and 
hence associated with a higher risk of PHN, or whether they are specifically risk factors for 
developing PHN. 
 
However, in terms of zoster vaccine policy, understanding risk factors for PHN in the general 
population may be valuable. The vaccine is, after all, not useful once a patient develops zoster, 
therefore vaccination policies ideally need to identify groups of patients at high risk of PHN 
within the general population.  
 
In this section, papers excluded from the published systematic review solely because they 
examined risk factors for PHN in a general population sample, were summarised.  
 
 Methods 
Full details of the methods are explained in the paper, “Systematic review and meta-analysis of 
risk factors for postherpetic neuralgia”, in section 6.2. The same inclusion and exclusion criteria 
were applied, except that the selected studies were those that compared PHN patients to a 
general population sample, rather than comparing PHN patients to zoster patients without 
PHN. Risk of bias assessment was based on the Cochrane Collaboration approach, where each 
study is assessed individually for pre-specified bias domains. 
 
 Results 
In the published systematic review of PHN risk factors (section 6.2) twelve studies were 
identified which were based in a general population sample, that is, they compared PHN 
patients to the general population (see figure 5). These 12 studies were re-reviewed to identify 
those meeting the inclusion criteria (see section 6.4.2. above).  Four of the 12 studies were 
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excluded as they did not adjust for age; these studies explored the association between PHN 
and plasma vitamin C levels,165  
Figure 5: Flow diagram describing study selection for additional review of studies assessing risk 

















































Full-text review of 
studies assessing risk 
factors in a general 
population sample: 12 
Included in additional review: 4 
 
Excluded after full-text review: 
Effect estimates for risk factors of 
interest are not age-adjusted (exclusion 
criteria not applied to studies on 
genetic risk factors): 4 
PHN not an outcome: 1 
No risk factors of interest: 2 
Article uses same data as study included 









Included in review: 
19 
 
Excluded after full text review: 97 
PHN patients compared to non-zoster controls: 12 
Article uses same data as study included in review: 6 
PHN not an outcome: 14 
No risk factors of interest: 3 
No effect estimates for risk factors of interest (including 
where the only risk factor was age, and the effect of age 
was not described as a continuous variable): 24 
Effect estimates for risk factors of interest are not age-
adjusted (exclusion criteria not applied to studies on 
genetic risk factors): 36 
Full text not in English: 1 
Data provided on effect estimates appear incorrect: 1 
Title and abstracts 
assessed for eligibility: 
2559 
 
Full text review: 116 
 
Articles 




Not an analytical epidemiological study (e.g. case 
reports, case series, reviews, guidelines): 877 
PHN not outcome: 1465 
Study restricted to subpopulation: 31 
Not among adults: 5 
Not in humans: 3 
No risk factors of interest: 62 
 
Duplicates excluded: 1055 
Reproduction of Figure 1: Flow diagram describing study selection, from published 





nutrient deficiencies,166 residual scarring167 and impaired glucose metabolism.168 Two studies 
used the same data, therefore only one of these reports was retained (one was a conference 
paper and thus excluded169). Two studies had no risk factors of interest (these risk factors 
specifically, were, VZV DNA and viral microarray-based transcriptomal measurements).170,171 
Finally, another paper was excluded because after further review, PHN was deemed to be the 
exposure, rather than the outcome.172  
 
Four studies met the inclusion criteria. Three were case-control studies and one used a cohort 
study design. The characteristics of these studies are described in Table 4 and their results are 
outlined in Table 5.   
 
6.4.3.1. Study findings 
All three case-control studies looked at genetic susceptibility to PHN. They all recruited PHN 
patients from outpatient hospital clinics.  Two studies assessed genes in the human leukocyte 
antigen (HLA) class I and II regions as predictors of genetic susceptibility for PHN in Japanese 
individuals, comparing individuals with PHN to patients with no history of zoster.173,174 Both 
studies reported associations between alleles within the HLA region and PHN. Another study 
found no evidence that PHN patients were more likely to have a family history of zoster than 
age and gender-matched controls (with no history of zoster themselves), suggesting 
susceptibility to PHN may not be inherited.175  
 
The cohort study used Israeli EHR data from primary and secondary care, to follow-up over one 
million patients during 2010 for PHN.50 Age was the strongest risk factor for PHN, with people 
between 65-74 years >20 times as likely to get PHN compared to patients aged 25-34 (hazard 
ratio (HR) 20.9, 95%CI 11.0-39.6).  Females and patients of higher SES were more likely to be 
diagnosed with PHN. HIV treatment and having a history of cancer in the last five years were 
strongly associated with PHN risk and the authors reported a borderline association between 
diabetes and PHN (HR 1.35, 95%CI 0.99-1.83).   
 
6.4.3.2. Assessment of bias  
Case control studies 
In the genetic association study by Ozawa et al (n=168), it is unclear how the controls were 
selected. Sato et al specified that the controls were selected from the same hospital as the 
cases, potentially reducing the possibility of selection bias as controls are likely to come from 
the same source population as the cases. However, the authors did not specify the reason 
166 
 
controls were visiting hospital, so it is not possible to assess if controls are likely to have an 
association with the exposure (HLA class I and II regions). 
 
Despite major differences in the age of the cases (68.3 years) and their controls (40.1 years) in 
the study by Sato et al (n=165), there were no associations between age and the haplotypes 
proposed as risk factors for PHN; thus the results are unlikely to be due to confounding by age.  
In the case-control study by Gatti et al, assessing family history as a risk factor for zoster, the 
researchers matched on age at the design stage. However, it is unclear how age was accounted 
for at the analysis stage; hence there may be residual confounding by age. The study also 
relied on patient recall from years (although the number of years was not specified) 
previously; therefore, misclassification of exposure status is likely, which may lead to 
underestimation of effects. 
 
Cohort study 
In the Israeli cohort study50 PHN was defined as any patient with an ICD-9 code for PHN 
anytime during 2010.  In practice, physicians may use general zoster or pain codes to record 
PHN.102  Patients with a specified PHN code are unlikely to be systematically different to PHN 
patients with other codes, therefore this would cause non-differential misclassification of the 
outcome and reduction in the effect sizes.  PHN codes were also selected without reference to 
the timing of acute zoster and the authors report physicians tended to use a 1-month 
definition of PHN. As a result, their findings may not reflect risk factors for the most commonly 
used definition of PHN (pain persisting for three months after zoster). There is also a possibility 
of ascertainment bias; that patients with risk factors of interest may seek healthcare more 
frequently and increase their likelihood of PHN diagnosis.  
 
The cohort study utilised a database that is broadly representative of the Israeli population in 
terms of age and sex, therefore the results are likely to be generalizable to the general 
population of Israel.  
 
 Discussion 
Four articles were identified which explored risk factors for PHN in the general population. 
Three studies investigated evidence of a genetic susceptibility to PHN, and two case-control 
studies found some indication that alleles within the HLA region were associated with PHN. 
There was a single cohort study assessing various risk factors for PHN in the general 
population, which reported female gender, high SES, recent cancer treatment, HIV and 
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diabetes were associated with increased risk of PHN. However, three of the four studies had at 
least one pre-specified domain with a high risk of bias, limiting the value of the evidence.  
  
From the perspective of zoster vaccination policy understanding the risk factors for PHN in the 
general population may be of greater value than information on risk factors for PHN among 
people already with zoster. Despite this, the majority of studies focusing on risk factors for 
PHN are nested within zoster cohorts. Exactly why risk factor studies using general population 
controls, rather than zoster controls, are far less common is not clear, however two reasons 
have been hypothesised here: 1) population-based studies may be more challenging to 
conduct compared to studies within zoster cohorts, as the comparison group is less easy to 
identify; 2) interpretation of population-based studies is more challenging as the risk of PHN is 
a combination of the risk of zoster, plus the risk of PHN, having developed zoster. 
 
HLAs regulate immune responses against viruses therefore may be involved in the 
pathogenesis of PHN: a study among zoster patients did not find any association between the 
risk of acute zoster and the HLA region, which is in contrast to the studies assessed here 
focussing on PHN risk.176 However, it should be emphasised that HLA alleles and haplotypes 
differ between populations; therefore the findings, if replicated in larger population-based 
studies, may only be generalizable to Japanese populations. Confirmation of findings from 
different ethnic populations would be important prior to considering if the HLA region is 
involved in the pathogenesis of PHN. Additionally the studies were very small and need to be 
substantiated in larger samples.  
 
Weitzman et al uniquely contributed to the literature by conducting a large cohort study 
within the general population. However, the definition of PHN used in Weitzman’s study was 
pain at one month following zoster, which may limit the applicability of their findings as the 
more widely used definition of PHN is pain three months or greater following zoster.  
Furthermore, the study may be subject to residual confounding by age, as age was included in 
the model as a categorical variable with very wide groupings. 
 
This brief review of studies investigating risk factors for PHN in the general population has 
demonstrated that there is some evidence that genes in the HLA region may be involved in 
PHN susceptibility, specifically among people of Japanese ethnicity.  It is however not known 
to what extent these genetic factors reflect the risk of zoster versus risk of PHN, which is a 
major limitation when assessing risk factors for PHN in general population studies. One study 
suggested that female gender, high SES, recent cancer treatment, HIV and diabetes were 
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associated with increased risk of PHN in the general population.  Each study had some major 









Table 4: Studies assessing risk factors for PHN within a general population sample: study characteristics  







Study population Cases  Controls Matching 
factors  











Risk factors assessed Statistical 
analysis 

















72.4 (12.4)  
Controls: 
71.4(11.9) 






Pain ≥3 (on 
score of 1-












Medical history (diabetes or 
other underlying diseases), 
zoster history (episodes, 
prodrome, pain intensity, 
clinical disease 
characteristics, antiviral 
treatments), occurrence of 
mechanical trauma or 
stressful events, family 

















hospital and healthy 
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history of zoster 
Unrelated 
Japanese 

































HLA class I and class II alleles Relative risks 
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hospital pain clinic 
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NKp30) 
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records as of 
1st January 
2010 
 Age, gender, anti-TNF-ἀ, ≥1 
prescription in 2010, history 
of transplantation, SES 
(categorized into tertiles 
according to a locale-specific 
poverty index), cancer 














Table 5: Association between PHN and various risk factors within a general population sample: risk factors, adjusted effect measure and 95% 
confidence interval by study.   
 
Note: All risk factors included in the final multivariate model are listed 
 
Age (in years) Sex 
Severe immune 
suppression 




and other risk factors 
Genetics 
Other risk factors in final 
model 
 
Studies assessing risk factors for PHN within a general population sample 
Case-control studies (OR, 95% CI unless otherwise specified) 
Gatti  
2010 
(matched on age) (matched on 
gender) 
- - - Family history of zoster among 
first degree relatives,  
RR 1.03 (0.78-1.37) and all 
relatives RR 1.03 (0.81-1.31), 





- - - - - HLA-A33: RR 4.79, P=0.00972, 
HLA-B44: RR 4.51, P=0.03499, 




- - - - - HLA-A3303: 3.27, P=0.0007, 
HLA-B*4403: 3.10, P=0.001, 
HLA-DRB1*1302: 3.36, P=0.001 
[95% CIs not given] 
- 
Cohort Studies (HR, 95% CI) 
Weitzman
2013 
65-74 vs 25-34: 
20.9 (11.0-39.6) 
 






Cancer history, vs none 
<1 year: 3.00 (1.23-7.30) 
1-5 years: 1.91 (1.16-3.14) 
5+ years: 1.17 (0.65-2.11)  
Diabetes Mellitus:  1.35 (0.99-
1.83) 









Table 6: Assessment of bias in individual studies set within the general population      
 Confounding Selection Bias 
 




Exposure  Outcome (PHN) 
Matched case-control studies            
Type of 
















Gatti   
2010 
  ?      - ? 
 
Handling of age in analysis is unclear 
Hospital controls with 
no history of zoster, 
however recruited 
from hypertension 
clinic thus may be a 
























N/A Missing data not 
reported 
Ozawa 
1999   ?      - ? 
 
Confounding by age not applicable 
in genetic studies:  confounding by 
population possible, however did 
select Caucasian patients 
Very unclear how 





Objective measures of 

























  ?      - ? 
 
Confounding by age not applicable 
in genetic studies:  confounding by 
population possible, however did 
select Caucasian patients 
Controls selected from 






Objective measures of 

































2013  ?     
Unclear how rate 
ratios were 
calculated: no 
raw data on 
follow-up time. 
 
Age adjusted using categorical 
variable with 10 year age intervals 
 
Unclear how many people were lost to 
follow-up during study period 
Exposures recorded prior to 
record of PHN, however PHN 
may have been diagnosed 
previously 
Several risk factors 
assessed: some 
coding errors are 
possible 
Data not collected for research purposes 
therefore study hypothesis not known 
when outcome recorded: however, 
patients with exposures (e.g. diabetes) 
may have higher medical attendance 
than healthy zoster patients, thus more 
likely to be diagnosed with PHN, causing 
a spurious association 
Only patients with 
diagnostic codes for 
PHN classified as 
cases: under capture 
of PHN is likely  
(= High risk, = Medium risk, =Low/No risk or ?=Unclear risk) 
6.5.   Chapter summary 
  
Systematic review of risk factors for PHN among zoster patients 
 Risk factors for PHN have been posited, but the evidence has never been 
systematically reviewed. 
 Nineteen studies were selected for review, which assessed risk factors for PHN 
among adult zoster patients and reported age-adjusted effect estimates. 
 The risk of PHN was significantly increased with clinical features of acute zoster 
including prodromal pain, severe acute pain, severe rash and ophthalmic 
involvement. Older age was significantly associated with PHN. Evidence for a 
difference in PHN risk by gender was conflicting, with considerable between-study 
heterogeneity. A proportion of studies reported an increased risk of PHN with 
severe immunosuppression (n=3/5 studies) and diabetes mellitus (n=1/4).  
 The review has confirmed that a number of clinical features of acute zoster are 
associated with PHN.  It identified a range of other possible risk factors for PHN, 
yet aside from age-associated risks, the evidence is currently limited. Larger 
studies with strict definitions of exposures and outcomes and control for 
confounding variables may elucidate some of the unknown risk factors for PHN. 
 
Systematic review of risk factors for PHN in the general population  
 Understanding risk factors for PHN within the general population may be 
particularly helpful in informing vaccination policy. 
 Four studies were identified investigating risk factors for PHN in the general 
population, however all studies had some limitations, therefore the findings must 
be treated cautiously.   
 Three case-control studies investigated genetic susceptibility to PHN; two found 
evidence that alleles in the HLA region, known to be involved in immunity, were 
associated with PHN in Japanese populations, whilst the third study found no 
evidence of family history of zoster being a risk factor for PHN.  The final cohort 
study reported female gender, high SES, recent cancer treatment, HIV and 
diabetes were associated with increased risk of PHN. 
 Interpreting results of these studies is more difficult, as the effect reflects both 
the risk of zoster plus the risk of PHN, once zoster developed.  This difficulty in 
interpreting study results may explain why the majority of studies investigating 




Chapter 7:   Quantification of risk 
factors for postherpetic neuralgia in a 
cohort of herpes zoster patients 
 
7.1.   Introduction 
As demonstrated in the systematic review in chapter 6, knowledge of the risk factors for PHN is 
limited, with studies often being small and yielding inconsistent results. An understanding of PHN 
risk factors may be helpful in informing zoster vaccination policy, as patients at high risk of PHN 
could be specifically targeted.  A large cohort study was therefore carried out to investigate risk 
factors for PHN among a cohort of zoster patients in CPRD.  The findings from this study were 
written up as an article and the paper is currently accepted for publication at Neurology.  
 
This chapter begins with the article, and is followed by the submitted appendices which were 
too detailed for the article. The appendices include detailed information of how age was 
modelled, how missing data were dealt with and a fuller investigation of gender as a risk factor 












Objective: We aimed to investigate risk factors for postherpetic neuralgia, the neuropathic 
pain that commonly follows herpes zoster.  
 
Methods: Using primary care data from the Clinical Practice Research Datalink, we fitted 
multivariable logistic regression models to investigate potential risk factors for postherpetic 
neuralgia (defined as pain ≥90 days after zoster, based on diagnostic and/or prescription 
codes), including demographic characteristics, co-morbidities, and characteristics of the acute 
zoster episode. We also assessed whether their effects were modified by antiviral use.  
 
Results: Of 119,413 zoster patients, 6,956 (5.8%) developed postherpetic neuralgia. 
Postherpetic neuralgia risk rose steeply with age, most sharply between 50-79 years (adjusted 
odds ratio for a 10-year increase, 1.70, 99% confidence interval 1.63-1.78). Postherpetic 
neuralgia risk was higher in women (6.3% vs 5.1% in men: OR=1.19, 1.10-1.27); and those with 
severely immunosuppressive conditions, including leukaemia (13.7%: 2.07, 1.08-3.96) and 
lymphoma (12.7%: 2.45, 1.53-3.92); autoimmune conditions, including rheumatoid arthritis 
(9.1%: 1.20, 0.99-1.46); and other comorbidities including asthma and diabetes. Current and 
ex-smokers, as well as underweight and obese individuals were at increased risk of 
postherpetic neuralgia. Antiviral use was not associated with postherpetic neuralgia (OR=1.04, 
0.97-1.11). However, the increased risk associated with severe immunosuppression appeared 
less pronounced in patients given antivirals. 
 
Conclusions: Postherpetic neuralgia risk was increased for a number of patient characteristics 
and comorbidities, notably with age and among those with severe immunosuppression.  As 
zoster vaccination is contraindicated for patients with severe immunosuppression, strategies 
to prevent zoster in these patients, which could include the new sub-unit zoster vaccine, are 





Postherpetic neuralgia (PHN) is the commonest complication of herpes zoster177 and may 
cause severe pain.178 The lifetime incidence of zoster is 30% and an estimated 12·5% of zoster 
patients aged ≥50 years develop PHN.23 Symptoms can persist for months or years, often 
profoundly affecting a patient’s quality of life.179  There are no known effective disease-
modifying therapies for PHN. Treatments instead target symptom control, yet are often 
inadequate at relieving pain and are ineffective in almost half of PHN patients.27,33,180  
 
To date, observational and trial data have provided inconsistent evidence that administering 
antivirals at rash onset reduces PHN risk.31  These trials also tend to exclude 
immunosuppressed patients, such that the efficacy of antivirals to prevent PHN in this patient 
group is greatly under-researched. The only proven and available intervention to reduce PHN 
risk is through VZV vaccination.19 However, the high-cost of the vaccine means many countries 
limit its coverage.  A recent review demonstrates our incomplete understanding of PHN risk 
factors;181 except for age, evidence is conflicting and studies are often underpowered to detect 
associations.  Considering the dearth of effective treatment options for PHN, identifying PHN 
risk factors to inform zoster vaccination policy could have important public health benefits.4 
 
This paper aims to quantify risk factors for PHN in a large prospective study among zoster 
patients. It also investigates whether antivirals modify the effect of these risk factors on PHN. 
 
 
 Methods  
7.2.3.1. Study design and setting  
We conducted a study among zoster patients using prospectively collected data from the 
Clinical Practice Research Datalink (CPRD), a large routinely collected UK database of 
anonymised primary care records. CPRD is broadly representative of UK patient and practice 
characteristics.85 60% of CPRD patients had data available in the Hospital Episode Statistics 
(HES) database (Version 9), a linked database of hospital attendances in England from 1997. 




7.2.3.2. Study population 
The study cohort included patients with first ever zoster (identified previously182), followed-up 
to determine who develops PHN. Briefly, these patients were diagnosed with zoster between 
01/01/2000 and 31/12/2011 in CPRD (Read code for zoster and >12 months follow-up in CPRD 
before zoster diagnosis [to ensure the code represented incident zoster]) or HES (ICD-10 code 
for zoster in the primary diagnosis field of any episode).  The zoster vaccine was introduced 
into the UK in 2013, therefore this was an unvaccinated population. 
 
7.2.3.3. Definition of PHN 
Our underlying definition of PHN was pain persisting ≥90 days following zoster diagnosis.27 The 
primary definition of PHN included patients classified as having diagnosed, probable or 
possible PHN, based on a validated algorithm of PHN within a US administrative database 
utilising diagnosis codes and prescription data.102 See Table 1 for full definition.  
 
Exclusions 
As anticonvulsant prescriptions were part of our PHN algorithm (Table 1), patients with other 
indications for anticonvulsants (e.g. epilepsy) recorded pre-zoster were excluded. We also 
excluded patients without 365 days follow-up after zoster diagnosis; we could not know 
whether individuals censored before 365 days without PHN met our PHN definition, which 
used data to 365 days.   
 
7.2.3.4. Risk factors of interest 
Demographic risk factors included age at zoster, gender and socioeconomic status. 
Comorbidities included severely immunosuppressive conditions, specifically a recent history 
(<2 years before zoster diagnosis) of leukaemia or lymphoma, or any history of HIV, 
hematopoietic stem cell transplantation, myeloma or ‘other unspecified cellular immune 
deficiencies’ (e.g. pancytopenia), or ≥14-day course of high-dose (≥20 mg/day) oral 
corticosteroids, or exposure to other immunosuppressive therapies, in the month prior to 
zoster diagnosis. Other comorbidities included autoimmune conditions (systemic lupus 
erythematosis (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD)), diabetes, 
chronic obstructive pulmonary disease (COPD), asthma, chronic kidney disease (CKD), 
personality disorder, recent depression and recent cancer. Other characteristics included 
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smoking, BMI, site of acute zoster rash and antivirals given within 7 days of zoster diagnosis 
(appendix, section e-I).  
 
7.2.3.5. Statistical analysis 
Crude and age-adjusted odds ratios (ORs) were calculated to estimate the strength of 
association of each potential risk factor with PHN at 90 days (defined above), using logistic 
regression. The age-PHN association was non-linear, therefore age was modelled as a 5-knot 
restricted cubic spline. To numerically summarise the effect of non-linear age on PHN risk we 
also fitted piecewise linear models (appendix, section e-II). 
 
Multivariable analyses using logistic regression were carried out on patients with complete 
data for all variables. All variables were included in the final model. Two models were built, 
first excluding then including immunosuppressive therapies, to assess whether some of the 
overall effects of diseases were mediated by their treatments.   
 
Antivirals given at zoster may modify the risk of PHN. Antivirals are given to approximately 60% 
of patients with zoster in CPRD.183 We calculated stratum-specific ORs for each variable in the 
multivariable model by whether patients received antivirals. Patients potentially receiving 
antivirals in hospital were excluded from this analysis (figure 1).  In a post-hoc analysis we also 
calculated the adjusted OR for the effect of antivirals on PHN risk among patients with 
immunosuppression using logistic regression.  
 
Finally, a potentially effect-modifying role of age was investigated by computing stratum-
specific ORs for each variable in the multivariable model by age groups “<70 years" and "≥70 
years” as well as “<60 years" and "≥60 years” (age groups chosen to reflect different 
vaccination ages, e.g. ≤60 years in the US38 and 70, 78 or 79 years184 in the UK).  
 
General practice was included in all models as a random effect to account for clustering, as 
data might be correlated within practices.  
 
Sensitivity analyses and bias assessments 
We repeated the main risk factor analysis: 1) for PHN at 30 days following zoster; 2) restricting 
PHN cases to diagnosed PHN only (Table 1); 3) excluding possible misdiagnosed herpes simplex 
patients (appendix, section e-I).  We tested for healthcare utilization bias by assessing the 
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association between PHN and hypothyroidism (a chronic condition requiring high-level health-
care use,185 not associated with PHN) and calculated mean yearly consultation rate pre-zoster 
to confirm hypothyroidism patients had the same opportunity for PHN diagnosis (i.e. via GP 
contact). We used multiple imputation by chained equations127 as an alternative approach to 
account for missing data (9% of patients had missing data for BMI or smoking) (appendix, 
section e-III). 
  
Bias may be introduced from excluding patients <365 days follow-up post-zoster if those 
included had a different association between our risk factors and PHN, compared to those 
excluded.  We repeated the main analysis, restricting our outcome definition to PHN identified 
up to 120 and 180 days after zoster; the follow-up requirements are less, thus any selection 
biases due to excluding patients with insufficient follow-up is reduced. 
 
7.2.3.6. Standard Protocol Approvals, Registrations, and Patient Consents 
The study was approved by ISAC [application no.11028] and the London School of Hygiene and 
Tropical Medicine [application no.5930].  
 
 Results  
Of 144,959 patients with zoster, 119,413 were eligible for inclusion (appendix, Figure e-1). 
Almost 60% of the sample was female (Table 2) and the median age was 61 years (IQR:48-72, 
range:18-101).  In total, 6,956 zoster patients (5.8%) developed PHN.  
 
The risk of PHN rose with age (appendix, Figure e-2) and the association was non-linear 
(P<0.001, appendix Figure e-3). Patients 50-79 years had the steepest increased risk of PHN 
(Table 3); a 10-year increase in age within this age-band was associated with 70% increased 
risk of PHN (adjusted OR (adjOR):1.70, 99%CI:1.63-1.78), whereas the effect of a 10-year 
increase in age was attenuated above age 80 years (adjOR:1.10, 99%CI:0.94-1.28). Women 
were more likely to develop PHN than men, an association which remained after adjustment 
(adjOR:1.19, 99%CI:1.10-1.27) (Table 3).  
 
Conditions and therapies causing severe immunosuppression were strong risk factors for PHN 
(Table 2 and 3). Patients with leukaemia or lymphoma in the previous two years, myeloma or 
other unspecified cellular immune deficiencies ever, or recently taking high-dose oral 
corticosteroids had over twice the risk of developing PHN, compared to unaffected patients. 
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For HIV, the point estimate was also large, however only 6 of 99 HIV patients developed PHN, 
hence the evidence for an association was weak (adjOR:2.17, 99%CI:0.64-7.37).  
 
Of the autoimmune conditions, SLE was most strongly associated with PHN (adjOR:1.76, 
99%CI:1.04-2.98) (Table 2 and 3). RA and IBD were also associated with a higher PHN risk (9.1% 
and 7.5% respectively) with some evidence they were associated with between 10-20% 
increased risk of PHN after adjustment for confounders; the effects of these two conditions 
were less pronounced after adjusting for immunosuppressive drugs. 
 
Of the other comorbidities assessed (Table 2 and 3), COPD was associated with a 53% 
increased risk (PHN risk 13.2%; adjOR:1.53, 99%CI:1.35-1.72) and recent depression a 40% 
increased risk (PHN risk 7.0%; adjOR:1.40, 99%CI:1.20-1.62).  Asthma and type 2 diabetes were 
associated with 20% increased risk of PHN. After fully adjusting for confounders, personality 
disorder, CKD or recent cancer diagnosis were not associated with PHN.   
 
The overall risk of PHN among current smokers was lower than the study sample overall (5.4% 
vs 5.8%), however after adjusting for age, there was around 30% increased risk of PHN in 
current smokers (adjOR:1.27, 99%CI:1.15-1.39) (Table 2).  Being underweight or obese was 
also associated with PHN.  PHN was more prevalent in patients with non-truncal zoster (Table 
2 and 3).  
 
The effects of the risk factors on PHN were broadly similar between those given and not given 
antivirals, except for individuals with leukaemia (P-value for interaction 0.045), SLE (0.026), 
COPD (0.043) and smoking (0.002); point estimates for their effect on PHN appeared higher in 
those not given antivirals (Figure 1 and appendix Table e-8). Post-hoc analysis found no 
evidence that antivirals reduced the risk of PHN in patients with immunosuppression 
(appendix, section e-V).   
 
The effect of COPD (P-value for interaction 0.006), diabetes (0.004), currently smoking (0.006), 
or being obese (0.037) were slightly stronger in patients <70 years (appendix, Table e-1); the 
effect of asthma (0.068), CKD (0.018), diabetes (0.018) and being underweight or obese were 
slightly stronger in patients <60 years (0.031) (appendix, Table e-2). However, no clear patterns 





We re-ran the main analysis varying the PHN definitions. Most confidence intervals included 
the point estimate from the main analysis (appendix, Table e-3), except for: PHN at 30 days 
was associated with antiviral use (adjOR:1.12, 99%CI:1.06-1.18), yet less strongly associated 
with ophthalmic zoster (adjOR:1.72, 99%CI:1.56-1.91); restricting the outcome to diagnosed 
PHN only, the effect of ophthalmic zoster (adjOR:2.67, 99%CI:2.24-3.19) and a 10-year increase 
in age between 50-79 years (adjOR:2.08, 99%CI:1.92-2.24)  became stronger and the effect of 
female gender disappeared (adjOR:1.00, 99%CI:0.89-1.14). 
 
We explored in post-hoc analysis this loss of an association with female gender (using the 
primary PHN definition).  The effect of female gender on PHN was driven by cases of PHN 
defined using tricyclic antidepressant use, yet we found evidence suggesting prescribing 
practices for PHN differ by gender (appendix, section e-IV).   
 
Of 7,416 patients with hypothyroidism, 599 (8.1%) developed PHN. The fully adjusted OR 
between hypothyroidism and PHN indicated no association (adjOR:1.01, 99%CI:0.90-1.14, 
adjusted for variables in Table 3 Model 2); furthermore, mean yearly consultation rates among 
patients with our risk factors of interest were very variable (appendix, Table e-6), showing no 
consistent pattern with PHN risk.  
 
Accounting for missing BMI and smoking data using multiple imputation made no difference to 
the results (appendix, Table e-7). Restricting to shorter follow-up periods (specifically 120 and 
180 days) also had no major effect on the results (appendix, Figure e-4).  
 
 Discussion 
This study shows older age and severe immunosuppression, such as recently having lymphoma 
or leukaemia, are the strongest risk factors for PHN among zoster patients. Although 
immunosuppressed patients are not currently eligible for vaccination, promising research on a 
new sub-unit zoster vaccine (HZ/su) may enable vaccination within this group.47 Other risk 
factors included: autoimmune conditions (RA, SLE and IBD), COPD, depression, diabetes, 
asthma, lower socioeconomic status, smoking, being under- or overweight and non-truncal 
zoster.  Antivirals given at zoster were not associated with PHN risk overall, but there was 
some weak evidence that their use mitigated the increased risks associated with leukaemia, 




This study addresses an absence in the literature of well-powered studies assessing PHN risk 
factors.181 The study benefits from: being the largest study addressing this question; being 
population-based; using a dataset broadly representative of the UK;85 tightly accounting for 
confounding by age; and using a more precise definition of PHN than earlier studies using 
routinely collected data.  
 
Despite its strengths, this study has some limitations. Although we attempted to reduce 
misclassification of PHN by basing our definition on a validated method for administrative 
data,102 PHN incidence is lower than previous studies (5.8% versus 7.2% in an Icelandic study 
with active follow-up of similar aged zoster cases186). The reported prevalence of PHN varies 
hugely across studies. We used a 90 (rather than 30) day definition and included patients <50 
years old, which may explain the relatively low PHN prevalence. However, some PHN 
diagnoses could have been missed. Unidentified cases are likely those with mild pain, who 
used over-the-counter medications for initial pain relief or (if GP-prescribed treatments were 
ineffective) for follow-on pain relief. These findings are therefore likely to be generalizable to 
patients with severe PHN. Another explanation for the low prevalence may be that some 
immunocompromised patients are treated exclusively in secondary care; however, this is likely 
to be a few cases only, because PHN is largely treated in primary care.  
 
Certain clinical features of zoster are accepted PHN risk factors, including prodromal pain and 
increased rash severity.181 In CPRD, these data are unavailable. These features may lie on the 
causal pathway or be mediators between our exposures and PHN. For example, leukaemia 
patients may experience greater viral load, which manifests as a severe rash and increase PHN 
risk. It would be inappropriate to control for rash severity, as we want the total effect of 
leukaemia on PHN; lacking data on these clinical features is therefore unlikely to limit our 
findings. 
 
In numerous studies increasing age is associated with a sharp increase in PHN risk.23,187  Our 
study identified a non-linear age effect; PHN risk increased steeply between 50-79 years and 
attenuated after age 80.  A Dutch cohort study among 837 zoster patients13 suggested PHN 
incidence continues to increase in individuals >80 years; however PHN was defined as 
analgesic prescription three months post-zoster, potentially causing misclassification, 
particularly among older individuals.  Other studies report PHN risk lessening around 80 
years.26,100,188 Our observed effect may arise from under-ascertainment of PHN in patients >80 
years due to: frailty preventing GP attendance; or PHN-associated pain being superseded by 




Previous studies have not identified depression as a risk factor for PHN,189-192 unlike our study. 
We acknowledge our result may be driven by patients requiring tricyclic antidepressants for 
depression, and being misclassified as PHN cases; when restricting PHN cases to diagnosed 
PHN only, the association with depression disappeared (adjOR:1.12, 99%CI:0.84-1.49). 
However, the wide confidence intervals suggest there may have been insufficient power to 
detect an effect.  
 
The study found no evidence that antivirals protected against PHN. This is unlikely to be 
attributed to inadequate dosing, as 93% of treated patients received at least the 
recommended minimum antiviral dose. However, other limitations could explain this null 
finding.  In primary care, patients with severe zoster are recommended to receive antivirals, 
yet are also more likely to develop PHN. This may introduce confounding by indication and 
mask a protective effect.  Also, trial data has assessed the efficacy of antivirals administered 
within 72 hours of rash onset.31 Although 97.5% of patients were prescribed antivirals on the 
day of zoster diagnosis, zoster treatment initiation may occur >72 hours after rash onset, when 
the effect of antivirals is unproven. Although data on time from actual rash onset to 
presentation at general practitioners is not available in this data set, two previous UK studies 
suggest 50-65% of patients present within 72 hours,193,194 leaving a number of patients treated 
after 72 hours from rash onset.  
 
Our recent systematic review of PHN risk factors concluded there was no consensus regarding 
immunosuppression as a risk factor for PHN.181 The present study demonstrates that 
immunosuppression is associated with greater PHN risk and the study had sufficient power to 
assess the effect of specific immunosuppressive conditions and therapies on PHN risk.  Our 
study is also novel in identifying autoimmune conditions as PHN risk factors; autoimmune 
conditions had scarcely been assessed previously, though SLE was associated with over two-
fold increased risk of PHN in a large Taiwanese cohort study.195 
 
Disentangling the role of diseases and their drug treatments on the PHN risk is challenging. 
There was little evidence that the increased risks associated with severely immunosuppressive 
conditions were mediated by immunosuppressive drugs.  However, treatment such as 
chemotherapy, given in secondary care, is not captured in CPRD and probably explains at least 
part of the increased risk.  The effects of IBD and RA on PHN were less pronounced after 
adjusting for immunosuppressive treatments, suggesting that the association is driven 
predominantly by exposure to these drugs. By contrast, the effect of SLE did not appear to be 
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mediated by immunosuppressive therapies, although CRPD lacks reliable data on newer 
biological therapies. 
 
Establishing the role of severe immunosuppression and autoimmune conditions on PHN risk 
may help shed light on the underlying pathophysiological mechanisms that lead to PHN, which 
are poorly understood. Two key aetiological hypotheses are: that PHN is caused by a 
persistence of varicella-zoster virus following zoster; or by increased neuronal excitability and 
alteration of pain perception.33,34 Our finding of a strong association between 
immunosuppression and PHN risk seems to support the former hypothesis; lower cell-
mediated immunity may lead to higher levels of virus during acute infection and thus an 
increased risk of PHN. 
 
Cost-effectiveness studies are needed to determine the value in vaccinating patients with 
identified risk factors for PHN against zoster. Those of older age and with severe 
immunosuppression were at the highest risk of PHN. Strategies to prevent zoster in patients 
with severe immunosuppression are an increasing priority as these patients are not currently 
eligible for zoster vaccination, although the new development of a subunit vaccine provides a 




























































































































Demographic characteristics     
Age (years) [Estimated ORs for 10 year increase in age within the specified age‐band]¹
Among those aged <50  1.48 (1.35‐1.63) ‐ 1.42 (1.28‐1.58)  1.42 (1.28‐1.57)
Among those aged 50‐79  1.74 (1.68‐1.81) ‐ 1.70 (1.63‐1.78)  1.70 (1.63‐1.78)
Among those aged ≥80  0.99 (0.87‐1.14) ‐ 1.09 (0.94‐1.27)  1.10 (0.94‐1.28)
Female   1.25 (1.17‐1.34) 1.17 (1.09‐1.25) 1.19 (1.10‐1.28)  1.19 (1.10‐1.27)
Socioeconomic status (practice level)²   
1 (least deprived)  1.00 1.00 1.00 1.00 
2  1.01 (0.89‐1.15) 1.05 (0.92‐1.19) 1.04 (0.91‐1.18)  1.04 (0.91‐1.18)
3  1.09 (0.96‐1.24) 1.09 (0.96‐1.24) 1.09 (0.96‐1.24)  1.09 (0.96‐1.24)
4  1.17 (1.03‐1.33) 1.19 (1.05‐1.35) 1.17 (1.03‐1.32)    1.17 (1.03‐1.32)
5 (most deprived)  1.19 (1.04‐1.35) 1.26 (1.11‐1.44) 1.20 (1.06‐1.37)    1.20 (1.06‐1.37)
   
Severe Immunosuppression   
HIV  1.04 (0.35‐3.08) 2.40 (0.80‐7.27) 2.23 (0.66‐7.53)    2.17 (0.64‐7.37)
Leukaemia  2.65 (1.44‐4.87) 2.32 (1.25‐4.33) 2.06 (1.08‐3.95)    2.07 (1.08‐3.96)
Lymphoma  2.38 (1.54‐3.70) 2.39 (1.53‐3.75) 2.44 (1.52‐3.90)    2.45 (1.53‐3.92)
Myeloma  3.33 (2.25‐4.93) 2.36 (1.58‐3.51) 2.18 (1.44‐3.31)    2.17 (1.43‐3.29)
Hematopoietic stem cell 
transplantation 
6.89 (1.73‐27.52) 11.25 (2.73‐46.44) 5.85 (1.30‐26.29)  5.91 (1.32‐26.59)
Other unspecified cellular immune 
deficiencies 
2.43 (0.91‐6.52) 2.19 (0.80‐6.02) 2.15 (0.78‐5.97)  2.12 (0.77‐5.89)
Oral corticosteroids³ 2.76 (1.88‐4.07) 2.55 (1.71‐3.78) ‐ 2.26 (1.51‐3.40)
Other immunosuppressive therapy³  1.52 (1.21‐1.91) 1.46 (1.16‐1.84) ‐ 1.21 (0.92‐1.58)
   
Autoimmune conditions   
Rheumatoid Arthritis 1.64 (1.36‐1.97) 1.27 (1.06‐1.54) 1.20 (0.99‐1.46)  1.13 (0.91‐1.39)
Systemic Lupus Erythematosis  1.70 (1.03‐2.82) 1.95 (1.16‐3.27) 1.82 (1.08‐3.08)  1.76 (1.04‐2.98)
Inflammatory Bowel Disease  1.31 (1.01‐1.70) 1.33 (1.03‐1.74) 1.27 (0.97‐1.67)  1.22 (0.93‐1.60)
   
Other comorbidities  
COPD  2.60 (2.32‐2.91) 1.66 (1.48‐1.86) 1.54 (1.36‐1.74)  1.53 (1.35‐1.72)
Asthma  1.07 (0.95‐1.21) 1.22 (1.08‐1.39) 1.21 (1.07‐1.38)  1.21 (1.06‐1.37)
Chronic Kidney Disease  2.01 (1.79‐2.25) 1.17 (1.04‐1.32) 1.09 (0.96‐1.23)  1.08 (0.96‐1.22)
Depression  1.21 (1.05‐1.40) 1.53 (1.32‐1.77) 1.39 (1.20‐1.62)  1.40 (1.20‐1.62)
Personality disorder 1.18 (0.81‐1.70) 1.37 (0.94‐1.99) 1.25 (0.85‐1.84)  1.25 (0.85‐1.85)
Diabetes  1.74 (1.57‐1.93) 1.26 (1.13‐1.40) 1.19 (1.07‐1.33)  1.19 (1.07‐1.33)
Diabetes Type   
No diabetes  1.00 1.00 1.00 1.00 
Type 1  0.62 (0.27‐1.44) 1.45 (0.62‐3.36) 1.53 (0.66‐3.55)  1.51 (0.65‐3.51)
Type 2  1.79 (1.61‐1.99) 1.24 (1.12‐1.38) 1.17 (1.05‐1.31)  1.17 (1.05‐1.31)
Type not specified  1.55 (1.00‐2.39) 1.62 (1.04‐2.52) 1.54 (0.99‐2.41)  1.54 (0.98‐2.40)
Recent cancer diagnosis  1.42 (1.08‐1.88) 1.05 (0.79‐1.38) 1.06 (0.79‐1.41)  1.06 (0.79‐1.41)
      
Health behaviours and characteristics of zoster episode 
Smoking     
Non‐smoker  1.00 1.00 1.00 1.00 
Current smoker  1.06 (0.97‐1.15) 1.32 (1.21‐1.45) 1.26 (1.15‐1.39)  1.27 (1.15‐1.39)
Ex‐smoker  1.42 (1.32‐1.54) 1.21 (1.12‐1.30) 1.14 (1.05‐1.24)  1.14 (1.05‐1.24)
BMI Category   
Underweight (BMI <18.5)  1.58 (1.29‐1.94) 1.38 (1.12‐1.70) 1.25 (1.01‐1.54)  1.25 (1.01‐1.54)
Normal Weight (BMI 18.5‐24.9)  1.00 1.00 1.00 1.00 
Overweight (BMI 25‐30)  1.05 (0.98‐1.14) 0.99 (0.92‐1.07) 1.01 (0.93‐1.09)  1.01 (0.93‐1.09)
Obese (BMI ≥30)  1.13 (1.04‐1.24) 1.18 (1.08‐1.29) 1.13 (1.03‐1.24)  1.13 (1.03‐1.24)
Antiviral record within 7 days of 
zoster  1.16 (1.09‐1.24)  1.05 (0.98‐1.12)  1.04 (0.97‐1.12)  1.04 (0.97‐1.11) 
Anatomical site of zoster   
Site Unspecified  1.00  1.00  1.00 1.00 
Non‐Truncal (excluding ophthalmic zoster)  1.94 (1.41‐2.67) 2.34 (1.68‐3.25) 2.20 (1.54‐3.12)  2.19 (1.54‐3.11)
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7.3.   Accepted appendices 
e-I: Further details on definitions of risk factors 
 
Aside from the discussion below about possible misdiagnosis of herpes simplex patients as 
zoster patients, this section (e-I) of the appendices repeats information written in chapter 3, 
“Data sources and variable definitions”, therefore has been placed in the thesis appendices 
(appendix IV).  
 
Possible misdiagnosis of herpes simplex as herpes zoster 
Of the 119,413 cohort, 1586 (1.6%) patients had a further zoster code 90-365 days after their 
first zoster. Of these 215 (13.6%) had a PHN medication or a PHN diagnostic code, and in the 
main analysis these were categorised as PHN.  However, the other 1371 patients had a zoster 
code without medications or codes suggesting PHN.  There were three possible explanations 
for these patients.  The first is that they were recurrent zoster; however this is very rare in 
immunocompetent patients, who made up 96% of the group. The second is that these are 
poorly coded PHN patients, however it seems unlikely that no PHN prescriptions would be 
given. The third, and perhaps most plausible explanation is that these patients were 
misdiagnosed herpes simplex cases.  Herpes simplex is known to recur more frequently than 
zoster and can, albeit rarely, present with dermatomal distribution similar to herpes zoster. 196 
Further to this, half of the patients were prescribed an antiviral at their later zoster diagnosis, 
which may further indicate misdiagnosis of herpes simplex. Therefore as a sensitivity analysis 
we excluded all 1586 patients with a further zoster code following first zoster diagnosis.  
 
 
e-II: Modelling age  
 
a) Using restricted cubic splines to adjust for age 
There was very good evidence that the relationship between PHN and age at zoster diagnosis 
was not linear (test for departure from linear trend P<0.001); in other words there was no 
evidence of a constant increase in the log odds of PHN per unit increase in age.  
 
Categorizing age into groups was considered but not pursued as this may lead to loss of 
information. Splitting age into categories would assume there is a single exposure effect within 
that category; considering age is such a strong risk factor for PHN this may be an unrealistic 
assumption. Further to that, cut-points are often arbitrarily chosen potentially heavily 
influencing the apparent shape of the age-PHN relationship.197 Allowing for a non-linear 
relationship would improve our understanding of the relationship between age and PHN, 
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reduce the possibility of residual confounding by age when including it as a confounder and 
improve the model from a statistical viewpoint. 
 
We therefore utilised restricted cubic splines to make better use of within category 
information and allow for non-linearity. Splines are a type of smoothing function which 
provide a continuous curve rather than a step function. Cubic splines are one type of spline 
where the effect measure is regressed on a cubic function of exposure (here, age), across 
several different regions or categories of exposure and spanning the entire range of exposure.  
So cubic splines consist of piecewise cubic polynomials (in other words curves with up to 2 
turning points) between specified “knots”. The “restricted” means the relationships will be 
linear before the first knot and after the last knot. A single smooth curve across these regions 
is then produced. 
 
As there was no obvious biological rationale for where to place the knots, they were placed at 
equal percentiles of age.  The number of knots was chosen by assessing the Akaike information 
criterion (AIC) when 3 to 7 knots were included: the AIC criterion is a measure of the relative 
quality of a model given a set of data and thus provides a method to select the most 
appropriate model. AIC rewards goodness of fit of a model but includes a penalty for 
increasing number of parameters; this therefore discourages over-fitting (including more 
parameters will almost always improve the fit of the model). The model with the minimum AIC 
is preferred. Here, the AIC reduced from 49825 to 49758 when modelling it as a 3-knot and 5-
knot respectively. The reduction in AIC beyond 5 knots was marginal (6 knots: 49753, 7 knots: 
49728), therefore 5 knots were chosen (with knots at 26, 49, 61, 71, 84 years).  
 
b) Using piecewise linear splines to estimate the effect of age on PHN  
Restricted cubic splines provide a smooth curve of the age-PHN relationship and impose few 
constraints on that curve; however, they have the drawback of not providing interpretable 
parameters. Linear splines were used to estimate the relationship between age and PHN as a 
piecewise linear function, in other words a function composed of linear (straight line) 
segments between the specified knots. The points (knots) at which the linear segments join 
were determined by first, looking at the restricted cubic spline graph to assess where the 
effect of age on PHN appeared to alter. We then fitted piecewise linear models across various 





e-III: Dealing with missing data 
 
 
We used multiple imputation to account for missing data. Missing data were present for BMI 
and smoking. In total, 91% percent of patients had complete data for all variables. To maximise 
the use of the data while properly incorporating the extra uncertainty arising due to missing 
data, multiple imputation by chained equations 127 was used to impute missing values for BMI 
and smoking from multinomial models. The imputation model included all covariates from the 
main outcome model (Model 2 in table 2), with age included as a 5-knot restricted cubic spline. 
We also included extra comorbidities, identified using medical Read codes, to look for 
additional markers of BMI or smoking related diseases. These included: stroke, peripheral 
artery disease, angina (stable and unstable), acute coronary syndrome, congestive heart 
failure, myocardial infarction, hypertension and alcoholic liver disease (including portal 
hypertension) and pancreatitis. Five imputed datasets were created and combined for analysis. 
Distributions of imputed values were visually checked for comparability with the observed 
data. This was not done as the primary approach due to possible violation of the “missing at 




e-IV: Investigating gender as a risk factor for PHN 
 
In a sensitivity analysis which restricted the PHN definition to diagnosed PHN only (that is, 
patients with a Read code for PHN 90-365 days following zoster), female gender was no longer 
associated with an increased risk of PHN (table e-2, sensitivity analysis 2). We carried out some 
post-hoc analysis to investigate this further. 
 
Gender distribution by PHN classification (diagnosed, probable and possible PHN) 
The proportion of females among those with diagnosed, probable and possible PHN was 
61.8%, 65.4%, 66.4% respectively. The effects of gender on PHN risk showed some variation 
across PHN classifications (see Table e-3); gender was not associated with diagnosed PHN, 
whilst females appeared to be at increased risk of probable and possible PHN.  The association 
between gender and PHN according to the exact source of evidence for PHN was calculated 
(see table e-6); PHN defined from prescription of tricyclic antidepressants was driving the 
increased risk of probable and possible PHN in females (see table e-4, analysis A).  
 
Three hypotheses were suggested and explored to explain this pattern: 
c) Patients with depression were being misclassified as PHN cases: Of particular concern 
was that PHN cases defined from tricyclic antidepressant use were actually patients 
with depression, a condition widely known to be more common in females. To explore 
whether there may be systematic misclassification of PHN, the effects of gender on 
PHN risk were stratified by history of mental health problems ever in CPRD prior to 
zoster. These mental health problems included symptoms or diagnoses suggesting 
depression, anxiety, bipolar, or suicidal ideation. In both strata there appeared to be 
an increased risk of tricyclic antidepressant-defined PHN, suggesting the association 
between PHN and gender isn’t driven entirely by previous mental health problems (see 
table e-4, analysis B and C). As a secondary check, patients with depression (using 
depression diagnosis and depression symptom codes) in the year prior to zoster or the 
year following zoster were excluded; there was still an increased risk of PHN defined 
by tricyclic antidepressant use among females (see table e-6; analysis D).   
d) Females with PHN are more likely to be prescribed medications than males with PHN:  
Among 2156 patients with “diagnosed PHN”, 33% (701/2156) did not receive any PHN 
medications 90-180 days following zoster.  It was hypothesised that females may be 
more likely to receive treatment when visiting their GP; however, there was little 
difference in the proportion of male and females prescribed medications 90-180 days 
following zoster (69.8% vs 66.1% respectively, chi-squared P-value=0.07).   
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e) Females with PHN are more likely to receive a tricyclic antidepressant than males with 
PHN:  Among patients with diagnosed PHN who received treatment 90-180 days 
following zoster (n=1455), females were more likely to receive tricyclic antidepressants 
in the 90-180 day period than males; 43.6% (384/880) females received a tricyclic, 
compared to 34.8% (200/575) of males (chi² P-Value=0.001).  This suggests GPs may 
have different prescribing practices for males and females, which may explain why 
PHN defined through tricyclic antidepressant use is associated with gender.   
 
We therefore concluded that the association between gender and probable and possible PHN 
reflects different prescribing practices; specifically that female PHN patients are more likely to 




e-V: Effect of antivirals in patients with immunosuppression 
 
Post-hoc analysis explored whether antivirals reduced the risk of PHN in patients with 
immunosuppression.  Among patients with any severely immunosuppressive condition 
(grouped due to small numbers; n=1614), 8.3% of those given antivirals developed PHN 
(86/1,043), compared to 10.9% not given antivirals (62/571); however this was compatible 
with chance variation (OR for the effect antiviral use on PHN risk, among those with severe 
immunosuppression: 0.73, 99%CI:0.45-1.18, adjusted for variables in Table 2 Model 2). 
 
Using antivirals to prevent PHN in patients with immunosuppression is under-researched; 
many trials exclude these patients.31 In this post-hoc analysis, the rate of PHN among severely 
immunosuppressed patients given antivirals was lower, than those not given antivirals, but the 
confidence interval around the OR was wide and included one, reflecting the small numbers 
available.  Given that a priori we assumed antiviral use would be associated with greater risk of 
PHN (due to confounding by indication; patients with severe zoster are more likely to develop 
PHN and receive antivirals) a lower risk of PHN in this group, albeit non-significant, suggests 
antiviral effectiveness in patients with severe immunosuppression should be investigated 
further.  Capture of antiviral therapy among the more severely immunosuppressed patients 
may be poor, as patients could be immediately referred for intravenous antiviral therapy; 
therefore, differential misclassification of antiviral exposure may be driving the higher risk of 
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Effect of 10-year increase in age on PHN





































































Measured using the Index of multiple deprivation (IMD)
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Total  82776 (100) 2959 (3.6)  36637 (100) 3997 (10.9)   
Demographic characteristics           
Female   48215 (58.2) 1850 (3.8) 1.20 (1.08‐1.32) 1.19 (1.07‐1.32) 22948 (62.6) 2639 (11.5) 1.14 (1.04‐1.25) 1.18 (1.07‐1.31) 0.872 
Socioeconomic status (practice level)¹          
1 (least deprived)  16525 (20.0) 528 (3.2) 1.00 1.00 7533 (20.6) 754 (10.0) 1.00 1.00 0.811 
2  16625 (20.1) 563 (3.4) 1.07 (0.89‐1.29) 1.08 (0.89‐1.30) 7028 (19.2) 725 (10.3) 1.04 (0.89‐1.20) 1.02 (0.87‐1.19)
3  16718 (20.2) 581 (3.5) 1.08 (0.90‐1.30) 1.08 (0.89‐1.29) 7850 (21.4) 862 (11.0) 1.10 (0.96‐1.27) 1.11 (0.96‐1.29)
4  17210 (20.8) 662 (3.8) 1.22 (1.02‐1.46) 1.17 (0.98‐1.40) 7784 (21.2) 895 (11.5) 1.17 (1.02‐1.35) 1.16 (1.00‐1.34)
5 (most deprived)  15698 (19.0) 625 (4.0) 1.31 (1.10‐1.58) 1.22 (1.01‐1.46) 6442 (17.6) 761 (11.8) 1.22 (1.05‐1.41) 1.18 (1.01‐1.38)
          
Severe Immunosuppression           
HIV  95 (0.1)  4 (4.2) 1.78 (0.47‐6.75) 1.73 (0.43‐6.93) 4 (0.0)  2 (50.0) 9.52 (0.71‐127.82) 5.09 (0.21‐121.53) 0.667 
Leukaemia  92 (0.1)  4 (4.3) 1.09 (0.29‐4.13) 1.11 (0.29‐4.27) 61 (0.2)  17 (27.9) 3.26 (1.55‐6.86) 2.84 (1.31‐6.16) 0.234 
Lymphoma  222 (0.3)  25 (11.3) 3.10 (1.77‐5.42) 3.08 (1.72‐5.51) 92 (0.3)  15 (16.3) 1.67 (0.80‐3.47) 1.88 (0.87‐4.06) 0.407 








Oral corticosteroids² 233 (0.3)  24 (10.3) 2.76 (1.56‐4.86) 2.14 (1.19‐3.87) 132 (0.4)  29 (22.0) 2.32 (1.34‐4.01) 2.26 (1.29‐3.96) 0.866 
Other immunosuppressive therapy²  1174 (1.4)  77 (6.6) 1.69 (1.24‐2.31) 1.28 (0.89‐1.84) 534 (1.5)  68 (12.7) 1.26 (0.89‐1.76) 1.09 (0.73‐1.62) 0.261 
           
Autoimmune conditions           
Rheumatoid Arthritis 1380 (1.7)  98 (7.1) 1.61 (1.22‐2.13) 1.29 (0.94‐1.76) 1094 (3.0)  127 (11.6) 1.09 (0.85‐1.40) 1.02 (0.77‐1.36) 0.110 
Systemic Lupus Erythematosis 226 (0.3)  16 (7.1) 2.23 (1.13‐4.40) 1.74 (0.87‐3.50) 81 (0.2)  13 (16.0) 1.65 (0.75‐3.62) 1.68 (0.76‐3.73) 0.826 
Inflammatory Bowel Disease 1051 (1.3)  54 (5.1) 1.41 (0.97‐2.03) 1.19 (0.80‐1.76) 418 (1.1)  56 (13.4) 1.28 (0.88‐1.86) 1.26 (0.86‐1.85) 0.863 
           
Other comorbidities           
COPD  1995 (2.4)  208 (10.4) 2.10 (1.72‐2.57) 1.83 (1.49‐2.26) 3065 (8.4)  461 (15.0) 1.51 (1.31‐1.73) 1.41 (1.22‐1.64) 0.006 
Asthma  6206 (7.5)  276 (4.4) 1.37 (1.16‐1.63) 1.33 (1.12‐1.58) 2061 (5.6)  236 (11.5) 1.08 (0.89‐1.29) 1.08 (0.89‐1.31) 0.129 
Chronic Kidney Disease 1891 (2.3)  124 (6.6) 1.39 (1.08‐1.78) 1.18 (0.92‐1.53) 4098 (11.2) 511 (12.5) 1.13 (0.99‐1.29) 1.06 (0.93‐1.22) 0.290 
Depression  4283 (5.2)  204 (4.8) 1.61 (1.32‐1.96) 1.42 (1.16‐1.74) 1176 (3.2)  176 (15.0) 1.44 (1.16‐1.79) 1.34 (1.07‐1.69) 0.548 
Personality disorder 609 (0.7)  33 (5.4) 1.56 (0.98‐2.50) 1.34 (0.83‐2.18) 165 (0.5)  20 (12.1) 1.12 (0.60‐2.07) 1.07 (0.56‐2.07) 0.572 
Diabetes  4357 (5.3)  298 (6.8) 1.53 (1.30‐1.81) 1.38 (1.16‐1.65) 4135 (11.3) 491 (11.9) 1.13 (0.99‐1.29) 1.09 (0.95‐1.25) 0.004 
Recent cancer diagnosis 625 (0.8)  43 (6.9) 1.50 (0.99‐2.27) 1.40 (0.90‐2.17) 578 (1.6)  54 (9.3) 0.83 (0.57‐1.21) 0.88 (0.60‐1.28) 0.106 
           
Health behaviours and characteristics of zoster episode        
Smoking            
Non‐smoker  31837 (38.5) 899 (2.8) 1.00 1.00 13938 (38.0) 1427 (10.2) 1.00 1.00 0.006 
Current smoker  24698 (29.8) 962 (3.9) 1.48 (1.31‐1.68) 1.39 (1.22‐1.59) 6058 (16.5) 684 (11.3) 1.17 (1.03‐1.33) 1.12 (0.97‐1.28)
Ex‐smoker  25414 (30.7) 1083 (4.3) 1.28 (1.14‐1.45) 1.18 (1.04‐1.34) 16317 (44.5) 1863 (11.4) 1.15 (1.05‐1.27) 1.10 (0.99‐1.23)
BMI Category            
Underweight (BMI <18.5) 1237 ( 1.5)  60 ( 4.9) 1.66 (1.16‐2.37) 1.42 (0.99‐2.05) 913 ( 2.5)  128 (14.0) 1.27 (0.98‐1.64) 1.18 (0.91‐1.53) 0.037 
Normal Weight (BMI 18.5‐24.9) 28856 (34.9) 960 ( 3.3) 1.00 1.00 13195 (36.0) 1438 (10.9) 1.00 1.00
201
    
Overweight (BMI 25‐30) 26905 (32.5) 979 ( 3.6) 0.95 (0.84‐1.07) 0.97 (0.86‐1.09) 13029 (35.6) 1416 (10.9) 1.02 (0.92‐1.13) 1.04 (0.94‐1.16)  
Obese (BMI ≥30) 17813 (21.5) 829 ( 4.7) 1.24 (1.10‐1.41) 1.17 (1.02‐1.33) 6436 (17.6) 731 (11.4) 1.11 (0.98‐1.26) 1.08 (0.95‐1.22)
Antiviral record within 7 days of zoster  46332 (56.0) 1775 (3.8) 1.08 (0.97‐1.19) 1.05 (0.95‐1.16) 22550 (61.6) 2473 (11.0) 1.03 (0.94‐1.12) 1.02 (0.93‐1.12) 0.800 
Anatomical site of zoster      
Site Unspecified 78915 (95.3) 2684 (3.4) 1.00 1.00 34085 (93.0) 3530 (10.4) 1.00 1.00 0.901 
Non‐Truncal (excluding ophthalmic zoster)  40 (1.4)  40 (7.1) 2.54 (1.64‐3.92) 2.31 (1.45‐3.68) 34 (0.9) 34 (19.5) 2.13 (1.29‐3.51) 2.04 (1.20‐3.47)































Total  56711 (100) 1377 (2.4)  62702 (100) 5579 (8.9)   
Demographic characteristics           
Female   33271 (58.7) 917 (2.8) 1.35 (1.16‐1.56) 1.31 (1.12‐1.54) 37892 (60.4) 3572 (9.4) 1.12 (1.04‐1.21) 1.16 (1.07‐1.26) 0.141 
Socioeconomic status (practice level)¹          
1 (least deprived)  11204 (19.8) 236 (2.1) 1.00 1.00 12854 (20.5) 1046 (8.1) 1.00 1.00 0.898 
2  11425 (20.1) 265 (2.3) 1.11 (0.86‐1.44) 1.11 (0.86‐1.45) 12228 (19.5) 1023 (8.4) 1.04 (0.91‐1.19) 1.03 (0.89‐1.18)
3  11281 (19.9) 265 (2.3) 1.13 (0.87‐1.46) 1.12 (0.86‐1.45) 13287 (21.2) 1178 (8.9) 1.09 (0.95‐1.24) 1.09 (0.95‐1.25)
4  11757 (20.7) 308 (2.6) 1.26 (0.98‐1.62) 1.19 (0.93‐1.54) 13237 (21.1) 1249 (9.4) 1.18 (1.03‐1.34) 1.16 (1.01‐1.33)
5 (most deprived)  11044 (19.5) 303 (2.7) 1.37 (1.06‐1.76) 1.24 (0.96‐1.61) 11096 (17.7) 1083 (9.8) 1.24 (1.08‐1.42) 1.19 (1.04‐1.37)
          
Severe Immunosuppression           
HIV  90 (0.2)  4 (4.4) 2.08 (0.55‐7.88) 2.38 (0.61‐9.31) 9 (0.0)  2 (22.2) 3.55 (0.44‐28.86) 1.60 (0.10‐26.75) 0.635 
Leukaemia  55 (0.1)  2 (3.6) 1.34 (0.21‐8.74) 1.29 (0.19‐8.61) 98 (0.2)  19 (19.4) 2.53 (1.30‐4.94) 2.21 (1.10‐4.44) 0.554 
Lymphoma  128 (0.2)  13 (10.2) 4.46 (2.07‐9.63) 4.32 (1.95‐9.54) 186 (0.3)  27 (14.5) 1.91 (1.11‐3.29) 2.04 (1.15‐3.62) 0.117 
Myeloma  56 (0.1)  6 (10.7) 3.61 (1.17‐11.18) 3.63 (1.12‐11.74) 256 (0.4)  47 (18.4) 2.23 (1.46‐3.41) 2.16 (1.40‐3.34) 0.358 
Other unspecified cellular immune 
deficiencies  20 (0.0)  2 (10.0)  5.21 (0.74‐36.80)  4.21 (0.55‐31.95)  40 (0.1)  6 (15.0)  1.80 (0.57‐5.72)  1.78 (0.55‐5.71) 
0.410 
Oral corticosteroids² 140 (0.2)  12 (8.6) 3.46 (1.57‐7.63) 2.66 (1.17‐6.02) 225 (0.4)  41 (18.2) 2.33 (1.48‐3.66) 2.10 (1.32‐3.36) 0.474 
Other immunosuppressive therapy²  691 (1.2)  31 (4.5) 1.71 (1.06‐2.78) 1.15 (0.65‐2.02) 1017 (1.6)  114 (11.2) 1.39 (1.07‐1.81) 1.18 (0.87‐1.60) 0.479 
           
Autoimmune conditions           
Rheumatoid Arthritis 659 (1.2)  33 (5.0) 1.73 (1.08‐2.78) 1.37 (0.81‐2.31) 1815 (2.9)  192 (10.6) 1.21 (0.99‐1.48) 1.09 (0.87‐1.38) 0.263 
Systemic Lupus Erythematosis 170 (0.3)  8 (4.7) 1.92 (0.75‐4.94) 1.41 (0.54‐3.73) 137 (0.2)  21 (15.3) 1.95 (1.05‐3.63) 1.86 (0.99‐3.49) 0.652 
Inflammatory Bowel Disease 713 (1.3)  28 (3.9) 1.56 (0.94‐2.58) 1.35 (0.79‐2.32) 756 (1.2)  82 (10.8) 1.27 (0.94‐1.73) 1.18 (0.86‐1.63) 0.559 
           
Other comorbidities           
COPD  549 (1.0)  32 (5.8) 1.75 (1.08‐2.84) 1.44 (0.88‐2.35) 4511 (7.2)  637 (14.1) 1.66 (1.48‐1.87) 1.54 (1.36‐1.74) 0.675 
Asthma  4449 (7.8)  150 (3.4) 1.52 (1.21‐1.92) 1.40 (1.10‐1.77) 3818 (6.1)  362 (9.5) 1.12 (0.97‐1.30) 1.14 (0.97‐1.32) 0.068 
Chronic Kidney Disease 773 (1.4)  41 (5.3) 1.92 (1.25‐2.93) 1.59 (1.02‐2.48) 5216 (8.3)  594 (11.4) 1.14 (1.01‐1.29) 1.06 (0.93‐1.20) 0.018 
Depression  3407 (6.0)  127 (3.7) 1.67 (1.31‐2.14) 1.43 (1.11‐1.85) 2052 (3.3)  253 (12.3) 1.47 (1.23‐1.75) 1.36 (1.13‐1.64) 0.427 
Personality disorder 424 (0.7)  21 (5.0) 2.04 (1.13‐3.67) 1.66 (0.91‐3.05) 350 (0.6)  32 (9.1) 1.11 (0.68‐1.79) 1.05 (0.64‐1.74) 0.180 
Diabetes  1949 (3.4)  98 (5.0) 1.78 (1.34‐2.35) 1.47 (1.09‐1.97) 6543 (10.4) 691 (10.6) 1.20 (1.08‐1.35) 1.16 (1.03‐1.30) 0.018 
Recent cancer diagnosis 283 (0.5)  14 (4.9) 1.68 (0.82‐3.43) 1.41 (0.65‐3.06) 920 (1.5)  83 (9.0) 0.98 (0.72‐1.32) 1.01 (0.74‐1.38) 0.380 
           
Health behaviours and characteristics of zoster episode        
Smoking            
Non‐smoker  22730 (40.1) 457 (2.0) 1.00 1.00 23045 (36.8) 1869 (8.1) 1.00 1.00 0.324 
Current smoker  18413 (32.5) 506 (2.7) 1.43 (1.21‐1.70) 1.39 (1.16‐1.67) 12343 (19.7) 1140 (9.2) 1.29 (1.16‐1.43) 1.21 (1.09‐1.36)
Ex‐smoker  14829 (26.1) 405 (2.7) 1.22 (1.02‐1.46) 1.15 (0.95‐1.38) 26902 (42.9) 2541 (9.4) 1.20 (1.10‐1.31) 1.13 (1.04‐1.24)
BMI Category            
Underweight (BMI <18.5) 909 (1.6)  29 (3.2) 1.76 (1.06‐2.93) 1.58 (0.95‐2.64) 1241 (2.0)  159 (12.8) 1.31 (1.04‐1.65) 1.19 (0.94‐1.50) 0.031 
Normal Weight (BMI 18.5‐24.9) 20643 (36.4) 457 (2.2) 1.00 1.00 21408 (34.1) 1941 (9.1) 1.00 1.00
Overweight (BMI 25‐30) 16932 (29.9) 419 (2.5) 1.00 (0.84‐1.19) 1.03 (0.86‐1.23) 23002 (36.7) 1976 (8.6) 0.99 (0.90‐1.08) 1.01 (0.92‐1.10)
Obese (BMI ≥30)  11506 (20.3) 396 (3.4) 1.39 (1.16‐1.66) 1.29 (1.07‐1.56) 12743 (20.3) 1164 (9.1) 1.12 (1.01‐1.24) 1.08 (0.97‐1.20)
203
    
   Antiviral record within 7 days of zoster  30510 (53.8) 796 (2.6) 1.10 (0.96‐1.28) 1.06 (0.91‐1.23) 38372 (61.2) 3452 (9.0) 1.03 (0.96‐1.11) 1.03 (0.95‐1.11) 0.548 
Anatomical site of zoster  
Site Unspecified  54309 (95.8) 1262 (2.3) 1.00 1.00 58691 (93.6) 4952 (8.4) 1.00 1.00 0.789 
Non‐Truncal (excluding ophthalmic zoster)  425 (0.7)  21 (4.9) 2.38 (1.32‐4.29) 1.94 (1.01‐3.73) 311 (0.5)  53 (17.0) 2.31 (1.56‐3.44) 2.27 (1.49‐3.46)





































<50  1.42 (1.28‐1.57) 922 (2.8) 1.54 (1.42‐1.67) 127 (0.4) 1.36 (1.10‐1.68) 569 (1.8) 1.41 (1.27‐1.56)
50‐79  1.70 (1.63‐1.78) 8104 (11.1) 1.73 (1.67‐1.78) 1396 (1.9) 2.08 (1.92‐2.24) 4530 (6.3) 1.71 (1.64‐1.79)
≥80  1.10 (0.94‐1.28)  2729 (20.0) 0.96 (0.85‐1.09) 633 (4.6) 0.89 (0.69‐1.15) 1711 (12.7) 1.10 (0.95‐1.28)
Female   1.19 (1.10‐1.27) 7467 (10.5) 1.15 (1.09‐1.22) 1332 (1.9) 1.00 (0.89‐1.14) 4382 (6.3)) 1.18 (1.10‐1.27)
Socioeconomic status (practice level)²     
1 (least deprived) 1.00  2208 (9.2) 1.00 461 (1.9) 1.00 1259 (5.3) 1.00
2  1.04 (0.91‐1.18) 2217 (9.4) 1.04 (0.93‐1.15) 401 (1.7) 0.94 (0.70‐1.25) 1257 (5.4) 1.03 (0.91‐1.18)
3  1.09 (0.96‐1.24) 2461 (10.0) 1.09 (0.98‐1.21) 430 (1.8) 0.89 (0.67‐1.19) 1415 (5.8) 1.09 (0.96‐1.24)
4  1.17 (1.03‐1.32) 2560 (10.2) 1.13 (1.02‐1.25) 477 (1.9) 0.99 (0.75‐1.32) 1529 (6.2) 1.17 (1.03‐1.33)
5 (most deprived) 1.20 (1.06‐1.37) 2309 (10.4) 1.18 (1.06‐1.31) 387 (1.7) 0.98 (0.74‐1.32) 1350 (6.2) 1.19 (1.04‐1.36)
Severe Immunosuppression    
HIV  2.17 (0.64‐7.37) 11 (11.1) 2.86 (1.16‐7.07) 2 (2.0)  1.71(0.12‐24.01) 6 (6.2) 2.22 (0.65‐7.56)
Leukaemia  2.07 (1.08‐3.96) 34 (22.2) 2.11 (1.22‐3.64) 7 (4.6)  2.07 (0.73‐5.87) 21 (14.4) 2.27 (1.18‐4.36)
Lymphoma  2.45 (1.53‐3.92) 61 (19.4) 2.27 (1.52‐3.40) 10 (3.2) 1.94 (0.79‐4.75) 37 (12.1) 2.34 (1.43‐3.82)















Oral corticosteroids³ 2.26 (1.51‐3.40) 79 (21.6) 2.08 (1.46‐2.96)) 20 (5.5) 2.83 (1.50‐5.33) 53 (14.6) 2.31 (1.54‐3.47)
Other immunosuppressive therapy³  1.21 (0.92‐1.58) 239 (14.0) 1.24 (1.00‐1.54) 40 (2.3) 1.14 (0.70‐1.86) 144 (8.6) 1.23 (0.94‐1.61)
Autoimmune conditions    
Rheumatoid Arthritis 1.13 (0.91‐1.39) 363 (14.7) 1.09 (0.92‐1.29) 66 (2.7) 1.04 (0.71‐1.52) 223 (9.1) 1.14 (0.92‐1.41)
Systemic Lupus Erythematosis 1.76 (1.04‐2.98) 40 (13.0) 1.32 (0.82‐2.12) 12 (3.9) 2.66 (1.20‐5.88) 29 (9.6) 1.80 (1.07‐3.05)



















COPD  1.53 (1.35‐1.72) 1054 (20.8) 1.49 (1.35‐1.65) 219 (4.3) 1.43 (1.17‐1.76) 654 (13.1) 1.52 (1.34‐1.72)
Asthma  1.21 (1.06‐1.37) 866 (10.5) 1.24 (1.12‐1.37) 147 (1.8) 1.17 (0.93‐1.48) 503 (6.2) 1.22 (1.07‐1.38)
Chronic Kidney Disease 1.08 (0.96‐1.22) 1006 (16.8) 1.05 (0.95‐1.16) 176 (2.9) 0.91 (0.73‐1.13) 621 (10.5) 1.07 (0.95‐1.21)
Depression  1.40 (1.20‐1.62) 575 (10.5) 1.27 (1.12‐1.45) 93 (1.7)  1.12 (0.84‐1.49) 372 (7.0) 1.41 (1.21‐1.64)
Personality disorder 1.25 (0.85‐1.85) 76 (9.8) 1.04 (0.74‐1.46) 17 (2.2) 1.48 (0.77‐2.84) 52 (6.8) 1.28 (0.87‐1.90)
Diabetes  1.19 (1.07‐1.33) 1300 (15.3) 1.19 (1.09‐1.29) 205 (2.4) 0.94 (0.77‐1.15) 773 (9.2) 1.18 (1.06‐1.32)




Non‐smoker  1.00  3978 (8.7) 1.00 743 (1.6) 1.00 2274 (5.0) 1.00
Current smoker 1.27 (1.15‐1.39) 2800 (9.1) 1.26 (1.17‐1.36) 491 (1.6) 1.19 (1.00‐1.40) 1610 (5.3) 1.27 (1.15‐1.39)
Ex‐smoker  1.14 (1.05‐1.24) 4907 (11.8) 1.11 (1.04‐1.19) 915 (2.2) 1.09 (0.94‐1.25) 2891 (7.0) 1.15 (1.06‐1.24)
BMI Category     
Underweight (BMI <18.5) 1.25 (1.01‐1.54) 282 (13.1) 1.15 (0.96‐1.38) 77 (3.6) 1.56 (1.13‐2.17) 187 (8.8) 1.27 (1.03‐1.57)
Normal Weight (BMI 18.5‐24.9)  1.00  4026 (9.6) 1.00 771 (1.8) 1.00  2345 (5.7) 1.00 
Overweight (BMI 25‐30) 1.01 (0.93‐1.09) 4131 (10.3) 1.03 (0.97‐1.10) 749 (1.9) 0.99 (0.86‐1.14) 2338 (5.9) 1.01 (0.93‐1.09)
Obese (BMI ≥30) 1.13 (1.03‐1.24) 2570 (10.6) 1.11 (1.03‐1.19) 425 (1.8) 1.03 (0.87‐1.21) 1536 (6.4) 1.14 (1.04‐1.25)
Antiviral record within 7 days of zoster  1.04 (0.97‐1.11) 7345 (10.7) 1.12 (1.06‐1.18) 1355 (2.0) 1.08 (0.96‐1.22) 4151 (6.1) 1.04 (0.97‐1.11)
Anatomical site of zoster    
Site Unspecified 1.00  10648 ( 9.4) 1.00 1854 (1.6) 1.00 6097 (5.5) 1.00 
Non‐Truncal (excluding ophthalmic zoster)  2.19 (1.54‐3.11) 110 (15.0) 2.00 (1.49‐2.70) 15 (2.0) 1.77 (0.88‐3.53) 74 (10.5) 2.34 (1.65‐3.34)
















Total  2156 (1.8)    3007 (2.5) 1793 (1.5)   
Male  824 (1.7)  1.00  1041 (2.2) 1.00  602 (1.3)  1.00















































Diagnosed   PHN code* 2156 (1.9)  1332 (2.0) 1.02 (0.91‐1.15) 1.02 (0.82‐1.27) 0.95 (0.82‐1.10) 1.01 (0.90‐1.15)
 
Presumed   Zoster code and prescription same day* 215 (0.2) 146 (0.2) 1.35 (0.92‐1.97) 1.41 (0.65‐3.08) 1.32 (0.85‐2.06) 1.33 (0.90‐1.96)
  Non‐specific neuralgia code*  783 (0.7) 511 (0.7) 1.21 (1.00‐1.48) 1.16 (0.80‐1.67) 1.19 (0.94‐1.51) 1.22 (1.00‐1.50)
  NEW anticonvulsant**  1120 (0.9) 699 (1.0) 1.04 (0.89‐1.23) 0.87 (0.66‐1.13) 1.02 (0.83‐1.26) 1.04 (0.88‐1.24)
  NEW capsaicin cream/lidocaine patch** 117 (0.1) 75 (0.1) 1.11 (0.67‐1.84) 1.58 (0.57‐4.41) 1.02 (0.83‐1.26) 1.11 (0.67‐1.84)
  NEW TCA ** with PHN/zoster code and zoster 
medication on the same day, 0‐89 days after zoster 
772 (0.7) 535 (0.8) 1.43 (1.16‐1.75) 1.36 (0.95‐1.96) 1.34 (1.04‐1.72) 1.39 (1.13‐1.72)
 






762 (0.6) 457 (0.6) 0.98 (0.81‐1.18) 0.86 (0.60‐1.24) 1.00 (0.79‐1.26) 0.96 (0.79‐1.17)
  Non‐specific neuropathy code*  113 (0.09) 81 (0.11) 1.71 (1.00‐2.93) 1.55 (0.62‐3.88) 1.63 (0.83‐3.21) 1.84 (1.04‐3.27)





























































































































































Total  30302 (100) 1416 (4.7) ‐ ‐ 39359 (100) 2250 (5.7) ‐ ‐  
Demographic characteristics         
Age (years) [Estimated ORs for 10 year increase in age within the specified age‐band]¹       
Among those aged <50 9785 (32.3) 152 (1.6) 1.52 (1.26‐1.83) 1.43 (1.18‐1.75)  9738 (24.8) 179 (1.8) 1.32 (1.12‐1.56) 1.30 (1.08‐1.55) 0.401 
Among those aged 50‐79 17273 (57.1) 901 (5.2) 1.71 (1.57‐1.87) 1.66 (1.52‐1.82)  24863 (63.3) 1467 (5.9) 1.77 (1.65‐1.90) 1.73 (1.60‐1.86) 0.465 
Among those aged ≥80 3200 (10.6) 329 (10.3) 1.05 (0.79‐1.40) 1.18 (0.86‐1.64)  4698 (12.0) 563 (12.0) 1.01 (0.80‐1.28) 1.05 (0.81‐1.37) 0.880 
Female   17526 (57.8) 919 (5.2) 1.25 (1.07‐1.45) 1.24 (1.05‐1.46)  23851 (60.6) 1453 (6.1) 1.14 (1.01‐1.28) 1.14 (1.00‐1.29) 0.288 
Socioeconomic status (practice level)²          
1 (least deprived) 5017 (16.6) 205 (4.1) 1.00 1.00 6773 (17.2) 382 (5.6) 1.00 1.00 0.636 
2  6785 (22.4) 291 (4.3) 1.08 (0.83‐1.42) 1.07 (0.81‐1.41)  8996 (22.9) 489 (5.4) 0.97 (0.79‐1.20)
3  6301 (20.8) 295 (4.7) 1.12 (0.85‐1.46) 1.09 (0.82‐1.44)  8450 (21.5) 477 (5.6) 0.98 (0.79‐1.21) 0.98 (0.80‐1.22)
4  6595 (21.8) 343 (5.2) 1.29 (1.00‐1.68) 1.21 (0.93‐1.59)  8151 (20.7) 513 (6.3) 0.98 (0.79‐1.21) 1.10 (0.89‐1.35)
5 (most deprived) 5604 (18.5) 282 (5.0) 1.32 (1.01‐1.73) 1.19 (0.90‐1.58)  6989 (17.8) 389 (5.6) 1.06 (0.85‐1.32) 1.02 (0.82‐1.27)
           
Severe Immunosuppression         








Lymphoma  60 (0.2) 7 (11.7) 2.81 (0.96‐8.23) 2.80 (0.87‐9.04)  110 (0.3) 7 (6.4) 1.16 (0.42‐3.22) 1.27 (0.45‐3.56) 0.199 
Myeloma  63 (0.2) 12 (19.1) 3.31 (1.41‐7.77) 2.47 (0.94‐6.45)  124 (0.3) 14 (11.3) 1.59 (0.76‐3.36) 1.64 (0.77‐3.48) 0.250 
   
Oral corticosteroids³ 87 (0.3) 10 (11.5) 2.31 (0.94‐5.64) 1.65 (0.60‐4.49)  137 (0.4) 18 (13.1) 2.12 (1.08‐4.14) 1.88 (0.94‐3.77) 0.792 
Other immunosuppressive therapy³  327 (1.1) 25 (7.7) 1.42 (0.82‐2.46) 1.09 (0.57‐2.06)  592 (1.5) 42 (7.1) 1.32 (0.87‐2.02) 1.05 (0.64‐1.71) 0.451 
           
Autoimmune conditions         
Rheumatoid Arthritis 495 (1.6) 51 (10.3) 1.72 (1.16‐2.56) 1.40 (0.86‐2.26)  911 (2.3) 77 (8.5) 1.26 (0.92‐1.74) 1.23 (0.86‐1.75) 0.112 
Systemic Lupus Erythematosis 68 (0.2) 10 (14.7) 3.69 (1.47‐9.31) 3.42 (1.31‐8.94)  117 (0.3) 7 (6.0) 1.24 (0.45‐3.45) 1.11 (0.39‐3.12) 0.026 
Inflammatory Bowel Disease 326 (1.1) 24 (7.4) 1.54 (0.88‐2.70) 1.53 (0.84‐2.79)  529 (1.3) 39 (7.4) 1.37 (0.88‐2.13) 1.22 (0.77‐1.95) 0.323 
           
Other comorbidities         
COPD  1092 (3.6) 144 (13.1) 2.01 (1.56‐2.58) 1.69 (1.29‐2.22)  1711 (4.4) 202 (11.8) 1.55 (1.26‐1.90) 1.42 (1.15‐1.77) 0.043 
Asthma  1992 (6.6) 106 (5.3) 1.33 (1.01‐1.75) 1.38 (1.04‐1.83)  2839 (7.2) 157 (5.5) 1.12 (0.90‐1.40) 1.07 (0.84‐1.34) 0.088 
Chronic Kidney Disease 1203 (4.0) 116 (9.6) 1.25 (0.96‐1.65) 1.14 (0.86‐1.53)  2173 (5.5) 228 (10.5) 1.26 (1.03‐1.53) 1.16 (0.95‐1.42) 0.916 
Depression  1315 (4.3) 70 (5.3) 1.44 (1.03‐2.00) 1.21 (0.85‐1.74)  1797 (4.6) 132 (7.4) 1.62 (1.26‐2.07) 1.51 (1.17‐1.95) 0.475 
Personality disorder 192 (0.6) 13 (6.8) 1.76 (0.82‐3.76) 1.64 (0.74‐3.64)  239 (0.6) 13 (5.4) 1.07 (0.51‐2.26) 0.93 (0.43‐2.03) 0.149 




Recent cancer diagnosis 265 (0.9) 20 (7.5) 1.10 (0.60‐2.04) 1.17 (0.62‐2.19)  417 (1.1) 37 (8.9) 1.30 (0.83‐2.05) 1.42 (0.90‐2.24) 0.421 
           
Health behaviours and characteristics of zoster episode        
Smoking          
Non‐smoker  11583 (38.7) 430 (3.7) 1.00 1.00 14876 (38.0) 791 (5.3) 1.00 1.00 0.002 
Current smoker 8505 (28.4) 399 (4.7) 1.66 (1.37‐2.01) 1.49 (1.21‐1.83)  9452 (24.2) 469 (5.0) 1.14 (0.97‐1.33) 1.09 (0.93‐1.29)
Ex‐smoker  9857 (32.9) 580 (5.9) 1.38 (1.16‐1.64) 1.29 (1.07‐1.56)  14779 (37.8) 981 (6.6) 1.08 (0.95‐1.23) 1.03 (0.90‐1.18)
BMI Category          
Underweight (BMI <18.5) 582 ( 2.1) 39 (6.7) 1.38 (0.87‐2.17) 1.18 (0.73‐1.93)  671 (1.9) 65 (9.7) 1.54 (1.07‐2.20) 1.45 (1.01‐2.09) 0.712 
Normal Weight (BMI 18.5‐24.9)  10981 (40.2) 497 (4.5) 1.00 1.00 14125 (39.2) 787 (5.6) 1.00 1.00
Overweight (BMI 25‐30) 9942 (36.4) 473 (4.8) 0.96 (0.81‐1.14) 1.01 (0.84‐1.21)  13320 (37.0) 793 ( 6.0) 1.03 (0.90‐1.18) 1.04 (0.90‐1.19)

















Identifying risk factors for PHN in CPRD 
 A large cohort study followed up 119,413 zoster patients, of whom 5.8% 
developed PHN. A range of medical conditions and patient characteristics were 
associated with increased risk of PHN, including; autoimmune conditions (RA, 
SLE and IBD), COPD, depression, diabetes, asthma, lower SES, smoking, under- 
or overweight and non-truncal zoster.  
 Antiviral use was not associated with PHN.  There was some evidence that the 
increased risk of PHN with SLE, leukaemia, COPD and smoking was attenuated 
in patients given antivirals.  
 The strongest risk factors for PHN are severely immunosuppressive conditions, 
which are vaccine contraindications for the currently available zoster vaccine, 
emphasising the need for alternative risk reduction strategies (such as a non-




Chapter 8:   Summary and conclusions 
 
 
The research presented in this thesis aimed to improve the understanding of risk factors for 
zoster and PHN to inform vaccination policy, by undertaking a literature review, a systematic 
review and meta-analysis, and three large observational studies using UK EHR data. The first 
observational study, a case-control study (reported in chapter 4) examined risk factors for 
zoster.  The second observational study, a cohort study (reported in chapter 7) examined risk 
factors for PHN. An additional observational study was conducted to evaluate the extent to 
which antiviral treatment during acute zoster is administered according to treatment 
guidelines.   
 
Specific issues relating to individual studies were discussed within the preceding chapters. This 
final chapter provides an overview of the key findings from these individual studies, in the 
context of previous research, and then sets out the strengths and limitations of using EHR data 
to address the research questions in this thesis.  The chapter ends by highlighting implications 
for clinical practice and outlining unanswered questions for future research.  
 
8.1.   Overview of key findings 
 Risk factors for zoster 
8.1.1.1. What was already known on this topic 
 A zoster vaccine became available in 2006 and vaccination programmes are underway 
in a number of high-income countries including the UK, USA, Canada and Japan. The 
zoster vaccine is currently targeted at older individuals only, as increasing age is one of 
the few well-established risk factors for zoster. 
 The other well known risk factor for zoster is severe immunosuppression, explaining 
around 5% of zoster cases. However, patients with severe immunosuppression are not 
eligible for the currently available vaccine, due to safety concerns with a live vaccine. 
 As described in the literature review of zoster risk factors (see chapter 2) a number of 
clinical conditions not currently listed as contraindications for the zoster vaccine were 
associated in some studies with an increased risk of zoster; these included certain 
autoimmune conditions such as RA, SLE, and IBD, and other chronic conditions such as 
diabetes mellitus, COPD, CKD, asthma and depression.  
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 However, these studies tended to be small and inadequately powered to investigate 
the association of these conditions with zoster. 
 Studies also suffered from poor control of confounding factors (for example age was 
often included as a categorical variable with wide intervals) and studies rarely 
investigated whether the effects of some conditions were mediated by 
immunosuppressive drugs. 
 Additionally, few studies assessed several risk factors simultaneously, and the lack of a 
consistent methodological approach did not allow direct comparison of the relative 
strength of various risk factors. 
 Finally, it is not clear if younger age groups, particularly individuals with specific 
patient characteristics, might benefit from vaccination. The zoster vaccine is currently 
only licensed for use in patients aged ≥50 years, however over 30% of zoster cases 
occur under the age of 50 years. No previous studies have assessed how the effects of 
a broad range of comorbid conditions on zoster risk vary by age. 
 
 
8.1.1.2. What the study adds 
 The zoster case-control study (described in chapter 4) showed that the highest risk of 
zoster was associated with severe immunosuppressive conditions, for example 
lymphoma (adjOR: 3.90, 99% CI 3.21-4.74) and myeloma (adjOR: 2.16, 99%CI 1.84-
2.53).  This study finding highlights how the patients most in need of zoster prevention 
are not able to benefit from the currently available zoster vaccine, emphasising the 
need for alternative risk reduction strategies in this group, such as non-live vaccines 
and antiviral prophylaxis.   
 Consistent with previous studies, patients with autoimmune conditions (specifically, 
SLE, IBD and RA) were 1.3 to 1.7 times more likely to develop zoster, compared to the 
general population. 
 Patients with the respiratory conditions asthma or COPD were at 20 to 30% greater 
risk of zoster.  
 The effects of RA, IBD, COPD and asthma were attenuated after adjusting for 
immunosuppressive medications.  Each of these conditions are frequently treated with 
immunomodulating drugs and this finding suggests that at least part of the risk 




 The other conditions which were associated with increased risk of zoster, albeit with 
associations that were smaller than reported in previous studies (ranging from 1.1 to 
1.3 times the odds), were depression, CKD and type 1, but not type 2, diabetes.   
 The relative effects of the observed risk factors were larger in younger patients. For 
example, the OR point estimates for CKD were 1.53, 1.21 and 1.11 among patients 18-
49 years, 50-59 years and 60-69 years respectively. The estimated rate of zoster in 
younger patients with CKD still remained low, due to the underlying low rate in 
younger patients. However, this finding raises questions about the utility of vaccinating 
younger patients with certain characteristics.  
 Of 97,789 zoster cases aged under 70 years, 3619 (3.7%) had a predicted risk of zoster 
as high as that for the general population aged 70 years or over. This finding indicates 
there may be some benefit to targeting specific patient groups under 70 years of age, 
though cost-effectiveness studies would be required to further investigate whether 
this approach is warranted.  
 By including a variety of risk factors in one study, it was possible to compare the 
strength of association between different risk factors.  This approach also allowed tight 
control of known and potential confounders.   
 
 Which zoster patients receive antivirals? 
8.1.2.1. What was already known 
 Antivirals are recommended for all immunosuppressed patients presenting with zoster 
and certain immunocompetent patients (specifically, people aged ≥50 years, or 
individuals with ophthalmic zoster, other non-truncal disease, moderate to severe pain 
or rash). Treatment within 72 hours of rash onset is recommended, although antivirals 
may be given up to one week after zoster onset.  The evidence base suggests that 
antiviral treatment reduces the severity and duration of the acute zoster episode, 
though the effect of antiviral treatment on PHN is disputed.  
 Little research existed exploring the extent to which antiviral prescription guidelines 
are adhered to. A previous study of CPRD data indicated that antivirals were under-
prescribed in the UK; 56.3% of 27,225 immunocompetent patients with zoster aged 
≥50 years received antivirals between 2000 and 2006. However, there were no data on 
the proportion of immunosuppressed patients receiving antivirals in UK primary care. 
 Studies from the USA, Italy, and Australia reported higher proportions of adult patients 
with zoster receiving antiviral prescriptions, of between 70 to 80%, though they 
included secondary care data and the health care systems have significant differences.  
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 Previous studies have tended to report overall use of antivirals, rather than use by 
specific risk groups, therefore it is difficult to identify who is receiving antivirals and 
whether certain patient groups are under-prescribed antivirals.  
 
8.1.2.2. What the study adds 
 The descriptive antiviral study (described in chapter 5) demonstrated that of 142,216 
zoster patients diagnosed with zoster between 2000 and 2011, 58.1% received 
antivirals within 7 days of zoster diagnosis, in keeping with an earlier study in CPRD. 
 This study additionally looked at patterns of use, in both immunosuppressed and 
immunocompetent patients, to better understand who receives antivirals in UK 
primary care.  
 The study demonstrated that antivirals are under-prescribed in patients for whom 
guidelines recommend treatment. Specifically: 
- Although immunosuppressed patients were 30% more likely to receive 
antivirals than immunocompetent patients, antivirals were not given routinely 
to this group. In total, 35.1% of patients with severe immunosuppression did 
not receive antivirals in primary care. 
- The proportion of patients receiving antivirals increased with age up to 65-74 
years, then declined among patients aged ≥85 years, for whom only 56.8% 
received treatment. 
- Patients were less commonly prescribed antivirals in primary care if they had 
ophthalmic (proportion given antivirals, 49.4%) or other non-truncal zoster 
(30.9%) than patients with zoster in whom site of zoster was not specified 
(58.4%).  This was a surprising finding, as the guidelines clearly advise 
treatment for these patients. This finding may in part be explained by patients 
with zoster in “high risk” sites being referred immediately to secondary care 
for treatment or attending emergency departments. 
 Being female and of higher SES were associated with higher antiviral receipt, which 
may be explained by greater health-seeking behaviours in these groups  Antiviral 
prescriptions increased every year from 45.7% in 2000 to 65.3% in 2010 and the trend 
remained after adjusting for confounders. Use also varied by region, with highest use 
in Northern Ireland (67.7%) and lowest use in the north-east of England, specifically 




 Patients with autoimmune conditions considered to be associated with moderate 
immunosuppression were more likely to receive antivirals; in particular, there was 
greater antiviral use among patients with RA and SLE, irrespective of whether they 
were receiving immunosuppressive therapy, and also patients with IBD treated with 
immunosuppressive therapy. 
 Under-treatment with antivirals cannot be attributed to adverse effects or cost, as 
these drugs are well-tolerated and relatively inexpensive. Patients may present too 
late to receive antiviral therapy, however previous research from UK data suggests 
that the majority of patients present soon after rash onset. It is therefore plausible 
that under-treatment may reflect poor adherence to treatment guidelines. 
 
 
 Risk factors for PHN 
8.1.3.1. What was known 
 Older age was a well-known risk factor for PHN, with very few cases occurring under 
the age of 50 years. 
 Other frequently reported risk factors for PHN related largely to characteristics of the 
acute zoster episode, such as the severity of the acute pain.  Despite these 
characteristics being commonly cited as predictors of PHN, the evidence had never 
been systematically reviewed and the magnitude of their effect was largely unknown. 
 Finally, an understanding of patient characteristics and conditions identifiable before 
the zoster episode which may increase the risk of PHN and potentially be useful when 
considering vaccination policy, had yet to be summarised. 
 
 
8.1.3.2. What the systematic review adds 
 The systematic review and meta-analyses of risk factors for PHN within zoster cohorts 
(described in chapter 6) demonstrated that risk factors for PHN are poorly understood 
and that existing evidence is often conflicting and underpowered.  
 Meta-analyses demonstrated that features of the acute zoster episode, including 
prodromal pain, severe acute pain or rash and ophthalmic involvement, were 
associated with greater than twice the risk of PHN.  
 Regarding vaccine-targetable risk factors for PHN, the review demonstrated a clear 
increased risk of PHN with greater age; nine studies reported an effect estimate for a 
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ten-year increase in age on PHN risk, with estimates ranging from 1.22 to 3.11. Exactly 
how the risk of PHN varies as people age is not understood. 
 There was a suggestion from three out of five studies in the systematic review that 
patients with immunosuppression may be at greater risk of PHN. However, the 
evidence was conflicting and different definitions of severe immunosuppression were 
used, limiting the ability to compare study results.  
 Other patient conditions associated with an increased risk of PHN (investigated in 
single studies only) were SLE, recent trauma and personality disorder symptoms.  
There was no evidence of higher PHN risk with depression (in four studies) or cancer 
(in five studies).  Diabetes was associated with increased risk of PHN in one of four 
studies.  
 No previous studies were identified which investigated the effects of RA, IBD, COPD, 
asthma or CKD on PHN risk.  
 There were key differences between studies included in the review, such as: (i) the 
demographic characteristics of participants, particularly their age distribution; (ii) the 
definition of PHN used, for example assessing pain at one, three or six months 
following zoster, as well as including “any” or “severe pain” following zoster; and (iii) 
differences in the confounders accounted for in the analyses.  Comparisons between 
study results must therefore be made cautiously. 
 Overall the majority of studies currently published are limited in size, reducing their 
power to detect associations; in total, 17 out of 19 studies included in the review had 
under 1000 participants. Although the review required effect estimates to be age-
adjusted, many studies included age as a binary or categorical variable with wide 
intervals, potentially leading to residual confounding by age.  
 
 
8.1.3.3. What the original research study adds 
 The cohort study (described in chapter 7) showed that PHN risk is increased for a 
number of patient characteristics and comorbidities, most notably age and 
immunosuppressive conditions. The study both confirmed previously described risk 
factors for PHN, as well as identifying novel risk factors.  
 One of the most well-reported and strongest risk factors for PHN is age.  This study 
confirmed older age as a key risk factor. The risk rose most sharply between 50 and 79 
years, where a 10-year increase in age within this age-band was associated with 70% 
increased risk of PHN. A 10-year increase among patients aged 80 years and above was 
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associated with just 10% increased risk of PHN, although patients in this age group 
would have a higher baseline risk.  
 Previous research on the impact of severe immunosuppression on PHN was 
inconclusive. This study demonstrated that severe immunosuppression was a strong 
risk factor for PHN. Furthermore, rather than combining patients with any condition or 
course of therapy associated with severe immunosuppression, this study had sufficient 
power to assess the effect of specific conditions and therapies on PHN risk. Leukaemia 
or lymphoma diagnosed in the previous two years, myeloma, other unspecified cellular 
immune deficiencies, or recently taking a course of high-dose (≥20 mg per day) 
corticosteroids, were each associated with a more than doubling in the risk of PHN.  
 Conditions also associated with increased risk of PHN, and recognised in previous 
studies, comprised SLE, which was associated with over 80% increased risk of PHN, and 
type 2 diabetes, which was associated with 20% increased risk.  In contrast with 
previous research, this study suggested recent depression was associated with almost 
40% increased risk of PHN, whereas there was no evidence that personality disorder 
predicted PHN, after adjusting for covariates. Novel risk factors for PHN, not identified 
in any previous research, included RA, IBD, COPD and asthma. 
 This study was one of the few to look at the association between lifestyle risk factors 
and PHN. Being a current or ex-smoker, as well as being underweight or obese, was 
associated with 10 to 30% greater risk of PHN.  
 The only clinical feature of acute zoster available in CPRD was site of zoster and, 
consistent with previous studies, PHN was twice as common in patients with non-
truncal (including ophthalmic) zoster.  
 The study was also unique in exploring the effects of antiviral use. Antiviral use was 
not associated with PHN (OR=1.04, 0.97-1.12). There was also some weak evidence 
that the increased risk of PHN associated with leukaemia, SLE, COPD and smoking was 
less pronounced in patients given antivirals. 
 This study benefited from being the largest to date exploring risk factors for PHN, as 
well as tightly accounting for the confounding effects of age by using a continuous 
non-linear function in the modelling. 
 
 
8.2.   Strengths and weaknesses of using electronic health 




The studies included in this thesis used primary care data from the UK (CPRD), linked to 
hospitalisation (HES) data. As data are routinely collected in these databases, they are hugely 
advantageous for researchers, as they reduce the time and cost involved in traditional data 
collection. This section reviews the strengths and weaknesses of using these databases in 
addressing the study questions. As HES data were used specifically to identify zoster and PHN 
patients, and as the large majority of individuals with zoster and PHN were identified in CPRD, 




8.2.1.1. Size and long-term follow-up 
A key strength of CPRD is its size, which allowed the studies to look at less common conditions, 
such as SLE, and explore age interactions, with sufficient statistical power. For example, the 
case-control study in chapter 4 included over half a million individuals (and more than 140,000 
zoster cases) who had an average of more than 8 years active follow-up.  Furthermore, the 
cohort study in chapter 7 was the largest known analysis to date of PHN risk factors. In all 
three studies, there was sufficient power to look at certain individual conditions associated 
with immunosuppression, rather than combining these conditions into one category.  
 
8.2.1.2. Breadth of data 
CPRD is one of the few EHR databases in the world holding information on lifestyle data, 
including BMI, smoking status, alcohol use and SES, as well as clinical diagnoses and 
prescription data.  The availability of lifestyle and anthropometric data allowed these factors 
to be explored and accounted for in the analyses, in contrast to much previous research on 
zoster and PHN risk factors. Furthermore, CPRD is one of the few large and ongoing databases 
to have linkage to secondary care data, which was used to identify cases of zoster and PHN 
diagnosed in hospital.  
 
8.2.1.3. Prospectively collected data 
Another strength of using CPRD and HES is that data are collected prospectively, as patients 
attend their general practice or hospital for healthcare. This meant that the studies assessing 
risk factors for zoster and PHN were not subject to biased ascertainment of past exposure 
status (when a patient’s outcome influences their memory and thereby reporting of the 
exposure) or observer bias (where the patient’s outcome influences the observer’s recording 
of the exposure). Furthermore, use of this prospectively collected data meant the matched 
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case control study of zoster risk factors was nested in the CPRD cohort.  This meant controls 
were drawn from the same population that gave rise to the cases, thus reducing the possibility 
of selection bias.  
 
8.2.1.4. Representativeness 
As described in chapter 3, CPRD patients are broadly representative of the UK population in 
terms of age, sex and ethnicity (although the database may not fully represent all practices in 
the UK in terms of geography and size).85 This means that by selecting all patients with zoster, 
and suitable controls, the conclusions for the studies presented in this thesis are likely to have 
good external validity and be generalizable to the UK population.  
 
 Limitations 
Although CPRD and HES have many strengths for investigating the study questions explored in 
this thesis, it must also be acknowledged that using the databases introduced some 
limitations. The limitations of each study have been described within the individual chapters. 
Below is a summary of these discussions, considering the research project as a whole.  
 
8.2.2.1. Information bias 
Information bias may have been introduced due to measurement or ascertainment errors 
within CPRD and HES data.  In the following section misclassification of zoster, PHN and other 
covariates are discussed, along with the potential impact of this misclassification on the study 
findings.  
 
Misclassification of zoster 
Zoster diagnosis in UK primary and secondary care is based on clinical judgement, without 
laboratory confirmation. As discussed in chapter 4, zoster diagnoses have not been validated in 
CPRD or HES. However a validation study of zoster in a primary care setting in the Netherlands 
demonstrated a high PPV of zoster diagnosis of 91%, when confirmed by the presence VZV of 
antibodies.198   
 
The most likely misclassification of zoster is believed to be with herpes simplex. However, 
herpes simplex rarely presents with a dermatomal distribution, therefore the extent of this 
misclassification in this body of research is believed to be minimal. If patients with herpes 
simplex were incorrectly included as zoster cases in the matched case-control study (chapter 
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4), assuming simplex is not associated with the risk factors of interest, any misclassification 
would have led to an underestimation of the effect estimates. If the risk factors of interest 
were associated with greater risk of herpes simplex, there might have been an overestimation 
of effect estimates. In chapter 7, the analysis of PHN risk factors within a zoster cohort, 
patients with herpes simplex potentially misdiagnosed as zoster patients were removed in a 
sensitivity analysis (specifically, zoster cases with zoster codes appearing within the year 
following first zoster diagnosis, many of whom had a further antiviral prescription on the same 
day) and there was no appreciable impact on the study findings.  
 
Zoster diagnoses may be missed in the EHR data, either due to: 1) misdiagnosis of zoster, for 
example misdiagnosing zoster cases as herpes simplex or difficulties in diagnosing zoster in the 
rare situation in which a rash does not appear, known as zoster sine herpete; or 2) zoster being 
recorded in the free text but not coded in CPRD; or 3) zoster patients not attending health 
services, for example if the pain is mild or patients are unable to seek healthcare. Use of both 
CPRD and linked HES data allowed more complete capture of zoster cases attending either 
healthcare setting. However, the frequency with which diagnoses of zoster are not captured in 
either CPRD or HES is not known. Missed zoster diagnoses may be more common in younger 
patients among whom zoster is less prevalent and may be less severe. Studies establishing the 
validity of “non-diagnoses” in EHR data (i.e. patients without specific diseases) are rarely 
carried out, as this requires sampling a number of patients without the disease (whereas the 
PPV only requires sampling of patients with the disease).89 Assuming inclusion of some zoster 
patients in the control pool is random and non-differential according to the exposures, this 
misclassification would have caused an underestimation of effect estimates.   
 
Patients were required to have 12-months registration in CPRD without a zoster diagnosis, to 
exclude past history of zoster recorded shortly after registration. It is possible that a 12-month 
cut-off was insufficient to remove past history of zoster or PHN cases (misdiagnosed as acute 
zoster). A 24-month cut-off may have increased the likelihood of the included patients being 
incident.   Previous research has however shown that the incidence rate of zoster is slightly 
higher in CPRD during the first 3 months after registration, however reached baseline levels 4-
6 months following registration, suggesting the chosen cut-off was appropriate.    
 
Validity of zoster diagnosis timing 
The precise timing of zoster onset may not always be attainable from CPRD and HES data. The 
date at which zoster patients presented to their GP with zoster was used as a proxy for rash 
onset date.  In reality, the true date of rash onset will, in some cases, be a few days prior to 
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this.  As acknowledged in chapter 7, incorrect rash onset date might have affected the 
observed null association between antiviral use during acute zoster and PHN; some studies 
have reported that antivirals are effective at reducing PHN risk if given within 72 hours of rash 
onset, therefore delay in presenting to primary care may explain the null finding.  
 
Misclassification of postherpetic neuralgia 
As with zoster, PHN has not been validated in CPRD or HES. As discussed in detail within 
chapter 3, section 3.3.2, diagnosing PHN in EHR databases is a particular challenge. The 
difficulties result from a variety of reasons, including different definitions of PHN being used, 
PHN treatments being non-specific to PHN and therapeutic indication not being recorded in 
CPRD.  
 
As discussed in chapter 3, of particular concern was that patients with depression were 
wrongly defined as having PHN, due to the use of tricyclic antidepressants in defining PHN 
patients. Several steps were taken to reduce this misclassification, such as ensuring all PHN 
cases had recently been diagnosed with zoster, ensuring PHN cases did not have diagnosis 
codes suggesting depression when PHN was defined through use of tricyclic antidepressants, 
and ensuring prescriptions were “new” (no previous prescriptions of a tricyclic antidepressant 
in the 12 months to two weeks prior to zoster). However, the association between PHN and 
depression disappeared when PHN was defined through use of diagnosis codes only (i.e. a 
Read or HES code for PHN), therefore it is possible that some misclassification of PHN 
occurred, which may have increased the association between depression and PHN.  
 
Part of the PHN definition incorporated use of anti-convulsants and hence patients with a 
history of epilepsy were excluded from the study cohort.  However, anticonvulsants can also 
be used a mood stabiliser for patients with bipolar, personality disorder and schizoaffective 
disorder. Therefore, there may have been some misclassification of PHN cases resulting from 
the inclusion of anticonvulsants as part of the PHN definition, which could have further 
increased the association observed between depression and PHN.  
 
It is also possible that some individuals with PHN will have been included in the non-PHN 
comparison cohort; this misclassification is potentially supported by the relatively low 
prevalence of PHN, compared to other non-EHR studies. As discussed in chapter 7, it was 
hypothesised a priori that misclassification of PHN status may be differential according to the 
investigated PHN risk factors, because patients with risk factors of interest may attend their 
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general practice more frequently, and thus be more commonly diagnosed with PHN. However, 
little evidence was found to suggest the presence of this bias (ascertainment bias, see section 
7.2.4).  Instead, misclassification of PHN status is more likely to be non-differential according 
to the explored PHN risk factors and therefore PHN patients may have made a small 
contribution to the risk estimates of the comparison group, which would marginally reduce the 
reported risk estimates.  
 
Finally, differential health-seeking behaviours may be driving the increased risk of PHN among 
females (compared to males), as women are known to attend general practice more 
commonly than men.    
 
Misclassification of other conditions 
Using stand-alone CPRD to define medical conditions 
Although GPs are requested to record all patient diagnoses, recording of some clinical 
outcomes in CPRD may be incomplete, particularly those made in secondary care. Hospital 
letters will be sent to the GP and may be stored on the system, but a Read code may not 
always be entered, therefore the information may be missed by researchers. Most risk factors 
in this study requiring secondary care were chronic and of sufficient significance that they are 
likely to be recorded in the patient’s primary care records; many conditions, such as diabetes, 
are treated largely in primary care (and also from 2004 diabetes has been part of QoF) and for 
these conditions this may be a reasonable assumption.  However, since the research in this 
thesis was conducted, there has been evidence to suggest that using stand-alone databases to 
identify patients with certain conditions can lead to under-capture.  This misclassification 
appears particularly pertinent to acute events such as myocardial infarction199 and community 
acquired pneumonia,200 but also with regard to some chronic conditions such as asthma.201  
Therefore, it seems likely that some patients with the conditions of interest will have been 
misclassified as “unexposed” patients. Misclassification of medical conditions is likely to be 
non-differential according to the outcomes (zoster or PHN), therefore in the risk factor 
analyses this would have caused an underestimation of effect estimates.   
 
Incomplete clinical information  
Detailed clinical information, which may be gathered in a traditional epidemiological study 
with active data collection, is also not always available to CPRD researchers. In CPRD, some 
information may never be recorded, or may be within the free text field. Incomplete clinical 
detail may have led to misclassification. For example, regarding the categorisation of diabetes 
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into type 1 or 2, the definition relied on: 1) age at diagnosis, which may be problematic if 
patients moved practice after their first diagnosis of diabetes; and 2) treatment, which could 
be missed if only given in secondary care. This categorisation may have led to some type 1 
diabetes patients being misclassified as type 2 diabetes, if their real age of first diagnosis was 
earlier than recorded and they were receiving insulin in secondary care.  
 
Misclassification of prescriptions 
Although the CPRD has excellent capture of primary care prescriptions, there are some 
limitations. First, CPRD doesn’t provide data on adherence to treatment or timing of treatment 
initiation; the issue date may not necessarily be the date the prescription was collected, or the 
date the patient started using the drug. The issue of non-adherence is particularly relevant to 
ICS prescriptions, which are often used intermittently when required.  Regarding severely 
immunosuppressive drug exposures prior to zoster onset (for example oral corticosteroids or 
methotrexate), non-adherent patients, or those initiating treatment after the issue date, could 
be misclassified as having been exposed when in fact they were unexposed. This 
misclassification may be differential according to the outcomes, zoster and PHN, specifically 
that non-adherent patients may be less likely to develop zoster or PHN. Thus any 
misclassification due to non-adherence may have caused an underestimation of the effects of 
immunosuppressive drugs on zoster risk. 
 
Secondly, neither CPRD nor HES record therapy given in secondary care. Antivirals given in 
secondary care would be missed, and as acknowledged in chapter 5, may partly explain the 
low use of antivirals among patients with ophthalmic or non-truncal zoster, for whom 
guidelines specifically recommend treatment. Additionally, immunosuppressive medications 
may be given in hospital, for example chemotherapy and biologics, and thus may be 
unrecorded in primary care. Part of the effect of cancers studied here (specifically, leukaemia, 
lymphoma and myeloma) will have been driven by chemotherapy and it was not possible to 
disentangle the effect of the cancers themselves versus their treatments. Regarding anti-TNF 
biologic medications, these drugs do not form the mainstay of treatment in the UK for 
inflammatory conditions, but are used in approximately 10% of RA patients and 13% of adult 
Crohn’s disease patients.202 As described in chapter 2, these drugs may be associated with an 
increased risk of zoster in RA and IBD patients. Part of the associations observed between 
autoimmune conditions and zoster or PHN may therefore be explained by biologic or other 




As discussed in section 3.4.2, daily prescription doses for oral corticosteroids were cleaned and 
some missing data imputed.  This imputation may have led to some misclassification of high-
dose oral corticosteroid exposure; however, this misclassification is unlikely to be related the 
outcomes (zoster and PHN), therefore estimates of the effect of oral corticosteroids on zoster 
risk would only have been reduced toward the null.   
 
Finally, over the counter medications are not recorded in CPRD.  This is not an issue for 
identifying antiviral or immunosuppressive medications, as these drugs are prescription only. 
However, patients may self-medicate for PHN with over the counter pain medications, if the 
pain can be controlled with mild analgesics, therefore some PHN patients are likely to have 
been misclassified.  As explained in chapter 7, this limitation may not cause biased results, 
however it may limit the generalisability of the results to patients with severe, rather than 
mild, PHN.   
 
 
8.2.2.2. Confounding by indication 
Confounding by indication can occur because within observational data, drugs are not 
randomly allocated but may instead be indicated for a disease based on severity and 
prognosis. Therefore risk of the outcome, prior to treatment, may not be similar between 
treated and untreated individuals. For example, in chapter 7, a priori it was anticipated that 
any protective effect of antiviral use during acute zoster on PHN risk may be attenuated; this is 
because patients with more severe zoster are more likely to receive antivirals as well as being 
at greater risk of PHN, potentially masking any protective effect of antivirals. In the final 
multivariable model, there was no association between antivirals and PHN, and this 
observation may therefore be explained by confounding by indication. Two statistical methods 
exist which can, in theory, better deal with confounding by indication: 1) propensity scores.203 




8.2.2.3. Residual confounding  
CPRD data are collected primarily as a tool for physicians to record a patient’s medical history 
and therefore certain data may not be sufficiently recorded to fully adjust for the confounding 
effects of that variable. Residual confounding by measured variables may arise from two 
sources. The first source is from confounders being misclassified. For example, as described in 
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section 8.2.2.1 above, part of the observed effect between RA and zoster may be due to 
residual confounding by biologics. The second source is from confounders being defined in 
broad categories, and residual confounding arises if the risk of the outcome varies within a 
category of the confounder. For example, patients classified as current smokers would have 
represented a range of smoking habits, from occasional to very heavy smokers, and this may 
have caused residual confounding by smoking.   
 
In addition to incomplete capture of included risk factors, uncontrolled variables not available 
within CPRD may have caused residual confounding. For examples, physicians do not routinely 
record certain factors associated with zoster, such as exposure to individuals with varicella and 
dietary habits, such as fruit intake. The possibility of residual confounding incurred from not 




Despite the evidence-base being limited and inconsistent, there is some suggestion that 
psychological stress may be an important risk factor for zoster (as outlined in chapter 2). The 
research presented in this thesis did not account for psychological stress.  Capturing all 
psychological stress in CPRD would have been challenging, as stress may be induced by a wide 
range of conditions or events, such as depression, anxiety, self-harm, bereavement, job loss or 
divorce.  Furthermore, many people who experience acute or chronic stress will not seek care 
from their GP. It is therefore plausible that this study may suffer from residual confounding by 
psychological stress.  If stress is a risk factor for zoster and was equally distributed among 
exposed and unexposed patients for specific conditions, this would have led to an 
underestimation of effect sizes.  However, it is plausible that stress may mediate the 
relationship between some of the conditions investigated in this thesis and zoster (in other 
words, stress may be on the causal pathway between the exposures and zoster). If this 
scenario is correct, it would have been inappropriate to control for stress. 
 
Ethnicity 
At the time this research project was planned, little was known about the reliability of 
ethnicity data and a decision was made not to investigate ethnicity as a covariate. Research 
has subsequently shown that for patients registered with a general practice after April 2006, 
ethnicity data in CPRD alone is available for 78.3% of patients.205 However, the authors 
recommend not using ethnicity data recorded in patients registered prior to April 2006, as 
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recording is low and likely to be selective.  Further investigation has shown that less than 5% of 
the zoster cases and their matched controls from the study in chapter 4 were registered after 
April 2006; thus, in retrospect, the decision not to include ethnicity data remains valid.  
However, not including ethnicity as a covariate may have implications on the study findings. As 
mentioned in chapter 4, the lack of association between type 2 diabetes and zoster may be 
partly driven by negative confounding by ethnic group (patients of South Asian origin are at 




8.2.2.4. Selection bias due to missing data 
In the thesis, lifestyle data, including BMI, smoking and alcohol were explored and accounted 
for in the analyses. All these variables contain some missing data. These lifestyle data are 
recorded opportunistically for many patients and missing data are unlikely to be ‘missing 
completely at random’.  For example, BMI completeness is higher in females, in clinical 
subgroups where BMI recording is incentivised (such as type 2 diabetes) and in older age 
groups.125 It is also plausible that the missing data depend on the variable itself (for example, 
patients with healthy BMI may not have their BMI recorded by the GP). In the main analyses in 
chapter 4 and 7, patients with missing data were excluded from the analysis (complete case 
analysis). This method may lead to biased effect estimates, as the included sample are unlikely 
to be representative of the full cohort, potentially introducing selection bias. However, 
complete case analysis is valid, if the reasons for missing-ness are unrelated to the outcome, 
given the covariates.206  In terms of the lifestyle variables BMI, smoking and alcohol use, it is 
assumed that non-recording of these variables is unlikely to be related to developing zoster or 
PHN.  
 
However, as an alternative approach to handling missing data, data that was missing for BMI, 
smoking and alcohol was also accounted for through multiple imputation in a sensitivity 
analysis. That the study findings were consistent when applying a complete case and multiple 
imputation method suggests the results are robust, and major selection bias is unlikely to have 





8.2.2.5. Data on underlying mechanisms 
The mechanisms through which exposures increase the risk of zoster and PHN is assumed to 
be through impairing T cell-mediated immunity.  It was not possible to confirm the pathway in 
this thesis, as the CPRD doesn’t contain biological markers of cellular immune-suppression.  
 
8.2.2.6. Multiple testing 
The risk factor analyses in chapter 4 and 7 involved testing multiple associations. Testing 
multiple associations results in the possibility that some of the observed “statistically 
significant” associations may have occurred by chance. However, in order to protect against 
this, 99% CIs were used.   Furthermore all risk factors were specified a priori, based on 
previous epidemiological research and/or supporting data regarding plausible biological 
mechanisms.  
 
8.2.2.7. Lack of clinical information on risk factor sub-groups  
The EHR data was insufficiently detailed to investigate potentially important differences 
between sub-groups of certain risk factors. For example, all stages of CKD severity were 
grouped together, as were symptomatic and asymptomatic HIV, the latter of whom may not 
be associated with cell-mediated immune suppression.104  It is therefore not possible to see 
how the effects of these risk factors on zoster and PHN varied according to severity of disease. 
Furthermore, it was not possible to determine whether the observed effects were driven 
solely by patients with more severe disease.  
 
8.3.   Implications for clinical practice 
Recognising that certain patients are at increased risk of zoster and PHN, as well as identifying 
the under-prescription of antivirals in patients with zoster, could have important implications 
for clinical practice: 
 This thesis adds to the case for vaccinating individuals against zoster prior to the 
introduction of immunosuppressive therapies. Given the increased risks of zoster and 
PHN in patients on immunosuppressive treatment, and the contraindication to use the 
currently available live vaccine in severely immunosuppressed individuals, vaccination 
prior to commencement of immunosuppressive treatment may warrant consideration, 
although evidence to support this strategy is currently lacking. The new sub-unit 
vaccine which has been designed for use in patients with immunosuppression (and is 
currently being investigated in Phase 3 trials) may enable vaccination in this group.   
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 This study highlights the need for greater prescribing of antivirals and considerations 
could be given to improving the implementation of the guidelines on antiviral 
prescription following acute zoster. Antivirals are important in lessening the time and 
severity of the acute zoster episode. Although antivirals have not conclusively been 
shown to protect against PHN, the study of PHN risk factors showed some weak 
evidence that their use may be associated with a reduction in PHN risk in patients with 
leukaemia, SLE, COPD and smoking.  Together, these factors support better adherence 
to antiviral treatment guidelines during acute zoster. 
 The UK guidelines for antiviral use currently recommend that patients presenting after 
72 hours of zoster onset be given antivirals within one week of rash onset, if they are 
at high risk of severe shingles or complications.  Considering that a number of 
conditions and patient characteristics have been identified which increase the risk of 
PHN in this thesis, consideration could be given to suggesting that patients with 
identified risk factors for PHN also be given antivirals if presenting after 72 hours of 
rash onset.  
 
8.4.   Implications for further research 
 Risk factors for zoster and PHN 
 This study has identified a number of patient characteristics as risk factors for zoster 
and/or PHN.  It also showed younger patients with certain conditions were at higher 
risk of zoster.  Cost-effectiveness studies would be needed to determine whether 
vaccination of groups with particular characteristics would be worthwhile. 
 Although this study has demonstrated that certain patient characteristics and 
conditions are associated with increased risks of zoster and PHN, further research is 
needed to understand the mechanisms underlying the increased risk, particularly for 
PHN for which the pathogenesis of continued pain is poorly understood.  
 The safety of the currently available Zostavax vaccine in immunosuppressed groups is 
also poorly understood and its contraindication is largely based on expert opinion 
rather than clinical data.  Further research assessing its safety among 
immunosuppressed patients is needed. Recent RCTs have supported zoster vaccine 
guidelines, such as a small RCT (n=295) demonstrating that the vaccine is safe in 
patients currently on a maintenance dose (5-20 mg per day) of corticosteroids207 and 
preliminary results suggest HIV patients with CD4 counts ≥200 per mmᶟ and on ART 
are not at increased risk of zoster after receiving the Zostavax vaccine.208 However, 
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research among patients with current vaccine contraindications is needed. For 
example, there is some evidence from observational studies that autoimmune patients 
on anti-TNF biologics and non-TNF biologics may not experience an increased risk of 
zoster following Zostavax vaccination in the primary safety risk window (42 days 
following vaccination),53 however trials are needed to confirm these findings to ensure 
the effects are causal.   
 The new subunit vaccine offers more potential for use in immunosuppressed patients 
and requires further research on safety and efficacy in this group. As this newer 
vaccine is not live, it does not pose the same risk of  triggering a varicella-like or herpes 
zoster illness as the Zostavax vaccine. Furthermore, initial results suggest the new 
subunit vaccine has limited safety concerns and appears equally as effective among 
older groups, wherein Zostavax vaccine efficacy is significantly reduced.209  
 Work is needed to establish the role of psychological stress on zoster risk. Despite 
stress being viewed as an important risk factor among the lay public and medical 
professionals, stress has not been consistently shown as a risk factor in the 
epidemiological literature. 
 Finally, this research used a current dose model when exploring the effect of 
prescription drugs on the risk of zoster and PHN; further research could take into 
account the impact of historical therapy on zoster and PHN risk. 
 
 Antiviral prescribing patterns in UK primary care 
 Further research into the causes of under-prescription of antivirals to acute zoster 
patients, specifically among older and immunosuppressed groups, would be helpful in 
determining strategies to increase the number of patients given antivirals. For example 
a qualitative research study among GPs may help clarify reasons for non-prescription 
of antivirals, where the guidelines specify antivirals should be administered. This could 
then be followed up by a quantitative cross-sectional survey to determine the most 
common reasons for under-prescription of antivirals.  
 Research on antiviral use during acute zoster is currently limited to assessing antiviral 
effectiveness when given within 72 hours of rash onset. This treatment window may 
be unrealistic in clinical practice, as there may be a delay of >72 hours between rash 
onset and presentation in primary care.  Therefore, to further encourage physicians to 
prescribe antivirals, research into the effectiveness of antivirals given within a week of 




8.5.   Overall conclusions 
Herpes zoster is a common disease with appreciable morbidity, which is preventable through 
vaccination. This thesis has carried out a systematic literature review, a literature review and 
two large observational studies using UK primary care data, to investigate risk factors for 
zoster and PHN. There was an increased risk of both zoster and PHN among patients with 
selected autoimmune conditions (RA, SLE and IBD), COPD, asthma and depression. The 
greatest risk of both zoster and PHN was among patients with severely immunosuppressive 
conditions, highlighting the need for alternative risk reduction strategies in this group, for 
which the new subunit vaccine appears promising.  Whilst data on the underlying mechanisms 
were not part of the work described in this thesis, the increased risk of PHN among patients 
with autoimmune and other immunosuppressive conditions suggests that lower cell-mediated 
immunity may play an important role in the pathogenesis of PHN, as well as zoster. A third 
study also draws attention to the under-prescription of antivirals during acute zoster in UK 
primary care, suggesting physicians are not fully adhering to treatment guidelines.  This thesis 
has highlighted a number of risk factors for PHN and zoster; cost-effectiveness studies are now 
needed to determine the value in providing zoster vaccination to patients with these risk 
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Appendix I: Scientific protocol 
 
The candidate was employed under an NIHR Clinician Scientist fellowship awarded to Sinéad 
Langan entitled, “The natural history and management of herpes zoster: the role of moderate 





The natural history and management of herpes zoster: the role of moderate immunosuppression 
from common diseases 
 
Lay Summary 
Shingles is a common disease with very important consequences that have lead to large scale 
vaccination programmes being introduced in the USA and planned in the UK. This research aims to 
answer a number of key questions which will inform the shingles vaccination policy in the UK 
Firstly, this research will find out how common shingles and important complications are; including 
possibly risks of heart attack. Secondly, it is well known that people with suppressed immune systems, 
e.g. from chemotherapy, are at increased risk of shingles. However we know very little about the impact 
of common disorders such as obesity and diabetes which may increase risks of shingles and related 
problems. Thirdly, this study will provide important information about patterns of use of shingles 
treatments and their effectiveness in clinical practice in the UK. Finally I will focus on the benefit of 
shingles vaccination in the population.  
To answer these questions, I will use a very large general population cohort in the UK. This is a novel 




Herpes zoster (HZ) is a common disease. The lifetime risk for HZ is between 25% and 35% rising to 
almost 50% among people surviving to aged 85 years or greater, and  it is estimated that there are more 
than 88,650 incident cases annually in the UK among immunocompetent people aged greater than 60 
years. [1-3] 
Common comorbidities 
Age is the major predictor of HZ incidence; this is believed to be due to waning specific cell mediated 
immunity. In specific profoundly immunosuppressed high risk groups, HZ incidence rates and 
complications are increased, e.g. HIV infection, immunosuppressive therapies for cancer/post-transplant 
and specific autoimmune diseases (e.g. inflammatory bowel disease and Wegener’s granulomatosis).[4-
7] Risks of HZ and its sequelae could also be increased among those with common disorders of major 
public health importance possibly associated with lesser degrees of immunosuppression, such as 
diabetes mellitus, obesity and chronic obstructive pulmonary disease (COPD).[8, 9] Despite the 
importance of these conditions, HZ natural history has not been adequately studied in these groups. 
Diabetes has been identified as a possible risk factor for HZ in a case-control study from Israel.[10] A 
recent study from Taiwan has also suggested that individuals with COPD may be at increased risk of 
HZ.[11] Obesity has not been previously studied in relation to HZ. Improved understanding of HZ among 
people with impaired cell mediated immunity is crucial to establish potential benefits and risks of 
vaccination.[12]  
Consequences of HZ 
The most common overall complication of HZ is post-herpetic neuralgia (PHN), affecting 30% of 
individuals with HZ aged 80-84 years in the UK  in routine practice and resulting in prolonged 
morbidity.[13] However, a range of other severe sequelae can occur following HZ, and the epidemiology 
of these outcomes is poorly understood. Specific areas requiring study in a population-based study 
include the incidence of serious events (encompassing cardiovascular and other sequelae), 
hospitalisation and all cause mortality. Work undertaken by my mentor established that  acute systemic 
infections in adults are associated with more than a three-fold transient increased risk of stroke in the first 
few days following infection and more than a two-fold increased risk of myocardial infarction.[14, 15] The 
effect of specific infections has been less explored; HZ could plausibly result in an increased risk of 





there is an association between herpes zoster and stroke. The incidence of myocardial infarction 
following HZ has not been investigated. Overall mortality may also be increased following HZ, e.g. related 
to pneumonia, venous thromboembolism and major cardiovascular events; this has not been specifically 
studied. Current UK mortality estimates are based on two sources: cause of death from death certificates 
(which may underreport HZ) and deaths during hospitalization which relate to short-term mortality 
only.[16]  
Antiviral therapy 
The efficacy of antivirals for treating acute HZ has been demonstrated in randomized controlled trials 
(RCTs). [17] No study has described overall patterns of use, effectiveness and adverse outcomes of 
antivirals for HZ in UK clinical practice. These studies will provide information needed about absolute 
event probabilities to inform risk- and cost-benefit studies.[18]  
Herpes zoster vaccine 
The development of a HZ vaccine has been a major breakthrough in this field. Oxman et al demonstrated 
a 51% reduction in episodes and a 66% reduction in post herpetic neuralgia in a US randomized 
controlled trial (RCT) of HZ vaccine.[19] It is unclear what the impact of HZ vaccination has on other HZ-
associated complications.  No stratification by comorbidity has been published showing HZ vaccine 
efficacy or side effects in individuals with mild to moderate immunosuppression. These individuals may 
have greater risks of HZ infection and adverse outcomes and may benefit from earlier vaccination, 
analogous to UK influenza vaccination policy.[20] This group may have also increased risks of vaccine 
adverse effects. 
Routine HZ vaccination was introduced in the US for immunocompetent individuals aged ≥60 
years in 2006.[19] A similar program is planned in the UK for people aged ≥70 years. HZ and varicella 
vaccines are currently not recommended in severe immunosuppression. Varicella vaccine has been used 
in children with leukaemia, HIV and following transplants.[21, 22] No similar published experience exists 
for HZ vaccine, the dose of which is 14 times higher than varicella vaccine. 
Further study is required to understand the natural history of HZ particularly in groups with 
common comorbidities and possible impaired cell mediated immunity. The proposed study combines 
cohort, nested case-control and self-controlled case series studies using the UK General Practice 
Research Database (GPRD) to study HZ outcomes, the impact of mild to moderate immunosuppression, 
patterns of use and effectiveness of antivirals and the benefit of HZ vaccination. Looking at GPRD data 
allows study of absolute outcomes in a large real population, rather than clinical trial populations. Study of 
the impact of vaccination on HZ incidence and sequelae may be monitored by the Health Protection 
Agency but its impact on less established HZ complications are likely to be outside routine surveillance 
and will require further study.  
What is not known? 
• What is the recent incidence of HZ in the UK, including among immunocompromised individuals? 
• What is the incidence of serious conditions e.g. myelitis, encephalitis, myocardial infarction and all 
cause mortality after incident HZ? 
• Do novel risk factors associated with some immunosuppression, such as diabetes, obesity and COPD, 
increase the risk of incident HZ and complications?  
• What are the patterns of use and effectiveness of HZ antivirals in clinical practice in the UK? 
• How effective is HZ vaccination at preventing HZ and complications in pragmatic use? 
• Should systemic antivirals and vaccination be considered at younger ages for treatment or prevention of 
HZ respectively in people with diabetes, obesity and COPD? 
 
Aims 
This project has two overall aims. Firstly, to update incidence estimates of HZ, the frequency of serious 





aim is to estimate the effect of HZ vaccination and antiviral therapy on the natural history and 
complications of HZ.  
The specific study objectives are: 
1. To obtain up-to-date detailed estimates of the incidence of HZ in the UK; 
2. To identify novel risk factors associated with increased incidence of HZ, namely comorbidities 
associated with some degree of immunosuppression such as diabetes, chronic obstructive pulmonary 
disease and obesity; 
3. To determine a) the frequency of serious medical conditions following HZ infection including myocardial 
infarction, post-herpetic neuralgia, myelitis, encephalitis, hospitalizations, all cause and cause-specific 
mortality , and b) to determine to what extent individuals with HZ are at increased risk of specific 
outcomes;  
4. To identify determinants of serious sequelae among individuals with HZ, including:   
(a) Age, sex;  
(b) Comorbidities associated with some degree of immunosuppression such as diabetes, chronic 
obstructive pulmonary disease and obesity; 
5. To describe patterns of use of antiviral therapy for HZ and to determine the effectiveness of antivirals in 
preventing severe sequelae of HZ in a routine clinical setting. 
6. To determine the effect of HZ vaccination in everyday use on HZ natural history and complications in 




Hypothesis generating and testing 
 
Plan of investigation, study design and study population 
Identification of incident herpes zoster group 
Incident HZ individuals will have been registered with their practice for at least 12 months and will be 
identified by the presence of diagnostic Read/OXMIS codes in GPRD. Incident HZ will be defined as an 
episode of HZ without evidence of HZ for at least two years previously.   
 
The GPRD has a number of key linkages which are highly useful for this study as follows: 
a) Hospital Episode Statistics (HES)  
HES contains details of all people admitted to NHS hospitals in England; the HES-GPRD link provides 
information on patients hospitalised from 1997 onwards. 
b) Office of National Statistics (ONS) 
ONS mortality data are linked to GPRD and record cause of death from death certificates 
c) Myocardial Infarction Audit Project (MINAP) 
MINAP is the United Kingdom's national register of acute coronary syndromes which includes all 230 
hospitals in England and Wales. 
 
All analyses will be carried out using Stata 10 (Stata Corp., College Station, TX, USA). Descriptive studies 
will provide updated HZ incidence and mortality data. These will be followed by a nested case control 
study to identify novel risk factors for incident zoster and a series of cohort studies to determine risk 
factors for HZ sequelae. Finally cohort studies will be used to study the effectiveness of HZ vaccination in 
the UK population. 
 
1.Descriptive analyses (Objectives 1,3a, and 5) 
Analysis  Incidence and mortality rates will be estimated using GPRD age and gender-specific 
denominators.  Incidence and mortality rates will be standardized to the European Standard population 
(2000). Antiviral usage patterns will be assessed by year, age, gender, region, socioeconomic status, 





Outcomes Incidence of HZ by age, gender, region, socioeconomic status and over time (2000-2010 in 
GPRD), mortality at 0-3, 4-6 and 7-12 months after HZ. Antiviral usage patterns and adverse events. 
 
2. Identifying novel risk factors for developing HZ (Objective 2) 
Study design Nested case control study 
Cases and controls  Individuals with incident HZ and age, gender and practice-matched controls with no 
history of HZ. 
Exposures  Diabetes, chronic obstructive pulmonary disease and obesity. 
Covariates  Age, gender, immunosuppression (HIV, malignant neoplasms, multiple myeloma, sickle cell 
disease, alcohol dependence syndrome, chronic liver or kidney disease, cirrhosis, nephrotic syndrome, 
organ/tissue transplant and immunosuppressive medications).  
Analysis  Conditional logistic regression will be used to study the effect of exposures on HZ incidence 
adjusting for relevant covariates. 
Outcomes Adjusted odds ratios for HZ 
 
3. Determining the increased risk of specific conditions after HZ (Objective 3b) 
Study designs: Cohort study and self-controlled case series (SCCS) studies 
Exposed and unexposed: i) Cohort study: individuals with and without HZ, matched for age, sex and 
practice; ii) SCCS studies: within-person comparison of exposed periods (following HZ) and non-exposed 
periods in individuals with HZ with specific outcomes. 
Covariates: Age, and (for cohort) gender, smoking, atrial fibrillation, body mass index, hypertension, 
diabetes, hyperlipidaemia. 
Analyses: Poisson regression will be used to model rates of events following incident episodes of HZ, 
adjusting for relevant covariates and examining whether any increased risk is modified by prior receipt of 
antivirals.  For SCCS analyses, age-adjusted relative incidence of events in defined intervals after HZ 
relative to all other observed time periods will be derived. 
Outcomes Adjusted rate ratios for myocardial infarction, myelitis, encephalitis, hospitalization within 180 
days of incident HZ and death. 
 
4. Investigating factors that increase the risk of sequelae among individuals with HZ (Objective 4) 
Study design: Cohort study of all people with incident HZ   
Exposures of interest Specific exposures to be assessed include diabetes, chronic obstructive 
pulmonary disease, obesity and antiviral medications. 
Covariates  Age, gender, other disorders associated with immunosuppression (objective 2); 
comorbidities, antivirals and duration of follow up. 
Analysis  Cox regression will be used to compare hazard ratios for outcomes in exposed individuals 
compared to unexposed adjusting for any relevant covariates. 
Outcomes Incidence rates and hazard ratios for serious complications including post-herpetic neuralgia, 
myocardial infarction, myelitis, encephalitis, hospitalization within 180 days of incident HZ and death.  
 
5.  The effect of HZ vaccination on natural history of HZ (Objective 6) 
Study design  Cohort study; Individuals aged ≥70 years (UK) after introduction of HZ vaccination.  
Exposed and unexposed groups  Exposed individuals have had HZ vaccination; unexposed individuals 
will not have had the HZ vaccine.  
Covariates See objective 4.  
Analysis  Incidence and hazard rates for HZ and complications in vaccinated and unvaccinated 
individuals.  Cox regression will model rates of events comparing these groups. Propensity scores will 









Power and sample size calculations 
There are 126,599 cases of HZ in the GPRD from 2000 to 2010 with five years total follow up.  
Novel risk factors for HZ If the true odds ratio for disease in exposed subjects, relative to unexposed 
subjects is 1.5, we will need to study 11152 HZ individuals with 1 matched control per case to be able to 
reject the null hypothesis that this odds ratio equals 1 with probability (power) 0.8 at the 5% level of 
significance, allowing for multivariable analysis. 
Factors increasing the risk of HZ sequelae  We need 2059 individuals with both COPD and HZ, or 34,317 
HZ patients in total (assuming 6% of the cohort have COPD) to have 80% power to detect a hazard ratio 
of 1.5 for myocardial infarction in exposed individuals with COPD at the 5% level of significance, allowing 
for multivariable analysis.  
Vaccine effectiveness  9843 exposed (vaccinated) individuals and equivalent numbers of unvaccinated 
individuals are required to have 80% power to detect a 50% reduction in incident HZ at the 95% level of 
significance. Assuming 3% of the GPRD population in the eligible age groups are vaccinated (n=14460), 
this should allow >99% power at the 95% level of significance to assess the effectiveness of the vaccine. 
 
Limitations 
Validation work on HZ has not been done in previous GPRD studies and documentation in GP records of 
clinical presentation or severity of HZ is likely to be limited. The key differential diagnosis for HZ is 
recurrent herpes simplex, which occasionally presents with a dermatomal distribution. Viral culture and 
PCR are highly unlikely to have been performed in routine practice and would be cost prohibitive to 
measure in a large population-based study. However, HZ is usually a straightforward clinical diagnosis 
based on classical clinical presentation. Excluding cases with recurrence intervals less than two years 
should exclude misclassified cases whilst not excluding immunosuppression-related HZ recurrence. A 
range of sensitivity analyses will be undertaken for all objectives, excluding recurrent cases of HZ with 
different intervals. The propensity score method will be used to address chanelling bias.  
 
Patient or user group involvement 
When I did my PhD in Nottingham, I involved service users in the development and selection of tools to 
measure exposures and outcomes and to disseminate study findings in conjunction with the Nottingham 
support group for carers of children with eczema. For this study, I will build on this expertise and work with 
a panel of individuals with a history of herpes zoster. A panel of people with a history of herpes zoster led 
by an experienced consumer, will advise on planning further studies and dissemination of results 
 
Plans for disseminating and communicating study results 
Study results will be widely disseminated by presenting study findings at scientific meetings and by 




Amendment 1 (APPROVED: 9 May 2012, protocol number 11_028A2R) 
We are now requesting to extract all COPD patients in GPRD to study zoster incidence and risk among 
COPD patients in greater detail.  
 
This will allow the following additional aim: 





- To calculate incidence of zoster among COPD patients. 
- To determine if the risk of zoster varies by COPD treatment group. 
- To determine if there is an increased risk of HZ after COPD exacerbation. 
Study Types: 
Incidence of zoster among COPD patients  
(as with study type 1 outlined above)  
 
Risk of zoster by COPD treatment group 
Study Design: Nested Case control study 
Cases and controls: Cases are COPD patients with incident HZ; controls are patients with no history of 
HZ who are age, gender and practice-matched to COPD cases. 
Exposures  Short-term treatment for COPD (treatment given three months before index date) and long-
term treatment 
Covariates  Age, gender, immunosuppression (HIV, malignant neoplasms, multiple myeloma, sickle cell 
disease, alcohol dependence syndrome, chronic liver or kidney disease, cirrhosis, nephrotic syndrome, 
organ/tissue transplant and immunosuppressive medications), moderate immunosuppression (Diabetes, 
chronic obstructive pulmonary disease and obesity). 
Analysis  Conditional logistic regression will be used to study the effect of exposures on HZ incidence 
adjusting for relevant covariates. 
Outcomes Adjusted odds ratios for HZ 
 
Is there an increased risk of HZ after COPD exacerbation?  
Study designs: Cohort study and self-controlled case series (SCCS) studies 
Exposed and unexposed: i) Cohort study: COPD individuals with and without COPD exacerbations, 
matched for age, sex and practice; ii) SCCS studies: within-person comparison of exposed periods (within 
one month following COPD exacerbation) and non-exposed periods in COPD patients with HZ. 
Covariates: Age, and (for cohort) gender, immunosuppression (HIV, malignant neoplasms, multiple 
myeloma, sickle cell disease, alcohol dependence syndrome, chronic liver or kidney disease, cirrhosis, 
nephrotic syndrome, organ/tissue transplant and immunosuppressive medications), moderate 
immunosuppression (Diabetes, chronic obstructive pulmonary disease and obesity). 
Analyses: Poisson regression will be used to model rates of zoster following COPD exacerbation, 
adjusting for relevant covariates.  For SCCS analyses, age-adjusted relative incidence of zoster in 
defined intervals after COPD exacerbations relative to all other observed time periods will be derived. 
Outcomes Adjusted rate ratios for myocardial infarction, myelitis, encephalitis, hospitalization and death 










- Aim 2: A wider range of risk factors for zoster will be assessed.  
Recent research has implicated a number of clinical conditions and lifestyle factors as risk factors for 
zoster including diabetes mellitus[23, 24], chronic obstructive pulmonary disorder (COPD) [24, 25], 
chronic kidney disease (CKD) [26-28], asthma[29] and depression [30, 31] all of which may be associated 
with cell-mediated immune suppression.[32-37] It has also been postulated that obesity leads to a degree 
of cell mediated immune suppression.[38] However, there has been a lack of large, highly powered 
studies using a systematic approach looking at a wide range of risk factors. Furthermore, adjustment for 
confounders has often been inadequate and studies have not quantified the population impact of these 
risk factors.  Given the limited current evidence on a wider range of risk factors than we originally planned 
to look at, all of which are plausibly associated with cell-mediated immunity, we would like to broaden our 
analysis to include all of the risk factors mentioned above. The above issues and the proposed change 
arose from discussions between the PhD student leading this study, and the supervisors and advisory 
group. Additionally, we wish to conduct a focused analysis to look at the effect of statin use on zoster risk. 
This will be done as an LSHTM MSc summer dissertation (supervised by Krishnan Bhaskaran), and is in 
response to a recent study (Antonou et al, Clin Infect Dis 2014, 58:350-6), suggesting an increased risk of 
zoster in statin patients, We felt that the dataset we have developed for the main study would be ideally 
suited to looking at this research question, and that this would make an interesting and useful training 
project for an MSc Epidemiology student. For the MSc project, the student will use the same case-control 
design, and will be able to adjust for the range of covariates already extracted. 
 
- Aim 4: As well as identifying risk factors for post-herpetic neuralgia (PHN) in zoster patients, we 
will also look at risk factors in the general population 
In our original plan (part 4), we specified a cohort analysis to look at risk factors for developing PHN in a 
cohort of patients with zoster. After further discussions among the PhD advisory group guiding this study, 
we would now like to also look at risk factors for PHN in the general population, by re-running the model 
developed in objective 2 (risk factors for zoster), restricted to cases of zoster who go on to get PHN and 
their non-zoster controls. This analysis will address the question “what are the risk factors in the general 
population for contracting ‘complicated zoster ‘, i.e. zoster complicated by PHN”, which is of relevance to 
informing zoster vaccination policy. The analysis will be stratified by whether PHN patients received 
antiviral therapy; this is because antivirals may themselves modify the risk of PHN. It will be stated a priori 
that we do not intend to measure the effectiveness of antivirals; this is due to confounding by indication 
















































































































GPRD Medcode  Term Type Read / OXMIS Code Read / OXMIS Term
201809  OXMIS   054 FK  HERPES ZOSTER GENICULATE
205942  READ  A53x100  Disseminated zoster
206066  READ  AyuA500  [X]Zoster without complications
206774  READ  F011200  Meningitis due to herpes zoster virus
214930  READ  A531.00  Herpes zoster with other central nervous system complication 
214931  READ  A531z00  Herpes zoster with other CNS complication NOS 
214932  READ  A532z00  Herpes zoster with other ophthalmic complication 
214933  READ  A53z.00  Herpes zoster NOS 
215755  READ  F011211  Herpes zoster meningitis 
215831  READ  F374400  Polyneuropathy in herpes zoster 
223962  READ  A532.00  Herpes zoster with ophthalmic complication 
223963  READ  A53xz00  Herpes zoster with other specified complication NOS 
224801  READ  F030911  Herpes zoster encephalitis
233111  READ  A531400  Zoster encephalitis
233222  READ  AyuA400  [X]Zoster with other complications
234142  READ  F501611  Herpes zoster ‐ otitis externa
242139  READ  A530.00  Herpes zoster with meningitis
242140  READ  A531100  Geniculate herpes zoster
242141  READ  A532000  Herpes zoster with dermatitis of eyelid
242142  READ  A532200  Herpes zoster iridocyclitis
251320  READ  A532100  Herpes zoster with keratoconjunctivitis
288977  READ  F501600  Infective otitis externa due to herpes zoster 
292813  OXMIS   054 HZ  HERPES ZOSTER AURICULARIS





305975  OXMIS   053 A  OPHTHALMIC HERPES ZOSTER 
      (continued overleaf) 
GPRD Medcode  Term Type  Read / OXMIS Code  Read / OXMIS Term 
260527  READ  A531000  Herpes zoster with other CNS complications 
260528  READ  A53x.00  Herpes zoster with other specified complication 
261337  READ  F030900  Encephalitis due to herpes zoster
269751  READ  A53..00  Herpes zoster
269753  READ  A532300  Ophthalmic herpes zoster infection
269754  READ  A532400  Herpes zoster ophthalmicus
269755  READ  A53x000  Herpes zoster otitis externa
269756  READ  A53y.00  Herpes zoster with unspecified complication 
287948  READ  A53..11  Shingles
302982  OXMIS   053 NG  SHINGLES
305976  OXMIS   053 AG  OPHTHALMIC SHINGLES













































































































































































220085      OXMIS   323 EN    ENCEPHALOMYELITIS 
220086      OXMIS   323 M    MYELITIS 
224834      READ  F210.00    Neuromyelitis optica 
238102      OXMIS   341 PT    NEUROMYELITIS OPTICA 
242989      READ  F03..11    Encephalomyelitis 
242990      READ  F03..13    Transverse myelitis 
252120      READ  F03z.11    Encephalomyelitis NOS 
252349      READ  Fyu0A00    [X]Encephalitis,myelitis+encephalomyelitis/other diseases CE 
261344      READ  F03y.11    Encephalomyelitis NOS 
270597      READ  F03..00    Encephalitis, myelitis and encephalomyelitis 
270609      READ  F037000    Varicella transverse myelitis 
279911      READ  Fyu0800    [X]Encephalitis,myelitis+encephalomyelitis/viral disease CE 
283961      OXMIS   3209MM   MENINGOMYELITIS 
288794      READ  F03..12    Myelitis 
289005      READ  Fyu0600    [X]Other encephalitis, myelitis and encephalomyelitis 
293080      OXMIS   323 B    TRANSVERSE MYELITIS 




Appendix II: Permissions to reprint published articles 
 
Article entitled, “The Epidemiology and Prevention of Herpes Zoster”, published in the Current 







Article entitled, “Quantification of risk factors for herpes zoster: population based case-control 




Article entitled, “Prescription of antiviral therapy after herpes zoster in general practice: who 







Article entitled, “A systematic review and meta-analysis of risk factors for postherpetic 







Appendix III: Section A of published appendices from 
BMJ zoster case control study 
The zoster case control study published in the BMJ (chapter 4) has an appendices, for which 
section A was not included in the main PhD, as its content was described in chapter 3, “Data 




A: Further detail on defining risk factors 
We assessed three autoimmune conditions; rheumatoid arthritis, systemic lupus 
erythematosis and inflammatory bowel disease. These were defined as a diagnosis 
prior to the index date. Chronic obstructive pulmonary disorder patients were defined 
as those with a diagnosis of chronic obstructive pulmonary disorder, including chronic 
bronchitis and emphysema, prior to the index date and ≥35 years at first chronic 
obstructive pulmonary disorder diagnosis). Asthma patients were those with an 
asthma diagnosis before the index date and an asthma-related prescription [short and 
long-acting beta-2 agonists and antimuscarinics, inhaled corticosteroids, 
cromoglycates and nedocromil, theophyllines, leukotriene receptor agonists and 
omalizumab] within 12 months prior to the index date; patients with a chronic 
obstructive pulmonary disorder diagnosis ever in their medical history were not 
classified as asthmatic). Chronic kidney disease patients were those with a diagnosis of 
mild, moderate or severe chronic kidney disease, kidney transplant or kidney dialysis, 
any time prior to the index date. Depression was defined as having a diagnosis or 
symptom of depression (such as “feeling depressed” or “sad mood”) or within one 
year prior to the index date; symptoms were included due to the trend post-2004 of 
using symptom rather than diagnosis codes in UK primary care122.  
 
 
To define diabetes we required a definite diabetes diagnosis, or a possible diabetes 
code [e.g. self- monitoring of blood glucose] with a subsequent diabetes-specific 
prescription [insulin or oral anti-diabetics], or ≥2 diabetes drug prescriptions prior to 
the index date; gestational diabetes and drug-induced diabetes were excluded. We 
also used age at first diagnosis, age at first treatment and treatment received to 
classify patients into Type 1 or 2 diabetes. Patients were categorised as type 1 or type 
 265 
 
2 diabetes where possible. Distinguishing between type 1 and type 2 diabetes is not 
always possible from diabetes codes as patients are frequently given a non-specific 
code. Furthermore, where type of diabetes is assigned, it has been found to be 
unreliable.111 Therefore we chose not to use this information, but instead use age at 
first diagnosis, age at first treatment and treatment received to classify diabetes type, 
as in previous Clinical Practice Research Datalink studies.112 113 Type 1 was assigned 
where; age at first diagnosis was ≤35 years and treatment ever was exclusively insulin, 
or patients received at least two insulin prescriptions ≤35 years, but had no diabetes 
diagnosis. Type 2 was assigned where; age at first diabetes diagnosis was >35; or 
patients received exclusively oral anti-diabetic’s >35 years. Patients with age at 
diagnoses >35 but treated exclusively with insulin and those not fitting into these 





Calculating duration of prescriptions in the Clinical Practice Research Datalink and 
identifying high-dose oral corticosteroids  
 
 
In order to identify relevant prescriptions, it was necessary to calculate the duration of 
individual prescriptions prior to the index date. 
 
Variables available 
The Clinical Practice Research Datalink does not provide researchers with duration and 
dose for individual prescriptions. Instead, these must be generated using information 
from other variables. On prescribing, general practitioners select the drug and can 
enter information on quantity (of tablets or inhalers prescribed), number of days, 
number of packs, pack type (number of tablets per pack or number of puffs per 
inhaler) and also enter free text.  The free text field contains the actual prescribing 
information; in other words how many tablets, grams, milligrams or puffs the patient 
should take each day. To utilize this prescribing information, the Clinical Practice 
Research Datalink developed an algorithm to derive a numerical value from the free 
text and provide this to researchers;105 this is referred to within the Clinical Practice 
Research Datalink as the numeric daily dose (NDD).  The dose (in milligrams or 





The completeness of each variable is described in table A1 below.  
Table A1: Completeness of variables used to identify duration and dose of corticosteroid 
prescriptions before cleaning. 
  % complete 







Quantity¹  Qty 99 99 99  
Number of days  numdays  9 7 8 
Number of 
packs  
numpacks  2 3 1 
Pack type²  packtype  <0.5 4 52 
Dose in mg  extract from 
product name  
100 100 100 
Numeric daily 
dose 
ndd  67 67 81 
¹ For ICS prescriptions quantity referred to number of inhalers, otherwise quantity referred to number of tablets 
² For ICS prescriptions pack type referred to numbers of puffs per inhaler, for OCS prescriptions pack type was 
largely missing 
 
 Data cleaning 
We carried out a series of data-checking and data-cleaning tasks including; checking 
the accuracy of NDD for the 500 most commonly occurring free-texts; extracting data 
for pack type from other variables (eg quantity variable); checking the clinical and 
referral records of 20 randomly selected patients to check the duration and dose was 
consistent with the clinical picture; excluding implausible values of quantity and NDD.  
 
As NDD was not always available it was necessary to impute missing data.  A “hot-
deck” style imputation method was adopted, which replaced missing data with 
comparable data from the same set.  An algorithm was developed which reviewed 
each oral corticosteroid and other immunosuppressive therapy record and imputed 
missing values. An extra binary variable for quantity was created, categorising quantity 
about the median (42 tablets for steroids, 36 for other immunosuppressants) into low 
and high. If a patient had any other record with the same quantity and dose, the 
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median NDD among those records was used where NDD was missing. If a patient had 
no recorded NDD but had any other record of the same dose and quantity as a binary 
variable, the median NDD among those records was used.  If a patient did not have a 
recorded NDD or quantity, but had records for the same dose, then the median NDD 
among those records was used.   If there was no record of NDD, dose or quantity, but 
there were other patients in the dataset in the same 5-year age band, of the same 
gender, with the same dose and quantity, the using median NDD for those records was 
used. Finally, if none of the above were possible, patients in the dataset in the same 5-
year age band, of the same gender, with the same dose and quantity as a binary 
variable, the median NDD among these records was used. 
 
Pack type for inhaled corticosteroids was imputed using the most common pack type 
for the quantity and dose of each prescription. Where NDD was missing for inhaled 
corticosteroids, the median value of 4 puffs per day was used.  
 
Calculating duration and dose 
Using this information we calculated duration of oral corticosteroid or other 
immunosuppressive therapy prescription as follows: total quantity of tablets 
prescribed / NDD. Duration of inhaled corticosteroids was calculated: (quantity x pack 
type)/NDD. Dose was calculated as follow; NDD x dose per tablet or puff. 
 
Algorithm to select smoking, alcohol and BMI status.  
Data were derived from medical Read codes and data from the additional details file. 
Read codes classifying patients by BMI category are very rarely recorded, therefore 
were not used. Where patients had multiple recordings, the nearest status in the 
 269 
 
period -1y to +1month from index was taken (best); if not available, then the nearest in 
the period +1month to +1y after index was taken (second best); if not available, then 
the nearest before -1y from index was taken (third best); if not available, then take 
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Appendix V: Code lists 





















Other Immune Disorders (OID) 
Other immunosuppressive therapies 
PHN diagnosis 
PHN - Neuralgia diagnosis 
PHN - Neuropathic pain 
PHN treatment - Anticonvulsants 
PHN treatment - Capsaicin Cream 
PHN treatment - Lidocaine patches 
PHN treatment - Mild painkillers (PKs) 
PHN treatment - Tramadol 
PHN treatment- Strong painkillers (PKs) 
PHN treatment- Tricyclic antidepressants 
Rheumatoid arthritis 
Smoking 
Systemic Lupus Erythematosis 
Alcohol
Medical code Read term Alcohol status
322 Moderate drinker - 3-6u/day current drinker
385 Drinks rarely current drinker
669 non-drinkerdependent alcohol abuse, unspecified current drinker
749 Drinks occasionally current drinker
956 ZERIDAME SR tablets 150mg [ACTAVIS] current drinker
967 Stopped drinking alcohol ex-drinker
1399 Alcohol problem drinking current drinker
1476 Delirium tremens current drinker
1618 Heavy drinker - 7-9u/day current drinker
2081 Alcoholism current drinker
2082 Alcohol withdrawal syndrome current drinker
2083 Alcohol detoxification current drinker
2084 Alcohol dependence syndrome current drinker
2689 Beer drinker current drinker
2925 Alcoholic polyneuropathy current drinker
3216 Acute alcoholic hepatitis current drinker
3782 Intoxication - alcohol current drinker
4447 Herpes zoster with meningitis non-drinker
4500 Korsakov's alcoholic psychosis current drinker
4506 Alcoholic gastritis current drinker
4743 Alcoholic cirrhosis of liver current drinker
4915 Alcoholic cardiomyopathy current drinker
5611 [X]Mental and behavioural disorders due to use of alcohol current drinker
5740 Acute alcoholic intoxication in alcoholism current drinker
5758 [X]Chronic alcoholism current drinker
6169 Alcohol dependence syndrome NOS current drinker
6467 [X]Alcoholic hallucinosis current drinker
7123 [V]Personal history of alcoholism current drinker
7545 [V] Alcohol use current drinker
7602 Chronic alcoholic hepatitis current drinker
7692 Patient advised about alcohol current drinker
7746 non-drinkerdependent alcohol abuse current drinker
7885 Alcoholic liver damage unspecified current drinker
7943 Alcoholic hepatitis current drinker
8030 [V]Alcohol abuse counselling and surveillance current drinker
8363 Oesophageal varices in alcoholic cirrhosis of the liver current drinker
8388 [V]Alcohol rehabilitation current drinker
8999 Heavy drinker current drinker
9169 [D]Alcohol blood level ex-drinkercessive current drinker
9489 Under care of community alcohol team current drinker
9508 [X]Acute alcoholic drunkenness current drinker
9849 Referral to community alcohol team current drinker
10161 O/E - alcoholic breath current drinker
10691 Alcoholic fatty liver current drinker
11106 Korsakov's alcoholic psychosis with peripheral neuritis current drinker
11140 Advice on alcohol consumption current drinker
11491 Health ed. - alcohol current drinker
11670 [X]Korsakov's psychosis, alcohol induced current drinker
11740 Alcohol misuse - enhanced services administration current drinker
12353 [X]Mental & behav dis due to use alcohol: psychotic disorder current drinker
12554 Referral to community drug and alcohol team current drinker
12949 Teetotaller non-drinker
12968 Drinks beer and spirits current drinker
12969 Drinks wine current drinker
12970 non-drinker drinker alcohol non-drinker
12971 Spirit drinker current drinker
12972 Light drinker - 1-2u/day current drinker
12974 non-drinkerdependent alcohol abuse, episodic current drinker
12975 Trivial drinker - <1u/day current drinker
12976 Suspect alcohol abuse - denied current drinker
12977 Very heavy drinker - >9u/day current drinker
12979 current drinkerent non-drinker drinker non-drinker
12980 Light drinker current drinker
12982 Alcohol intake above recommended sensible limits current drinker
12983 ex-drinker-very heavy drinker-(>9u/d) ex-drinker
12984 Very heavy drinker current drinker
12985 Moderate drinker current drinker
16225 Alcohol withdrawal delirium current drinker
16237 Alcoholic psychoses current drinker
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Alcohol
Medical code Read term Alcohol status
16587 [V]Problems related to lifestyle alcohol use current drinker
17259 [X]Delirium tremens, alcohol induced current drinker
17330 Alcoholic hepatic failure current drinker
17607 [X]Alcoholic psychosis NOS current drinker
18156 Alcoholics anon-drinkerymous current drinker
18636 Wernicke-Korsakov syndrome current drinker
18711 Lifestyle advice regarding alcohol current drinker
19217 Alcohol causing toxic effect current drinker
19401 Binge drinker current drinker
19493 ex-drinker-heavy drinker - (7-9u/day) ex-drinker
19494 Hazardous alcohol use current drinker
19495 ex-drinker-moderate drinker - (3-6u/d) ex-drinker
20407 Drunkenness - pathological current drinker
20514 [X]Mental and behav dis due to use alcohol: withdrawal state current drinker
20762 Alcohol amnestic syndrome current drinker
21624 Episodic acute alcoholic intoxication in alcoholism current drinker
21650 Admitted to alcohol detoxification centre current drinker
21713 Alcoholic fibrosis and sclerosis of liver current drinker
21879 [X]Mental and behav dis due to use of alcohol: harmful use current drinker
22277 DTs - delirium tremens current drinker
22707 Drinking problem scale current drinker
22933 ex-drinker-trivial drinker (<1u/day) ex-drinker
23610 non-drinkerdependent alcohol abuse, continuous current drinker
23945 Fetal alcohol syndrome current drinker
23978 [X]Evid of alcohol involv determind by level of intoxication current drinker
24064 Continuous chronic alcoholism current drinker
24485 Chronic alcoholism in remission ex-drinker
24735 O/E - breath - alcohol smell current drinker
24984 Alcohol-induced chronic pancreatitis current drinker
25110 Alcohol withdrawal hallucinosis current drinker
26106 Episodic chronic alcoholism current drinker
26323 [X]Alcoholic dementia NOS current drinker
26471 ex-drinker-light drinker - (1-2u/day) ex-drinker
26472 Alcohol intake within recommended sensible limits current drinker
27342 Alcoholic dementia NOS current drinker
27518 Hangover (alcohol) current drinker
27670 Maternal care for (suspected) damage to fetus from alcohol current drinker
28150 non-drinkerdependent alcohol abuse NOS current drinker
28780 [X]Alcohol addiction current drinker
29691 Aversion therapy - alcoholism current drinker
30162 [X]Alcoholic paranoia current drinker
30404 Alcoholic paranoia current drinker
30460 Alcoholism counselling current drinker
30604 Alcohol-induced epilepsy current drinker
30695 Harmful alcohol use current drinker
31443 Chronic alcoholism current drinker
31569 non-drinkerdependent alcohol abuse in remission current drinker
31742 Alcoholic myopathy current drinker
32927 [X]Alcohol withdrawal-induced seizure current drinker
33635 Chronic alcoholism NOS current drinker
33670 Other alcoholic psychosis current drinker
33839 Cerebellar ataxia due to alcoholism current drinker
35330 Alcohol consumption counselling current drinker
36296 Acute alcoholic intoxication in alcoholism NOS current drinker
36748 Alcoholic encephalopathy current drinker
37264 Alcohol leaflet given current drinker
37691 [X]Chronic alcoholic brain syndrome current drinker
37946 Chronic alcoholic brain syndrome current drinker
38061 Alcohol induced hallucinations current drinker
39327 [X]Mental and behav dis due to use alcohol: dependence syndr current drinker
39799 [X]Mental and behav dis due to use alcohol: amnesic syndrome current drinker
40530 Acute alcoholic intoxication, unspecified, in alcoholism current drinker
41920 Alcohol amnestic syndrome NOS current drinker
41983 Alcohol detoxification current drinker
42843 Other non-drinker-alcoholic chronic liver disease current drinker
43193 Unspecified chronic alcoholism current drinker
44299 [X]Mental & behav dis due to use alcohol: acute intoxication current drinker
44783 Pain in lymph nodes after alcohol consumption current drinker
45169 [X]Men & behav dis due to use alcohol: oth men & behav dis current drinker
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Medical code Read term Alcohol status
46677 Alcohol withdrawal regime current drinker
46848 DPS - Drinking problem scale current drinker
47123 Alcohol counselling by other agencies current drinker
47555 Cerebral degeneration due to alcoholism current drinker
54209 Advice to change alcohol intake current drinker
54505 Other alcoholic dementia current drinker
56410 Delivery of rehabilitation for alcohol addiction current drinker
56947 Continuous acute alcoholic intoxication in alcoholism current drinker
57714 Alcohol dependence with acute alcoholic intoxication current drinker
57939 Pathological alcohol intoxication current drinker
59574 Acute alcoholic intoxication in remission, in alcoholism current drinker
61383 Planned reduction of alcohol consumption current drinker
63529 Alcohol misuse - enhanced service completed current drinker
64389 [X]Ment & behav dis due use alcohol: unsp ment & behav dis current drinker
64409 Self-monitoring of alcohol intake current drinker
65754 Alcohol-induced pseudo-Cushing's syndrome current drinker
65932 [X]Alcoholic jealousy current drinker
66019 Suspect fetal damage from maternal alcohol current drinker
66699 Fetus and newborn affected by maternal use of alcohol current drinker
67651 Alcoholic psychosis NOS current drinker
68111 Other alcoholic psychosis NOS current drinker
84218 Disqualified from driving due to ex-drinkercess alcohol current drinker
94553 Referral to specialist alcohol treatment service current drinker
94670 Alcohol misuse current drinker
95181 Alcohol reduction programme current drinker
95650 Advice to change drink intake current drinker
96053 Brief intervention for ex-drinkercessive alcohol consumptn completed current drinker
96054 ex-drinkertended intervention for ex-drinkercessive alcohol consumptn complt current drinker
96993 Referral to alcohol brief intervention service current drinker
97163 Advice to change alcoholic drink intake current drinker
97261 Brief intervention for ex-drinkercessive alcohol consumptn declined current drinker
97309 Advised to contact primary care alcohol worker current drinker
97680 Declined referral to specialist alcohol treatment service current drinker
97916 Fetal alcohol syndrome current drinker
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Medical code Read term
78 asthma
81 asthma monitoring
185 acute exacerbation of asthma
232 asthma attack








3665 late onset asthma
4442 asthma unspecified
4606 exercise induced asthma
4836 nocturnal cough / wheeze
4892 status asthmaticus nos
5267 Herpes zoster with meningitis
5627 hay fever with asthma
5867 exercise induced asthma
6707 extrinsic asthma with asthma attack
7058 emergency admission, asthma
7146 extrinsic (atopic) asthma
7191 asthma limiting activities
7229 asthma prophylactic medication used
7378 asthma management plan given
7416 asthma disturbing sleep
7731 pollen asthma
8335 asthma attack nos
8355 asthma monitored
9018 number of asthma exacerbations in past year
9552 change in asthma management plan
9663 step up change in asthma management plan
10043 asthma annual review
10274 asthma medication review






13173 asthma not disturbing sleep
13174 asthma not limiting activities
13175 asthma disturbs sleep frequently
13176 asthma follow-up
14777 extrinsic asthma without status asthmaticus
15248 hay fever with asthma
16070 asthma nos
16667 asthma control step 2
16785 asthma control step 1
18141 asthma monitoring due
18223 step down change in asthma management plan
18224 asthma control step 3
18323 intrinsic asthma with asthma attack
19167 asthma monitoring by nurse
19519 asthma treatment compliance unsatisfactory
19520 asthma treatment compliance satisfactory
19539 asthma monitoring check done
20860 asthma control step 5
20886 asthma control step 4




Medical code Read term
24479 emergency asthma admission since last appointment
24506 further asthma - drug prevent.
24884 asthma causes daytime symptoms 1 to 2 times per week
25181 asthma restricts exercise
25791 asthma clinical management plan
25796 mixed asthma
26501 asthma never causes daytime symptoms
26503 asthma causes daytime symptoms most days
26504 asthma never restricts exercise
26506 asthma severely restricts exercise
26861 asthma sometimes restricts exercise
27926 extrinsic asthma with status asthmaticus
29325 intrinsic asthma without status asthmaticus
29645 asthma control step 0
30458 asthma monitoring by doctor
30815 asthma causing night waking
31167 asthma night-time symptoms
31225 asthma causes daytime symptoms 1 to 2 times per month
38143 asthma never disturbs sleep
38144 asthma limits walking up hills or stairs
38145 asthma limits walking on the flat
38146 asthma disturbs sleep weekly
39478 wood asthma
39570 asthma causes night symptoms 1 to 2 times per month
40823 brittle asthma
40864 [x] adverse reaction to theophylline - asthma
41017 aspirin induced asthma
41020 absent from work or school due to asthma
42824 asthma daytime symptoms
45073 intrinsic asthma nos
45782 extrinsic asthma nos
46529 attends asthma monitoring
47337 asthma accident and emergency attendance since last visit
47684 detergent asthma
48591 adverse reaction to theophylline (asthma)
58196 intrinsic asthma with status asthmaticus
73522 work aggravated asthma
98185 asthma control test
99793 patient has a written asthma personal action plan
100397 asthma control questionnaire
100509 under care of asthma specialist nurse
100740 health education - structured asthma discussion
102170 asthma review using roy colleg of physicians three questions
102209 mini asthma quality of life questionnaire
102301 asthma trigger - seasonal
102341 asthma trigger - pollen
102395 asthma causes symptoms most nights
102400 asthma causes night time symptoms 1 to 2 times per week
102449 asthma trigger - respiratory infection
102713 asthma limits activities 1 to 2 times per month
102871 asthma trigger - exercise
102888 asthma limits activities 1 to 2 times per week
102952 asthma trigger - warm air
103318 health education - structured patient focused asthma discuss
103321 asthma trigger - animals
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Product Code Product Name
26987 bricanyl compound tablets [astrazenec]
46551 salbutamol cfc free inhaler 100micrograms/inhalation [neolab]
41549 salbutamol tablets 2mg [cp pharm]
23047 ephedrine hydrochloride tablets 60mg
33434 ZERIDAME SR tablets 150mg [ACTAVIS]
27573 ventolin
25218 salbutamol cfc/free b/a
40709 salbutamol unit dose nebulising solution 2.5mg/2.5ml [hillcross]
42103 tulobuterol sugar free syrup 1mg/5ml
32283 orciprenaline injection 0.5mg/ml
32102 salbutamol tablets 4mg [hillcross]
25829 pirbuterol syrup 7.5mg/5ml
44713 salbutamol aerosol inhaler 100micrograms/inhalation [celltech]
26873 cobutolin tablets 2mg [actavis]
36677 reproterol elixir 10mg/5ml
23688 ventolin rotacaps
41832 monovent syrup 1.5mg/5ml [sandoz]
23054 Herpes zoster with meningitis
22082 alupent expectorant tablets [boeh ingl]
33461 iso-autohaler aerosol inhaler [3m]
33373 salbutamol cyclocaps capsules (for inhalation) 200micrograms [teva]
26829 brelomax tablets 2mg [abbott]
31082 salbuvent respirator solution 5mg/ml [pharmacia]
32033 dextromethorphan with ephedrine syrup 7.5mg + 15mg/5ml
27340 salbuvent injection 0.5mg/ml [pharmacia]
31290 salbulin cfc free
29267 salbuvent tablets 4mg [pharmacia]
22790 reproterol respirator solution 10mg/ml
26654 aerolin inhaler auto refil
25820 bronchodil elixir 10mg/5ml [viatris]
42867 terbutaline syrup 1.5mg/5ml [sandoz]
20838 salbuvent tablets 2mg [pharmacia]
26525 ventolin
34702 salbutamol aerosol inhaler 100micrograms/inhalation [cp pharm]
31262 orciprenaline with bromhexine hydrochloride mixture
20781 salbutamol u.dose nebulising 2.5mg/2.5ml
42497 salbutamol tablets 8mg
17874 monovent syrup 1.5mg/5ml [lagap]
43046 salipraneb unit dose nebulising solution 500micrograms + 2.5mg/2.5ml [breath]
38419 terbutaline syrup 1.5mg/5ml [hillcross]
15356 ephedrine hydrochloride tablets 30mg [cp pharm]
22512 salbutamol inhaler
42921 isoprenaline sulphate aerosol inhaler 400micrograms/actuation
42279 steripoule salbutamol unit dose nebuliser solution 2.5mg/2.5ml [galen]
22467 salbutamol respirator soln
25073 salbutamol
41691 salbutamol sugar free oral solution 2mg/5ml [sandoz]
26744 expulin decongestant sugar free linctus [shire]
28577 ventolin injection 50micrograms/ml [a & h]
32812 numotac tablets 10mg [3m]
31845 salapin syrup 2mg/5ml [pinewood]
41548 salbutamol tablets 2mg [aps]
40655 salbuvent aerosol inhaler 100micrograms/actuation [pharmacia]
44064 onbrez breezhaler capsules for inhalation + inhaler 300micrograms [novartis]
26716 airomir autohaler cfc free b/a
37612 terbutaline unit dose nebulising solution 2.5mg/ml [galen]
12470 alupent expectorant mixture [boeh ingl]
33089 salbutamol aerosol inhaler 100micrograms/inhalation [kent]
10353 salbuvent rondo
40599 steripoule salbutamol unit dose nebuliser solution 5mg/2.5ml [galen]
9720 ephedrine hydrochloride elixir 15mg/5ml
25821 exirel syrup 7.5mg/5ml [3m]
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Product Code Product Name
45863 salbutamol unit dose nebulising solution 5mg/2.5ml [gen (uk)]
22225 beclomethasone /salbutamol
27793 salbutamol cyclohaler type 5 insufflator [bms]
10958 salbutamol .25 mg inj
19121 beclometasone with salbutamol capsules (for inhalation) 100micrograms + 200micrograms
34618 salbutamol tablets 2mg [actavis]
34938 salbutamol tablets 4mg [actavis]
45610 indacaterol capsules for inhalation + inhaler 300micrograms
31091 ephedrine hydrochloride tablets 15mg [cp pharm]
38097 salbutamol cyclocaps 200micrograms [du pont]
22550 duovent
8252 pirbuterol capsules 15mg
15483 bricanyl expectorant [astrazenec]
24380 sodium cromoglicate with salbutamol inhaler and spacer
34311 salbutamol aerosol inhaler 100micrograms/inhalation [berk]
22430 spacehaler salbutamol spacehaler 100micrograms/inhalation [celltech]
20180 sodium cromoglicate with isoprenaline capsules (for inhalation)
17875 terbutaline with guaifenesin expectorant
19732 cobutolin inh
19376 beclometasone with salbutamol capsules (for inhalation) 200micrograms + 400micrograms
27505
ipratropium bromide with fenoterol hydrobromide breath actuated inhaler 40micrograms + 
100micrograms/actuation
15613 salbutamol injection 500micrograms/1ml
30212 salbutamol cyclohaler
12463 pirbuterol 15 mg tab
28881 salbutamol sugar free oral solution [hillcross]
32050 salbutamol cyclocaps capsules (for inhalation) 400micrograms [teva]
7452 ventolin .25 mg inj
34018 salbutamol unit dose nebulising solution 5mg/2.5ml [galen]
33817 salbutamol cfc free inhaler 100micrograms/inhalation [actavis]
34619 salbutamol cfc free inhaler 100micrograms/inhalation [kent]
18456 salbutamol with beclometasone capsules (for inhalation) 200micrograms + 100micrograms
18622 salbulin tablets 2mg [3m]
20675 salbutamol rotahaler complete unit
15441 fenoterol hydrobromide .5 % sol
4055 salbulin syrup 2mg/5ml [3m]
9706 ephedrine elixir 15mg/5ml
15075 bronchodil tablets 20mg [viatris]
34134 aerolin 400 aerosol inhaler 100micrograms/actuation [3m]
38214 salbutamol dry powder inhalation cartridge (refill) 100micrograms
38416 salbutamol cyclocaps 400micrograms [du pont]
1346 salbutamol injection 0.05mg/ml
3322 aerolin inh 400 100 mcg aer
23269 maxivent steripoule unit dose nebulising solution 2.5mg/2.5ml [ashbourne]
19799 tulobuterol tablets 2mg
33588 salbutamol aerosol inhaler 100micrograms/inhalation [gen (uk)]
10490 isoprenaline sulphate aerosol inhaler 80micrograms/actuation
25339 maxivent steripoule unit dose nebulising solution 5mg/2.5ml [ashbourne]
12479 aerolin inh auto refil 100 mcg aer
26420 exirel 10 mg tab
30118 salbutamol cfc free inhaler 100micrograms/inhalation [aps]
34162 salbutamol unit dose nebulising solution 2.5mg/2.5ml [galen]
35522 bricanyl injection 500micrograms/1ml [astrazenec]
17901 bricanyl nebule 2.5 ml
8151 orciprenaline aerosol refill 750micrograms/inhalation
24645 ventolin concentrate for solution for infusion 5mg/5ml [a & h]
14482 bricanyl 2.5 mg inj
9651 asmasal spacehaler 100micrograms/inhalation [celltech]
22663 respacal tablets 2mg [ucb]
8504 exirel 15 mg tab
34310 salbutamol cfc free inhaler 100micrograms/inhalation [hillcross]
8429 ventolin i/v 5 mg inj
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15165 reproterol aerosol inhaler 500micrograms/dose
43085 bricanyl respules unit dose nebuliser solution 5mg/2ml [astrazenec]
21102 salbutamol sugar free syrup 2mg/5ml [lagap]
35862 terbutaline injection 500micrograms/1ml
13365 berotec nebuliser solution 5mg/ml [boeh ingl]
15467 ephedrine tablets 60mg
13996 salamol cfc free inhaler 100micrograms/inhalation [sandoz]
38079 salbutamol dry powder inhalation cartridge with device 100micrograms
19726 ventolin s/r
22330 ephedrine hydrochloride sugar free liquid 4mg/5ml
3254 salbulin tablets 4mg [3m]
18968 salbutamol concentrate for solution for infusion 5mg/5ml
19653 ventolin respirator
43893 onbrez breezhaler capsules for inhalation + inhaler 150micrograms [novartis]
22661 pirbuterol capsules 10mg
43738 indacaterol capsules for inhalation + inhaler 150micrograms
35557 ipramol steri-neb unit dose nebulising solution 500micrograms + 2.5mg/2.5ml [ivax]
23787 exirel capsules 10mg [3m]
35744 bricanyl injection 2.5mg/5ml [astrazenec]
26616 ipratropium bromide with fenoterol hydrobromide aerosol inhaler 40micrograms + 100micrograms/actuation
8676 terbutaline respirator solution 10mg/ml
35861 terbutaline injection 2.5mg/5ml
31933 salbutamol aerosol inhaler 100micrograms/inhalation [hillcross]
14561 salbutamol with beclometasone capsules (for inhalation) 400micrograms + 200micrograms
18299 fenoterol with ipratropium bromide unit dose nebulising solution 1.25mg + 500micrograms/4ml
10858 pulmadil auto aerosol inhaler [3m]
4842 fenoterol aerosol inhaler 100micrograms/actuation
8012 exirel capsules 15mg [3m]
17185 ventolin injection 500micrograms/1ml [a & h]
8572 rimiterol aerosol inhaler
28508 salbutamol aerosol inhaler 100micrograms/inhalation [ivax]
1635 salbuvent syrup 2mg/5ml [pharmacia]
38226 salbulin mdpi novolizer dry powder inhalation cartridge (refill) 100micrograms [meda]
18484 ventide paediatric rotacaps [a & h]
30204 salbutamol capsules (for inhalation) 200micrograms
20680 aerolin autohaler
16236 pirbuterol acetate aerosol inhaler
9270 ipratropium bromide with fenoterol hydrobromide unit dose nebulising solution 500micrograms + 1.25mg/4ml
15816 ephedrine hydrochloride tablets 30mg
38136 salbulin mdpi novolizer dry powder inhalation cartridge with device 100micrograms [meda]
14525 salbutamol vortex metered dose inhaler 100micrograms/inhalation
35165 serevent diskhaler inhalation powder 50micrograms [glaxo]
8339 fenoterol hydrobromide complete unit inh
30240 aerolin autohaler cfc free breath actuated inhaler 100micrograms/actuation [3m]
18314 aerocrom syncroner [castlemead]
19649 ventolin rotahaler
13956 ephedrine hydrochloride with chlorphenamine tablets 15mg + 10mg
14382 ephedrine hydrochloride tablets 15mg
34029 salbutamol capsules (for inhalation) 400micrograms
3838 salbutamol 400mcg/beclometh.100mcg r/cap inh
35542 salmeterol inhalation powder blisters with device 50micrograms
3189 salbuvent inh inh
7965 salbutamol respirator solution 5mg/ml
12486 bronchodil aerosol inhaler 500micrograms/dose [viatris]
13575 bambec tablets 20mg [astrazenec]
8267 sodium cromoglicate with salbutamol aerosol inhaler
8149 alupent aerosol refill 750micrograms/inhalation [boeh ingl]
35825 serevent diskhaler (refill) inhalation powder 50micrograms [glaxo]
4222 bricanyl respirator solution 10mg/ml [astrazenec]
7943 orciprenaline tablets 20mg
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13307 bricanyl injection 500micrograms/ml [astrazenec]
35725 easyhaler formoterol dry powder inhaler 12micrograms/actuation [orion]
3443 salbutamol spacehaler 100micrograms/inhalation [celltech]
16207 duovent udvs nebuliser solution [boeh ingl]
461 orciprenaline aerosol inhaler 750micrograms/inhalation
25784 atimos modulite cfc free inhaler 12micrograms/actuation [chiesi]
19642 ventolin nebules
12808 fenoterol with ipratropium bromide breath actuated inhaler 100micrograms + 40micrograms/actuation
14483 terbutaline injection 500micrograms/ml
7711 terbutaline spacer inhaler 250micrograms/actuation
7719 ephedrine tablets 30mg
2259 medihaler -iso forte aerosol inhaler [3m]
1436 haymine tablets [chemidex]
10979 ephedrine tablets 15mg
8321 alupent tablets 20mg [boeh ingl]
8872 medihaler -iso aerosol [3m]
35503 salmeterol inhalation powder blisters (refill) 50micrograms
8636 ventolin s/r 8 mg spa
10360 aerocrom aerosol inhaler [castlemead]
14306 formoterol fumarate cfc free inhaler 12micrograms/actuation
14527 bambec tablets 10mg [astrazenec]
3763 terbutaline respules inh
22313 ventmax sr modified release capsules 8mg [opus]
11307 salbutamol with beclometasone aerosol inhaler 100mcg + 50mcg
1794 berotec aerosol inhaler 100micrograms/actuation [boeh ingl]
12563 exirel aerosol inhaler [3m]
2395 salbutamol 2 mg/5ml syr
17696 ventmax sr modified release capsules 4mg [opus]
8522 terbutaline modified release tablet 7.5mg
16625 ventide rotacaps [a & h]
5185 fenoterol aerosol inhaler 200micrograms/actuation
5837 salamol steri-neb unit dose nebulising solution 5mg/2.5ml [numark]
10458 ventolin cr tablets 4mg [a & h]
510 ventolin respirator solution 5mg/ml [a & h]
37470 beclometasone extrafine particle with formoterol cfc free inhaler 100micrograms + 6micrograms/actuation
5898 salamol steri-neb unit dose nebulising solution 2.5mg/2.5ml [numark]
21859 asmaven aerosol inhaler 100micrograms [berk]
10825 terbutaline tablets 5mg
3758 pulmadil aerosol inhaler [3m]
30230 salbutamol breath actuated inhaler 100micrograms/actuation
4908 ventolin rotahaler insufflator [a & h]
12909 salbutamol with ipratropium bromide aerosol inhaler 100micrograms + 20micrograms/actuation
1628 terbutaline refill canister 250micrograms/actuation
7954 bricanyl spacer inhaler [astrazenec]
696 salbutamol modified release capsules 8mg
8508 alupent aerosol inhaler 750micrograms/inhalation [boeh ingl]
3556 beclometasone with salbutamol aerosol inhaler 50micrograms + 100micrograms/inhalation
9805 salbutamol infusion 100micrograms/ml
4541 bricanyl sa tablets 7.5mg [astrazenec]
12144 bambuterol tablets 20mg
4640 bricanyl unit dose nebuliser solution 5mg/2ml [astrazenec]
16577 easyhaler salbutamol dry powder inhaler 200micrograms/actuation [orion]
8511 cam sugar free liquid 4mg/5ml [cambhealth]
12822 salbutamol with ipratropium bromide unit dose nebulising solution 2.5mg + 500micrograms/2.5ml
3534 bricanyl tablets 5mg [astrazenec]
2149 steri-neb salamol 2.5 mg inh
2862 duovent autohaler breath actuated inhaler [boeh ingl]
1975 oxis 6 turbohaler dry powder inhaler 6 micrograms/actuation [astrazenec]
7192 bambuterol tablets 10mg
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13273 fluticasone with salmeterol dry powder inhaler 100micrograms + 50micrograms/inhalation
9384 salbutamol modified release capsules 4mg
12042 ventolin cr tablets 8mg [a & h]
5308 terbutaline unit dose nebuliser solution 5mg/2ml
5889 salamol cfc free inhaler 100micrograms/inhalation [kent]
6526 formoterol fumarate capsules (for inhalation) 12mcg
9711 formoterol fumarate dry powder inhaler 6 micrograms/actuation
3764 bricanyl respules (5mg/2ml) 2.5 mg/ml inh
10968 foradil capsules (for inhalation) 12mcg [nov/ciba]
2610 intal compound capsules (for inhalation) [rhone]
4634 steri-neb salamol unit dose nebulising solution 2.5mg/2.5ml [ivax]
7935 maxivent aerosol inhaler 100micrograms/inhalation [ashbourne]
13038 pulvinal salbutamol dry powder inhaler 200micrograms/actuation [chiesi]
4171 ventolin tablets 2mg [a & h]
2020 berotec aerosol inhaler 200micrograms/actuation [boeh ingl]
12994 fluticasone with salmeterol cfc free inhaler 50micrograms + 25micrograms/actuation
13181 easyhaler salbutamol dry powder inhaler 100micrograms/actuation [orion]
13040 fluticasone with salmeterol dry powder inhaler 250micrograms + 50micrograms/inhalation
7017 salbutamol dry powder inhaler 100micrograms/actuation
7953 terbutaline sugar free oral solution 1.5mg/5ml
42886 bricanyl turbohaler dry powder inhaler 500micrograms [astrazenec]
2758 bricanyl refill canister [astrazenec]
3584 bricanyl sugar free oral solution 1.5mg/5ml [astrazenec]
1414 steri-neb salamol unit dose nebulising solution 5mg/2.5ml [ivax]
881 salbutamol tablets 2mg
4665 salbulin cfc free inhaler 100micrograms/actuation [3m]
11410 fluticasone with salmeterol dry powder inhaler 500micrograms + 50micrograms/inhalation
42858 ventolin accuhaler dry powder inhaler 200micrograms/actuation [glaxo]
11046 ipratropium bromide with salbutamol unit dose nebulising solution 500micrograms + 2.5mg/2.5ml
3786 fenoterol with ipratropium bromide aerosol inhaler 100micrograms + 40micrograms/actuation
37432 fostair cfc free inhaler 100micrograms + 6micrograms/actuation [chiesi]
11588 fluticasone with salmeterol cfc free inhaler 125micrograms + 25micrograms/actuation
6462 salbutamol dry powder inhaler 95micrograms
862 salbulin aerosol inhaler [3m]
3994 salbutamol modified release tablet 4mg
3163 salbutamol disc 200micrograms
987 ventolin tablets 4mg [a & h]
7268 serevent evohaler cfc free inhaler 25micrograms/actuation [glaxo]
882 salbutamol capsules (for inhalation) 200micrograms
2869 salbutamol modified release tablet 8mg
1087 asmasal clickhaler dry powder inhaler 95micrograms [focus]
11618 fluticasone with salmeterol cfc free inhaler 250micrograms + 25micrograms/actuation
1974 oxis 12 turbohaler dry powder inhaler 12micrograms/actuation [astrazenec]
1801 ventide aerosol inhaler [a & h]
7133 formoterol fumarate dry powder inhaler 12micrograms/actuation
2490 orciprenaline sugar free oral solution 10mg/5ml
3297 salmeterol disc 50micrograms
860 salbutamol tablets 4mg
957 salamol easi-breathe breath actuated inhaler 100micrograms/actuation [ivax]
1961 volmax tablets 4mg [a & h]
5753 salbutamol disc 400micrograms
10218 budesonide with formoterol dry powder inhaler 100micrograms + 6micrograms/actuation
1957 ventolin nebules unit dose nebulising solution 5mg [a & h]
1960 volmax tablets 8mg [a & h]
2901 alupent sugar free oral solution 10mg/5ml [boeh ingl]
910 serevent diskhaler 50micrograms [glaxo]
1093 salamol aerosol inhaler 100micrograms/actuation [ivax]
2224 serevent accuhaler 50micrograms/actuation [glaxo]
5740 airomir autohaler cfc free breath actuated inhaler 100micrograms/actuation [ivax]
958 ventolin easi-breathe breath actuated inhaler 100micrograms/actuation [a & h]
6938 salmeterol with fluticasone dry powder inhaler 50micrograms + 100micrograms/inhalation
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3305 combivent udvs nebuliser solution 2.5ml [boeh ingl]
2851 ventolin rotacaps 200micrograms [a & h]
7013 symbicort turbohaler dry powder inhaler 100micrograms + 6micrograms/actuation [astrazenec]
6746 budesonide with formoterol dry powder inhaler 400micrograms + 12micrograms/actuation
856 ventolin syrup 2mg/5ml [a & h]
942 aerolin autohaler breath actuated inhaler 100micrograms/actuation [3m]
674 ventolin nebules unit dose nebulising solution 2.5mg [a & h]
665 seretide 100 accuhaler dry powder inhaler [glaxo]
2850 salbutamol capsules (for inhalation) 400micrograms
5143 seretide 50 evohaler cfc free inhaler [a & h]
2655 airomir cfc free inhaler 100micrograms/inhalation [teva]
6616 salmeterol with fluticasone cfc free inhaler 25micrograms + 50micrograms/actuation
6780 symbicort turbohaler dry powder inhaler 400micrograms + 12micrograms/actuation [astrazenec]
2722 duovent aerosol inhaler 40micrograms + 100micrograms/actuation [boeh ingl]
1882 ventodisks disc 200micrograms/blister [a & h]
2978 salbutamol dry powder inhaler 200micrograms/actuation
1620 terbutaline aerosol inhaler 250micrograms/actuation
719 salmeterol dry powder inhaler 50micrograms/actuation
5170 salamol cfc free inhaler 100micrograms/inhalation [ivax]
235 bricanyl aerosol inhaler [astrazenec]
5558 salmeterol with fluticasone dry powder inhaler 50micrograms+ 500micrograms/inhalation
4497 ventolin accuhaler 200micrograms/actuation [glaxo]
282 salbutamol sugar free oral solution 2mg/5ml
5942 salmeterol with fluticasone dry powder inhaler 50micrograms + 250micrograms/inhalation
1950 ventodisks disc 400micrograms/blister [a & h]
1952 ventolin rotacaps 400micrograms [a & h]
7270 salmeterol cfc free inhaler 25micrograms/actuation
1711 salbutamol unit dose nebulising solution 5mg/2.5ml
638 seretide 250 accuhaler dry powder inhaler [glaxo]
1630 salbutamol unit dose nebulising solution 2.5mg/2.5ml
3666 seretide 500 accuhaler dry powder inhaler [glaxo]
2152 ipratropium bromide with salbutamol aerosol inhaler 20mcg + 100mcg
5516 salamol easi-breathe cfc free breath actuated inhaler 100micrograms/actuation [ivax]
6796 budesonide with formoterol dry powder inhaler 200micrograms + 6micrograms/actuation
1698 salbutamol breath actuated inhaler 100micrograms/actuation
6569 salmeterol with fluticasone cfc free inhaler 25micrograms + 125micrograms/actuation
549 serevent aerosol inhaler 25micrograms/actuation [glaxo]
5161 seretide 125 evohaler cfc free inhaler [a & h]
6325 symbicort turbohaler dry powder inhaler 200micrograms + 6micrograms/actuation [astrazenec]
556 combivent aerosol inhaler 20mcg + 100mcg [boeh ingl]
5864 salmeterol with fluticasone cfc free inhaler 25micrograms + 250micrograms/actuation
907 bricanyl turbohaler 500micrograms [astrazenec]
5172 seretide 250 evohaler cfc free inhaler [a & h]
1619 terbutaline dry powder inhaler 500micrograms
1741 salbutamol cfc free breath actuated inhaler 100micrograms/actuation
42830 ventolin evohaler cfc free inhaler 100micrograms/inhalation [glaxo]
465 salmeterol aerosol inhaler 25micrograms/actuation
898 ventolin evohaler 100micrograms/inhalation [glaxo]
31 ventolin aerosol inhaler 100micrograms/inhalation [glaxo]
8 salbutamol aerosol inhaler 100micrograms/inhalation
17 salbutamol cfc free inhaler 100micrograms/inhalation
25020 ipratropium bromide (forte)
30229 ipratropium bromide unit dose nebuliser solution 250micrograms/ml [galen]
20803 ipratropium bromide nebuliser solution
37791 ipratropium bromide inhalation solution 250micrograms/ml
40177 ipratropium bromide unit dose nebulising solution 250micrograms/ml [hillcross]
20720 atrovent forte
40637 steripoule ipratropium unit dose nebuliser solution 250micrograms/ml [galen]
23961 ipratropium bromide inhalation solution 250micrograms/ml [galen]
40832 steripoule ipratropium unit dose nebuliser solution 500micrograms/2ml [galen]
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43090 atrovent aerocaps inhalation powder capsules 40mcg [boeh ingl]
43105 atrovent aerohaler inhalation powder capsules with device 40mcg [boeh ingl]
19737 atrovent nebuliser solution (1ml vial)
13757 tropiovent steripoule unit dose nebulising solution 250micrograms/ml [ashbourne]
19805 atrovent
18140 respontin nebules unit dose nebulising solution 500micrograms/2ml [glaxo]
23567 respontin nebules unit dose nebulising solution 250micrograms/ml [glaxo]
23709 steri-neb ipratropium unit dose nebulising solution 500micrograms/2ml [ivax]
6758 steri-neb ipratropium unit dose nebulising solution 250micrograms/ml [ivax]
18421 respontin nebules unit dose nebulising solution 250micrograms/ml [glaxo]
9658 oxitropium bromide breath actuated inhaler 100micrograms/actuation
11779 ipratropium bromide capsules for inhalation + inhaler 40mcg
3850 oxivent autohaler breath actuated inhaler 100micrograms/actuation [boeh ingl]
9681 atrovent aerohaler 40mcg [boeh ingl]
2994 atrovent aerocaps 40mcg [boeh ingl]
8333 ipratropium bromide capsules (for inhalation) 40mcg
6911 atrovent udvs nebuliser solution 250micrograms/1ml [boeh ingl]
1410 ipratropium bromide nebuliser solution 0.25mg/ml
7140 atrovent udvs nebuliser solution 500micrograms/2ml [boeh ingl]
1415 steri-neb ipratropium unit dose nebulising solution 250micrograms/ml [ivax]
1697 atrovent autohaler breath actuated inhaler 20micrograms/actuation [boeh ingl]
2437 oxitropium bromide aerosol inhaler 100micrograms/actuation
6081 ipratropium bromide breath actuated inhaler 20micrograms/dose
6772 ipratropium bromide unit dose nebuliser solution 250micrograms/ml
3306 atrovent forte aerosol inhaler 40micrograms/actuation [boeh ingl]
36869 spiriva respimat inhalation solution 2.5 micrograms/actuation [boeh ingl]
34995 spiriva inhalation powder capsules with device 18 micrograms [boeh ingl]
6719 ipratropium bromide unit dose nebuliser solution 500micrograms/2ml
3039 oxivent aerosol inhaler 100micrograms/actuation [boeh ingl]
36864 tiotropium inhalation solution 2.5 micrograms/actuation
4268 ipratropium bromide aerosol inhaler 40micrograms/metered inhalation
6512 atrovent cfc free inhaler 20micrograms/actuation [boeh ingl]
35000 spiriva inhalation powder capsules (refill) 18 micrograms [boeh ingl]
1411 ipratropium bromide unit dose nebulising solution 250micrograms/ml
6050 spiriva capsules (for inhalation) 18 micrograms [boeh ingl]
35014 tiotropium inhalation powder capsules with device 18 micrograms
1962 atrovent udvs nebuliser solution 0.25mg/ml [boeh ingl]
534 atrovent aerosol inhaler 20micrograms/actuation [boeh ingl]
746 tiotropium capsules (for inhalation) 18 micrograms
1409 ipratropium bromide aerosol inhaler 20micrograms/dose
6522 ipratropium bromide cfc free inhaler 20micrograms/actuation
35011 tiotropium inhalation powder capsules (refill) 18 micrograms
32461 choline theophyllinate 90 mg tab
42910 aminophylline injection 250mg/10ml [martindale]
25937 aminophylline intramuscular 500 mg inj
27558 choledyl
42511 aminophylline injection 25mg/ml [celltech]
32893 theophylline 100mg/lysine 74mg mg tab
26724 ephedrine hcl/aminophylline e/c tab
25093 theophylline s/r
26079 uniphyllin paediatric continus
27842 aminophylline 2 ml inj
28786 ephedrine hcl 25mg/aminophylline 130mg mg cap
19350 aminophylline 62.5 mg sup
8705 ephedrine hcl 24mg/theophylline 120mg mg tab
31758 uniphyllin continus
38120 theophylline modified release tablet 500mg
28241 min-i-jet aminophylline injection 250mg/10ml [ucb]
27944 tedral elixir [parke]
22080 aminophylline 20 ml inj
30596 aminophylline modified release tablet 225mg [actavis]
10432 theophylline 300 mg sup
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15409 theophylline 3 mg sol
10289 aminophylline 200 mg sup
19735 uniphyllin continus
20225 aminophylline 500 mg inj
22669 choline theophyllinate 270 mg tab
20171 aminophylline 180 mg sup
25125 aminophylline suppository 360mg
25022 aminophylline 150 mg sup
29273 aminophylline modified release tablet 225mg [hillcross]
27593 aminophylline 350 mg sup
6988 aminophylline hydrate modified release tablet 100mg
24117 aminophylline 300 mg sup
10744 theophylline 80 mg eli
18308 aminophylline 100 mg sup
27040 phyllocontin continus
15025 aminophylline 25 mg sup
24207 aminophylline paed 50 mg sup
180 phyllocontin sup
15365 theophylline sugar free elixir 10mg/5ml
24023 theodrox tablets [3m]
1832 theograd tablets 350mg [abbott]
27249 do-do chesteze tablets [novartis]
8470 aminophylline 225 mg sup
24674 biophylline tablets 500mg [lorex]
19953 theophylline with ephedrine and caffeine tablets
8610 aminophylline 1 gm sup
18288 choline theophyllinate tablets 100mg
8955 theophylline 100 mg tab
26860 theophylline with ephedrine sulphate tablets 120mg + 15mg
23572 aminophylline sr tablets 225mg [ivax]
24418 biophylline tablets 350mg [lorex]
10723 theophylline syrup 125mg/5ml
24035 ephedrine 15mg/theophylline 120mg 15 mg tab
9092 theophylline modified release tablet 350mg
12699 pecram sustained release tablets 225mg [novartis]
218 aminophylline 100 mg cap
17140 aminophylline tablets 200mg
18988 choline theophyllinate syrup 62.5mg/5ml
14991 aminophylline injection 250mg/10ml
7832 choline theophyllinate tablets 200mg
10561 aminophylline injection 250mg/ml
15561 ephedrine 11mg/theophylline 120mg 11 mg tab
18937 sabidal sr 270 270 mg tab
12274 tedral tablets [parke]
8653 aminophylline 360 mg sup
15153 theophylline with ephedrine hydrochloride tablets 120mg + 11mg
273 theophylline 200 mg cap
10831 biophylline syrup 125mg/5ml [lorex]
4591 choledyl tablets 100mg [parke]
16994 aminophylline hydrate modified release tablet 350mg
12240 theophylline modified release capsules 300mg
21769 lasma tablets 300mg [pharmax]
14739 norphyllin sr tablets 225mg [ivax]
8056 aminophylline tablets 100mg
39040 phyllocontin forte continus tablets 350mg [napppharm]
11993 pro-vent capsules 300mg [wellcome]
3187 choledyl syrup 62.5mg/5ml [parke]
8057 aminophylline modified release tablet 100mg
10433 theophylline liquid 60mg/5ml
4593 theophylline tablets 125mg
4592 choledyl tablets 200mg [parke]
4514 aminophylline modified release tablet 350mg
287
Asthma therapy
Product Code Product Name
11719 slo-phyllin capsules 60mg [merck ser]
880 theophylline modified release capsules 60mg
10407 phyllocontin continus paediatric tablets 100mg [napppharm]
13529 amnivent sustained release tablets 225mg [ashbourne]
7477 franol plus tablets [sanofi/ave]
7841 nuelin tablets 125mg [3m]
7730 theo-dur tablets 300mg [astrazenec]
7731 theo-dur tablets 200mg [astrazenec]
879 theophylline modified release capsules 125mg
8806 phyllocontin continus forte tablets 350mg [napppharm]
15284 slo-phyllin capsules 125mg [merck ser]
7733 theophylline modified release tablet 250mg
2609 franol tablets [sanofi s]
10331 nuelin liquid 60mg/5ml [3m]
1097 slo-phyllin capsules 60mg [lipha]
7732 theophylline modified release tablet 300mg
3388 theophylline modified release tablet 175mg
863 slo-phyllin capsules 125mg [lipha]
17002 aminophylline hydrate modified release tablet 225mg
6315 slo-phyllin capsules 250mg [merck ser]
2147 theophylline modified release capsules 250mg
1834 theophylline modified release tablet 400mg
1833 theophylline modified release tablet 200mg
5261 nuelin sa-250 tablets [meda]
2757 slo-phyllin capsules 250mg [lipha]
5941 uniphyllin continus prolonged release tablet 300mg [napppharm]
2995 nuelin sa tablets 175mg [meda]
5453 uniphyllin continus prolonged release tablet 400mg [napppharm]
1423 uniphyllin continus prolonged release tablet 200mg [napppharm]
555 aminophylline modified release tablet 225mg
590 phyllocontin continus tablets 225mg [napppharm]
25087 betamethasone /clioquinol
20763 becloforte
20825 spacehaler bdp spacehaler 250micrograms/actuation [celltech]
27915 fluticasone prop disk refill
24660 betamethasone valerate
41269 beclometasone cyclocaps capsules (for inhalation) 400micrograms [teva]
24205 betamethasone /neomycin
24219 becotide rotacaps
27083 betamethasone valerate .1 mg tab
27583 pulmicort
29322 betamethasone loz
28311 betamethasone /salicylic acid
26665 pulmicort complete
41412 beclometasone aerosol inhaler 400micrograms/actuation
22827 betamethasone .1 mg pel
30805 betamethasone valerate pel
21465 betamethasone .1 mg tab
34428 beclometasone aerosol inhaler 50micrograms/actuation [neolab]
27970 betamethasone sod phos 0.1%/neomycin 0.5
28761 spacehaler bdp spacehaler 50micrograms/actuation [celltech]
46157 beclometasone cyclocaps capsules (for inhalation) 200micrograms [teva]
34794 beclometasone aerosol inhaler 200micrograms/actuation [hillcross]
22180 betamethasone 0.1%/neomycin 0.5% een dro
19736 becotide susp for nebulisation
24898 spacehaler bdp spacehaler 100micrograms/actuation [celltech]
27525 becotide 50
34859 beclometasone aerosol inhaler 250micrograms/actuation [neolab]
20707 becotide 100
26414 betamethasone benzoate % cre
23675 pulmicort l.s. refil
32874 beclometasone aerosol inhaler 50micrograms/actuation [actavis]
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20750 betamethasone sodium phosphate eye
7643 betamethasone dipropionate .1 % oin
36021 fluticasone inhalation powder blisters with device 50micrograms
33849 beclometasone aerosol inhaler 100micrograms/actuation [neolab]
18394 bdp spacehaler 50micrograms/actuation [celltech]
22160 betamethasone sod.phos. ear/eye/nose dro
34315 beclometasone aerosol inhaler 250micrograms/actuation [actavis]
19389 asmabec spacehaler 50micrograms/actuation [celltech]
37447 fluticasone inhalation powder blisters (refill) 50micrograms
34739 beclometasone aerosol inhaler 50micrograms/actuation [aps]
35986 flixotide diskhaler (refill) inhalation powder 50micrograms [a & h]
8232 betamethasone valerate /lignocaine hyd./ .05 % oin
7706 betamethasone 1 % oin
30238 beclometasone breath actuated inhaler 50micrograms/actuation [aps]
10321 budesonide capsules (for inhalation) 400micrograms
35392 flixotide diskhaler inhalation powder 500 micrograms [a & h]
36290 flixotide diskhaler inhalation powder 50micrograms [a & h]
18537 budesonide capsules (for inhalation) 200micrograms
2720 betamethasone /clioquinol oin
20812 pulmicort refill
33258 beclometasone aerosol inhaler 250micrograms/actuation [hillcross]
39200 aerobec forte autohaler 250micrograms/actuation [meda]
35374 flixotide diskhaler (refill) inhalation powder 500 micrograms [a & h]
35700 fluticasone inhalation powder blisters with device 500 micrograms
8251 pulmicort refil 50 mg inh
35225 flixotide diskhaler inhalation powder 100micrograms [a & h]
3860 betamethasone drops eye
35580 beclometasone inhalation powder blisters with device 100micrograms
4803 beclazone aerosol inhaler 250micrograms/actuation [actavis]
8829 betamethasone .05 % lot
16054 budesonide refillable breath actuated dry powder inhaler 200micrograms/actuation
7724 betamethasone valerate aerosol inhaler 100micrograms/actuation
14590 asmabec spacehaler 250micrograms/actuation [celltech]
28073 beclometasone breath actuated inhaler 250micrograms/actuation [aps]
3188 pulmicort complete 50 mcg inh
35638 fluticasone inhalation powder blisters with device 100micrograms
7964 beclometasone nebuliser suspension 50micrograms/ml
34919 beclometasone aerosol inhaler 50micrograms/actuation [hillcross]
36090 flixotide diskhaler (refill) inhalation powder 100micrograms [a & h]
35602 budesonide dry powder inhalation cartridge (refill) 200micrograms
35107 beclometasone inhalation powder blisters with device 400micrograms
9477 asmabec spacehaler 100micrograms/actuation [celltech]
35106 becodisks diskhaler inhalation powder 100micrograms [a & h]
36462 fluticasone inhalation powder blisters (refill) 500 micrograms
19031 bdp spacehaler 100micrograms/actuation [celltech]
35772 fluticasone inhalation powder blisters (refill) 100micrograms
14700 budesonide aerosol inhaler 400micrograms/actuation
26063 beclometasone aerosol inhaler 100micrograms/actuation [aps]
11198 beclometasone vortex metered dose inhaler 50micrograms/actuation
35461 flixotide diskhaler inhalation powder 250micrograms [a & h]
9599 beclazone aerosol inhaler 50micrograms/actuation [actavis]
35510 budesonide dry powder inhalation cartridge with device 200micrograms
3442 pulmicort complete 200 mcg inh
36401 fluticasone inhalation powder blisters with device 250micrograms
28640 beclometasone aerosol inhaler 100micrograms/actuation [actavis]
14524 bdp spacehaler 250micrograms/actuation [celltech]
35611 flixotide diskhaler (refill) inhalation powder 250micrograms [a & h]
35118 becodisks diskhaler inhalation powder 400micrograms [a & h]
35652 beclometasone inhalation powder blisters (refill) 100micrograms
19401 beclometasone inhaler with compact spacer 250micrograms/actuation
35293 beclometasone inhalation powder blisters with device 200micrograms
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30649 easyhaler budesonide dry powder inhaler 400micrograms/actuation [orion]
35430 becodisks diskhaler inhalation powder 200micrograms [a & h]
35408 becodisks inhalation powder (refill) 100micrograms [a & h]
35288 beclometasone inhalation powder blisters (refill) 400micrograms
35905 fluticasone inhalation powder blisters (refill) 250micrograms
23741 novolizer budesonide breath actuated dry powder inhaler 200micrograms/actuation [meda]
43074 flixotide accuhaler dry powder inhaler 500micrograms/inhalation [a & h]
11497 beclometasone dry powder inhaler 400micrograms/actuation
31774 beclometasone aerosol inhaler 50micrograms/actuation [gen (uk)]
9571 beclometasone vortex metered dose inhaler 250micrograms/actuation
13815 beclazone aerosol inhaler 100micrograms/actuation [actavis]
35299 becodisks inhalation powder (refill) 400micrograms [a & h]
25204 beclometasone aerosol inhaler 100micrograms/actuation [hillcross]
35631 budelin novolizer inhalation powder with device 200micrograms [meda]
8433 budesonide aerosol inhaler 100micrograms/actuation
35724 budelin novolizer inhalation powder (refill) 200micrograms [meda]
42985 flixotide accuhaler dry powder inhaler 50micrograms/inhalation [a & h]
27679 beclometasone breath actuated inhaler 100micrograms/actuation [aps]
15706 beclometasone vortex metered dose inhaler 100micrograms/actuation
2124 pulmicort refil 200 mcg inh
21224 alvesco cfc free inhaler 80micrograms/actuation [nycomed]
27188 easyhaler budesonide dry powder inhaler 200micrograms/actuation [orion]
39099 pulmicort cfc free inhaler 100micrograms [astrazenec]
35071 becodisks inhalation powder (refill) 200micrograms [a & h]
11478 fluticasone unit dose nebulising suspension 2mg/2ml
29325 beclometasone aerosol inhaler 250micrograms/actuation [gen (uk)]
39102 budesonide cfc free inhaler 100micrograms
17590 asmanex twisthaler dry powder inhaler 400micrograms/actuation [m s d]
14736 pulvinal beclometasone dipropionate dry powder inhaler 400micrograms/actuation [chiesi]
40057 pulmicort cfc free inhaler 200micrograms [astrazenec]
8450 flixotide diskhaler-community pack 50 mcg
42994 flixotide accuhaler dry powder inhaler 250micrograms/inhalation [a & h]
35113 beclometasone inhalation powder blisters (refill) 200micrograms
16433 asmanex twisthaler dry powder inhaler 200micrograms/actuation [m s d]
16305 flixotide nebules unit dose nebulising suspension 2mg/2ml [a & h]
2892 becloforte disks (refill pack) 400micrograms/actuation [a & h]
19563 becotide for nebuliser
17465 fluticasone unit dose nebulising suspension 500micrograms/2ml
5992 beclometasone dry powder inhaler 50micrograms/actuation
6839 alvesco cfc free inhaler 160micrograms/actuation [nycomed]
3363 becloforte diskhaler 400micrograms/actuation [a & h]
5551 flixotide nebules unit dose nebulising suspension 500micrograms/2ml [a & h]
17670 easyhaler budesonide dry powder inhaler 100micrograms/actuation [orion]
3065 bextasol aerosol inhaler [a & h]
42928 flixotide accuhaler dry powder inhaler 100micrograms/inhalation [a & h]
16018 mometasone furoate dry powder inhaler 200micrograms/actuation
3570 budesonide refill canister 200micrograms/actuation
3743 filair aerosol inhaler 50micrograms/actuation [meda]
30210 beclometasone aerosol inhaler 250micrograms/actuation [aps]
7356 ciclesonide cfc free inhaler 80micrograms/actuation
9356 becotide rotahaler insufflator [a & h]
9577 asmabec clickhaler dry powder inhaler 50micrograms [focus]
39879 budesonide cfc free inhaler 200micrograms
10254 mometasone furoate dry powder inhaler 400micrograms/actuation
14757 pulvinal beclometasone dipropionate dry powder inhaler 100micrograms/actuation [chiesi]
3988 flixotide diskhaler-community pack 100 mcg
947 budesonide refill canister 50micrograms/actuation
7602 fluticasone disc 50micrograms
3119 becloforte integra inhaler with compact spacer 250micrograms/actuation [glaxo]
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21482 beclometasone aerosol inhaler 100micrograms/actuation [gen (uk)]
10102 ciclesonide cfc free inhaler 160micrograms/actuation
2159 aerobec autohaler 50micrograms/actuation [meda]
8111 becloforte vm pack 250micrograms/actuation [a & h]
5804 beclometasone dry powder inhaler 250micrograms/actuation
13037 pulvinal beclometasone dipropionate dry powder inhaler 200micrograms/actuation [chiesi]
21005 beclometasone cfc free inhaler 250micrograms/actuation
8635 flixotide disc 50micrograms [a & h]
17654 easyhaler beclometasone dry powder inhaler 200micrograms/actuation [orion]
5521 beclometasone dry powder inhaler 200micrograms/actuation
1727 becotide easi-breathe breath actuated inhaler 50micrograms/actuation [a & h]
11732 beclometasone extrafine particle cfc free breath actuated inhaler 50micrograms/actuation
4545 pulmicort ls refill canister 50micrograms [astrazenec]
3753 flixotide diskhaler-community pack 250 mcg
16584 beclometasone cfc free inhaler 50micrograms/actuation
14321 beclometasone cfc free inhaler 200micrograms/actuation
3993 filair forte aerosol inhaler 250micrograms/actuation [meda]
1725 beclazone easi-breathe breath actuated inhaler 50micrograms/actuation [ivax]
4801 budesonide nebuliser suspension 0.5mg/2ml
7891 fluticasone disc 500micrograms
9921 beclometasone extrafine particle cfc free breath actuated inhaler 100micrograms/actuation
1426 flixotide disc 500micrograms [a & h]
4131 fluticasone disc 100micrograms
14567 asmabec clickhaler dry powder inhaler 250micrograms [focus]
4759 beclometasone capsules (for inhalation) 100micrograms
4365 beclometasone disc 100micrograms
3289 flixotide aerosol inhaler 25micrograms/actuation [a & h]
4499 aerobec forte autohaler 250micrograms/actuation [meda]
3989 flixotide disc 100micrograms [a & h]
1269 becotide nebuliser suspension 50micrograms/ml [a & h]
5522 beclometasone dry powder inhaler 100micrograms/actuation
2723 fluticasone aerosol inhaler 25micrograms/actuation
1885 beclazone aerosol inhaler 200micrograms/actuation [ivax]
4942 budesonide nebuliser suspension 1mg/2ml
3927 filair aerosol inhaler 100micrograms/actuation [meda]
5580 flixotide accuhaler 50micrograms/inhalation [a & h]
1518 flixotide aerosol inhaler 50micrograms/actuation [a & h]
4601 asmabec clickhaler dry powder inhaler 100micrograms [focus]
7653 beclometasone capsules (for inhalation) 400micrograms
4688 fluticasone aerosol inhaler 50micrograms/actuation
9164 fluticasone dry powder inhaler 50micrograms/inhalation
14294 qvar easi-breathe cfc free breath actuated inhaler 50micrograms/actuation [ivax]
2160 beclometasone breath actuated inhaler 50micrograms/actuation
18848 qvar easi-breathe cfc free breath actuated inhaler 100micrograms/actuation [ivax]
5309 flixotide evohaler cfc free inhaler 50micrograms/actuation [a & h]
2440 flixotide accuhaler 500micrograms/inhalation [a & h]
9233 beclometasone capsules (for inhalation) 200micrograms
7638 fluticasone disc 250micrograms
1552 becloforte easi-breathe breath actuated inhaler 250micrograms/actuation [a & h]
1959 pulmicort respules nebuliser suspension 0.5mg/2ml [astrazenec]
2992 beclazone aerosol inhaler 50micrograms/actuation [ivax]
5718 flixotide evohaler cfc free inhaler 125micrograms/actuation [a & h]
2125 pulmicort refill canister 200micrograms [astrazenec]
2282 fluticasone dry powder inhaler 500micrograms/inhalation
959 budesonide aerosol inhaler 50micrograms/actuation
2148 beclometasone disc 400micrograms
15326 beclometasone cfc free inhaler 100micrograms/actuation
10090 beclometasone extrafine particle cfc free inhaler 50micrograms/actuation
1676 flixotide aerosol inhaler 125micrograms/actuation [a & h]
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1680 pulmicort ls aerosol inhaler 50micrograms [astrazenec]
1424 flixotide disc 250micrograms [a & h]
2893 beclometasone disc 200micrograms
4926 flixotide accuhaler 100micrograms/inhalation [a & h]
4132 fluticasone aerosol inhaler 125micrograms/actuation
1243 beclazone easi-breathe breath actuated inhaler 250micrograms/actuation [ivax]
3220 qvar autohaler cfc free breath actuated inhaler 50micrograms/actuation [ivax]
3150 beclometasone extrafine particle cfc free inhaler 100micrograms/actuation
1861 aerobec autohaler 100micrograms/actuation [meda]
1956 pulmicort respules nebuliser suspension 1mg/2ml [astrazenec]
5885 fluticasone dry powder inhaler 100micrograms/inhalation
911 flixotide accuhaler 250micrograms/inhalation [a & h]
7948 fluticasone dry powder inhaler 250micrograms/inhalation
5683 flixotide evohaler cfc free inhaler 250micrograms/actuation [a & h]
3947 becotide rotacaps 100micrograms [a & h]
896 becotide easi-breathe breath actuated inhaler 100micrograms/actuation [a & h]
2229 becodisks disc 100micrograms [a & h]
16148 clenil modulite cfc free inhaler 250micrograms/actuation [chiesi]
3437 becotide rotahaler type 4 insufflator [a & h]
5223 fluticasone cfc free inhaler 50micrograms/actuation
3075 becotide rotacaps 400micrograms [a & h]
7788 budesonide dry powder inhaler 100micrograms/actuation
2600 beclometasone breath actuated inhaler 250micrograms/actuation
4413 qvar autohaler cfc free breath actuated inhaler 100micrograms/actuation [ivax]
5975 fluticasone cfc free inhaler 125micrograms/actuation
1412 flixotide aerosol inhaler 250micrograms/actuation [a & h]
895 beclazone easi-breathe breath actuated inhaler 100micrograms/actuation [ivax]
1551 beclazone aerosol inhaler 250micrograms/actuation [ivax]
960 pulmicort turbohaler dry powder inhaler 100micrograms/actuation [astrazenec]
2951 fluticasone aerosol inhaler 250micrograms/actuation
883 becodisks disc 200micrograms [a & h]
1951 becodisks disc 400micrograms [a & h]
16151 clenil modulite cfc free inhaler 200micrograms/actuation [chiesi]
909 budesonide aerosol inhaler 200micrograms/actuation
1642 budesonide dry powder inhaler 400micrograms/actuation
5822 fluticasone cfc free inhaler 250micrograms/actuation
1100 beclazone aerosol inhaler 100micrograms/actuation [ivax]
1537 becotide rotacaps 200micrograms [a & h]
16158 clenil modulite cfc free inhaler 50micrograms/actuation [chiesi]
454 pulmicort aerosol inhaler 200micrograms [astrazenec]
908 pulmicort turbohaler dry powder inhaler 400micrograms/actuation [astrazenec]
1258 becotide 200 aerosol inhaler 200micrograms/actuation [a & h]
1406 becotide 50 aerosol inhaler 50micrograms/actuation [a & h]
2092 budesonide dry powder inhaler 200micrograms/actuation
1734 beclometasone breath actuated inhaler 100micrograms/actuation
956 pulmicort turbohaler dry powder inhaler 200micrograms/actuation [astrazenec]
3546 qvar cfc free inhaler 50micrograms/actuation [ivax]
3018 beclometasone aerosol inhaler 50micrograms/actuation
2335 qvar cfc free inhaler 100micrograms/actuation [ivax]
1236 becloforte aerosol inhaler 250micrograms/actuation [a & h]
13290 clenil modulite cfc free inhaler 100micrograms/actuation [chiesi]
1259 beclometasone aerosol inhaler 200micrograms/actuation
1242 beclometasone aerosol inhaler 250micrograms/actuation
99 becotide 100 aerosol inhaler 100micrograms/actuation [a & h]
38 beclometasone aerosol inhaler 100micrograms/actuation
28977 intal spincaps
24387 intal
12633 tilarin nasal spray 1% [rhone]
14448 nedocromil sodium nasal spray 1%
19643 intal nebuliser solution (2ml)
3585 steri-neb cromogen nebuliser solution 10mg/ml [ivax]
37615 sodium cromoglicate aerosol inhaler 1mg/inhalation
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15765 sodium cromoglicate inhaler and spacer 5mg/inhalation
4647 intal syncroner 5mg/inhalation [aventis]
14603 sodium cromoglicate inhaler and spacer 5mg/actuation
38501 intal cfc free inhaler 5mg [sanofi/ave]
10361 intal syncroner 5 mg inh
7580 intal whistle
25119 tilade cfc free inhaler 2mg/inhalation [sanofi/ave]
38471 sodium cromoglicate cfc free inhaler 5mg
8498 sodium cromoglicate nebuliser solution 10mg/ml
19597 intal
2158 sodium cromoglicate breath actuated inhaler 5mg/inhalation
13256 nedocromil sodium cfc free inhaler 2mg/inhalation
1728 cromogen easi-breathe breath actuated inhaler 5mg/inhalation [ivax]
10597 tilade mint syncroner 2mg/inhalation [sanofi/ave]
4100 intal autohaler 5mg/inhalation [aventis]
7972 intal fisonair aerosol inhaler 5mg/inhalation [aventis]
8608 nedocromil sodium aerosol inhaler 2mg/inhalation
1629 intal nebuliser solution 10mg/ml [aventis]
2911 sodium cromoglicate capsules (for inhalation) 20mg
3688 tilade mint inhaler 2mg/inhalation [sanofi/ave]
8215 tilade aerosol inhaler 2mg/inhalation [sanofi/ave]
1422 cromogen aerosol inhaler 5mg/inhalation [ivax]
2260 intal spinhaler insufflator [aventis]
964 sodium cromoglicate aerosol inhaler 5mg/inhalation
1683 intal spincaps inhalation powder capsules [aventis]




14200 singulair paediatric granules 4mg/sachet [m s d]
1973 accolate tablets 20mg [astrazenec]
14162 singulair paediatric chewable tablet 4mg [m s d]
7088 montelukast (as sodium salt) granules 4mg/sachet
5594 singulair paediatric chewable tablet 5mg [m s d]
7132 zafirlukast tablets 20mg
622 montelukast (as sodium salt) chewable tablet 4mg
5957 montelukast (as sodium salt) chewable tablet 5mg
695 singulair tablets 10mg [m s d]
808 montelukast (as sodium salt) tablets 10mg
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Chronic Kidney Disease 
Medical code Read term
512 Chronic renal failure
1803 Nephrotic syndrome with membranous glomerulonephritis
2088 Acute glomerulonephritis
2471 Nephrotic syndrome in diabetes mellitus
2475 ZERIDAME SR tablets 150mg [ACTAVIS]
2773 Nephritis, nephrosis and nephrotic syndrome
2994 Peritoneal dialysis
2995 Acquired arteriovenous fistula
2996 Haemodialysis NEC
2999 Nephrotic syndrome
3205 Creation of arteriovenous fistula NEC
4480 Renal sclerosis NOS
4668 Hypertensive renal disease
4669 Chronic focal glomerulonephritis
4809 Uraemia NOS
4850 Nephritis and nephropathy unspecified
5182 Unspecified glomerulonephritis NOS
5291 Herpes zoster with meningitis
5417 Acute nephritis
6712 End stage renal failure
7190 Glomerulosclerosis
7804 Chronic glomerulonephritis
8037 Insertion of ambulatory peritoneal dialysis catheter




8919 Impaired renal function disorder
9379 Acute interstitial nephritis
9765 Ligation of acquired arteriovenous fistula
9840 Nephrotic syndrome with proliferative glomerulonephritis
10081 Chronic uraemia
10418 Type 1 diabetes mellitus with nephropathy
10636 Hepatorenal syndrome
10647 Nephritis - chronic
10809 Chronic membranous glomerulonephritis
11553 Kidney transplant failure and rejection
11773 Dialysis for renal failure
11873 Nephropathy, unspecified
11875 Nephropathy - chronic
12465 Membranoproliferative nephritis unspecified
12479 Chronic kidney disease stage 4
12566 Chronic kidney disease stage 3
12585 Chronic kidney disease stage 5
12586 Chronic kidney disease stage 2
12640 Type 2 diabetes mellitus with nephropathy
12720 Chronic renal impairment
13279 Other specified diabetes mellitus with renal complications
15097 Chronic glomerulonephritis NOS
15106 Hypertensive renal disease NOS
15780 Nephritis, nephrosis and nephrotic syndrome NOS
16008 Proliferative nephritis unspecified
16465 Persistent proteinuria
16502 Diabetes mellitus with renal manifestation
16929 Anaemia secondary to renal failure
17253 Renal transplant planned
17365 Nephrotic syndrome, diffuse crescentic glomerulonephritis
17434 Nephrosclerosis
18209 Type 2 diabetes mellitus with renal complications
18390 Type 2 diabetes mellitus with persistent microalbuminuria
18777 Type 2 diabetes mellitus with renal complications
18779 Repair of acquired arteriovenous fistula
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19316 Nephrotic syndrome, diffuse membranous glomerulonephritis
19454 Polyneuropathy in uraemia
20027 Acute glomerulonephritis in diseases EC
20073 Renal dialysis
20074 Bright's disease
20129 Acute glomerulonephritis NOS
20196 H/O: renal dialysis
20516 Salt-losing nephritis
21297 Chronic nephritic syndrome
21423 Berger's IgA or IgG nephropathy
21687 Gout due to impairment of renal function
21837 Hypertensive heart&renal dis wth (congestive) heart failure
21947 Nephrotic syn difus mesangial prolifertiv glomerulonephritis
21983 Type 1 diabetes mellitus with renal complications
21989 Nephrotic syn,diffuse mesangiocapillary glomerulonephritis
22205 Lupus nephritis
22252 [V]Renal dialysis status
22852 Nephrotic syndrome, focal and segmental glomerular lesions
22897 Henoch-Schonlein nephritis
23773 Removal of ambulatory peritoneal dialysis catheter
23913 Nephrotic syndrome, minor glomerular abnormality
23990 Tubulo-interstit nephritis, not specif as acute or chron
24151 Arteriovenous shunt
24384 Familial glomerulonephritis in Alport's syndrome
24736 Drug/heavy-metal-induced tubulo-interstitial and tub conditn
24836 Type 2 diabetes mellitus with nephropathy
25394 Anaemia secondary to chronic renal failure
25521 Creation of brachial-cephalic fistula
25980 Impaired renal function disorder NOS
26054 Type 2 diabetes mellitus with persistent proteinuria
26220 Renal sclerosis unspecified
26862 Exploration of renal transplant
27335 Other nephritis and nephrosis in diseases EC
27427 Nephrotic syndrome NOS
28158 Kidney dialysis with complication, without blame
28269 Creation of radial-cephalic fistula
28684 Hypertensive heart and renal disease with renal failure
29013 Chronic kidney disease stage 1
29384 Acute proliferative glomerulonephritis
29634 Nephrotic syndrome with minimal change glomerulonephritis
29638 Renal osteodystrophy
30294 Type 1 diabetes mellitus with persistent microalbuminuria
30301 Unsp nephrit synd, diff mesang prolif glomerulonephritis
30323 Type 1 diabetes mellitus with persistent proteinuria
30709 Insertion of temporary peritoneal dialysis catheter
30756 Continuous ambulatory peritoneal dialysis
31478 Removal of infected arteriovenous shunt
31549 Compensation for renal failure
31581 Acute nephritic syndrome
32423 Hypertensive renal disease with renal failure
33580 Nephritis and nephropathy unspecified
34637 Renal osteodystrophy NOS
34648 Renal dwarfism
34669 Other interstitial nephritis
34998 Chronic proliferative glomerulonephritis
35065 Other nephritis and nephrosis unspecified
35105 Diabetes mellitus  adult onset  with renal manifestation
35107 Diabetes mellitis with nephropathy NOS
35921 Failure of sterile precautions during perfusion
36125 Unspecif nephr synd, diff concentric glomerulonephritis
36205 Hereditary nephropathy not elsewhere classified
36342 Mesangioproliferative glomerulonephritis NEC
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36442 Placement ambulatory dialysis apparatus - compens renal fail
38572 Xanthogranulomatous pyelonephritis
39649 Malignant hypertensive renal disease
39840 Other impaired renal function disorder
40349 Lipoid nephrosis
40413 Chronic nephritic syndrm focal+segmental glomerular lesions
40956 Acute pericarditis - uraemic
41013 Renal function impairment with growth failure
41148 Renal tubulo-interstitial disorder in SLE
41159 Nephropathy induced by other drugs meds and biologl substncs
41239 Hereditary nephropathy NEC,focal+segmnt glomerular lesion
41285 Rapid progres neph syn diffuse membranous glomerulonephritis
41676 Renal cortical necrosis unspecified
41881 Mesangiocapillary glomerulonephritis NEC
42632 Medullary cystic disease
43611 Isolated proteinuria with specified morphological lesion
43935 Benign hypertensive renal disease
44055 Other nephritis and nephrosis NOS
44270 Hereditry nephropathy NEC,difus membran glomerulnephritis
44422 H/O: kidney dialysis
44541 Recurrent and persistent haematuria  dense deposit disease
44804 Isolatd proteinur/specifd morphlgcl les foc+seg glom lesn
45160 [V]Aftercare involving peritoneal dialysis
45499 Kimmelstiel - Wilson disease
45523 Renal tubulo-interstitial disorders in diseases EC
45867 Renal medullary necrosis unspecified
45904 Ren tub-interst disordr/blood dis+disordr inv immune mech
46145 [V]Aftercare involving renal dialysis NOS
46438 [X] Peritoneal dialysis associated peritonitis
46963 Insulin-dependent diabetes mellitus with renal complications
47135 Medullary cystic disease  adult type
47582 Type 1 diabetes mellitus with renal complications
47672 Nephrotic syndrome in systemic lupus erythematosus
47838 Other acute glomerulonephritis NOS
47922 Nephrotic syndrome in amyloidosis
48022 Other specified compensation for renal failure
48057 Renal tubulo-interstitial disordrs in transplant rejectn
48261 Acute focal nephritis
48475 Renal acidaemia
48639 Mechanical complication of dialysis catheter
49150 Other specified nephritis, nephrosis or nephrotic syndrome
49642 Recur+persist haemuria df mesangial prolif glomerulnephritis
50200 Rapid progressive nephritic syndrome, dense deposit disease
50225 Type II diabetes mellitus with renal complications
50305 Hypocomplementaemic persistent glomerulonephritis NEC
50472 Nephrotic syn,difus endocapilary proliftv glomerulonephritis
50728 Renal infantilism
50804 Other impaired renal function disorder NOS
50893 Toxic nephropathy, not elsewhere classified
51039 Bilateral nephrectomy
51113 Hereditary nephropathy NEC, minor glomerular abnormality
52088 [V]Preparatory care for dialysis
52303 Non-insulin-dependent diabetes mellitus with renal comps
52969 Gouty nephropathy
53852 End stage renal failure
53940 [X]Other chronic renal failure
54312 Acute neph syn, diffuse mesangiocapillary glomerulonephritis
54844 [X]Failure sterile precautions dur kidney dialys/other perf
55100 Acute diffuse nephritis
55389 Acut neph syn, diffuse mesangial prolifrative glomnephritis
55548 Glom disordr in blood diseas+disordr invlvg imun mechansm
56760 Placement ambulatory apparatus compensation renal failure
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56893 Chron neph syn difus mesangial prolifrtiv glomerulonephritis
56939 Hypokalaemic nephropathy
56987 Nephrotic syndrome, dense deposit disease
57072 Other familial glomerulonephritis
57168 Chron nephritic syndrom difuse membranous glomerulonephritis
57278 Type II diabetes mellitus with renal complications
57621 Insulin dependent diabetes mellitus with nephropathy
57784 Nephropathy induced by unspec drug medicament or biol subs
57926 Steroid sensitive nephrotic syndrome
57987 Hyperten heart&renal dis+both(congestv)heart and renal fail
58060 Rpd prog neph syn df mesangial prolifratv glomerulonephritis
58164 Rapidly progressive nephritis unspecified
58618 Arteriovenous shunt NOS
58671 Heredtry nephrpthy NEC difus mesangial prolif glomnephrit
58750 Nephrotic syndrome in polyarteritis nodosa
59194 Placement ambulatory apparatus- compensate renal failure OS
59315 Stenosis of arteriovenous dialysis fistula
59365 Non-insulin dependent diabetes mellitus with nephropathy
59992 Isolated proteinuria  with unspecified morpholog changes
60128 Unspecified nephritic syndrome, dense deposit disease
60198 Chronic nephritic syndrome, dense deposit disease
60302 Creation of graft fistula for dialysis
60446 Care of haemodialysis equipment
60484 Recur+persist hmuria df mesangiocapilary glomerulonephritis
60498 Reversing haemodialysis lines
60743 [V]Aftercare involving intermittent dialysis
60796 Type II diabetes mellitus with persistent proteinuria
60856 Recur+persist haematuria difus crescentic glomerulonephritis
60857 Chronic nephritic syn diffuse crescentic glomerulonephritis
60960 Other chronic glomerulonephritis
61145 Gouty nephropathy NOS
61317 Recur+persist haematuria difus membranous glomerulonephritis
61344 Type I diabetes mellitus with renal complications
61494 Chronic membranoproliferative glomerulonephritis
61811 Isoltd prteinur+specfd morph les df mesangiocap glomnephr
61814 Acute nephrotic syndrm diffuse crescentic glomerulonephritis
62320 Rapid progres nephritic syn df crescentic glomerulonephritis
62520 Unsp nephrit synd, diff endocap prolif glomerulonephritis
62868 Anaphylactoid glomerulonephritis
62980 Hereditary nephropathy, unspecif morphological changes
63000 Benign hypertensive heart and renal disease
63038 [V]Unspecified aftercare involving intermittent dialysis
63063 Insertion of arteriovenous prosthesis
63190 Attention to arteriovenous shunt
63305 Thrombectomy of arteriovenous fistula
63466 Hypertensive heart and renal disease
63488 [V]Other specified aftercare involving intermittent dialysis
63502 Peritoneal dialysis bag procedure
63599 Other acute glomerulonephritis
63615 Other chronic glomerulonephritis NOS
63786 Congenital nephrotic syndrome
64030 [X]Persistent proteinuria  unspecified
64571 Type II diabetes mellitus with nephropathy
64622 Renal tubulo-interstitial disorder/ neoplastic diseases
64636 Compensation for renal failure NOS
64828 Peritoneal dialysis NEC
65064 Chronic rapidly progressive glomerulonephritis
65089 Placement other apparatus- compensate for renal failure NOS
65398 Other specified arteriovenous shunt
65400 Chronic diffuse glomerulonephritis
66062 Renal rickets
66136 Acute nephritic syndrome, focal+segmental glomerular lesions
297
Chronic Kidney Disease 
Medical code Read term
66503 Acute nephritic syn, diffuse membranous glomerulonephritis
66505 Chronic nephritic syndrome, minor glomerular abnormality
66613 Isoltd prteinur/spcfd morph lesn df mesngl prolf glomneph
66714 Renal dialysis with complication, without blame
66872 Type I diabetes mellitus with nephropathy
67193 Nephritis unsp+OS membranoprolif glomerulonephritis lesion
67197 Haemorrhagic nephrosonephritis
67232 Malignant hypertensive heart and renal disease
67261 Ren tub-interstitl disordr/systemc connectv tiss disorder
67460 Acute nephritis with lesions of necrotising glomerulitis
67995 Focal membranoproliferative glomerulonephritis
68112 Nephropathic amyloidosis
68364 Recur+persist haematuria  focal+segmental glomerular lesions
68659 Hypertensive heart and renal disease NOS
69266 Failure of sterile precautions during kidney dialysis
69427 Accid cut puncture perf h'ge - perfusion NOS
69760 [X]Other dialysis
71124 Haemofiltration
71174 Rapidly progressive nephritic syndrome
71709 [X]Unsp nephrit synd, diff mesang prolif glomerulonephritis
71964 Isolatd proteinur/specfd morphlgcl les df membrn glomneph
72303 Finnish nephrosis syndrome
72336 Priming haemodialysis lines
72478 [X]Nephropathy induced by other drugs+biological substances
73026 Chronic neph syn difus mesangiocapillary glomerulonephritis
74905 Haemodialysis training
83513 Placement other apparatus for compensation for renal failure
85659 IgA nephropathy
85991 Type II diabetes mellitus with persistent microalbuminuria
88597 Automated peritoneal dialysis
89332 Predicted stage chronic kidney disease
90952 Pre-transplantation of kidney work-up, recipient
91738 Hereditary nephropathy, NEC, dense deposit disease
93922 Diabetes mellitus  juvenile type  with renal manifestation
94261 Acute exudative nephritis
94350 Nephritis unsp+membranoprolif glomerulonephritis lesion NOS
94373 Nephrotic syndrome with other pathological kidney lesions
94789 Chronic kidney disease stage 1 with proteinuria
94793 Chronic kidney disease stage 3 with proteinuria
94842 [X]Renal tubulo-interstitial diseases
94965 Chronic kidney disease stage 3A
95121 Chronic kidney disease stage 2 without proteinuria
95122 Chronic kidney disease stage 4 with proteinuria
95123 Chronic kidney disease stage 3 without proteinuria
95145 CKD stage 3 with proteinuria
95146 Chronic kidney disease stage 2 with proteinuria
95175 Chronic kidney disease stage 3A without proteinuria
95176 CKD stage 3A without proteinuria
95177 Chronic kidney disease stage 3B without proteinuria
95178 Chronic kidney disease stage 3B with proteinuria
95179 Chronic kidney disease stage 3B
95180 CKD stage 3B with proteinuria
95188 CKD stage 3 without proteinuria
95405 Chronic kidney disease stage 5 without proteinuria
95406 Chronic kidney disease stage 4 without proteinuria
95408 Chronic kidney disease stage 3A with proteinuria
95508 Chronic kidney disease stage 5 with proteinuria
95546 Recurrent+persistnt haematuria minor glomerular abnormality
95571 CKD stage 3A with proteinuria
95572 Chronic kidney disease stage 1 without proteinuria
96131 Banding of arteriovenous fistula
96184 Accid cut,puncture,perf,h'ge - kidney dialysis
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96347 Ligation of arteriovenous dialysis fistula
96819 [X]Other disorders resulting/impaired renal tubular function
97388 Mixed membranous and proliferative glomerulonephritis NEC
97533 [X]Hypertension secondary to other renal disorders
97587 CKD stage 4 without proteinuria
97683 CKD stage 5 without proteinuria
97734 Rapid progres nephritic syn focal+segmental glomerulr lesion
97758 Chronic glomerulonephritis + diseases EC
97978 CKD stage 2 without proteinuria
97979 CKD stage 2 with proteinuria
97980 CKD stage 1 with proteinuria
99139 Balkan nephropathy
99160 CKD stage 5 with proteinuria
99312 CKD stage 4 with proteinuria
99628 [X]Glomerular disorders in diabetes mellitus
99644 Nephrotic syndrome+membranoproliferative glomerulonephritis
99685 Acute nephritic syndrome  dense deposit disease
100205 Acute-on-chronic renal failure
100235 Ligation of acquired arteriovenous fistula
100292 [X]Unspecified diabetes mellitus with renal complications
100558 Acute nephritic syndrome  minor glomerular abnormality
100633 CKD stage 3B without proteinuria
100693 [X]Renal tubulo-interstitial disorders/transplant rejection
101358 Ac neph syn difus endocaplry prolifrative glomerulonephritis
101453 [X]Other chronic tubulo-interstitial nephritis
101572 Isolated proteinuria  with oth specif morpholog changes
101756 Thomas intravascular shunt for dialysis
102163 Insulin dependent diabetes mellitus with nephropathy
102201 Type II diabetes mellitus with nephropathy
102620 Type I diabetes mellitus with persistent microalbuminuria
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794 emphysema
998 chronic obstructive airways disease
1001 chronic obstructive pulmonary disease
1446 acute exacerbation of chronic obstructive airways disease
3243 ZERIDAME SR tablets 150mg [ACTAVIS]
5710 chronic obstructive airways disease nos
7884 chron obstruct pulmonary dis wth acute exacerbation, unspec
9520 chronic obstructive pulmonary disease monitoring
9876 severe chronic obstructive pulmonary disease
10802 moderate chronic obstructive pulmonary disease
10863 mild chronic obstructive pulmonary disease
10980 centrilobular emphysema
11019 admit copd emergency
11150 mucopurulent chronic bronchitis
11287 chronic obstructive pulmonary disease annual review
12166 other specified chronic obstructive airways disease
14798 emphysematous bronchitis
15157 Herpes zoster with meningitis
15626 chronic catarrhal bronchitis
18476 copd follow-up
18501 copd self-management plan given
18621 chronic obstructive pulmonary disease follow-up
18792 chronic obstructive pulmonary disease monitoring admin
19003 emergency copd admission since last appointment
19106 copd accident and emergency attendance since last visit
21061 chronic obstruct pulmonary dis with acute lower resp infectn
23492 chronic bullous emphysema nos
24248 mixed simple and mucopurulent chronic bronchitis
25603 simple chronic bronchitis
26018 chronic obstructive pulmonary disease monitoring by nurse
26306 chronic bullous emphysema
27819 obstructive chronic bronchitis
28755 chronic obstructive pulmonary disease monitoring 1st letter
33450 emphysema nos
34202 chronic obstructive pulmonary disease monitoring 2nd letter
34215 chronic obstructive pulmonary disease monitoring 3rd letter
37247 chronic obstructive pulmonary disease nos
37371 chronic obstructive pulmonary disease monitoring due
37959 fetid chronic bronchitis
38074 chronic obstructive pulmonary disease monitor phone invite
40159 purulent chronic bronchitis
42258 chronic obstructive pulmonary disease monitoring verb invite
42624 coad follow-up
44525 obstructive chronic bronchitis nos
45770 chronic obstructive pulmonary disease disturbs sleep
45771 chronic obstructive pulmonary disease does not disturb sleep
45777 chronic obstructive pulmonary disease clini management plan
45998 chronic obstructive pulmonary disease monitoring by doctor
46036 multiple copd emergency hospital admissions
46578 panlobular emphysema
56860 segmental bullous emphysema
60188 giant bullous emphysema
61118 simple chronic bronchitis nos
61513 mucopurulent chronic bronchitis nos
64721 chronic emphysema due to chemical fumes
65733 [x]other specified chronic obstructive pulmonary disease
66043 other chronic bronchitis
67040 other specified chronic obstructive pulmonary disease
68066 other chronic bronchitis nos
93568 very severe chronic obstructive pulmonary disease
96931 at risk of chronic obstructive pulmonary diseas exacerbation
98283 copd structured smoking assessment declined - enh serv admin
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98284 refer copd structured smoking assessment - enhanc serv admin
99536 bullous emphysema with collapse
99948 copd patient unsuitable for pulmonary rehab - enh serv admin
101042 issue of chronic obstructive pulmonary disease rescue pack
102685 chronic obstructive pulmonary disease 3 monthly review
103007 chronic obstructive pulmonary disease 6 monthly review
103400 referred for copd structured smoking assessment
301
Depression
Medical code Read term
324 Depressive disorder NEC
543 [X]Depression NOS
595 Endogenous depression
655 Anxiety with depression
1055 ZERIDAME SR tablets 150mg [ACTAVIS]
1131 Neurotic depression reactive type
1533 Brief depressive reaction
1908 O/E - depressed
1996 Depressed




2930 C/O - feeling unhappy
2970 [X]Depressive episode, unspecified
2972 Postviral depression
3291 [X]Depressive disorder NOS
3292 Herpes zoster with meningitis
4323 Chronic depression
4639 [X]Depressive episode
4824 C/O - feeling depressed
4979 [X]Postpartum depression NOS
5879 Agitated depression
5987 [X] Reactive depression NOS
6482 Recurrent depression
6546 Endogenous depression first episode
6854 [X]Other depressive episodes
6932 Endogenous depression - recurrent
6950 Endogenous depression first episode
7011 Single major depressive episode NOS
7412 Loss of confidence
7604 [X]Single episode of reactive depression
7737 [X]Neurotic depression
7749 [X]Mild anxiety depression
7953 [X]Dysthymia
8478 Reactive depressive psychosis
8584 [X]Depressive neurosis
8826 [X]SAD - Seasonal affective disorder
8851 [X]Recurrent episodes of depressive reaction
8902 [X]Recurrent episodes of reactive depression
8928 Low mood
9055 [X]Single episode of depressive reaction
9183 Masked depression
9211 [X]Moderate depressive episode
9667 [X]Severe depressive episode without psychotic symptoms
9796 Symptoms of depression
10015 Depressed mood
10290 [X]Depressive personality disorder
10438 Depressive symptoms
10455 Depressive personality disorder
10610 Single major depressive episode
10667 [X]Mild depression
10720 [X]Atypical depression
10825 Seasonal affective disorder
11055 [X]Schizoaffective disorder, depressive type
11252 [X]Major depression, recurrent without psychotic symptoms
11329 [X]Endogenous depression without psychotic symptoms
11717 [X]Mild depressive episode
11913 [X]Mixed anxiety and depressive disorder
12099 [X]Severe depressive episode with psychotic symptoms
12122 Depression medication review
12399 Depression annual review
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13307 [X]Postnatal depression NOS
14709 Recurrent major depressive episodes, moderate
15099 Recurrent major depressive episode
15155 Single major depressive episode, moderate
15219 Single major depressive episode, severe, without psychosis
15220 [X]Persistant anxiety depression
16506 Single major depressive episode, mild
16632 Prolonged depressive reaction
16861 [X]Recurrent severe episodes of psychotic depression
17770 Psychotic reactive depression
18510 [X]Single episode of psychogenic depression
19054 [X]Recurrent brief depressive episodes
19696 [X]Recurrent episodes of psychogenic depression
20785 [X]Post-schizophrenic depression
21887 Senile dementia with depression
22806 [X]Single episode major depression w'out psychotic symptoms
23731 [X]Endogenous depression with psychotic symptoms
24112 [X]Single episode of psychotic depression
24117 [X]Single episode of major depression and psychotic symptoms
24171 Recurrent major depressive episodes, severe, with psychosis
25435 Loss of capacity for enjoyment
25563 Recurrent major depressive episode NOS
25697 Recurrent major depressive episodes, severe, no psychosis
26028 Sad mood
27491 Atypical depressive disorder
27677 Presenile dementia with depression
27759 [X] Senile dementia, depressed or paranoid type
28248 [X]Prolonged single episode of reactive depression
28756 [X]Seasonal depressive disorder
28863 [X]Single episode of reactive depressive psychosis
29342 Recurrent major depressive episodes, mild
29520 [X]Recurrent depressive disorder, current episode moderate
29527 [D]Postoperative depression
29784 [X]Recurrent depressive disorder, current episode mild
30405 Depression interim review
30740 Loss of interest
31757 [X]Recurr severe episodes/psychogenic depressive psychosis
32159 Single major depressive episode, severe, with psychosis
32941 [X]Recurr severe episodes/major depression+psychotic symptom
33469 [X]Recurr depress disorder cur epi severe without psyc sympt
34390 Single major depressive episode, unspecified
35274 [X]Schizoaffective psychosis, depressive type
35671 Recurrent major depressive episodes, unspecified
36246 Brief depressive reaction NOS
36616 [X]Monopolar depression NOS
37764 [X]Recurrent severe episodes/reactive depressive psychosis
41022 [X]Schizophreniform psychosis, depressive type
41089 Senile dementia with depressive or paranoid features NOS
41989 [X]Single episode agitated depressn w'out psychotic symptoms
43292 Arteriosclerotic dementia with depression
44300 [X]Recurrent depressive disorder, unspecified
44674 Senile dementia with depressive or paranoid features
44848 Depression management programme
47009 [X]Recurrent depress disorder cur epi severe with psyc symp
47731 [X]Other recurrent depressive disorders
52678 [X]Single episode of psychogenic depressive psychosis
53148 Loss of hope for the future
56609 [X]Single episode of masked depression NOS
59386 [X]Single episode vital depression w'out psychotic symptoms
59869 Loss of interest in previously enjoyable activity
73991 [X]Vital depression, recurrent without psychotic symptoms
98252 [X]Major depression, moderately severe
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98346 [X]Major depression, mild
98414 [X]Major depression, severe without psychotic symptoms
98417 [X]Major depression, severe with psychotic symptoms
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1038 Insulin dependent diabetes mellitus Type 1 diabetes mellitus
1549 Type 1 diabetes mellitus Type 1 diabetes mellitus
1647 Insulin dependent diabetes mellitus Type 1 diabetes mellitus
6509 Insulin dependent diabetes mellitus with retinopathy Type 1 diabetes mellitus
6791 Insulin dependent diabetes mellitus - poor control Type 1 diabetes mellitus
10418 Type 1 diabetes mellitus with nephropathy Type 1 diabetes mellitus
10692 Type 1 diabetes mellitus with ketoacidosis Type 1 diabetes mellitus
12455 Type I diabetes mellitus Type 1 diabetes mellitus
17545 Type I diabetes mellitus with diabetic cataract Type 1 diabetes mellitus
17858 Type 1 diabetes mellitus Type 1 diabetes mellitus
18230 Type 1 diabetes mellitus with neuropathic arthropathy Type 1 diabetes mellitus
18387 Type 1 diabetes mellitus with retinopathy Type 1 diabetes mellitus
18505 IDDM-Insulin dependent diabetes mellitus Type 1 diabetes mellitus
18642 Type 1 diabetes mellitus with arthropathy Type 1 diabetes mellitus
18683 Type 1 diabetes mellitus with ulcer Type 1 diabetes mellitus
21983 Type 1 diabetes mellitus with renal complications Type 1 diabetes mellitus
22871 Type 1 diabetes mellitus with exudative maculopathy Type 1 diabetes mellitus
24423 Type I diabetes mellitus Type 1 diabetes mellitus
24490 Diabetes mellitus, juvenile type, no mention of complication Type 1 diabetes mellitus
24694 Insulin dependent diabetes mellitus with mononeuropathy Type 1 diabetes mellitus
26855 Unstable insulin dependent diabetes mellitus Type 1 diabetes mellitus
30294 Type 1 diabetes mellitus with persistent microalbuminuria Type 1 diabetes mellitus
30323 Type 1 diabetes mellitus with persistent proteinuria Type 1 diabetes mellitus
31310 Insulin dependent diabetes maturity onset Type 1 diabetes mellitus
32359 Perceived control of insulin-dependent diabetes Type 1 diabetes mellitus
35288 Type 1 diabetes mellitus - poor control Type 1 diabetes mellitus
38076 Insulin lipohypertrophy Type 1 diabetes mellitus
38161 Type I diabetes mellitus with retinopathy Type 1 diabetes mellitus
39070 Type 1 diabetes mellitus with hypoglycaemic coma Type 1 diabetes mellitus
39809 Insulin dependent diab mell with neuropathic arthropathy Type 1 diabetes mellitus
40023 Diabetes mellitus, juvenile type, with hyperosmolar coma Type 1 diabetes mellitus
40682 Type 1 diabetes mellitus maturity onset Type 1 diabetes mellitus
40837 Type 1 diabetes mellitus with ketoacidotic coma Type 1 diabetes mellitus
41049 Type 1 diabetes mellitus with retinopathy Type 1 diabetes mellitus
41716 Insulin dependent diabetes mellitus with polyneuropathy Type 1 diabetes mellitus
42567 Diabetes mellitus, juvenile type, with ketoacidotic coma Type 1 diabetes mellitus
42729 Type I diabetes mellitus with hypoglycaemic coma Type 1 diabetes mellitus
42831 Type 1 diabetes mellitus with neurological complications Type 1 diabetes mellitus
43493 Insulin site lipohypertrophy Type 1 diabetes mellitus
43921 Unstable type 1 diabetes mellitus Type 1 diabetes mellitus
44260 Insulin dependent diabetes mellitus with diabetic cataract Type 1 diabetes mellitus
44440 Insulin dependent diabetes mellitus with hypoglycaemic coma Type 1 diabetes mellitus
44443 Insulin dependent diabetes mellitus with ulcer Type 1 diabetes mellitus
45276 Insulin dependent diabetes mellitus with multiple complicat Type 1 diabetes mellitus
45914 Type 1 diabetes mellitus - poor control Type 1 diabetes mellitus
46301 Type 1 diabetes mellitus with polyneuropathy Type 1 diabetes mellitus
46850 Type I diabetes mellitus - poor control Type 1 diabetes mellitus
47582 Type 1 diabetes mellitus with renal complications Type 1 diabetes mellitus
47649 Type 1 diabetes mellitus with ophthalmic complications Type 1 diabetes mellitus
47650 Type 1 diabetes mellitus with multiple complications Type 1 diabetes mellitus
49146 Type I diabetes mellitus with neurological complications Type 1 diabetes mellitus
49276 Insulin-dependent diabetes mellitus with ophthalmic comps Type 1 diabetes mellitus
49554 Type 1 diabetes mellitus with diabetic cataract Type 1 diabetes mellitus
49949 Unstable type I diabetes mellitus Type 1 diabetes mellitus
50960 Pre-existing diabetes mellitus, insulin-dependent Type 1 diabetes mellitus
51261 Insulin dependent diabetes mellitus Type 1 diabetes mellitus
51957 Type I diabetes mellitus with ulcer Type 1 diabetes mellitus
52104 Insulin dependent diabetes mellitus with multiple complicatn Type 1 diabetes mellitus
52283 Insulin-dependent diabetes mellitus with neurological comps Type 1 diabetes mellitus
53200 Diabetes mellitus, juvenile type, with ketoacidosis Type 1 diabetes mellitus
54008 Type 1 diabetes mellitus with neuropathic arthropathy Type 1 diabetes mellitus
54600 Unstable insulin dependent diabetes mellitus Type 1 diabetes mellitus
55239 Type 1 diabetes mellitus with gastroparesis Type 1 diabetes mellitus
56448 Insulin-dependent diabetes without complication Type 1 diabetes mellitus
57621 Insulin dependent diabetes mellitus with nephropathy Type 1 diabetes mellitus
60107 Unstable type I diabetes mellitus Type 1 diabetes mellitus
60208 Type I diabetes mellitus with neuropathic arthropathy Type 1 diabetes mellitus
60499 Insulin dependent diabetes mellitus with gangrene Type 1 diabetes mellitus
61344 Type I diabetes mellitus with renal complications Type 1 diabetes mellitus
61829 Type 1 diabetes mellitus with neurological complications Type 1 diabetes mellitus
62209 Type I diabetes mellitus with ketoacidosis Type 1 diabetes mellitus
62352 Type I diabetes mellitus with arthropathy Type 1 diabetes mellitus
62613 Type I diabetes mellitus without complication Type 1 diabetes mellitus
63017 Type I diabetes mellitus maturity onset Type 1 diabetes mellitus
64446 Insulin dependent diab mell with peripheral angiopathy Type 1 diabetes mellitus
65616 Insulin dependent diabetes mellitus with arthropathy Type 1 diabetes mellitus
66145 Type I diabetes mellitus with ketoacidotic coma Type 1 diabetes mellitus
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66872 Type I diabetes mellitus with nephropathy Type 1 diabetes mellitus
67853 Diabetes mellitus, juvenile, + neurological manifestation Type 1 diabetes mellitus
68105 Type 1 diabetes mellitus with mononeuropathy Type 1 diabetes mellitus
68390 Type 1 diabetes mellitus with ulcer Type 1 diabetes mellitus
68792 Diabetes mellitus, juvenile type, + unspecified complication Type 1 diabetes mellitus
69043 Dietary advice for type I diabetes Type 1 diabetes mellitus
69124 IDDM with peripheral circulatory disorder Type 1 diabetes mellitus
69676 Type 1 diabetes mellitus without complication Type 1 diabetes mellitus
69748 Diabetes mellitus, juvenile type, + ophthalmic manifestation Type 1 diabetes mellitus
69993 Type 1 diabetes mellitus with gangrene Type 1 diabetes mellitus
70448 Diabetes mellitus, juvenile +peripheral circulatory disorder Type 1 diabetes mellitus
70766 Type 1 diabetes mellitus with hypoglycaemic coma Type 1 diabetes mellitus
72702 Insulin dependent diabetes mellitus - poor control Type 1 diabetes mellitus
85660 Diabetes type 1 review Type 1 diabetes mellitus
91942 Type I diabetes mellitus with multiple complications Type 1 diabetes mellitus
91943 Type I diabetes mellitus with polyneuropathy Type 1 diabetes mellitus
93468 Type 1 diabetes mellitus with peripheral angiopathy Type 1 diabetes mellitus
93875 Insulin dependent diabetes mellitus with retinopathy Type 1 diabetes mellitus
93878 Type I diabetes mellitus with ulcer Type 1 diabetes mellitus
93922 Diabetes mellitus, juvenile type, with renal manifestation Type 1 diabetes mellitus
95343 Type I diabetes mellitus with retinopathy Type 1 diabetes mellitus
95992 Type I diabetes mellitus without complication Type 1 diabetes mellitus
96235 Type I diabetes mellitus maturity onset Type 1 diabetes mellitus
97446 Type 1 diabetes mellitus maturity onset Type 1 diabetes mellitus
97474 Unstable type 1 diabetes mellitus Type 1 diabetes mellitus
97849 Insulin dependent diabetes maturity onset Type 1 diabetes mellitus
97894 Type I diabetes mellitus with exudative maculopathy Type 1 diabetes mellitus
98071 Insulin-dependent diabetes mellitus with ophthalmic comps Type 1 diabetes mellitus
98392 Maturity onset diabetes in youth type 1 Type 1 diabetes mellitus
98704 Insulin dependent diabetes mellitus with ulcer Type 1 diabetes mellitus
99231 Type I diabetes mellitus with mononeuropathy Type 1 diabetes mellitus
99311 Type I diabetes mellitus with ophthalmic complications Type 1 diabetes mellitus
99716 Insulin dependent diabetes mellitus with hypoglycaemic coma Type 1 diabetes mellitus
99719 Insulin-dependent diabetes without complication Type 1 diabetes mellitus
100770 Insulin dependent diabetes mellitus with diabetic cataract Type 1 diabetes mellitus
101311 Insulin dependent diabetes mellitus with polyneuropathy Type 1 diabetes mellitus
101735 Insulin-dependent diabetes mellitus with neurological comps Type 1 diabetes mellitus
102112 Type I diabetes mellitus with gangrene Type 1 diabetes mellitus
102163 Insulin dependent diabetes mellitus with nephropathy Type 1 diabetes mellitus
102620 Type I diabetes mellitus with persistent microalbuminuria Type 1 diabetes mellitus
102704 Type I diabetic dietary review Type 1 diabetes mellitus
102740 Type 1 diabetes mellitus with ophthalmic complications Type 1 diabetes mellitus
506 Non-insulin dependent diabetes mellitus Type 2 diabetes mellitus
758 Type 2 diabetes mellitus Type 2 diabetes mellitus
1407 Insulin treated Type 2 diabetes mellitus Type 2 diabetes mellitus
4513 Non-insulin dependent diabetes mellitus Type 2 diabetes mellitus
5884 NIDDM - Non-insulin dependent diabetes mellitus Type 2 diabetes mellitus
8403 Non-insulin dependent diabetes mellitus - poor control Type 2 diabetes mellitus
12640 Type 2 diabetes mellitus with nephropathy Type 2 diabetes mellitus
12736 Type 2 diabetes mellitus with gangrene Type 2 diabetes mellitus
14803 Diabetes mellitus, adult onset, no mention of complication Type 2 diabetes mellitus
14889 Maturity onset diabetes Type 2 diabetes mellitus
17262 Non-insulin-dependent diabetes mellitus with retinopathy Type 2 diabetes mellitus
17859 Type 2 diabetes mellitus Type 2 diabetes mellitus
18143 Type II diabetes mellitus with arthropathy Type 2 diabetes mellitus
18209 Type 2 diabetes mellitus with renal complications Type 2 diabetes mellitus
18219 Type II diabetes mellitus Type 2 diabetes mellitus
18264 Insulin treated Type II diabetes mellitus Type 2 diabetes mellitus
18278 Insulin treated Type 2 diabetes mellitus Type 2 diabetes mellitus
18390 Type 2 diabetes mellitus with persistent microalbuminuria Type 2 diabetes mellitus
18425 Type 2 diabetes mellitus with polyneuropathy Type 2 diabetes mellitus
18496 Type 2 diabetes mellitus with retinopathy Type 2 diabetes mellitus
18777 Type 2 diabetes mellitus with renal complications Type 2 diabetes mellitus
22884 Type II diabetes mellitus Type 2 diabetes mellitus
24458 Type II diabetes mellitus - poor control Type 2 diabetes mellitus
24693 Non-insulin dependent diabetes mellitus with arthropathy Type 2 diabetes mellitus
24836 Type 2 diabetes mellitus with nephropathy Type 2 diabetes mellitus
25041 Dietary advice for type II diabetes Type 2 diabetes mellitus
25591 Type 2 diabetes mellitus with exudative maculopathy Type 2 diabetes mellitus
25627 Type 2 diabetes mellitus - poor control Type 2 diabetes mellitus
26054 Type 2 diabetes mellitus with persistent proteinuria Type 2 diabetes mellitus
29979 Non-insulin-dependent diabetes mellitus without complication Type 2 diabetes mellitus
32627 Type 2 diabetes mellitus with ketoacidosis Type 2 diabetes mellitus
33807 Diabetes mellitus, adult with gangrene Type 2 diabetes mellitus
34268 Type 2 diabetes mellitus with neurological complications Type 2 diabetes mellitus
34450 Hyperosmolar non-ketotic state in type 2 diabetes mellitus Type 2 diabetes mellitus
34912 Non-insulin dependent diabetes mellitus with ulcer Type 2 diabetes mellitus
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35105 Diabetes mellitus, adult onset, with renal manifestation Type 2 diabetes mellitus
35385 Type 2 diabetes mellitus with neuropathic arthropathy Type 2 diabetes mellitus
36633 Hyperosmolar non-ketotic state in type 2 diabetes mellitus Type 2 diabetes mellitus
36695 Diabetes mellitus autosomal dominant type 2 Type 2 diabetes mellitus
37648 Insulin treated non-insulin dependent diabetes mellitus Type 2 diabetes mellitus
37806 Type 2 diabetes mellitus with peripheral angiopathy Type 2 diabetes mellitus
39317 Diabetes mellitus, adult onset, + neurological manifestation Type 2 diabetes mellitus
40401 Non-insulin dependent diabetes mellitus with gangrene Type 2 diabetes mellitus
40962 Non-insulin dependent d m with neuropathic arthropathy Type 2 diabetes mellitus
41389 Diabetes mellitus, adult onset, + ophthalmic manifestation Type 2 diabetes mellitus
42762 Type 2 diabetes mellitus with retinopathy Type 2 diabetes mellitus
43139 Diabetes mellitus, adult onset, with hyperosmolar coma Type 2 diabetes mellitus
43227 Type II diabetes mellitus with multiple complications Type 2 diabetes mellitus
43785 Non-insulin dependent diabetes mellitus with hypoglyca coma Type 2 diabetes mellitus
44779 Type 2 diabetes mellitus with diabetic cataract Type 2 diabetes mellitus
44982 Type 2 diabetes mellitus with diabetic cataract Type 2 diabetes mellitus
45467 Non-insulin dependent diabetes mellitus with polyneuropathy Type 2 diabetes mellitus
45913 Type 2 diabetes mellitus - poor control Type 2 diabetes mellitus
45919 Type 2 diabetes mellitus with neurological complications Type 2 diabetes mellitus
46150 Type 2 diabetes mellitus with gangrene Type 2 diabetes mellitus
46624 Maturity onset diabetes in youth Type 2 diabetes mellitus
46917 Type 2 diabetes mellitus with hypoglycaemic coma Type 2 diabetes mellitus
47315 Type II diabetes mellitus - poor control Type 2 diabetes mellitus
47321 Type 2 diabetes mellitus with ophthalmic complications Type 2 diabetes mellitus
47409 Type II diabetes mellitus with polyneuropathy Type 2 diabetes mellitus
47816 Type II diabetes mellitus with neuropathic arthropathy Type 2 diabetes mellitus
47954 Type 2 diabetes mellitus without complication Type 2 diabetes mellitus
48192 Type II diabetes mellitus with diabetic cataract Type 2 diabetes mellitus
49074 Type 2 diabetes mellitus with ulcer Type 2 diabetes mellitus
49655 Type II diabetes mellitus with retinopathy Type 2 diabetes mellitus
49869 Type 2 diabetes mellitus with arthropathy Type 2 diabetes mellitus
50225 Type II diabetes mellitus with renal complications Type 2 diabetes mellitus
50429 Non-insulin-dependent diabetes mellitus with ophthalm comps Type 2 diabetes mellitus
50527 Type II diabetes mellitus with polyneuropathy Type 2 diabetes mellitus
50609 Pre-existing diabetes mellitus, non-insulin-dependent Type 2 diabetes mellitus
50813 Type II diabetes mellitus with mononeuropathy Type 2 diabetes mellitus
51756 Type 2 diabetes mellitus with ketoacidotic coma Type 2 diabetes mellitus
52303 Non-insulin-dependent diabetes mellitus with renal comps Type 2 diabetes mellitus
53392 Type II diabetes mellitus without complication Type 2 diabetes mellitus
54212 Non-insulin-dependent d m with peripheral angiopath Type 2 diabetes mellitus
54856 Diabetes mellitus, adult onset, with ketoacidosis Type 2 diabetes mellitus
54899 Type II diabetes mellitus with peripheral angiopathy Type 2 diabetes mellitus
55075 Type II diabetes mellitus with ulcer Type 2 diabetes mellitus
55842 Non-insulin-dependent diabetes mellitus with neuro comps Type 2 diabetes mellitus
56268 Type II diabetes mellitus with hypoglycaemic coma Type 2 diabetes mellitus
56803 NIDDM with peripheral circulatory disorder Type 2 diabetes mellitus
57278 Type II diabetes mellitus with renal complications Type 2 diabetes mellitus
58604 Type II diabetes mellitus with retinopathy Type 2 diabetes mellitus
59253 Type 2 diabetes mellitus with arthropathy Type 2 diabetes mellitus
59365 Non-insulin dependent diabetes mellitus with nephropathy Type 2 diabetes mellitus
59725 Type II diabetes mellitus with ophthalmic complications Type 2 diabetes mellitus
59991 Maturity onset diabetes in youth type 2 Type 2 diabetes mellitus
60699 Type 2 diabetes mellitus with peripheral angiopathy Type 2 diabetes mellitus
60796 Type II diabetes mellitus with persistent proteinuria Type 2 diabetes mellitus
61071 Type 2 diabetes mellitus with hypoglycaemic coma Type 2 diabetes mellitus
62107 Type II diabetes mellitus with gangrene Type 2 diabetes mellitus
62146 Non-insulin-dependent diabetes mellitus with multiple comps Type 2 diabetes mellitus
62674 Type 2 diabetes mellitus with mononeuropathy Type 2 diabetes mellitus
63357 Diabetes mellitus, adult, + peripheral circulatory disorder Type 2 diabetes mellitus
63371 Diabetes mellitus, adult, + other specified manifestation Type 2 diabetes mellitus
63690 Type 2 diabetes mellitus with gastroparesis Type 2 diabetes mellitus
63762 Diabetes mellitus, adult onset, + unspecified complication Type 2 diabetes mellitus
64571 Type II diabetes mellitus with nephropathy Type 2 diabetes mellitus
64668 Insulin treated Type II diabetes mellitus Type 2 diabetes mellitus
65267 Type 2 diabetes mellitus with multiple complications Type 2 diabetes mellitus
65704 Type 2 diabetes mellitus with ulcer Type 2 diabetes mellitus
66965 Type 2 diabetes mellitus with neuropathic arthropathy Type 2 diabetes mellitus
67905 Type II diabetes mellitus with neurological complications Type 2 diabetes mellitus
68843 Diabetes mellitus, adult onset, with ketoacidotic coma Type 2 diabetes mellitus
69278 Non-insulin depend diabetes mellitus with diabetic cataract Type 2 diabetes mellitus
70316 Type 2 diabetes mellitus with ophthalmic complications Type 2 diabetes mellitus
72320 Non-insulin dependent diabetes mellitus with mononeuropathy Type 2 diabetes mellitus
83532 Diabetes type 2 review Type 2 diabetes mellitus
85991 Type II diabetes mellitus with persistent microalbuminuria Type 2 diabetes mellitus
91646 Type II diabetes mellitus with ulcer Type 2 diabetes mellitus
93727 Type II diabetes mellitus with diabetic cataract Type 2 diabetes mellitus
95351 Type II diabetes mellitus with mononeuropathy Type 2 diabetes mellitus
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95636 Latent autoimmune diabetes mellitus in adult Type 2 diabetes mellitus
98616 Type II diabetes mellitus with neurological complications Type 2 diabetes mellitus
98723 Type II diabetes mellitus with hypoglycaemic coma Type 2 diabetes mellitus
100964 Type II diabetes mellitus with ophthalmic complications Type 2 diabetes mellitus
101801 Type II diabetic dietary review Type 2 diabetes mellitus
102201 Type II diabetes mellitus with nephropathy Type 2 diabetes mellitus
102611 Type 2 diabetic dietary review Type 2 diabetes mellitus
711 Diabetes mellitus Diabetes mellitus, Type not specified
1323 Diabetic retinopathy Diabetes mellitus, Type not specified
1682 Diabetes mellitus with ketoacidosis Diabetes mellitus, Type not specified
1684 Diabetic on oral treatment Diabetes mellitus, Type not specified
2340 Diabetic amyotrophy Diabetes mellitus, Type not specified
2342 Diabetic neuropathy Diabetes mellitus, Type not specified
2378 Diabetic - poor control Diabetes mellitus, Type not specified
2471 Nephrotic syndrome in diabetes mellitus Diabetes mellitus, Type not specified
2475 Diabetic nephropathy Diabetes mellitus, Type not specified
2478 Brittle diabetes Diabetes mellitus, Type not specified
2986 Preproliferative diabetic retinopathy Diabetes mellitus, Type not specified
3286 Proliferative diabetic retinopathy Diabetes mellitus, Type not specified
3837 Diabetic maculopathy Diabetes mellitus, Type not specified
5002 Diabetic polyneuropathy Diabetes mellitus, Type not specified
6125 Diabetic annual review Diabetes mellitus, Type not specified
6430 Attending diabetes clinic Diabetes mellitus, Type not specified
7059 Admit diabetic emergency Diabetes mellitus, Type not specified
7069 Background diabetic retinopathy Diabetes mellitus, Type not specified
7328 Cellulitis in diabetic foot Diabetes mellitus, Type not specified
7563 Diabetic on diet only Diabetes mellitus, Type not specified
7795 Diabetes mellitus with neuropathy Diabetes mellitus, Type not specified
8836 Diabetes management plan given Diabetes mellitus, Type not specified
8842 Diabetic on insulin Diabetes mellitus, Type not specified
9013 Unstable diabetes Diabetes mellitus, Type not specified
9835 O/E - diabetic maculopathy present both eyes Diabetes mellitus, Type not specified
9881 Mixed diabetic ulcer - foot Diabetes mellitus, Type not specified
9958 Hb. A1C - diabetic control Diabetes mellitus, Type not specified
10098 Other specified diabetes mellitus with other spec comps Diabetes mellitus, Type not specified
10099 Advanced diabetic maculopathy Diabetes mellitus, Type not specified
10642 Dietary advice for diabetes mellitus Diabetes mellitus, Type not specified
10659 Diabetic cataract Diabetes mellitus, Type not specified
10755 Non proliferative diabetic retinopathy Diabetes mellitus, Type not specified
10977 Diabetic peripheral neuropathy screening Diabetes mellitus, Type not specified
11018 Diabetic retinopathy 12 month review Diabetes mellitus, Type not specified
11047 Conversion to insulin Diabetes mellitus, Type not specified
11094 Under care of diabetic foot screener Diabetes mellitus, Type not specified
11129 O/E - left eye background diabetic retinopathy Diabetes mellitus, Type not specified
11433 O/E - right eye background diabetic retinopathy Diabetes mellitus, Type not specified
11471 Diabetes medication review Diabetes mellitus, Type not specified
11599 Pan retinal photocoagulation for diabetes Diabetes mellitus, Type not specified
11626 Diabetic retinopathy NOS Diabetes mellitus, Type not specified
11663 Neuropathic diabetic ulcer - foot Diabetes mellitus, Type not specified
11677 Refer to diabetic foot screener Diabetes mellitus, Type not specified
11930 Under care of diabetes specialist nurse Diabetes mellitus, Type not specified
12213 Patient on maximal tolerated therapy for diabetes Diabetes mellitus, Type not specified
12247 Diabetic foot examination not indicated Diabetes mellitus, Type not specified
12262 Diabetic retinopathy screening refused Diabetes mellitus, Type not specified
12307 Diabetes care by hospital only Diabetes mellitus, Type not specified
12506 Diabetes: practice programme Diabetes mellitus, Type not specified
12675 Diabetes: shared care programme Diabetes mellitus, Type not specified
12682 Patient offered diabetes structured education programme Diabetes mellitus, Type not specified
12703 Education score - diabetes Diabetes mellitus, Type not specified
13057 Health education - diabetes Diabetes mellitus, Type not specified
13069 Has seen dietician - diabetes Diabetes mellitus, Type not specified
13071 Diabetic - good control Diabetes mellitus, Type not specified
13074 Diabetic diet Diabetes mellitus, Type not specified
13078 Diabetic weight reducing diet Diabetes mellitus, Type not specified
13097 O/E - right eye proliferative diabetic retinopathy Diabetes mellitus, Type not specified
13099 O/E - right eye preproliferative diabetic retinopathy Diabetes mellitus, Type not specified
13100 O/E - no right diabetic retinopathy Diabetes mellitus, Type not specified
13101 O/E - left eye proliferative diabetic retinopathy Diabetes mellitus, Type not specified
13102 O/E - right eye diabetic maculopathy Diabetes mellitus, Type not specified
13103 O/E - left eye preproliferative diabetic retinopathy Diabetes mellitus, Type not specified
13104 O/E - no left diabetic retinopathy Diabetes mellitus, Type not specified
13108 O/E - left eye diabetic maculopathy Diabetes mellitus, Type not specified
13279 Other specified diabetes mellitus with renal complications Diabetes mellitus, Type not specified
14049 Hb. A1C - diabetic control NOS Diabetes mellitus, Type not specified
14050 HbA1 - diabetic control Diabetes mellitus, Type not specified
15690 Diabetes mellitus with ketoacidotic coma Diabetes mellitus, Type not specified
16230 Diabetes mellitus with neurological manifestation Diabetes mellitus, Type not specified
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16490 Diabetic treatment changed Diabetes mellitus, Type not specified
16491 Diabetes mellitus with polyneuropathy Diabetes mellitus, Type not specified
16502 Diabetes mellitus with renal manifestation Diabetes mellitus, Type not specified
16881 [V]Dietary counselling in diabetes mellitus Diabetes mellitus, Type not specified
17067 Autonomic neuropathy due to diabetes Diabetes mellitus, Type not specified
17095 O/E - Right diabetic foot at risk Diabetes mellitus, Type not specified
17247 Diabetic mononeuritis NOS Diabetes mellitus, Type not specified
17313 Diabetic iritis Diabetes mellitus, Type not specified
17817 Subcutaneous injection of insulin Diabetes mellitus, Type not specified
17869 Diabetic-uncooperative patient Diabetes mellitus, Type not specified
17886 Diabetic - follow-up default Diabetes mellitus, Type not specified
18056 Foot abnormality - diabetes related Diabetes mellitus, Type not specified
18142 Diabetic cheiroarthropathy Diabetes mellitus, Type not specified
18167 Annual diabetic blood test Diabetes mellitus, Type not specified
18311 Diabetic retinopathy screening Diabetes mellitus, Type not specified
18662 Diabetic retinopathy 6 month review Diabetes mellitus, Type not specified
18747 Diabetic retinopathy screening not indicated Diabetes mellitus, Type not specified
19381 Referral to diabetic eye clinic Diabetes mellitus, Type not specified
19739 Diabetic retinopathy screening offered Diabetes mellitus, Type not specified
20696 Injection sites - diabetic Diabetes mellitus, Type not specified
21482 Diabetes mellitus with hyperosmolar coma Diabetes mellitus, Type not specified
21689 Diabetic lipid lowering diet Diabetes mellitus, Type not specified
22023 Diabetic - poor control NOS Diabetes mellitus, Type not specified
22573 Diabetes mellitus NOS with neurological manifestation Diabetes mellitus, Type not specified
22823 Diabetic foot examination Diabetes mellitus, Type not specified
22967 Retinal abnormality - diabetes related Diabetes mellitus, Type not specified
23479 Bronzed diabetes Diabetes mellitus, Type not specified
24327 Ischaemic ulcer diabetic foot Diabetes mellitus, Type not specified
24363 Diabetic stabilisation Diabetes mellitus, Type not specified
24571 Asymptomatic diabetic neuropathy Diabetes mellitus, Type not specified
25636 Diabetic diet - poor compliance Diabetes mellitus, Type not specified
26604 Diabetic diet - good compliance Diabetes mellitus, Type not specified
26605 Attended diabetes structured education programme Diabetes mellitus, Type not specified
26664 O/E - Left diabetic foot at risk Diabetes mellitus, Type not specified
26666 O/E - Right diabetic foot at low risk Diabetes mellitus, Type not specified
26667 O/E - Left diabetic foot at low risk Diabetes mellitus, Type not specified
27891 Diabetic Charcot arthropathy Diabetes mellitus, Type not specified
27921 Foot abnormality - diabetes related Diabetes mellitus, Type not specified
28769 Diabetic on insulin and oral treatment Diabetes mellitus, Type not specified
28856 Transition of diabetes care options discussed Diabetes mellitus, Type not specified
28873 Diabetic 6 month review Diabetes mellitus, Type not specified
29041 Date diabetic treatment start Diabetes mellitus, Type not specified
30247 Adverse reaction to insulins Diabetes mellitus, Type not specified
30477 High risk proliferative diabetic retinopathy Diabetes mellitus, Type not specified
31053 [D]Widespread diabetic foot gangrene Diabetes mellitus, Type not specified
31156 O/E - Left diabetic foot at moderate risk Diabetes mellitus, Type not specified
31157 O/E - Right diabetic foot at moderate risk Diabetes mellitus, Type not specified
31171 O/E - Right diabetic foot at high risk Diabetes mellitus, Type not specified
31172 O/E - Left diabetic foot at high risk Diabetes mellitus, Type not specified
31790 Polyneuropathy in diabetes Diabetes mellitus, Type not specified
32403 Diabetes mellitus with gangrene Diabetes mellitus, Type not specified
32556 Diabetes with gangrene Diabetes mellitus, Type not specified
32619 Patient diabetes education review Diabetes mellitus, Type not specified
33254 Diabetes mellitus with ophthalmic manifestation Diabetes mellitus, Type not specified
33343 Diabetes mellitus with other specified manifestation Diabetes mellitus, Type not specified
34152 Diabetic peripheral angiopathy Diabetes mellitus, Type not specified
34283 Diabetes mellitus NOS with ophthalmic manifestation Diabetes mellitus, Type not specified
34528 Diabetes well being questionnaire Diabetes mellitus, Type not specified
35107 Diabetes mellitus with nephropathy NOS Diabetes mellitus, Type not specified
35116 O/E - Left diabetic foot - ulcerated Diabetes mellitus, Type not specified
35316 O/E - Right diabetic foot - ulcerated Diabetes mellitus, Type not specified
35321 Non-urgent diabetic admission Diabetes mellitus, Type not specified
35383 Diabetic patient unsuitable for digital retinal photography Diabetes mellitus, Type not specified
35399 Diabetes mellitus with peripheral circulatory disorder Diabetes mellitus, Type not specified
35785 Chronic painful diabetic neuropathy Diabetes mellitus, Type not specified
36798 Continuous subcutaneous infusion of insulin Diabetes mellitus, Type not specified
37315 Diabetic mononeuropathy Diabetes mellitus, Type not specified
38078 Understands diet - diabetes Diabetes mellitus, Type not specified
38130 Diabetes wellbeing questionnaire Diabetes mellitus, Type not specified
38617 Other specified diabetes mellitus with ketoacidosis Diabetes mellitus, Type not specified
38986 Diabetes mellitus with no mention of complication Diabetes mellitus, Type not specified
39420 Myasthenic syndrome due to diabetic amyotrophy Diabetes mellitus, Type not specified
41686 [X]Other specified diabetes mellitus Diabetes mellitus, Type not specified
42505 Diabetes mellitus NOS with ketoacidosis Diabetes mellitus, Type not specified
43453 Diabetes mellitus autosomal dominant Diabetes mellitus, Type not specified
43857 Lipoatrophic diabetes mellitus Diabetes mellitus, Type not specified
43951 Diabetic - cooperative patient Diabetes mellitus, Type not specified
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44033 Diabetic mononeuritis multiplex Diabetes mellitus, Type not specified
44312 Informed dissent for diabetes national audit Diabetes mellitus, Type not specified
45250 Under care of diabetic liaison nurse Diabetes mellitus, Type not specified
45491 Diabetes mellitus with unspecified complication Diabetes mellitus, Type not specified
46290 Other specified diabetes mellitus with multiple comps Diabetes mellitus, Type not specified
46577 Diabetes: shared care in pregnancy - diabetol and obstet Diabetes mellitus, Type not specified
47032 Diabetes care plan agreed Diabetes mellitus, Type not specified
47144 O/E - diabetic maculopathy absent both eyes Diabetes mellitus, Type not specified
47328 O/E - right eye stable treated prolif diabetic retinopathy Diabetes mellitus, Type not specified
47341 Diabetic crisis monitoring Diabetes mellitus, Type not specified
47370 Diabetology D.V. done Diabetes mellitus, Type not specified
47377 Other specified diabetes mellitus with ophthalmic complicatn Diabetes mellitus, Type not specified
47584 Advanced diabetic retinal disease Diabetes mellitus, Type not specified
48078 Acute painful diabetic neuropathy Diabetes mellitus, Type not specified
48310 [V]Admitted for commencement of insulin Diabetes mellitus, Type not specified
49640 O/E - left chronic diabetic foot ulcer Diabetes mellitus, Type not specified
49884 Diabetic pre-pregnancy counselling Diabetes mellitus, Type not specified
50175 Diabetic foot risk assessment Diabetes mellitus, Type not specified
50972 Diabetes mellitus NOS with no mention of complication Diabetes mellitus, Type not specified
51939 [V]Admitted for conversion to insulin Diabetes mellitus, Type not specified
52041 O/E - left eye stable treated prolif diabetic retinopathy Diabetes mellitus, Type not specified
52212 [X]Diabetes mellitus Diabetes mellitus, Type not specified
52237 Patient held diabetic record issued Diabetes mellitus, Type not specified
52630 O/E - sight threatening diabetic retinopathy Diabetes mellitus, Type not specified
53238 Diabetic drug side effects Diabetes mellitus, Type not specified
53630 Insulin coma Diabetes mellitus, Type not specified
53634 [D]Gangrene of toe in diabetic Diabetes mellitus, Type not specified
54601 Under care of diabetologist Diabetes mellitus, Type not specified
55431 Pre-existing diabetes mellitus, unspecified Diabetes mellitus, Type not specified
57333 Diabetic cheiropathy Diabetes mellitus, Type not specified
57389 Patient consent given for addition to diabetic register Diabetes mellitus, Type not specified
57723 Referral to diabetic register Diabetes mellitus, Type not specified
59288 Other specified diabetes mellitus with coma Diabetes mellitus, Type not specified
59903 Diabetic amyotrophy Diabetes mellitus, Type not specified
61021 Diabetic digital retinopathy screening offered Diabetes mellitus, Type not specified
61210 Adverse reaction to insulins and antidiabetic agents NOS Diabetes mellitus, Type not specified
61461 Informed consent for diabetes national audit Diabetes mellitus, Type not specified
61520 Iatrogenic hyperinsulinism Diabetes mellitus, Type not specified
61523 Other specified diabetes mellitus with neurological comps Diabetes mellitus, Type not specified
61670 Diab mellit insulin-glucose infus acute myocardial infarct Diabetes mellitus, Type not specified
62384 O/E - right chronic diabetic foot ulcer Diabetes mellitus, Type not specified
63364 [X] Adverse reaction to insulins Diabetes mellitus, Type not specified
63412 Diabetes clinical management plan Diabetes mellitus, Type not specified
64142 Referral for diabetic retinopathy screening Diabetes mellitus, Type not specified
64283 Other specified diabetes mellitus with unspecified comps Diabetes mellitus, Type not specified
64357 Diabetes mellitus NOS with unspecified complication Diabetes mellitus, Type not specified
64449 Unspecified diabetes mellitus with multiple complications Diabetes mellitus, Type not specified
65025 Diabetes mellitus NOS with peripheral circulatory disorder Diabetes mellitus, Type not specified
65062 Diabetes mellitus NOS with ketoacidotic coma Diabetes mellitus, Type not specified
65463 High risk non proliferative diabetic retinopathy Diabetes mellitus, Type not specified
65684 [X] Adverse reaction to insulins and antidiabetic agents Diabetes mellitus, Type not specified
66274 Insulin needles changed for each injection Diabetes mellitus, Type not specified
67664 Education score - diabetes Diabetes mellitus, Type not specified
68546 Diabetes clinic satisfaction questionnaire Diabetes mellitus, Type not specified
68818 DTSQ - Diabetes treatment satisfaction questionnaire Diabetes mellitus, Type not specified
68928 Adverse reaction to insulins and antidiabetic agents Diabetes mellitus, Type not specified
69152 Insulin needles changed less than once a day Diabetes mellitus, Type not specified
70821 Diabetes mellitus NOS with other specified manifestation Diabetes mellitus, Type not specified
72345 Diabetes mellitus NOS with hyperosmolar coma Diabetes mellitus, Type not specified
83485 Insulin dose changed Diabetes mellitus, Type not specified
90301 Insulin needles changed daily Diabetes mellitus, Type not specified
91164 CSQ - Diabetes clinic satisfaction questionnaire Diabetes mellitus, Type not specified
93390 Attended DAFNE diabetes structured education programme Diabetes mellitus, Type not specified
93491 DAFNE diabetes structured education programme completed Diabetes mellitus, Type not specified
93529 DESMOND diabetes structured education programme completed Diabetes mellitus, Type not specified
93631 XPERT diabetes structured education programme completed Diabetes mellitus, Type not specified
94011 Attended XPERT diabetes structured education programme Diabetes mellitus, Type not specified
94186 Diabetes structured education programme completed Diabetes mellitus, Type not specified
94699 Diabetes treatment satisfaction questionnaire Diabetes mellitus, Type not specified
95994 Diabetic foot screen Diabetes mellitus, Type not specified
96010 Insulin treatment initiated Diabetes mellitus, Type not specified
96143 Insulin initiation - enhanced services administration Diabetes mellitus, Type not specified
97824 DWBQ - Diabetes wellbeing questionnaire Diabetes mellitus, Type not specified
98954 Diabetes treatment satisfaction questionnaire Diabetes mellitus, Type not specified
99628 [X]Glomerular disorders in diabetes mellitus Diabetes mellitus, Type not specified
100033 [X] Adverse reaction to insulins and antidiabetic agents NOS Diabetes mellitus, Type not specified
100292 [X]Unspecified diabetes mellitus with renal complications Diabetes mellitus, Type not specified
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100436 Education in self management of diabetes Diabetes mellitus, Type not specified
101177 Diabetic dietary review Diabetes mellitus, Type not specified
101728 Diabetic on subcutaneous treatment Diabetes mellitus, Type not specified
101881 Impaired vision due to diabetic retinopathy Diabetes mellitus, Type not specified
102767 Pre-conception advice for diabetes mellitus Diabetes mellitus, Type not specified
608 Follow-up diabetic assessment Possible diabetes
2379 Seen in diabetic clinic Possible diabetes
3550 Diabetic monitoring Possible diabetes
7777 Referral to diabetologist Possible diabetes
8306 Referral to diabetes nurse Possible diabetes
8414 Pt advised re diabetic diet Possible diabetes
8618 Seen by diabetic liaison nurse Possible diabetes
9145 DNA - Did not attend diabetic clinic Possible diabetes
9897 Diabetes monitoring admin. Possible diabetes
9974 Seen in diabetic eye clinic Possible diabetes
10824 Seen in diabetic foot clinic Possible diabetes
11041 Excepted from diabetes qual indicators: Patient unsuitable Possible diabetes
11348 Excepted from diabetes quality indicators: Informed dissent Possible diabetes
11977 Referral to diabetes nurse Possible diabetes
12030 Diabetes monitoring 3rd letter Possible diabetes
12225 Refer, diabetic liaison nurse Possible diabetes
12483 Advice about blood glucose control Possible diabetes
12507 Seen by diabetic liaison nurse Possible diabetes
13067 Diabetic monitoring NOS Possible diabetes
13070 Initial diabetic assessment Possible diabetes
13191 Diabetes clinic administration Possible diabetes
13192 Diabetes monitor. check done Possible diabetes
13194 Diabetes monitoring 1st letter Possible diabetes
13195 Diabetes monitoring 2nd letter Possible diabetes
13196 Fundoscopy - diabetic check Possible diabetes
13197 Attends diabetes monitoring Possible diabetes
13678 Referral to diabetic liaison nurse Possible diabetes
17478 Self monitoring of blood glucose Possible diabetes
17846 Self monitoring of urine glucose Possible diabetes
18824 Diabetic foot examination declined Possible diabetes
20900 Diabetes monitored Possible diabetes
22130 Diabetes monitoring default Possible diabetes
26603 Refuses diabetes monitoring Possible diabetes
28574 Exception reporting: diabetes quality indicators Possible diabetes
30648 Did not attend diabetic retinopathy clinic Possible diabetes
31141 Diabetes monitor.phone invite Possible diabetes
31240 Diabetes monitor.verbal invite Possible diabetes
31241 Diabetes monitoring admin.NOS Possible diabetes
32739 Seen in community diabetes specialist clinic Possible diabetes
32770 Glucose tol. test diabetic Possible diabetes
34541 Private referral to diabetologist Possible diabetes
36669 Diabetic monitoring not required Possible diabetes
38103 Seen in diabetic nurse consultant clinic Possible diabetes
38129 Seen in community diabetic specialist nurse clinic Possible diabetes
42217 Self monitoring of blood and urine glucose Possible diabetes
46521 Seen by diabetologist Possible diabetes
47011 Referral to diabetes structured education programme Possible diabetes
47058 Discharged from care of diabetes specialist nurse Possible diabetes
50937 Referral to diabetes preconception counselling clinic Possible diabetes
55123 Date diabetic treatment stopp. Possible diabetes
58133 Discharge by diabetic liaison nurse Possible diabetes
58159 Insulin therapy declined Possible diabetes
58639 Patient held diabetic record declined Possible diabetes
61470 Diabetic monitoring - higher risk albumin excretion Possible diabetes
66475 Diabetic monitoring - lower risk albumin excretion Possible diabetes
69163 Referral to multidisciplinary diabetic clinic Possible diabetes
82474 Referral to community diabetes specialist nurse Possible diabetes
93657 Referral to DESMOND diabetes structured education programme Possible diabetes
93704 Referral to DAFNE diabetes structured education programme Possible diabetes
93854 Diabetes structured education programme declined Possible diabetes
93870 Referral to XPERT diabetes structured education programme Possible diabetes
94330 Referral to diabetes special interest general practitioner Possible diabetes
94955 Did not attend XPERT diabetes structured education programme Possible diabetes
94956 Did not complete XPERT diabetes structured education program Possible diabetes
95093 Did not complete DESMOND diabetes structured educat program Possible diabetes
95094 Did not complete diabetes structured education programme Possible diabetes
95159 Did not attend DESMOND diabetes structured education program Possible diabetes
95553 Did not attend diabetes structured education programme Possible diabetes
95813 Seen in multidisciplinary diabetic clinic Possible diabetes
97281 Seen by general practitioner special interest in diabetes Possible diabetes
97809 Did not complete DAFNE diabetes structured education program Possible diabetes
99277 Did not attend DAFNE diabetes structured education programme Possible diabetes
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100422 Discharged from diabetes shared care programme Possible diabetes
100791 Insulin treatment stopped Possible diabetes
101190 Declined consent for diabetes year of care programme Possible diabetes
101455 Diabetes monitor invitation by SMS (short message service) Possible diabetes
101456 Diabetic dietary review declined Possible diabetes
101834 Excepted from diabetes qual indicators: service unavailable Possible diabetes
102316 Suspected diabetes mellitus Possible diabetes
102490 Diabetic assessment of erectile dysfunction Possible diabetes
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23 metformin tablets 500mg Oral anti-diabetics *
32 gliclazide tablets 80mg Oral anti-diabetics
93 metformin tablets 850mg Oral anti-diabetics *
321 insulin human actrapid (neutral) 40 i/u inj Insulin
322 ZERIDAME SR tablets 150mg [ACTAVIS] Insulin
469 rosiglitazone tablets 4mg Oral anti-diabetics
547 glipizide tablets 2.5mg Oral anti-diabetics
548 pioglitazone tablets 15mg Oral anti-diabetics
735 metformin oral suspension 100mg/ml Oral anti-diabetics *
1253 chlorpropamide tablets 100mg Oral anti-diabetics
1254 glibenclamide tablets 5mg Oral anti-diabetics
1587 monotard injection 100 units/ml [novo] Insulin
1588 actrapid injection 100 iu/ml [novo] Insulin
1592 actrapid penfill 100 iu/ml [novo] Insulin
1593 insulatard penfill 100 iu/ml [novo] Insulin
1594 actrapid novolet 100 iu/ml [novo] Insulin
1595 insulatard novolet 100 iu/ml [novo] Insulin
1643 Herpes zoster with meningitis Insulin
1645 insulin novo actrapid mc 100 i/u inj Insulin
1649 human actraphane injection 100 iu/ml [novo] Insulin
1805 mixtard 30/70 injection 100 units/ml [novo] Insulin
1806 penmix 30/70 penfill injection 100 iu/ml [novo] Insulin
1839 insulin humulin i (isophane) 100 i/u inj Insulin
1840 humulin s injection 100 units/ml [lilly] Insulin
1842 pork velosulin injection 100 units/ml [novo] Insulin
1843 pork insulatard vial injection suspension 100 units/ml [novo] Insulin
1844 ultratard injection 100 units/ml [novo] Insulin
1847 chlorpropamide tablets 250mg Oral anti-diabetics
1886 insulatard ge injection 100 iu/ml [novo] Insulin
1964 diamicron tablets 80mg [servier] Oral anti-diabetics
1965 tolbutamide tablets 500mg Oral anti-diabetics
2219 glibenclamide tablets 2.5mg Oral anti-diabetics
2220 penmix 20/80 pen [novo] Insulin
2221 mixtard 30 novolet 100 iu/ml [novo] Insulin
2373 insulin human velosulin 100 i/u inj Insulin
2454 mixtard 30 penfill 100 iu/ml [novo] Insulin
2455 mixtard 20 novolet 100 iu/ml [novo] Insulin
2456 mixtard 10 novolet 100 iu/ml [novo] Insulin
2459 pork mixtard 30 vial injection suspension 100 units/ml [novo] Insulin
2808 insulin lentard inj Insulin
2812 mixtard 40 novolet 100 iu/ml [novo] Insulin
2928 metformin hcl 850 mg tab Oral anti-diabetics *
2929 mixtard 30 ge injection 100 iu/ml [novo] Insulin
3252 metformin hcl 500 mg tab Oral anti-diabetics *
3396 penmix 10/90 penfill penfill [novo] Insulin
3439 penmix 10/90 pen [novo] Insulin
3550 mixtard 40 penfill 100 iu/ml [novo] Insulin
3551 mixtard 20 penfill 100 iu/ml [novo] Insulin
4093 humulin m2 injection 100 units/ml [lilly] Insulin
4129 insulin soluble porcine injection 100 units/ml Insulin
4163 rapitard mc injection 100 units/ml [novo] Insulin
4198 humulin m3 injection 100 units/ml [lilly] Insulin
4199 humulin m1 injection 100 units/ml [lilly] Insulin
4247 insulin isophane porcine injection 100 units/ml Insulin
4248 insulin novo ultratard mc 100 i/u inj Insulin
4706 velosulin vial injection solution 100 units/ml [novo] Insulin
4715 humalog mix 25 injection 25:75; 100 units/ml [lilly] Insulin
4760 humulin i injection 100 units/ml [lilly] Insulin
4784 lentard mc injection 100 units/ml [novo] Insulin
4790 mixtard 50 penfill 100 iu/ml [novo] Insulin
4862 diabetamide tablets 2.5mg [ashbourne] Oral anti-diabetics
5021 novorapid penfill injection solution 100 units/ml [novo] Insulin
5214 insulin lispro human prb injection 100 iu/ml Insulin
5227 rosiglitazone tablets 8mg Oral anti-diabetics
5250 insulin biphasic lispro human prb injection 25:75; 100 units/ml Insulin
5255 mixtard 10 penfill 100 iu/ml [novo] Insulin
5276 glimepiride tablets 1mg Oral anti-diabetics
5316 glimepiride tablets 4mg Oral anti-diabetics
5353 glimepiride tablets 2mg Oral anti-diabetics
5501 insuman basal injection 100 iu/ml [aventis] Insulin
5627 gliclazide modified release tablet 30mg Oral anti-diabetics
5636 glipizide tablets 5mg Oral anti-diabetics
5678 nateglinide tablets 120mg Oral anti-diabetics
5845 mixtard 30 innolet injection suspension 30:70; 100 units/ml [novo] Insulin
5891 insulatard flexpen injection 100 iu/ml [novo] Insulin
5892 novorapid flexpen injection solution 100 units/ml [novo] Insulin
5933 mixtard 50 novolet 100 iu/ml [novo] Insulin
5953 insulin glargine injection 100 iu/ml Insulin
5989 nateglinide tablets 180mg Oral anti-diabetics
6057 lantus injection 100 iu/ml [aventis] Insulin
6061 novomix 30 injection 30:70; 100 units/ml [novo] Insulin
6209 novorapid vial injection solution 100 units/ml [novo] Insulin
6337 glimepiride tablets 3mg Oral anti-diabetics
6447 insulin aspart human pyr injection 100 iu/ml Insulin
6855 avandamet tablets 2mg + 500mg [glaxsk pha] Oral anti-diabetics
6958 levemir flexpen injection solution 100 units/ml [novo] Insulin
6965 levemir penfill injection solution 100 units/ml [novo] Insulin
7048 metformin modified release tablet 500mg Oral anti-diabetics *
7166 glucophage tablets 500mg [merck ser] Oral anti-diabetics
7228 novomix 30 flexpen injection suspension 100 units/ml [novo] Insulin
7231 mixtard 30 penfill injection suspension 100 units/ml [novo] Insulin
7237 lantus optiset injection solution 100 units/ml [aventis] Insulin
7266 lantus cartridge injection solution 100 units/ml [aventis] Insulin
7267 novomix 30 penfill injection suspension 100 units/ml [novo] Insulin
7284 amaryl tablets 2mg [aventis] Oral anti-diabetics
7300 mixtard 30 vial injection suspension 100 units/ml [novo] Insulin
7318 humalog cartridge injection solution 100 units/ml [lilly] Insulin
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7319 mixtard 20 penfill injection suspension 100 units/ml [novo] Insulin
7325 avandamet tablets 4mg + 1000mg [glaxsk pha] Oral anti-diabetics
7332 amaryl tablets 1mg [aventis] Oral anti-diabetics
7349 actrapid vial injection solution 100 units/ml [novo] Insulin
7350 insulin isophane porcine vial injection suspension 100 units/ml Insulin
7375 rosiglitazone with metformin tablets 4mg + 1000mg Oral anti-diabetics *
7393 insulin glargine cartridge injection solution 100 units/ml Insulin
7400 insulin glargine disposable pen injection solution 100 units/ml Insulin
7402 lantus vial injection solution 100 units/ml [aventis] Insulin
7409 amaryl tablets 3mg [aventis] Oral anti-diabetics
7537 humulin zn injection 100 units/ml [lilly] Insulin
7610 glucophage tablets 850mg [merck ser] Oral anti-diabetics
7744 daonil tablets 5mg [aventis] Oral anti-diabetics
7757 insulin neulente (zinc susp)(purified) 100 i/u inj Insulin
7763 insulin neuphane (isophane)(purified) 100 i/u inj Insulin
7764 insulin neusulin (neutral)(purified) 100 i/u inj Insulin
7765 insulin neutral (human) 100 i/u inj Insulin
7771 human protaphane penfill 100 units/ml [novo] Insulin
7772 human protaphane injection 100 units/ml [novo] Insulin
7783 insulin isophane (human) 100 i/u inj Insulin
7793 humaject m3 pen 100 iu/ml [lilly] Insulin
7815 metformin 800 mg tab Oral anti-diabetics *
7861 insulin humulin s (neutral) cartridge 100 i/u Insulin
7912 semi-daonil tablets 2.5mg [aventis] Oral anti-diabetics
7959 insulin mixtard 30/70 40 i/u inj Insulin
8034 diabinese tablets 100mg [pfizer] Oral anti-diabetics
8118 humaject i pen 100 iu/ml [lilly] Insulin
8168 diabinese tablets 250mg [pfizer] Oral anti-diabetics
8203 penmix 50/50 penfill injection 100 iu/ml [novo] Insulin
8322 insulin zinc suspension mixed human pyr injection 100 units/ml Insulin
8354 insulin isophane 70%/neutral 30% 100 i/u inj Insulin
8376 insulin isophane 100 i/u Insulin
8390 gliquidone tablets 30mg Oral anti-diabetics
8646 insulin zinc crystalline susp 100 i/u inj Insulin
8838 insulin semitard 40 i/u inj Insulin
8839 insulin semitard 100 i/u inj Insulin
8841 humulin m5 injection 100 units/ml [lilly] Insulin
8895 initard 50/50 injection 100 units/ml [novo] Insulin
8976 euglucon tablets 2.5mg [aventis] Oral anti-diabetics
9079 insulin soluble 100 i/u inj Insulin
9108 tolbutamide 250 mg tab Oral anti-diabetics
9341 insulin biphasic isophane human prb injection 30:70; 100 units/ml Insulin
9376 insulin zinc suspension crystalline human pyr - long acting injection 100 units/ml Insulin
9503 hypurin bovine protamine zinc vial injection suspension 100 units/ml [wockhardt] Insulin
9521 pork actrapid vial injection solution 100 units/ml [novo] Insulin
9565 humaject s disposable pen injection solution 100 units/ml [lilly] Insulin
9618 hypurin porcine 30/70 mix injection 100 iu/ml [wockhardt] Insulin
9662 avandia tablets 4mg [glaxsk pha] Oral anti-diabetics
9699 pioglitazone tablets 30mg Oral anti-diabetics
9707 repaglinide tablets 1mg Oral anti-diabetics
9737 insulatard innolet injection 100 iu/ml [novo] Insulin
9748 repaglinide tablets 2mg Oral anti-diabetics
9865 repaglinide tablets 500 micrograms Oral anti-diabetics
10001 humalog mix 50 disposable pen injection suspension 100 units/ml [lilly] Insulin
10051 pioglitazone tablets 45mg Oral anti-diabetics
10067 insulin biphasic aspart human pyr injection 30:70; 100 units/ml Insulin
10175 insulin isophane human pyr injection 100 iu/ml Insulin
10184 insulin detemir injection solution 100 iu/ml Insulin
10207 insulin isophane human cartridge injection suspension 100 units/ml Insulin
10208 insulatard innolet injection suspension 100 units/ml [novo] Insulin
10225 lantus opticlik injection solution 100 units/ml [aventis] Insulin
10229 humulin i disposable pen injection suspension 100 units/ml [lilly] Insulin
10243 humalog mix 25 cartridge injection suspension 100 units/ml [lilly] Insulin
10244 mixtard 40 penfill injection suspension 100 units/ml [novo] Insulin
10245 mixtard 10 penfill injection suspension 100 units/ml [novo] Insulin
10259 insulin glargine vial injection solution 100 units/ml Insulin
10264 humalog disposable pen injection solution 100 units/ml [lilly] Insulin
10277 humulin m3 cartridge injection suspension 100 units/ml [lilly] Insulin
10427 tolazamide tablets 250mg Oral anti-diabetics
10484 penmix 20/80 penfill penfill [novo] Insulin
10545 insulin humulin m4 cartridge 100 i/u Insulin
10546 insulin humulin m4 100 i/u inj Insulin
10547 humulin lente injection 100 units/ml [lilly] Insulin
10566 insulin humulin m cartridge 100 i/u Insulin
10572 insulin soluble bovine injection 100 units/ml Insulin
10691 insulin isophane (nph) 100 i/u inj Insulin
10887 penmix 40/60 penfill injection 100 iu/ml [novo] Insulin
10910 humaject m2 pen 100 iu/ml [lilly] Insulin
10915 humaject m1 pen 100 iu/ml [lilly] Insulin
11055 insulin biphasic isophane human pyr injection 20:80; 100 units/ml Insulin
11056 insulin biphasic isophane human pyr injection 30:70; 100 units/ml Insulin
11080 insulin isophane human prb injection 100 iu/ml Insulin
11107 humulin m4 injection 100 units/ml [lilly] Insulin
11284 amaryl tablets 4mg [aventis] Oral anti-diabetics
11316 novonorm tablets 500 micrograms [novo] Oral anti-diabetics
11321 novonorm tablets 1mg [novo] Oral anti-diabetics
11337 novorapid novolet injection 100 iu/ml [novo] Insulin
11366 novonorm tablets 2mg [novo] Oral anti-diabetics
11483 nateglinide tablets 60mg Oral anti-diabetics
11601 rosiglitazone with metformin tablets 2mg + 500mg Oral anti-diabetics *
11604 rosiglitazone with metformin tablets 1mg + 500mg Oral anti-diabetics *
11609 metformin with rosiglitazone tablets 500mg + 1mg Oral anti-diabetics *
11610 metformin with rosiglitazone tablets 500mg + 2mg Oral anti-diabetics *
11695 diamicron mr tablets 30mg [servier] Oral anti-diabetics
11717 rosiglitazone with metformin tablets 2mg + 1000mg Oral anti-diabetics *
11737 metformin with rosiglitazone tablets 1000mg + 4mg Oral anti-diabetics *
11760 metformin with rosiglitazone tablets 1000mg + 2mg Oral anti-diabetics *
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11946 tolbutamide injection 50mg/ml Oral anti-diabetics
11990 metformin oral solution 500mg/5ml Oral anti-diabetics *
12035 insulin zinc lente bovine vial injection suspension 100 units/ml Insulin
12060 insulin quicksol (soluble neutral) 100 i/u inj Insulin
12244 insulin zinc bovine susp 100 i/u inj Insulin
12245 glutril tablets 25mg [roche] Oral anti-diabetics
12259 glibornuride tablets 25mg Oral anti-diabetics
12297 hypurin bovine neutral injection 100 units/ml [cp pharm] Insulin
12299 semitard mc injection 100 units/ml [novo] Insulin
12455 rastinon tablets 500mg [hoechstmar] Oral anti-diabetics
12513 glibenese tablets 5mg [pfizer] Oral anti-diabetics
12638 insulin soluble human pyr injection 100 units/ml Insulin
12654 insulin soluble human prb injection 100 units/ml Insulin
12818 mixtard 50 injection 50:50; 100 units/ml [novo] Insulin
13277 mixtard 50 penfill injection suspension 100 units/ml [novo] Insulin
13331 euglucon tablets 5mg [aventis] Oral anti-diabetics
13416 insulin biphasic injection 100 units/ml Insulin
13516 hypurin bovine isophane injection 100 units/ml [cp pharm] Insulin
13550 insulin bp 100 i/u Insulin
13622 hypurin porcine neutral injection 100 units/ml [cp pharm] Insulin
13628 romozin tablets 400mg [glaxo] Oral anti-diabetics
13729 insulin isophane human emp injection 100 units/ml Insulin
13819 hypurin porcine isophane injection 100 units/ml [wockhardt] Insulin
13837 insulin biphasic isophane human prb injection 10:90; 100 units/ml Insulin
14164 avandamet tablets 2mg + 1000mg [glaxsk pha] Oral anti-diabetics
14270 humalog mix 25 disposable pen injection suspension 100 units/ml [lilly] Insulin
14290 insulatard penfill injection suspension 100 units/ml [novo] Insulin
14299 insulin glulisine cartridge injection solution 100 units/ml Insulin
14301 insulin detemir cartridge injection solution 100 units/ml Insulin
14313 insulin lispro cartridge injection solution 100 units/ml Insulin
14330 insulin detemir disposable pen injection solution 100 units/ml Insulin
14339 hypurin bovine neutral vial injection solution 100 units/ml [wockhardt] Insulin
14340 hypurin bovine isophane vial injection suspension 100 units/ml [wockhardt] Insulin
14345 apidra cartridge injection solution 100 units/ml [sanofi/ave] Insulin
14357 humulin i cartridge injection suspension 100 units/ml [lilly] Insulin
14362 insulin lispro disposable pen injection solution 100 units/ml Insulin
14504 insulin hypurin protamine zinc 100 i/u inj Insulin
14505 insulin protamine zinc bovine vial injection suspension 100 units/ml Insulin
14506 insulin bovine protamine zinc 100 i/u inj Insulin
14619 insulin biphasic isophane porcine injection 30:70; 100 units/ml Insulin
14644 insulin biphasic isophane human prb injection 20:80; 100 units/ml Insulin
14649 insulin biphasic isophane human pyr injection 10:90; 100 units/ml Insulin
14918 humulin i vial injection suspension 100 units/ml [lilly] Insulin
14925 insulin isophane human vial injection suspension 100 units/ml Insulin
14928 insulatard vial injection suspension 100 units/ml [novo] Insulin
14930 hypurin porcine neutral cartridge injection solution 100 units/ml [wockhardt] Insulin
14933 hypurin porcine isophane cartridge injection suspension 100 units/ml [wockhardt] Insulin
14938 insulin soluble bovine cartridge injection solution 100 units/ml Insulin
14944 humulin s cartridge injection solution 100 units/ml [lilly] Insulin
15040 insulin monophane (isophane) 100 i/u inj Insulin
15199 insuman comb 25 injection 100 iu/ml [aventis] Insulin
15232 avandia tablets 8mg [glaxsk pha] Oral anti-diabetics
15374 gliclazide oral suspension 40mg/5ml Oral anti-diabetics
15484 insulin isophane bovine injection 100 units/ml Insulin
15624 insulin isophane (highly purified) 100 i/u inj Insulin
15710 insulin soluble human emp injection 100 units/ml Insulin
15955 starlix tablets 120mg [novartis] Oral anti-diabetics
15961 insulin isophane human crb injection 100 iu/ml Insulin
16044 glucophage sr tablets 500mg [merck ser] Oral anti-diabetics
16129 insulin soluble human cartridge injection solution 100 units/ml Insulin
16142 insulin aspart cartridge injection solution 100 units/ml Insulin
16152 insulin biphasic isophane human cartridge injection suspension 30:70; 100 units/ml Insulin
16160 humulin m3 disposable pen injection suspension 100 units/ml [lilly] Insulin
16209 insulin hypurin soluble 100 i/u inj Insulin
16211 tolbutamide 100 mg tab Oral anti-diabetics
16213 metformin 250 mg tab Oral anti-diabetics *
16602 calabren tablets 2.5mg [berk] Oral anti-diabetics
16682 tempulin injection 100 units/ml [knoll] Insulin
16700 insulin zinc mixed bovine vial injection suspension 100 units/ml Insulin
17336 novopen injection device 100 units/ml [novo] Insulin
17343 gliclazide tablets 80mg [hillcross] Oral anti-diabetics
17580 avandamet tablets 1mg + 500mg [glaxsk pha] Oral anti-diabetics
17698 minodiab tablets 5mg [pharmacia] Oral anti-diabetics
17706 minodiab tablets 2.5mg [pharmacia] Oral anti-diabetics
17712 hypurin bovine lente vial injection suspension 100 units/ml [wockhardt] Insulin
17731 penmix 50/50 injection 100 iu/ml [novo] Insulin
17809 humaject m4 pen 100 iu/ml [lilly] Insulin
18220 pioglitazone with metformin tablets 15mg + 850mg Oral anti-diabetics *
18224 humalog vial injection solution 100 units/ml [lilly] Insulin
18301 insulin soluble inj i/u^2 Insulin
18461 insulin zinc suspension mixed human prb injection 100 units/ml Insulin
18590 insulin isophane bovine vial injection suspension 100 units/ml Insulin
18592 insulin soluble bovine vial injection solution 100 units/ml Insulin
18593 humalog mix 50 cartridge injection suspension 100 units/ml [lilly] Insulin
18645 insulin neutral (purified) 100 i/u inj Insulin
18931 insulin zinc suspension crystalline human prb - intermediate acting injection 100 units/ml Insulin
19336 tolazamide tablets 100mg Oral anti-diabetics
19472 actos tablets 45mg [takeda] Oral anti-diabetics
19491 apidra vial injection solution 100 units/ml [sanofi/ave] Insulin
19513 humulin m3 vial injection suspension 100 units/ml [lilly] Insulin
19658 glurenorm tablets 30mg [sanofi s] Oral anti-diabetics
19707 insulin humulin s (neutral soluble) Insulin
19829 insulin novo monotard mc Insulin
19877 insulin aspart disposable pen injection solution 100 units/ml Insulin
19878 insulin biphasic isophane human disposable pen injection suspension 30:70; 100 units/ml Insulin
20195 insulin bovine protamine zinc 40 i/u inj Insulin
20196 insulin soluble 40 i/u inj Insulin
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20287 actos tablets 15mg [takeda] Oral anti-diabetics
20422 insuman comb 15 injection 100 iu/ml [aventis] Insulin
20671 insulin hum/actraphane Insulin
20672 insulin hum/actrapid Insulin
20810 metformin Oral anti-diabetics *
20889 actos tablets 30mg [takeda] Oral anti-diabetics
20995 hypurin porcine 30/70 mix cartridge injection suspension 100 units/ml [wockhardt] Insulin
21110 insulin biphasic isophane human prb injection 50:50; 100 units/ml Insulin
21232 insulin biphasic isophane human vial injection suspension 30:70; 100 units/ml Insulin
21235 humulin s vial injection solution 100 units/ml [lilly] Insulin
21347 penmix 40/60 injection 100 iu/ml [novo] Insulin
21374 insulin biphasic isophane human prb injection 40:60; 100 units/ml Insulin
21395 insulin biphasic isophane human pyr injection 40:60; 100 units/ml Insulin
21422 insulin biphasic isophane human cartridge injection suspension 40:60; 100 units/ml Insulin
21424 glibenclamide oral suspension 5mg/5ml Oral anti-diabetics
21489 tolanase tablets 250mg [pharmacia] Oral anti-diabetics
21554 insuman comb 50 injection 100 iu/ml [aventis] Insulin
21564 gliclazide tablets 80mg [wockhardt] Oral anti-diabetics
21583 apidra optiset injection solution 100 units/ml [sanofi/ave] Insulin
21590 insulin glulisine disposable pen injection solution 100 units/ml Insulin
21832 diabetamide tablets 5mg [ashbourne] Oral anti-diabetics
21892 diaglyk tablets 80mg [ashbourne] Oral anti-diabetics
21945 insulin pork insulatard Insulin
22058 pur-in mix 15/85 injection [cp pharm] Insulin
22094 insulin humulin m2 vial Insulin
22145 tolanase tablets 100mg [pharmacia] Oral anti-diabetics
22155 humaject m5 pen 100 iu/ml [lilly] Insulin
22161 insulin humulin m1 vial Insulin
22496 insulin zinc lente purified suspension Insulin
22636 tolbutamide 1 gm tab Oral anti-diabetics
22697 insulin biphasic isophane human pyr injection 50:50; 100 units/ml Insulin
22806 insulin pork actrapid Insulin
22823 insulin isophane (purified) 100 i/u inj Insulin
22858 acetohexamide tablets 500mg Oral anti-diabetics
22945 insuman rapid injection 100 iu/ml [aventis] Insulin
22983 insuman rapid cartridge injection solution 100 units/ml [aventis] Insulin
23003 insulin isophane (nph) 40 i/u Insulin
23099 insulin biphasic aspart disposable pen injection suspension 30:70; 100 units/ml Insulin
23231 hypurin bovine neutral cartridge injection solution 100 units/ml [wockhardt] Insulin
23945 starlix tablets 60mg [novartis] Oral anti-diabetics
23992 insuman basal optiset injection suspension 100 units/ml [aventis] Insulin
23993 insuman rapid optiset injection solution 100 units/ml [aventis] Insulin
24002 insuman comb 25 vial injection suspension 100 units/ml [aventis] Insulin
24485 insulin zinc animal suspension Insulin
24593 neutral insulin bovine injection 100 iu/ml Insulin
24722 insulin isophane 50%/neutral 50% 100 i/u inj Insulin
24795 insulin biphasic aspart cartridge injection suspension 30:70; 100 units/ml Insulin
24800 hypurin porcine 30/70 mix vial injection suspension 100 units/ml [wockhardt] Insulin
24845 insulin pur-in isophane 100 i/u inj Insulin
24846 pur-in neutral injection 100 units/ml [cp pharm] Insulin
24848 glymidine sodium tablets 500mg Oral anti-diabetics
24866 insulin insulatard (leo retard) 40 i/u inj Insulin
24993 insuman comb 25 cartridge injection suspension 100 units/ml [aventis] Insulin
25006 insulin human actrapid (neutral) Insulin
25133 insuman comb 25 optiset injection suspension 100 units/ml [aventis] Insulin
25479 insulin soluble porcine cartridge injection solution 100 units/ml Insulin
25636 libanil tablets 2.5mg [aps] Oral anti-diabetics
25678 glucamet tablets 500mg [opus] Oral anti-diabetics
25735 insulin biphasic isophane human cartridge injection suspension 20:80; 100 units/ml Insulin
25736 insulin biphasic isophane human cartridge injection suspension 10:90; 100 units/ml Insulin
25812 insulin isophane human disposable pen injection suspension 100 units/ml Insulin
26060 insulin lispro vial injection solution 100 units/ml Insulin
26098 hypurin porcine neutral vial injection solution 100 units/ml [wockhardt] Insulin
26118 dimelor tablets 500mg [lilly] Oral anti-diabetics
26218 calabren tablets 5mg [berk] Oral anti-diabetics
26258 glucamet tablets 850mg [opus] Oral anti-diabetics
26403 pur-in mix 25/75 injection [cp pharm] Insulin
26498 insulin zinc suspension mixed bovine and porcine injection 100 units/ml Insulin
26621 insulin soluble human crb injection 100 iu/ml Insulin
26784 insulin zinc semilente susp bp 100 i/u inj Insulin
27125 starlix tablets 180mg [novartis] Oral anti-diabetics
27177 insulin biphasic lispro human prb injection 50:50; 100 units/ml Insulin
27280 insulin biphasic isophane porcine vial injection suspension 30:70; 100 units/ml Insulin
27396 insulin soluble porcine vial injection solution 100 units/ml Insulin
27402 insulin soluble human vial injection solution 100 units/ml Insulin
27461 insuman basal cartridge injection suspension 100 units/ml [aventis] Insulin
27501 orabet tablets 500mg [lagap] Oral anti-diabetics
27614 penmix 30/70 injection 100 iu/ml [novo] Insulin
27911 insulin human actrapid penfill Insulin
27969 glymese tablets 250mg [ddsa] Oral anti-diabetics
28096 insulin biphasic isophane human cartridge injection suspension 50:50; 100 units/ml Insulin
28101 insulin glulisine vial injection solution 100 units/ml Insulin
28183 hypurin porcine isophane vial injection suspension 100 units/ml [wockhardt] Insulin
28185 insulin biphasic lispro cartridge injection suspension 25:75; 100 units/ml Insulin
28442 insulin glulisine injection solution 100 units/ml Insulin
28588 hypurin bovine isophane cartridge injection suspension 100 units/ml [wockhardt] Insulin
28708 malix tablets 2.5mg [lagap] Oral anti-diabetics
28723 insulin zinc bovine suspension Insulin
28978 insulin pur-in mix 15/85 100 i/u inj Insulin
29326 glipizide tablets 5mg [gen (uk)] Oral anti-diabetics
29567 insulin aspart vial injection solution 100 units/ml Insulin
29837 insulin biphasic isophane human prb injection 25:75; 100 units/ml Insulin
29939 gliclazide tablets 80mg [gen (uk)] Oral anti-diabetics
29953 apidra opticlik injection solution 100 units/ml [sanofi/ave] Insulin
30209 actrapid mc injection 100 units/ml [arun] Insulin
30236 isophane insulin injection 100 iu/ml Insulin
30316 metformin with pioglitazone tablets 850mg + 15mg Oral anti-diabetics *
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30460 malix tablets 5mg [lagap] Oral anti-diabetics
30686 insulin isophane porcine cartridge injection suspension 100 units/ml Insulin
30819 insuman comb 15 optiset injection suspension 100 units/ml [aventis] Insulin
30861 insulin zinc human suspension Insulin
31077 competact film coated tablets [takeda] Oral anti-diabetics
31146 metsol oral solution 500mg/5ml [orbis] Oral anti-diabetics
31205 insuman comb 50 optiset injection suspension 100 units/ml [aventis] Insulin
31212 gliclazide tablets 80mg [actavis] Oral anti-diabetics
31258 insulin biphasic lispro disposable pen injection suspension 25:75; 100 units/ml Insulin
31267 insulin pur-in mix 50/50 100 i/u inj Insulin
31465 exubera powder for inhalation 1mg [pfizer] Insulin
31467 exubera powder for inhalation 3mg [pfizer] Insulin
31474 libanil tablets 5mg [aps] Oral anti-diabetics
32053 insulin humalog mix 25 Insulin
33087 metformin tablets 500mg [actavis] Oral anti-diabetics *
33167 insulin biphasic isophane human crb injection 25:75; 100 units/ml Insulin
33232 insulin biphasic isophane human crb injection 50:50; 100 units/ml Insulin
33562 duclazide tablets 80mg [dumex] Oral anti-diabetics
33673 tolbutamide tablets 500mg [actavis] Oral anti-diabetics
33674 metformin tablets 850mg [hillcross] Oral anti-diabetics *
33966 insulatard injection 100 units/ml [novo] Insulin
34004 metformin tablets 500mg [ivax] Oral anti-diabetics *
34020 metformin tablets 850mg [ivax] Oral anti-diabetics *
34031 monotard mc injection 100 units/ml [novo] Insulin
34097 human initard 50/50 injection 100 units/ml [novo] Insulin
34135 metformin tablets 500mg [m&a pharm] Oral anti-diabetics *
34323 metformin tablets 500mg [hillcross] Oral anti-diabetics *
34399 gliclazide tablets 80mg [ivax] Oral anti-diabetics
34504 metformin tablets 500mg [wockhardt] Oral anti-diabetics *
34507 glibenclamide tablets 2.5mg [wockhardt] Oral anti-diabetics
34563 glibenclamide tablets 5mg [wockhardt] Oral anti-diabetics
34598 metformin tablets 500mg [gen (uk)] Oral anti-diabetics *
34676 glibenclamide tablets 2.5mg [hillcross] Oral anti-diabetics
34697 metformin tablets 850mg [wockhardt] Oral anti-diabetics *
34706 glibenclamide tablets 2.5mg [ivax] Oral anti-diabetics
34742 metformin tablets 850mg [teva] Oral anti-diabetics *
34802 glipizide tablets 5mg [ivax] Oral anti-diabetics
34836 metformin tablets 850mg [actavis] Oral anti-diabetics *
34917 metformin tablets 500mg [teva] Oral anti-diabetics *
34932 gliclazide tablets 80mg [genus] Oral anti-diabetics
34957 tolbutamide tablets 500mg [hillcross] Oral anti-diabetics
35022 sitagliptin tablets 100mg Oral anti-diabetics
35144 byetta injection 5 micrograms [lilly] Oral anti-diabetics
35149 exenatide injection 10micrograms Oral anti-diabetics
35150 byetta injection 10micrograms [lilly] Oral anti-diabetics
35251 exenatide injection 5 micrograms Oral anti-diabetics
35253 insuman comb 50 cartridge injection suspension 100 units/ml [aventis] Insulin
35260 levemir innolet injection solution 100 units/ml [novo] Insulin
35462 januvia tablets 100mg [m s d] Oral anti-diabetics
35468 insuman basal vial injection suspension 100 units/ml [aventis] Insulin
35561 prandin tablets 2mg [novo] Oral anti-diabetics
35701 insulin biphasic lispro disposable pen injection suspension 50:50; 100 units/ml Insulin
36031 insulin biphasic isophane porcine cartridge injection suspension 30:70; 100 units/ml Insulin
36066 insulin isophane bovine cartridge injection suspension 100 units/ml Insulin
36146 insulin biphasic lispro cartridge injection suspension 50:50; 100 units/ml Insulin
36194 insulin biphasic isophane human cartridge injection suspension 25:75; 100 units/ml Insulin
36355 insulin human powder for inhalation 1mg Insulin
36356 insulin human powder for inhalation 3mg Insulin
36430 insulin soluble human disposable pen injection solution 100 units/ml Insulin
36513 velosulin cartridge injection 100 units/ml [novo] Insulin
36774 prandin tablets 1mg [novo] Oral anti-diabetics
36853 lantus solostar injection solution 100 units/ml [sanofi/ave] Insulin
36856 gliclazide tablets 80mg [sandoz] Oral anti-diabetics
36920 apidra solostar injection solution 100 units/ml [sanofi/ave] Insulin
36948 prandin tablets 500 micrograms [novo] Oral anti-diabetics
37617 rosiglitazone tablets 2mg Oral anti-diabetics
37874 vildagliptin with metformin tablets 50mg + 850mg Oral anti-diabetics *
37875 vildagliptin tablets 50mg Oral anti-diabetics
37902 vildagliptin with metformin tablets 50mg + 1000mg Oral anti-diabetics *
38355 metformin modified release tablet 750mg Oral anti-diabetics *
38400 glucophage sr tablets 750mg [merck ser] Oral anti-diabetics
38422 isophane injection 100 iu/ml [celltech] Insulin
38551 eucreas tablets 50mg + 1000mg [novartis] Oral anti-diabetics
38986 humalog kwikpen injection solution 100 units/ml [lilly] Insulin
39006 humalog mix 25 kwikpen injection suspension 100 units/ml [lilly] Insulin
39086 humalog mix 50 kwikpen injection suspension 100 units/ml [lilly] Insulin
39149 galvus tablets 50mg [novartis] Oral anti-diabetics
39203 eucreas tablets 50mg + 850mg [novartis] Oral anti-diabetics
39560 bolamyn sr tablets 500mg [teva] Oral anti-diabetics
39598 metformin modified release tablet 1000mg Oral anti-diabetics *
39729 glucophage sr tablets 1000mg [merck ser] Oral anti-diabetics
39988 metformin oral powder 500mg Oral anti-diabetics *
40007 glucophage sachets 1000mg [merck ser] Oral anti-diabetics
40110 glucophage sachets 500mg [merck ser] Oral anti-diabetics
40233 metformin oral powder 1000mg Oral anti-diabetics *
40365 glimepiride tablets 1mg [actavis] Oral anti-diabetics
40425 nazdol mr tablets 30mg [teva] Oral anti-diabetics
40642 victoza injection 18mg/3ml [novo] Oral anti-diabetics
40693 liraglutide injection 18mg/3ml Oral anti-diabetics
41120 insulin biphasic isophane human disposable pen injection suspension 50:50; 100 units/ml Insulin
41204 saxagliptin tablets 5mg Oral anti-diabetics
41431 onglyza tablets 5mg [bms] Oral anti-diabetics
41558 glibenclamide tablets 5mg [teva] Oral anti-diabetics
41559 glibenclamide tablets 5mg [hillcross] Oral anti-diabetics
41593 glibenclamide tablets 2.5mg [teva] Oral anti-diabetics
41834 insulin zinc suspension lente injection 100 iu/ml [celltech] Insulin
41898 glibenclamide Oral anti-diabetics
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41959 penject injection device 100 units/ml [hypoguard] Insulin
42161 orabet tablets 500mg [sandoz] Oral anti-diabetics
42395 humalog mix 25 vial injection suspension 100 units/ml [lilly] Insulin
42790 gliclazide tablets 80mg [merck-gen] Oral anti-diabetics
42954 insulin biphasic isophane human vial injection suspension 25:75; 100 units/ml Insulin
43065 gliclazide tablets 40mg Oral anti-diabetics
43270 metformin sugar free oral solution 500mg/5ml [rosemont] Oral anti-diabetics *
43465 zicron tablets 40mg [bristol lb] Oral anti-diabetics
43619 sitagliptin with metformin tablets 50mg + 1000mg Oral anti-diabetics *
43684 janumet tablets 50mg + 1000mg [m s d] Oral anti-diabetics
43950 humulin i kwikpen injection suspension 100 units/ml [lilly] Insulin
43953 insulin biphasic lispro vial injection suspension 25:75; 100 units/ml Insulin
43991 humulin m3 kwikpen injection suspension 100 units/ml [lilly] Insulin
44250 metformin oral solution 500mg/5ml [hillcross] Oral anti-diabetics *
44251 insulin zinc suspension mixed porcine injection 100 units/ml Insulin
44304 glyconon tablets 500mg [ddsa] Oral anti-diabetics
44378 insulin biphasic isophane human disposable pen injection suspension 25:75; 100 units/ml Insulin
44473 edicil mr tablets 30mg [ratiopharm] Oral anti-diabetics
44480 insuman comb 25 solostar injection suspension 100 units/ml [aventis] Insulin
44738 niddaryl tablets 1mg [dee] Oral anti-diabetics
45158 insuman comb 15 cartridge injection suspension 100 units/ml [aventis] Insulin
45215 gliclazide tablets 80mg [neolab] Oral anti-diabetics
45581 metabet sr tablets 500mg [morningsid] Oral anti-diabetics
45775 saxagliptin tablets 2.5mg Oral anti-diabetics
45821 onglyza tablets 2.5mg [bms] Oral anti-diabetics
45831 dacadis modified release tablet 30mg [gen (uk)] Oral anti-diabetics
46001 insuman basal solostar injection suspension 100 units/ml [aventis] Insulin
46458 exenatide powder for prolonged release injection suspension 2mg Oral anti-diabetics
46469 bydureon powder for prolonged release injection suspension 2mg [lilly] Oral anti-diabetics
46665 linagliptin tablets 5mg Oral anti-diabetics
46666 novorapid flextouch injection solution 100 units/ml [novo] Insulin
46716 trajenta tablets 5mg [boeh ingl] Oral anti-diabetics
46927 tolbutamide tablets 500mg [teva] Oral anti-diabetics
46989 metabet sr tablets 1000mg [morningsid] Oral anti-diabetics
47074 gliclazide oral suspension 80mg/5ml Oral anti-diabetics
47360 neutral insulin injection 100 units/ml [celltech] Insulin
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Medical Code Read Term
573 Epilepsy
988 Grand mal (major) epilepsy
1715 Epileptic absences
2907 Petit mal (minor) epilepsy
3175 ZERIDAME SR tablets 150mg [ACTAVIS]





4801 Epileptic seizures - myoclonic
5117 Grand mal status
5152 Epileptic seizures - tonic
5525 Focal epilepsy
5668 Grand mal seizure
6271 Status epilepticus, unspecified
6709 [X]Epileptic psychosis NOS
7809 Herpes zoster with meningitis




9326 Epilepsy medication review
9569 Jacksonian, focal or motor epilepsy
9747 Epilepsy NOS
9886 Petit mal status
9887 Locl-rlt(foc)(part)idiop epilep&epilptic syn seiz locl onset
9979 Other forms of epilepsy NOS
11015 Seizure free >12 months
11186 Generalised nonconvulsive epilepsy
11394 Complex partial epileptic seizure
11454 Trigger factor for seizure
11505 Seizures in response to acute event
11752 Patient on maximal tolerated anticonvulsant therapy
13073 Epilepsy drug side effects
13219 No seizures on treatment
13220 Epilepsy control poor
13221 2 to 4 seizures a month
17399 Juvenile absence epilepsy
18471 Epileptic seizures - clonic
18899 Daily seizures
19170 Benign Rolandic epilepsy
19363 Juvenile myoclonic epilepsy
19549 1 to 7 seizures a week
19550 Epilepsy control good
19551 Epilepsy care arrangement
19552 Epilepsy does not limit activities





24309 Epileptic seizures - atonic
25330 Complex partial status epilepticus
26015 Partial epilepsy without impairment of consciousness
26144 Generalised convulsive epilepsy
26511 Follow-up epilepsy assessment
26512 Epilepsy treatment changed
26618 1 to 12 seizures a year
26619 Epilepsy limits activities
26620 Epilepsy restricts employment
26733 Partial epilepsy without impairment of consciousness OS
319
Epilepsy
Medical Code Read Term
26961 Anticonvulsant level therapeutic




31830 Epileptic seizures - akinetic
31877 [X]Schizophrenia-like psychosis in epilepsy
31920 Partial epilepsy with impairment of consciousness NOS
32288 Partial epilepsy with impairment of consciousness
34079 Epileptic automatism
34473 Epilepsy treatment started
36203 Psychosensory epilepsy
37592 Somatosensory epilepsy
37644 Progressive myoclonic epilepsy
37782 Neonatal myoclonic epilepsy
38307 Other forms of epilepsy
38919 Transient epileptic amnesia
39160 Many seizures a day
40105 Simple partial epileptic seizure
40806 Generalised convulsive epilepsy NOS
40863 Epilepsy impairs education
43679 [X]Acquired aphasia with epilepsy [Landau - Kleffner]
44252 Generalised nonconvulsive epilepsy NOS
45746 Initial epilepsy assessment
45927 Other specified generalised convulsive epilepsy
46603 Emergency epilepsy treatment since last appointment
48134 Sensory induced epilepsy
48462 [X]Limbic epilepsy personality
49889 Acquired epileptic aphasia
50012 Epilepsy associated problems
50702 Epilepsy prevents employment
52273 [X] Adverse reaction to anticonvulsants NOS
52632 No epilepsy drug side effects
53483 Gelastic epilepsy
55260 Cursive (running) epilepsy
55665 Limbic system epilepsy
55706 Epilepsy management plan given
55739 Visual reflex epilepsy
56359 Menstrual epilepsy
59120 [X]Other status epilepticus
59185 Other specified generalised nonconvulsive epilepsy
60306 Adverse reaction to anticonvulsants NOS






71801 [X]Status epilepticus, unspecified
73542 Visceral reflex epilepsy
73879 [X]Oth unspec antiepileptics caus adverse eff in therap use
95658 [X] Adverse reaction to other anticonvulsant
98870 Partial epilepsy with autonomic symptoms
99548 Pykno-epilepsy
99731 [X]Other generalized epilepsy and epileptic syndromes
99834 [D]Nocturnal seizure
100652 Contraceptive advice for patients with epilepsy
100920 Pre-conception advice for patients with epilepsy
101143 Contraceptiv advice for patients with epilepsy not indicated
102190 Contraceptive advice for patients with epilepsy declined
102191 Pregnancy advice for patients with epilepsy declined
102264 Pre-conception advic fr patients with epilepsy not indicated
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102265 Pre-conception advice for patients with epilepsy declined
102359 Pregnancy advice for patients with epilepsy
102375 Pregnancy advice for patients with epilepsy not indicated
321
Herpes Zoster (CPRD)
Medical code Read term Site of zoster
390 Herpes zoster Site Unspecified
516 Shingles Site Unspecified
7331 Ramsey Hunt Syndrome Non-truncal
8936 Ophthalmic herpes zoster infection Ophthalmic herpes zoster
14718 Herpes zoster with ophthalmic complication Ophthalmic herpes zoster 
14793 Herpes zoster otitis externa Non-truncal 
18918 Herpes zoster ophthalmicus Ophthalmic herpes zoster 
21069 Herpes zoster with unspecified complication Site Unspecified
21471 Herpes zoster NOS Site Unspecified
25320 Herpes zoster with dermatitis of eyelid Ophthalmic herpes zoster 
27403 Geniculate herpes zoster Non-truncal 
27546 Herpes zoster with keratoconjunctivitis Ophthalmic herpes zoster 
31681 Herpes zoster - otitis externa Non-truncal 
33810 Herpes zoster with other ophthalmic complication Ophthalmic herpes zoster 
38531 Herpes zoster with other specified complication NOS Site Unspecified
39692 Polyneuropathy in herpes zoster Site Unspecified
43235 Herpes zoster with other specified complication Site Unspecified
44944 Herpes zoster with meningitis Non-truncal 
47375 Zoster encephalitis Site Unspecified
50537 Herpes zoster with other CNS complications Non-truncal 
51692 Encephalitis due to herpes zoster Site Unspecified
52126 Herpes zoster with other central nervous system complication Non-truncal 
52319 Disseminated zoster Site Unspecified
55940 Herpes zoster iridocyclitis Ophthalmic herpes zoster 
57895 Herpes zoster meningitis Non-truncal 
62558 Infective otitis externa due to herpes zoster Non-truncal 
63739 Herpes zoster with other CNS complication NOS Non-truncal 
69405 Herpes zoster encephalitis Site Unspecified
70197 [X]Zoster without complications Site Unspecified
71464 Meningitis due to herpes zoster virus Non-truncal 
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B02 Herpes zoster Site Unspecified
B02.0 Zoster encephalitis Site Unspecified
B02.1 Zoster meningitus Non-truncal
B02.3 Zoster ocular disease Ophthalmic herpes zoster 
B02.7 Disseminated zoster Site Unspecified
B02.8 Zoster with other complications Site Unspecified
B02.9 Zoster without complications Site Unspecified
G53.0 Ramsay Hunt Syndrome Non-truncal
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Medical code Read term
2835 HIV positive
8281 HIV disease resulting in wasting syndrome
9130 Human immunodeficiency virus infection
23763 AIDS carrier
23951 ZERIDAME SR tablets 150mg [ACTAVIS]
27519 Pneumonia with pneumocystis carinii
27641 HIV disease resulting in Pneumocystis carinii pneumonia
27853 HIV disease resulting in Kaposi's sarcoma
32018 HTLV 1 nucleic acid detection
33943 Notification of AIDS
36294 Acquired human immunodeficiency virus infection syndrome NOS
37006 HIV disease resulting in mycobacterial infection
41185 [X]Dementia in human immunodef virus [HIV] disease
43537 HIV 1 nucleic acid detection
44288 [D]Laboratory evidence of human immunodeficiency virus [HIV]
44617 HIV disease resulting in Burkitt's lymphoma
46442 Retrovirus infection
47632 Herpes zoster with meningitis
50076 HIV disease resulting in multiple infections
51708 HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu
53636 Human immunodeficiency virus with neurological disease
54423 Retrovirus as cause of diseases classified to other chapters
58857 Acute human immunodeficiency virus infection
58859 Asymptomatic human immunodeficiency virus infection
62854 [X]Human immunodeficiency virus disease
62891 Human immunodeficiency virus with other clinical findings
65117 HIV disease resulting in lymphoid interstitial pneumonitis
66367 HIV dis resulting oth types of non-Hodgkin's lymphoma
66368 HIV disease resulting in cytomegaloviral disease
67575 HIV disease resulting in unspecified malignant neoplasm
69766 HIV infection with persistent generalised lymphadenopathy
69767 [X]HIV disease resulting in other non-Hodgkin's lymphoma
70528 Human immunodeficiency virus with secondary infection
70869 Human immunodeficiency virus with constitutional disease
71450 HIV disease resulting/unspcf infectious+parasitic disease
72065 HTLV 2 nucleic acid detection
93642 Human immunodeficiency virus RNA/DNA ratio
96751 [X]HIV disease result/haematological+immunologic abnorms,NEC
96902 Human immunodeficiency virus viral load by log rank
98966 Human immunodeficiency virus monitoring
100769 [X]Unspecified human immunodeficiency virus [HIV] disease
101191 Human immunodeficiency virus annual review
101836 Human immunodeficiency virus with secondary cancers
102117 [X]HIV disease resulting in multiple infections
102252 [X]HIV disease resulting in other specified conditions
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Medical code Read term
28232 Peripheral blood stem cell graft
86063 Autologous peripheral blood stem cell transplant
89920 Allogeneic peripheral blood stem cell transplant
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273 hypothyroidism










15743 hypothyroidism resulting from para-aminosalicylic acid
18282 hypothyroid goitre, acquired
19367 hypothyroidism monitoring verbal invite
20310 pretibial myxoedema - hypothyroid
23014 thyroid insufficiency
24748 other acquired hypothyroidism
25913 other iatrogenic hypothyroidism
27533 cretinism
28735 hypothyroidism monitoring administration
28852 postsurgical hypothyroidism
31612 congenital hypothyroidism with diffuse goitre
31971 autoimmune myxoedema
34221 iodine hypothyroidism
38976 iatrogenic hypothyroidism nos
39166 congenital iodine-deficiency syndrome, myxoedematous type
46057 hypothyroidism monitoring first letter
46345 acquired atrophy of thyroid
46630 hypothyroidism monitoring second letter
46640 hypothyroidism monitoring third letter
47449 goitrous cretin
47521 post ablative hypothyroidism
47658 cerebral degeneration due to myxoedema
50275 other postablative hypothyroidism
50860 postinfectious hypothyroidism
51416 myopathy due to myxoedema
51481 congenital hypothyroidism nos
51706 postablative hypothyroidism nos
56722 premature puberty due to hypothyroidism
58833 neonatal jaundice with congenital hypothyroidism
59702 myxoedema coma
61069 myasthenic syndrome due to hypothyroidism
67513 cretinism
69290 other specified congenital hypothyroidism
73107 [x]other sp cified hypothyroidism
85661 hypothyroidism monitoring telephone invitation
85955 hypothyroidism clinical management plan
93159 congenital hypothyroidism without goitre
93323 congenital thyroid insufficiency
94915 hypothyroidism resulting from resorcinol
95830 subclinical hypothyroidism
95885 hypothyroidism annual review
97090 hypothyroidism resulting from phenylbutazone
102442 suspected hypothyroidism
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Medical code Read term
593 Crohn's disease
704 Ulcerative colitis
1784 Ulcerative colitis and/or proctitis
1796 Inflammatory bowel disease
5133 ZERIDAME SR tablets 150mg [ACTAVIS]




9359 Crohn's disease of the small bowel NOS
11119 CDAI - Crohn's disease activity index
11286 Regional enteritis - Crohn's disease
11337 Crohn's disease activity index
12575 Juvenile arthritis in Crohn's disease
15207 Idiopathic proctocolitis NOS
15773 Regional ileocolitis
17641 Arthropathy in ulcerative colitis
20480 Herpes zoster with meningitis
20688 Crohn's disease of the large bowel NOS
22516 Exacerbation of ulcerative colitis
24550 Other idiopathic proctocolitis
24858 Ulcerative rectosigmoiditis
28476 Crohn's disease of the terminal ileum
29616 Orofacial Crohn's disease
30433 Ulcerative (chronic) enterocolitis
33456 Ulcerative proctocolitis NOS
36913 Exacerbation of Crohn's disease of small intestine
39037 Exacerbation of Crohn's disease of large intestine
39278 Crohn's disease of the ileum NOS
42822 Ulcerative (chronic) ileocolitis
43090 Other idiopathic proctocolitis NOS
44426 Regional enteritis of the large bowel
48732 Ulcerative ileocolitis
51576 Regional enteritis of the small bowel
51578 Granulomatous enteritis
52449 Regional enteritis NOS
53743 [X]Other ulcerative colitis
59994 Crohn's disease NOS
62628 Regional enteritis of the colon
63036 Regional enteritis of the jejunum
64773 Regional enteritis of the rectum
66238 Crohn's disease of the ileum unspecified
69959 [X]Other Crohn's disease
71083 Juvenile arthritis in ulcerative colitis
71945 Regional enteritis of the duodenum
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Leukaemia 
Medical code Read term
4072 Acute leukaemia NOS
4222 Lymphatic leukaemia
4250 Leukaemia NOS
4251 Acute lymphoid leukaemia
4413 ZERIDAME SR tablets 150mg [ACTAVIS]
4637 [M]Leukaemias
5915 [M]Hairy cell leukaemia
6316 [M]Acute leukaemia NOS
7176 Myeloid leukaemia
8625 Chronic lymphoid leukaemia
10726 Chronic myeloid leukaemia
12146 [M]Lymphoid leukaemia NOS
16416 Chronic leukaemia NOS
19372 Lymphoid leukaemia
19974 Acute monocytic leukaemia
20440 Myelomonocytic leukaemia
20635 [M]Lymphatic leukaemia
22050 Herpes zoster with meningitis
22071 [M]Blast cell leukaemia
25191 Leukaemia of unspecified cell type
27458 Chronic monocytic leukaemia
27520 Chronic myeloid leukaemia NOS
27664 Acute promyelocytic leukaemia
27790 Chronic lymphatic leukaemia
29335 [M]Adult T-cell leukaemia/lymphoma
30632 Other specified leukaemia NOS
31586 Prolymphocytic leukaemia
31701 Chronic granulocytic leukaemia
31750 [M]Chronic leukaemia NOS
33344 Myeloid leukaemia NOS
34692 Other leukaemia of unspecified cell type
35697 [M]Myeloid leukaemias
35875 Monocytic leukaemia
37272 Other specified leukaemia
37410 [M]Acute lymphoid leukaemia
37461 Adult T-cell leukaemia
37723 [M]Granulocytic leukaemia NOS
38331 Other lymphoid leukaemia NOS
38914 Lymphoid leukaemia NOS
39187 Plasma cell leukaemia
40420 [M]Leukaemias unspecified
41500 [M]Chronic lymphoid leukaemia
41734 [M]Leukaemia NOS
42297 [M]Leukaemia NOS
42539 Acute erythraemia and erythroleukaemia
46048 [M]Prolymphocytic leukaemia
46263 [M]Acute myelomonocytic leukaemia
46444 [M]Erythroleukaemias
48049 [M]Chronic myelomonocytic leukaemia
48155 [M]Lymphoid leukaemias
49327 [M]Acute megakaryoblastic leukaemia
49725 Other lymphoid leukaemia
50928 [M]Burkitt's cell leukaemia
52942 [M]Chronic myeloid leukaemia
53477 [V]Follow-up examination after chemotherapy for leukaemia
54585 [M]Acute myeloid leukaemia
54793 Subacute leukaemia NOS
57316 [M]Acute promyelocytic leukaemia
57671 Megakaryocytic leukaemia
57713 [M]Eosinophilic leukaemias
59929 [M]Leukaemia unspecified, NOS
61500 Acute myelomonocytic leukaemia
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61693 [X]Other myeloid leukaemia
62330 [M]Other myeloid leukaemia NOS
63475 Subacute myeloid leukaemia
63570 [M]Stem cell leukaemia
64618 [M]Plasma cell leukaemias
64963 [M]Blastic leukaemia
65165 [X]Other leukaemia of unspecified cell type
65721 Mast cell leukaemia
65777 Thrombocytic leukaemia
66089 Other myeloid leukaemia NOS
66694 [M]Naegeli-type monocytic leukaemia





71850 [M]Myeloid leukaemia NOS
72179 [M]Subacute leukaemia NOS
72197 Lymphosarcoma cell leukaemia
72222 [M]Megakaryocytic leukaemia
72310 [M]Aleukaemic leukaemia NOS
72774 Subacute lymphoid leukaemia
73066 [M]Miscellaneous leukaemias
73088 [M]Monocytic leukaemia NOS
87335 Hairy cell leukaemia
89329 [X]Other specified leukaemias
89762 [X]Other monocytic leukaemia
93342 Monocytic leukaemia NOS
94174 Other and unspecified leukaemia
99015 Other monocytic leukaemia
99413 Other and unspecified leukaemia NOS
100786 Chronic eosinophilic leukaemia
100927 [M]Erythroleukaemia NOS
101606 Subacute monocytic leukaemia
103645 Other monocytic leukaemia NOS
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3371 [M]Non Hodgkins lymphoma
3604 ZERIDAME SR tablets 150mg [ACTAVIS]
5179 Nodular lymphoma (Brill - Symmers disease)
7940 [X]Non-Hodgkin's lymphoma NOS
8649 [X]Non-Hodgkin's lymphoma, unspecified type
12335 Malignant lymphoma NOS
12464 Peripheral T-cell lymphoma
15027 Malignant lymphoma NOS
15504 Malignant lymphoma NOS of lymph nodes of multiple sites
16460 [M]Malignant lymphoma, non Hodgkin's type
16774 [M] Cutaneous lymphoma
17178 [M]Lymphomas, NOS or diffuse
17182 Follicular lymphoma NOS
17460 Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma
17887 Herpes zoster with meningitis
18383 [M] Large cell lymphoma
19140 Hodgkin's nodular sclerosis of lymph nodes of multiple sites
20437 [M]Lymphomas, nodular or follicular
20710 [M]Hodgkin's disease
21402 Burkitt's lymphoma
21463 [M]Lymphocytic lymphoma NOS
21549 Follicular non-Hodgkin's lymphoma
23711 [M]Malignant lymphoma, diffuse NOS
27416 Lymphosarcoma
27562 [M]Follicular lymphosarcoma NOS
27965 [M]AngiocentricT-cell lymphoma
28639 Follicular non-Hodgkin's small cleaved cell lymphoma
29178 Hodgkin's disease, nodular sclerosis
29876 Hodgkin's, lymphocytic-histiocytic predominance NOS
31492 [M] Monocytoid B-cell lymphoma
31537 [M]Hodgkin,s disease, lymphocytic predominance, nodular
31576 Other types of follicular non-Hodgkin's lymphoma
31726 [M]Malignant lymphoma, small cleaved cell, diffuse
31741 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic deplet
31749 [M]Monocytoid B-cell lymphoma
31794 Unspecified B-cell non-Hodgkin's lymphoma
32240 Lymphoma stage III
33869 [M]Malignant lymphoma, large cell, diffuse NOS
34089 Malignant lymphoma NOS of lymph nodes of axilla and arm
34352 [M]Lymphoblastic lymphoma NOS
35014 Sezary's disease
36114 [M]Malignant lymphoma NOS
38939 Hodgkin's disease, lymphocytic-histiocytic predominance
39798 Diffuse non-Hodgkin's lymphoma, unspecified
39883 [M]Malig lymp, follicular centre cell, cleaved, follicular
39906 [M]Malignant lymphoma, centrocytic
40508 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic predom
40513 [M]Lymphoma, nodular or follicular NOS
40766 [M] Peripheral T-cell lymphoma NOS
41369 Lymphosarcoma and reticulosarcoma
41754 [M]Malignant lymphoma, lymphoplasmacytoid type
41841 [M]Malignant lymphoma, follicular centre cell NOS
42198 [M]Hodgkin's disease, nodular sclerosis NOS
42461 Hodgkin's disease NOS
42579 Malignant lymphoma NOS of intra-abdominal lymph nodes
42769 [M]Hodgkin's disease NOS
43415 [X]Other Hodgkin's disease
44196 Hodgkin's granuloma
44318 Oth and unspecif peripheral & cutaneous T-cell lymphomas
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Medical code Read term
44617 HIV disease resulting in Burkitt's lymphoma
45264 Nodular lymphoma of lymph nodes of head, face and neck
46877 [M]Malignant lymphoma, small lymphocytic NOS
46931 [M]Malignant lymphoma, stem cell type
48253 [M]Malignant lymphoma, immunoblastic type
49253 [M]Giant follicular lymphoma
49262 Follicular non-Hodgkin's large cell lymphoma
49605 Hodgkin's disease, mixed cellularity
49825 [M]Reticulum cell sarcoma NOS
50668 Diffuse non-Hodgkin's small cell (diffuse) lymphoma
50695 Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lymphoma
50696 Malignant lymphoma NOS of lymph nodes of head, face and neck
51285 [M]Hodgkin's disease, mixed cellularity
51680 [M]Malignant lymphoma, small cell, noncleaved, diffuse
51852 [M]Malig lymphoma, lymphocytic, intermediate different NOS
51895 [M]Lymphoma, diffuse or NOS
53397 Hodgkin's disease NOS
53551 Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma
55303 Hodgkin's nodular sclerosis of head, face and neck
56041 [M]Hodgkin's disease, lymphocytic predominance
57225 Hodgkin's disease, nodular sclerosis of unspecified site
57427 Malignant lymphoma NOS of unspecified site
57544 [M]True histiocytic lymphoma
57737 Lymphoepithelioid lymphoma
58015 [M]Malignant lymphomatous polyposis
58082 Nodular lymphoma of lymph nodes of multiple sites
58684 Hodgkin's mixed cellularity of intrathoracic lymph nodes
58953 [M]Malig lymp,follicular centre cell,noncleaved,follicular
59115 Burkitt's lymphoma of lymph nodes of head, face and neck
59755 Hodgkin's disease NOS of intrathoracic lymph nodes
59778 Hodgkin's disease NOS of lymph nodes of head, face and neck
60092 Malignant lymphoma NOS of spleen
60242 Reticulosarcoma of unspecified site
60275 [M]Malignant lymphoma, centroblastic type NOS
60504 [M]Lymphocytic lymphosarcoma NOS
60918 Lymphoma stage I
61149 Hodgkin's nodular sclerosis of intra-abdominal lymph nodes
61251 [M]Malign lymphoma,lymphocytic,intermediate differn, diffuse
61662 Hodgkin's disease NOS, unspecified site
61997 [M]Hodgkin's disease NOS
62380 Lymphosarcoma of intrathoracic lymph nodes
62437 Malignant reticulosis
63054 Hodgkin's disease, nodular sclerosis NOS
63105 Malignant lymphoma NOS of lymph node inguinal region and leg
63375 [X]Unspecified B-cell non-Hodgkin's lymphoma
63625 Hodgkin's lymphocytic depletion lymph nodes axilla and arm
63699 [M]Malignant lymphoma, nodular NOS
63723 Lymphosarcoma NOS
63973 [M]Microglioma
63994 [M]Malignant lymphoma, large cell, cleaved, diffuse
64036 Hodgkin's sarcoma
64336 [X]Other specified types of non-Hodgkin's lymphoma
64343 [M]Hodgkin,s disease, nodular sclerosis, mixed cellularity
64515 [X]Diffuse non-Hodgkin's lymphoma, unspecified
64670 Lymphosarcoma of intra-abdominal lymph nodes
64947 [M]Brill - Symmers' disease
65180 Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse)
65483 Hodgkin's nodular sclerosis of lymph nodes of axilla and arm
65489 Hodgkin's paragranuloma
65584 [M]Hodgkin,s disease, lymphocytic predominance, diffuse
65701 Nodular lymphoma NOS
66327 Nodular lymphoma of unspecified site
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66367 HIV dis resulting oth types of non-Hodgkin's lymphoma
66603 [M]Malig lymphoma, follicular centre cell, non-cleaved NOS
67203 [M]Lymphoblastic lymphosarcoma NOS
67506 Hodgkin's nodular sclerosis of intrathoracic lymph nodes
67518 [X]Other types of follicular non-Hodgkin's lymphoma
67703 Hodgkin's disease, lymphocytic depletion
68039 Hodgkin's sarcoma of lymph nodes of axilla and upper limb
68330 Hodgkin's, lymphocytic-histiocytic pred of head, face, neck
68964 [M]Malignant lymphoma, centroblastic-centrocytic, diffuse
69301 [M]Malignant lymphoma, convoluted cell type NOS
69767 [X]HIV disease resulting in other non-Hodgkin's lymphoma
69980 [M]Malignant lymphoma, lymphocytic, well differentiated NOS
70374 Reticulosarcoma of intra-abdominal lymph nodes
70509 Diffuse non-Hodgkin's centroblastic lymphoma
70740 [M]Malignant reticulosis
70842 Follicular non-Hodg mixed sml cleavd & lge cell lymphoma
71031 Reticulosarcoma of lymph nodes of head, face and neck
71117 [M]Malignant lymphoma, undifferentiated cell type NOS
71142 Hodgkin's, lymphocytic-histiocytic predominance unspec site
71238 Lymphosarcoma of lymph nodes of head, face and neck
71262 Malignant lymphoma NOS of intrapelvic lymph nodes
71304 Burkitt's lymphoma NOS
71619 [M]Malignant lymphoma, large cell, noncleaved, diffuse
71625 Lymphosarcoma of unspecified site
71652 [M]Malignant lymphoma, mixed small and large cell, diffuse
71672 Lymphoma stage IV
72196 [M]Malignant lymphoma, lymphocytic, poorly different NOS
72241 [M]Prolymphocytic lymphosarcoma
72433 [M]Reticulosarcoma NOS
72714 Mycosis fungoides of lymph nodes of inguinal region and leg
72725 Malignant lymphoma NOS of intrathoracic lymph nodes
73532 Hodgkin's, lymphocytic-histiocytic pred intra-abdominal node
89230 [M]Hodgkin's granuloma
90201 T-zone lymphoma
91674 Mycosis fungoides of intra-abdominal lymph nodes
91900 Hodgkin's disease NOS of lymph nodes of axilla and arm
92068 Nodular lymphoma of intra-abdominal lymph nodes
92245 Hodgkin's, lymphocytic-histiocytic pred intrathoracic nodes
92380 Burkitt's lymphoma of lymph nodes of inguinal region and leg
93951 Hodgkin's, lymphocytic-histiocytic pred inguinal and leg
94005 Hodgkin's disease, mixed cellularity NOS
94279 Hodgkin's disease NOS of spleen
94407 Hodgkin's mixed cellularity of lymph nodes head, face, neck
94935 Lymphoma stage II
94995 Nodular lymphoma of lymph nodes of inguinal region and leg
95012 Mycosis fungoides of lymph nodes of multiple sites
95049 Hodgkin's lymphocytic depletion of unspecified site
95058 Reticulosarcoma of spleen
95338 Hodgkin's, lymphocytic-histiocytic pred intrapelvic nodes
95545 Maltoma
95630 True histiocytic lymphoma
95715 Mucosa-associated lymphoma
96183 [M]Hodgkin's disease,lymphocytic depletion,diffuse fibrosis
96379 Mycosis fungoides of lymph nodes of axilla and upper limb
97577 Burkitt's lymphoma of intra-abdominal lymph nodes
97746 Hodgkin's disease NOS of lymph nodes of multiple sites
97756 [M]Sezary's disease
97852 [M]Malignant lymphoma, centroblastic type, follicular
97863 Hodgkin's disease, mixed cellularity of unspecified site
98596 [X]Other types of diffuse non-Hodgkin's lymphoma
98840 Hodgkin's paragranuloma of intra-abdominal lymph nodes
98909 Hodgkin's granuloma of lymph nodes of head, face and neck
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98961 [M]Malignant lymphoma, centroblastic-centrocytic, follicular
99012 Hodgkin's disease NOS of lymph nodes inguinal region and leg
99200 [M]Hodgkin's disease, nodular sclerosis, cellular phase
99240 Reticulosarcoma NOS
99655 [M]Lymphosarcoma NOS
99887 Other specified reticulosarcoma or lymphosarcoma
99951 Reticulosarcoma or lymphosarcoma NOS
100006 Burkitt's lymphoma of intrathoracic lymph nodes
100352 Lymphosarcoma of lymph nodes of inguinal region and leg
100423 Hodgkin's paragranuloma of lymph nodes of head, face, neck
100532 Sezary's disease NOS
100544 [M]Reticulosarcoma, nodular
101114 Diffuse non-Hodgkin's large cell lymphoma
101429 [M]Lymphogranuloma, malignant
101530 Hodgkin's disease, lymphocytic depletion NOS
101715 Hodgkin's disease, lymphocytic depletion of spleen
102158 Letterer-Siwe disease of intrathoracic lymph nodes
102594 Diffuse large B-cell lymphoma
103245 Lymphosarcoma of spleen
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Myeloma





10395 ZERIDAME SR tablets 150mg [ACTAVIS]
12386 Paraproteinaemia NOS






31671 [M]Plasma cell myeloma
37182 Multiple myeloma and immunoproliferative neoplasms
39244 Urine paraprotein level
39490 [M]Plasmacytic myeloma
43312 Myeloma - solitary
43450 Herpes zoster with meningitis
43552 Kahler's disease
46042 Lambda light chain myeloma
52946 Bone marrow: myeloma cells
53647 [M]Myelomatosis










5002 ZERIDAME SR tablets 150mg [ACTAVIS]
6908 Other idiopathic peripheral neuropathy NOS
7635 Hereditary sensory neuropathy
7795 Diabetes mellitus with neuropathy
8591 Peripheral neuropathy - hereditary or idiopathic
9193 Phantom limb syndrome
10722 Inflammatory and toxic neuropathy
11544 Neuropathic pain
11663 Neuropathic diabetic ulcer - foot
14883 Hereditary or idiopathic peripheral neuropathy NOS
14884 Other idiopathic peripheral neuropathy
15481 Toxic or inflammatory neuropathy NOS
16230 Diabetes mellitus with neurological manifestation
16491 Herpes zoster with meningitis
18016 Phantom limb syndrome with pain
18075 Hereditary and idiopathic peripheral neuropathy
18425 Type 2 diabetes mellitus with polyneuropathy
18534 Ulnar neuropathy
19454 Polyneuropathy in uraemia
22573 Diabetes mellitus NOS with neurological manifestation
24121 Intercostal neuropathy
24216 Postinfectious polyneuritis
24222 Polyneuropathy due to drugs
24226 Polyneuropathy unspecified
24355 Polyneuropathy in vitamin B deficiency
24571 Asymptomatic diabetic neuropathy
24694 Insulin dependent diabetes mellitus with mononeuropathy
28333 Familial neuropathic amyloid
30537 Polyneuropathy in malignant disease
31551 Inflammatory polyneuropathy, unspecified
31790 Polyneuropathy in diabetes
32527 Hereditary motor and sensory neuropathy
34268 Type 2 diabetes mellitus with neurological complications
35465 Hereditary motor and sensory neuropathy type II
35537 [X] Polyneuropathy, unspecified
35785 Chronic painful diabetic neuropathy
36643 Neuropathic arthritis
37315 Diabetic mononeuropathy
38401 Hereditary peripheral neuropathy NOS
39317 Diabetes mellitus, adult onset, + neurological manifestation
39528 Hereditary peripheral neuropathy
39858 [X]Inflammatory polyneuropathy, unspecified
40751 Polyneuropathy in sarcoidosis
41652 Other toxic or inflammatory neuropathy
41716 Insulin dependent diabetes mellitus with polyneuropathy
42831 Type 1 diabetes mellitus with neurological complications
44095 Polyneuropathy in disseminated lupus erythematosus
44512 Idiopathic progressive polyneuropathy
45081 Toxic neuropathy
45467 Non-insulin dependent diabetes mellitus with polyneuropathy
45919 Type 2 diabetes mellitus with neurological complications
46301 Type 1 diabetes mellitus with polyneuropathy
46937 Neuropathy in association with hereditary ataxia
47409 Type II diabetes mellitus with polyneuropathy
47465 Polyneuropathy in polyarteritis nodosa
49146 Type I diabetes mellitus with neurological complications
50527 Type II diabetes mellitus with polyneuropathy
50813 Type II diabetes mellitus with mononeuropathy
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Medical Code Read Term
52089 Polyneuropathy in diphtheria
52283 Insulin-dependent diabetes mellitus with neurological comps
54124 Other toxic agent polyneuropathy
55076 [X]Polyneuropathies & other disord of peripheral nerv syst
55842 Non-insulin-dependent diabetes mellitus with neuro comps
56159 Control of phantom sensation technique
56272 Polyneuropathy in disease EC
56910 Hereditary motor and sensory neuropathy type I
57313 Polyneuropathy in collagen vascular disease
58758 Polyneuropathy in porphyria
59903 Diabetic amyotrophy
61523 Other specified diabetes mellitus with neurological comps
61829 Type 1 diabetes mellitus with neurological complications
62401 Polyneuropathy in rheumatoid arthritis
62674 Type 2 diabetes mellitus with mononeuropathy
63555 Polyneuropathy in disease NOS
66336 Polyneuropathy in amyloidosis
67853 Diabetes mellitus, juvenile, + neurological manifestation
67905 Type II diabetes mellitus with neurological complications
68105 Type 1 diabetes mellitus with mononeuropathy
68960 Polyneuropathy in hypoglycaemia
69047 Serum neuropathy
71258 Polyneuropathy in collagen vascular disease NOS
72320 Non-insulin dependent diabetes mellitus with mononeuropathy
72922 [X]Other mononeuropathies of lower limb
73337 Polyneuropathy in beriberi
91741 [X]Other specified mononeuropathies
91943 Type I diabetes mellitus with polyneuropathy
93228 [X]Paraneoplastic neuromyopathy and neuropathy
93868 [X]Other mononeuropathies of upper limb
95351 Type II diabetes mellitus with mononeuropathy
96256 Axonal sensorimotor neuropathy
97306 [X]Other specified polyneuropathies
97449 [X]Other hereditary and idiopathic neuropathies
97479 [X]Other inflammatory polyneuropathies
97848 Mumps polyneuropathy
98616 Type II diabetes mellitus with neurological complications
99231 Type I diabetes mellitus with mononeuropathy
99855 Neuropathic foot ulcer
100064 Polyneuropathy in mumps
101311 Insulin dependent diabetes mellitus with polyneuropathy
101735 Insulin-dependent diabetes mellitus with neurological comps
105825 Familial amyloid polyneuropathy type III
106103 Hereditary motor and sensory neuropathy type III
107322 [X]Other mononeuropathies in diseases classified elsewhere
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Medical code Read term
938 Pancytopenia NOS
5823 Pancytopenia - acquired
10955 Di George syndrome
18781 Chronic granulomatous disease
21975 ZERIDAME SR tablets 150mg [ACTAVIS]
31275 Pancytopenia with malformation
31322 Wiskott - Aldrich syndrome
31491 Pancytopenia-dysmelia
42394 Job's syndrome
42439 Thrombocytopenic eczema with immunodeficiency
48293 Severe combined immunodeficiency
57322 Common variable immunodeficiency
61326 Pancytopenia with pancreatitis
62236 Combined immunity deficiency
62328 Combined immunity deficiency NOS
73583 Ataxia-telangiectasia
Herpes zoster with meningitis
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Oral corticosteroids
Product Code Product Name
44 prednisolone enteric coated tablets 5mg
95 prednisolone tablets 5mg
186 dexamethasone elixir 0.5mg/5ml
229 cortisone acetate tablets 25mg
557 ZERIDAME SR tablets 150mg [ACTAVIS]
578 prednisolone tablets 1mg
955 prednisolone sodium phosphate soluble tablet 5mg
1063 PREDNESOL tablets 5mg [SOVEREIGN]
1280 dexamethasone tablets 2mg
1380 ENTOCORT CR modified release capsules 3mg [ASTRAZENEC]
1709 hydrocortisone pellets 2.5 mg loz
1971 BETNESOL tablets 0.5mg [FOCUS]
2044 prednisone 2.5 mg tab
2130 methylprednisolone tablets 4mg
2368 prednisolone tablets 2.5mg
2390 prednisolone e/c 1 mg tab
2704 prednisolone tablets 25mg
2799 Herpes zoster with meningitis
2949 prednisone tablets 5mg
3059 prednisolone 50 mg tab
3345 SINTISONE tablets [PHARMACIA]
3418 hydrocortisone tablets 10mg
3557 prednisone tablets 1mg
3898 budesonide modified release capsules 3mg
3969 dexamethasone 8 mg tab
3992 deflazacort tablets 6mg
4535 hydrocortisone tablets 20mg
4779 dexamethasone tablets 0.5mg
4943 dexamethasone sugar free oral solution 2mg/5ml
5157 dexamethasone oral solution 2mg/5ml
5490 DELTACORTRIL ENTERIC tablets 5mg [ALLIANCE]
5913 DELTACORTRIL ENTERIC tablets 2.5mg [ALLIANCE]
6095 budesonide capsules 3mg
6098 HYDROCORTONE tablets 10mg [M S D]
7286 betamethasone sodium phosphate soluble tablet 500micrograms
7548 cortisone acetate capsules 5mg
7584 prednisolone 4 mg tab
7710 prednisolone 15 mg tab
7934 prednisone 30 mg tab
8261 MEDRONE tablets 16mg [PHARMACIA]
9375 deflazacort tablets 1mg
9727 prednisolone tablets 50mg
9994 DECADRON tablets 0.5mg [M S D]
10552 methylprednisolone tablets 16mg
10574 cortisone acetate tablets 5mg
10683 MEDRONE tablets 2mg [PHARMACIA]
10684 methylprednisolone tablets 2mg
10754 HYDROCORTISTAB tablets 20mg [WAYMADE]
10864 betamethasone tablets 500micrograms
11149 BETNELAN tablets 0.5mg [FOCUS]
12398 CORTELAN tablets 25mg [GLAXO]
12400 CORTISYL tablets 25mg [AVENTIS]
13043 HYDROCORTONE tablets 20mg [M S D]
13522 prednisolone 2 mg tab
13615 prednisone 10 mg tab
14076 hydrocortisone sugar free oral suspension 5mg/5ml
14172 methylprednisolone tablets 100mg
15471 hydrocortisone 25 mg tab
15555 MEDRONE tablets 4mg [PHARMACIA]
15617 LEDERCORT tablets 4mg [WYETH PHAR]
16525 BUDENOFALK capsules 3mg [DR FALK]
16724 prednisone 50 mg tab
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Product Code Product Name
17101 dexamethasone 750 mcg tab
17410 deflazacort tablets 30mg
18042 MEDRONE tablets 100mg [PHARMACIA]
18637 CORTISTAB tablets 25mg [WAYMADE]
18955 hydrocortisone 4.5 mg loz
19141 PREDNISOLONE soluble tablet 5mg [SOVEREIGN]
19908 triamcinolone tablets 2mg
20095 PRECORTISYL FORTE tablets 25mg [AVENTIS]
20577 CALCORT tablets 6mg [SHIRE]
20670 prednisolone e/c
20731 hydrocortisone pellets
21218 DEXSOL oral solution 2mg/5ml [ROSEMONT]
21417 PREDNISOLONE tablets 5mg [HILLCROSS]
21465 betamethasone .1 mg tab
21833 DECORTISYL tablets 5mg [ROUSSEL]
21903 ORADEXON-ORGANON tablets 2mg [ORGANON]
22555 CALCORT tablets 1mg [SHIRE]
22827 betamethasone .1 mg pel
23111 triamcinolone tablets 4mg
23210 CORTISTAB tablets 5mg [WAYMADE]
23512 PRECORTISYL tablets 5mg [HOECHSTMAR]
23788 cortisone acetate 2.5 mg tab
24014 LEDERCORT tablets 2mg [WYETH PHAR]
24716 prednisolone e/c
25272 PRECORTISYL tablets 1mg [HOECHSTMAR]




27962 DELTASTAB tablets 1mg [WAYMADE]
28375 PREDNISOLONE enteric coated tablets 2.5mg [HILLCROSS]
28376 PREDNISOLONE enteric coated tablets 2.5mg [BIOREX]
28615 methylprednisolone l/a 4 mg cap
28859 DELTASTAB tablets 5mg [WAYMADE]
29112 CALCORT tablets 30mg [SHIRE]
29322 betamethasone loz
29333 PREDNISOLONE tablets 5mg [ACTAVIS]
31327 prednisolone steaglate tablets 6.65mg
31532 PREDNISOLONE enteric coated tablets 5mg [HILLCROSS]
32803 PREDNISOLONE enteric coated tablets 5mg [ACTAVIS]
32835 PREDNISOLONE tablets 5mg [WOCKHARDT]
33639 cortisone acetate msd 25 mg tab
33691 PREDNISOLONE enteric coated tablets 5mg [BIOREX]
33988 PREDNISOLONE tablets 5mg [CO-PHARMA]
33990 PREDNISOLONE tablets 5mg [IVAX]
34109 prednisolone enteric coated tablets 5mg
34393 PREDNISOLONE enteric coated tablets 5mg [TEVA]
34404 PREDNISOLONE tablets 1mg [ACTAVIS]
34452 PREDNISOLONE tablets 1mg [HILLCROSS]
34461 PREDNISOLONE enteric coated tablets 2.5mg [ACTAVIS]
34631 PREDNISOLONE tablets 1mg [CO-PHARMA]
34660 PREDNISOLONE tablets 1mg [KENT]
34748 PREDNISOLONE tablets 1mg [TEVA]
34781 PREDNISOLONE tablets 5mg [KENT]
34801 DEXAMETHASONE elixir 0.5mg/5ml [ROSEMONT]
34880 DEXAMETHASONE tablets 2mg [ORGANON]
34914 PREDNISOLONE tablets 1mg [CELLTECH]
34915 DEXAMETHASONE tablets 0.5mg [ORGANON]
34978 PREDNISOLONE tablets 1mg [WOCKHARDT]
36055 DEXAMETHASONE tablets 2mg [HILLCROSS]
36686 cortisone acetate msd 5 mg tab
37203 beclometasone gastro-resistant modified release tablets 5mg
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Product Code Product Name
38022 hydrocortisone oral suspension 10mg/5ml
38054 hydrocortisone tablets
38407 prednisolone (roi) tablets 20mg
39067 CLIPPER gastro-resistant modified release tablets 5mg [CHIESI]
41335 CALCORT tablets 6mg [SANOFI/AVE]
41515 PREDNISOLONE tablets 5mg [TEVA]
41745 PREDNISOLONE tablets 25mg [WINTHROP]
43544 PREDNISONE tablets 5mg [KNOLL]
44380 prednisone modified release tablet 1mg
44723 prednisone modified release tablet 5mg
44802 LODOTRA modified release tablet 5mg [NAPPPHARM]
44803 LODOTRA modified release tablet 2mg [NAPPPHARM]
45234 dexamethasone capsules
45302 PREDNISOLONE tablets 5mg [BIOREX]
46711 prednisone modified release tablet 2mg
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Other immunosuppressive therapy
Product Code Product Name
270 azathioprine injection 50mg/vial
451 azathioprine tablets 25mg
571 azathioprine tablets 50mg
671 IMURAN tablets 25mg [WELLCOME]
770 azathioprine capsules
823 methotrexate tablets 2.5mg
877 methotrexate tablets 10mg
972 NEORAL capsules 25mg [NOVARTIS]
973 NEORAL capsules 100mg [NOVARTIS]
1626 ciclosporin oral solution 100mg/ml
1899 IMURAN tablets 50mg [WELLCOME]
1905 NEORAL oral solution 100mg/ml [NOVARTIS]
2181 methylprednisolone/lignocaine hcl (1ml) 40 mg/ml inj
2837 ciclosporin capsules 50mg
2838 ciclosporin capsules 25mg
2839 tacrolimus twice daily capsules 1mg
3450 mercaptopurine tablets 50mg
3683 PROGRAF twice daily capsules 1mg [ASTELLAS]
3788 hydrocortisone i/v 100 mg inj
3873 hydroxyurea capsules 500mg
3874 busulfan tablets 2mg
3896 ciclosporin capsules 100mg
3918 azathioprine 10 mg tab
3920 SANDIMMUN capsules 25mg [NOVARTIS]
3984 cyclophosphamide tablets 10mg
3985 cyclophosphamide tablets 50mg
4230 mycophenolate mofetil tablets 500mg
4231 NEORAL capsules 50mg [NOVARTIS]
4233 dexamethasone sodium phosphate injection 4mg/ml
4257 hydrocortisone 100 mg inj
4438 mycophenolate mofetil capsules 250mg
4970 leflunomide tablets 100mg
4971 leflunomide tablets 10mg
5089 tacrolimus twice daily capsules 5mg
5600 chlorambucil tablets 2mg
5870 PROGRAF twice daily capsules 500 micrograms [ASTELLAS]
6333 hydroxycarbamide capsules 500mg
6484 sirolimus tablets 2mg
6495 tacrolimus twice daily capsules 500 micrograms
6600 sirolimus tablets 1mg
6882 adalimumab injection 40mg
6884 HYDREA capsules 500mg [SQUIBB]
6934 leflunomide tablets 20mg
7077 mycophenolate mofetil powder for concentrate for solution for infusion 500mg
7336 methotrexate injection 12.5mg/0.5ml
7337 methotrexate injection 10mg/0.4ml
7340 capecitabine tablets 150mg
7341 capecitabine tablets 500mg
7480 cortisone acetate 25 mg inj
8327 methotrexate injection 50mg/3ml
8404 CCNU capsules 40mg [LUNDBECK]
8583 methotrexate injection 25mg/ml
8665 chlorambucil tablets 5mg
8756 etoposide capsules 50mg
8776 azathioprine 100 mg tab
9117 methylprednisolone 40 mg/ml inj
9528 methotrexate injection 5mg/2ml
10328 carboplatin concentrate for solution for infusion 10mg/ml
10729 ENDOXANA tablets 50mg [BAXTER ONC]
11003 CERUBIDIN powder for concentrate for solution for injection 20mg/vial [RHONE]
11334 dexamethasone sodium phosphate IV injection 4mg/ml
12066 RAZOXIN tablets 125mg [CAMBRIDGE]
12067 lomustine capsules 40mg
12150 melphalan tablets 5mg
12339 AZAMUNE tablets 50mg [PENN]
12816 methotrexate injection 100mg/ml
13271 PROGRAF twice daily capsules 5mg [ASTELLAS]
13320 azathioprine tablets 10mg
13428 MAXTREX tablets 2.5mg [PHARMACIA]
13494 SANDIMMUN sugar free solution 100mg/ml [NOVARTIS]
13556 SANDIMMUN capsules 100mg [NOVARTIS]
13604 ESTRACYT capsules 140mg [PHARMACIA]
13735 estramustine phosphate capsules 140mg
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Product Code Product Name
13952 DECADRON injection 4mg/ml [MSD MORSON]
13972 dexamethasone sodium phosphate injection 5mg/ml
14347 methotrexate injection 20mg/0.8ml
14348 METOJECT injection 20mg/2ml [MEDAC UK]
14381 paclitaxel concentrate for solution for infusion 6mg/ml
14395 IMURAN injection 50mg/vial [ASPEN EURO]
14748 methotrexate sodium injection 25mg/ml
14886 ENBREL powder for solution for injection 25mg [PFIZER]
15405 NOVANTRONE concentrate for solution for infusion 2mg/ml [WYETH PHAR]
15556 azathioprine 125 mg tab
15596 SANDIMMUN capsules 50mg [NOVARTIS]
15921 etanercept powder for solution for injection 25mg
16035 ciclosporin capsules 10mg
16105 cyclophosphamide powder for solution for injection 500mg
16137 NEORAL capsules 10mg [NOVARTIS]
16173 TAXOL concentrate for solution for infusion 6mg/ml [BMS]
16519 methotrexate injection 25mg/1ml
16522 ARAVA tablets 10mg [AVENTIS]
16540 methotrexate injection 15mg/0.6ml
16570 methotrexate injection 7.5mg/0.3ml
16822 infliximab powder for concentrate for solution for infusion 100mg
16838 LEUKERAN tablets 2mg [WELLCOME]
16879 mycophenolate mofetil oral suspension 1g/5ml
16919 CELLCEPT capsules 250mg [ROCHE]
16929 melphalan tablets 2mg
17035 methotrexate suspension 2.5mg/5ml
17186 procarbazine capsules 50mg
17206 azathioprine 50 mg sus
17642 ARAVA tablets 20mg [AVENTIS]
17672 methotrexate injection 22.5mg/0.9ml
18063 XELODA tablets 500mg [ROCHE]
18070 fluorouracil capsules 250mg
18236 carboplatin injection 50mg/vial
18238 dacarbazine powder for solution for injection 100mg
18424 methotrexate sodium tablets 2.5mg
18460 ARAVA tablets 100mg [AVENTIS]
18476 fludarabine tablets 10mg
18751 etoposide capsules 100mg
18804 CELLCEPT tablets 500mg [ROCHE]
18890 methotrexate injection 17.5mg/0.7ml
19072 OPRISINE tablets 50mg [OPUS]
19257 ENBREL powder for solution for injection 50mg [WYETH PHAR]
19259 dexamethasone injection 8mg/2ml
19335 CYTOSAR injection 500mg [PHARMACIA]
19370 ciclosporin concentrate for solution for infusion 50mg/ml
19556 FLUORO-URACIL capsules 250mg [CAMBRIDGE]
19982 mercaptopurine capsules 10mg
20094 tioguanine tablets 40mg
20097 sirolimus oral solution 1mg/ml
20229 FLUORO-URACIL injection 25mg/ml [CAMBRIDGE]
20951 METHOTREXATE tablets 2.5mg [GOLDSHIELD]
21249 temozolomide capsules 100mg
21250 temozolomide capsules 250mg
21286 imatinib capsules 100mg
21295 GLIVEC capsules 100mg [NOVARTIS]
21318 imatinib tablets 400mg
21668 DECADRON SHOCK PAK 20mg/ml [M S D]
21732 CELLCEPT oral suspension 1g/5ml [ROCHE]
21753 MAXTREX tablets 10mg [PHARMACIA]
21889 methotrexate 25mg/1ml
21899 IMMUNOPRIN tablets 50mg [ASHBOURNE]
22204 busulfan tablets 500micrograms
22392 REMICADE powder for concentrate for solution for infusion 100mg [SCHERING-P]
22640 razoxane tablets 125mg
22982 azathioprine oral solution 50mg/5ml
23270 ALKERAN tablets 5mg [WELLCOME]
23289 RAPAMUNE tablets 1mg [PFIZER]
23832 ELOXATIN powder for concentrate for solution for infusion 100mg [SANOFI S]
23849 TAXOTERE concentrate for intravenous infusion 40mg/ml [AVENTIS]
23850 HUMIRA injection 40mg [ABBOTT]
23871 TREOSULFAN capsules 250mg [FARILLON]
24096 carboplatin injection 150mg
24448 treosulfan capsules 250mg
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Product Code Product Name
24634 methotrexate injection 25mg/2.5ml
24657 prednisolone pivalate 50 mg inj
24681 fludarabine powder for solution for injection 50mg
24783 methotrexate injection 50mg/2ml
24997 CAELYX concentrate for solution for infusion 2mg/ml [SCHERING-P]
25740 AVASTIN concentrate for solution for infusion 100mg/4ml [ROCHE]
25848 CCNU capsules 10mg [LUNDBECK]
26064 methotrexate injection 20mg/2ml
26066 cyclophosphamide injection 200mg
26097 mycophenolic acid gastro-resistant tablets 360mg
26119 CHLORMETHINE injection 10mg/ml [SOVEREIGN]
26261 BERKAPRINE tablets 50mg [RORER]
26300 dexamethasone shock treatment pack 20mg/ml
26301 MYLERAN tablets 2mg [WELLCOME]
26315 LEUKERAN tablets 5mg [WELLCOME]
26322 cyclophosphamide injection 100mg
26332 thiotepa 15 mg inj
26343 ALKERAN tablets 2mg [WELLCOME]
26387 etanercept powder for solution for injection 50mg
26454 DECADRON injection 4mg/ml [MSD MORSON]
26502 LANVIS tablets 40mg [ALKOPHARMA]
26580 melphalan injection 100mg/vial
26680 ADRIAMYCIN injection 10mg/vial [PHARMACIA]
26790 SANDIMMUN concentrate for solution for infusion 50mg/ml [NOVARTIS]
26947 doxorubicin injection 2mg/ml
27071 dactinomycin powder for solution for injection 500micrograms
27289 MYFORTIC tablets 360mg [NOVARTIS]
27290 MYFORTIC tablets 180mg [NOVARTIS]
27293 oxaliplatin powder for concentrate for solution for infusion 50mg
27342 MAXTREX injection 2.5mg/ml [PHARMACIA]
27400 METOJECT injection 15mg/1.5ml [MEDAC UK]
27404 methotrexate injection 15mg/1.5ml
27428 prednisolone sodium phosphate 16 mg inj
27469 ADRIAMYCIN injection 50mg/vial [PHARMACIA]
27579 methotrexate
27642 methotrexate injection 27.5mg/1.1ml
27922 temozolomide capsules 5mg
28041 methotrexate oral suspension 12.5mg/5ml
28215 dexamethasone sodium phosphate injection 120mg/5ml
28324 cisplatin powder 25mg/vial
28325 epirubicin hydrochloride powder for solution for injection 50mg
28490 rituximab concentrate for solution for infusion 100mg/10ml
28605 NATULAN capsules 50mg [CAMBRIDGE]
28682 dacarbazine powder for solution for injection 200mg
28709 chlormethine injection 10mg
28726 treosulfan leo
28800 GLIVEC tablets 400mg [NOVARTIS]
28889 PHARMORUBICIN injection solution 2mg/ml [PHARMACIA]
28999 RAPAMUNE tablets 2mg [PFIZER]
29069 methotrexate sterile powder 500mg/vial
29229 imatinib tablets 100mg
29340 AZATHIOPRINE tablets 50mg [IVAX]
29652 epirubicin hydrochloride injection 2mg/ml
29675 PURI-NETHOL tablets 50mg [ALKOPHARMA]
29700 TEMODAL capsules 250mg [SCHERING-P]
29743 FLUDARA ORAL tablets 10mg [GENZYME]
29761 VEPESID capsules 50mg [BRISTOL]
29840 cyclophosphamide powder for solution for injection 1000mg
30014 MITHRACIN injection 2.5mg/vial [PFIZER]
30495 IMURAN tablets 10mg [WELLCOME]
30581 CELLCEPT powder for concentrate for solution for infusion 500mg [ROCHE]
30703 methotrexate injection 30mg/1.2ml
30757 mitobronitol (named patient only) 125 mg tab
30780 METHOTREXATE tablets 2.5mg [PHARMACIA]
30836 doxorubicin powder for solution for injection 10mg
30932 methotrexate injection 5mg/0.2ml
31115 etoposide concentrate for solution for infusion 20mg/ml
31193 ENDOXANA tablets 10mg [BAXTER ONC]
31215 AZATHIOPRINE tablets 50mg [KENT]
31223 vinblastine sulphate injection 10mg/vial
31339 idarubicin hydrochloride capsules 10mg
31494 mithramycin injection 2.5mg/vial
31539 epirubicin hydrochloride injection (powder) 20mg
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31598 MABCAMPATH concentrate for solution for infusion 10mg/ml [SCHERING]
31948 DEXAMETHASONE injection 4mg/ml [MAYNE]
31984 idarubicin hydrochloride capsules 5mg
32101 AZATHIOPRINE tablets 25mg [HILLCROSS]
32111 METHOTREXATE tablets 2.5mg [HOSPIRA]
32204 DTIC-DOME injection 100mg/vial [BAYER]
32229 methotrexate injection 500mg/20ml
32412 MYLERAN tablets 500micrograms [WELLCOME]
32490 temozolomide capsules 20mg
32604 vinblastine sulphate injection 10mg/10ml
32614 SIMULECT powder for solution for infusion 20mg [NOVARTIS]
32774 vinorelbine capsules 20mg
32824 cisplatin concentrate for solution for infusion 1mg/ml
32865 methotrexate injection 10mg/1ml
32972 mercaptopurine tablets 10mg
33123 tacrolimus concentrate for solution for infusion 5mg/1ml
33127 XELODA tablets 150mg [ROCHE]
33171 vinorelbine injection solution 10mg/ml
33174 mitoxantrone concentrate for solution for infusion 2mg/ml
33227 HYCAMTIN powder for concentrate for solution for infusion 4mg [GLAXSK PHA]
33330 HYDROXYCARBAMIDE capsules 500mg [MEDAC UK]
33385 thiotepa powder for solution for injection 15mg
33418 gemcitabine powder for solution for infusion 200mg/vial
33519 UFTORAL capsules 224mg + 100mg [MERCK SER]
33520 uracil with tegafur capsules 224mg + 100mg
33560 docetaxel concentrate for intravenous infusion 40mg/ml
33601 METOJECT injection 25mg/2.5ml [MEDAC UK]
33728 RAPAMUNE oral solution 1mg/ml [PFIZER]
33803 TEMODAL capsules 5mg [SCHERING-P]
33823 GLIVEC tablets 100mg [NOVARTIS]
33878 MYOCET powder for concentrate for solution for infusion 50mg [CEPHALON]
34083 DEXAMETHASONE injection 5mg/ml [ORGANON]
34258 METHOTREXATE injection 20mg/0.8ml [CENT HOME]
34451 AZATHIOPRINE tablets 50mg [GEN (UK)]
34687 AZATHIOPRINE tablets 50mg [HILLCROSS]
34728 CYCLOPHOSPHAMIDE tablets 50mg [PHARMACIA]
34816 AZATHIOPRINE tablets 25mg [GEN (UK)]
34929 METHOTREXATE tablets 10mg [HOSPIRA]
35126 etanercept injection solution 50mg
35226 TEMODAL capsules 20mg [SCHERING-P]
35301 mycophenolic acid gastro-resistant tablets 180mg
35384 TAXOL concentrate for solution for infusion 30mg/5ml [BMS]
35402 methotrexate injection 7.5mg/0.75ml
35419 ENBREL injection solution 25mg [PFIZER]
35518 azathioprine oral suspension 50mg/5ml
35752 methotrexate oral suspension 7.5mg/5ml
35826 mitotane tablets 500mg
35854 paclitaxel concentrate for solution for infusion 30mg/5ml
35855 carboplatin concentrate for solution for infusion 50mg/5ml
35865 METOJECT injection 7.5mg/0.75ml [MEDAC UK]
36008 etanercept injection solution 25mg
36062 dasatinib tablets 50mg
36167 methotrexate injection 1000mg/10ml
36263 EPOSIN concentrate for solution for infusion 20mg/ml [MEDAC UK]
36294 rituximab concentrate for solution for infusion 500mg/50ml
36552 TAXOTERE concentrate for solution for infusion 20mg/0.5ml [AVENTIS]
36556 ENBREL injection solution 50mg [PFIZER]
36575 fluorouracil injection 50mg/ml
36714 oxaliplatin powder for concentrate for solution for infusion 100mg
36792 azathioprine oral solution 50mg/ml
36800 methotrexate oral solution 10mg/5ml
36831 docetaxel concentrate for dilution for infusion solution 20mg/0.5ml
36849 methotrexate oral suspension 10mg/5ml
36957 dasatinib tablets 70mg
37099 melphalan powder for solution for injection 50mg
37117 METOJECT injection 10mg/1ml [MEDAC UK]
37155 tacrolimus suspension 1mg/ml
37238 dasatinib tablets 20mg
37272 pemetrexed powder for concentrate for solution for infusion 500mg
37375 VEPESID capsules 100mg [BRISTOL]
37396 MYELOBROMOL tablets 125mg [DURBIN]
37506 ADVAGRAF once daily modified release capsules 1mg [ASTELLAS]
37542 PARAPLATIN injection 150mg [BRISTOL]
344
Other immunosuppressive therapy
Product Code Product Name
37784 CAELYX concentrate for solution for infusion 20mg/10ml [JANSSEN]
37915 basiliximab powder for solution for infusion 10mg
37942 doxorubicin citrate liposomal complex powder for concentrate for solution for infusion 50mg
37985 tacrolimus once daily modified release capsules 1mg
38056 ciclosporin concentrate for solution for infusion 50mg/1ml
38081 ERWINASE powder for solution for injection 10000 units/vial [OPI]
38113 tacrolimus once daily modified release capsules 500 micrograms
38145 bevacizumab concentrate for solution for infusion 100mg/4ml
38185 cisplatin powder for concentrate for solution for infusion 50mg
38254 TYSABRI concentrate for solution for infusion 300mg/15ml [BIOGEN]
38317 nilotinib capsules 200mg
38319 hydroxycarbamide oral solution 500mg/5ml
38453 cisplatin concentrate for solution for infusion 10mg/10ml
38919 ADVAGRAF once daily modified release capsules 5mg [ASTELLAS]
38989 tacrolimus once daily modified release capsules 5mg
38999 docetaxel concentrate for dilution for infusion solution 80mg/2ml
39111 rituximab concentrate for intravenous infusion 10mg/ml
39115 azathioprine capsules 10mg
39307 doxorubicin injection 10mg/5ml
39366 mitoxantrone concentrate for solution for infusion 10mg/5ml
39387 epirubicin hydrochloride injection 100mg/50ml
39388 fluorouracil injection 1g/20ml
39450 carboplatin concentrate for solution for infusion 600mg/60ml
39548 hydroxycarbamide film coated tablets 1000mg
39553 oxaliplatin concentrate for solution for infusion 50mg/10ml
39633 ADVAGRAF once daily modified release capsules 500 micrograms [ASTELLAS]
39895 oxaliplatin concentrate for solution for infusion 100mg/20ml
39919 paclitaxel albumin bound powder for suspension for infusion 100mg
40250 CAELYX concentrate for solution for infusion 50mg/25ml [JANSSEN]
40251 epirubicin hydrochloride injection 200mg/100ml
40273 methotrexate injection 20mg/0.4ml
40280 METOJECT injection 7.5mg/0.15ml [MEDAC UK]
40281 methotrexate injection 15mg/0.3ml
40284 METOJECT injection 15mg/0.3ml [MEDAC UK]
40292 METOJECT injection 20mg/0.4ml [MEDAC UK]
40293 METOJECT injection 25mg/0.5ml [MEDAC UK]
40301 methotrexate injection 7.5mg/0.15ml
40328 methotrexate injection 25mg/0.5ml
40356 METOJECT injection 10mg/0.2ml [MEDAC UK]
40371 methotrexate injection 10mg/0.2ml
40453 TORISEL concentrate for solution for infusion 30mg/1.2ml [PFIZER]
40454 cladribine injection 10mg/5ml
40626 lenalidomide capsules 25mg
40632 basiliximab powder for solution for infusion 20mg
40732 VELCADE powder for solution for injection 3.5mg [ORTHO BIO]
40749 dexamethasone sodium phosphate 5 mg inj
40765 ADVAGRAF once daily modified release capsules 3mg [ASTELLAS]
40780 gemcitabine powder for solution for infusion 1g/vial
40781 carboplatin concentrate for solution for infusion 150mg/15ml
40816 epirubicin hydrochloride injection 50mg/25ml
40964 tacrolimus once daily modified release capsules 3mg
40983 irinotecan hydrochloride concentrate for solution for infusion 40mg/2ml
41058 ENBREL FOR PAEDIATRIC USE powder for solution for injection 25mg [PFIZER]
41086 methotrexate injection 5000mg/50ml
41104 METHOTREXATE tablets 2.5mg [CP PHARM]
41139 REVLIMID capsules 25mg [CELGENE]
41191 natalizumab concentrate for solution for infusion 300mg/15ml
41266 cytarabine injection solution 1g/10ml
41267 mitoxantrone concentrate for solution for infusion 20mg/10ml
41281 carmustine implant 7.7mg
41502 tocilizumab concentrate for solution for infusion 80mg/4ml
41585 METHOTREXATE SODIUM tablets 2.5mg [WYETH PHAR]
41620 AZATHIOPRINE tablets 50mg [TEVA]
41670 AZATHIOPRINE tablets 50mg [CP PHARM]
41960 topotecan powder for concentrate for solution for infusion 1mg
41963 PARAPLATIN concentrate for solution for infusion 10mg/ml [BRISTOL]
42056 lenalidomide capsules 5mg
42273 alemtuzumab concentrate for solution for infusion 30mg/1ml
42372 temozolomide capsules 140mg
42390 dasatinib tablets 100mg
42448 DEXIMUNE capsules 50mg [DEXCEL]
42449 DEXIMUNE capsules 100mg [DEXCEL]
42637 DEXIMUNE capsules 25mg [DEXCEL]
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42684 vinorelbine concentrate for solution for infusion 10mg/1ml
42696 THYMOGLOBULINE powder for solution for infusion 25mg [GENZYME]
42817 daclizumab concentrate for solution for infusion 25mg/5ml
42924 ciclosporin concentrate for solution for infusion 250mg/5ml
42988 IMURAN tablets 50mg [ASPEN EURO]
43077 IMURAN tablets 25mg [ASPEN EURO]
43081 tacrolimus granules for oral suspension 1mg
43082 tacrolimus granules for oral suspension 200micrograms
43168 ifosfamide injection 2g/vial
43562 AZATHIOPRINE tablets 50mg [ACTAVIS]
43639 PHARMORUBICIN powder for solution for injection 50mg [PHARMACIA]
43703 CIMZIA injection solution 200mg/1ml [UCB]
43781 AFINITOR tablets 10mg [NOVARTIS]
43805 daunorubicin powder for concentrate for solution for injection 20mg/vial
43888 pentostatin powder for solution for injection 10mg
44087 TAXOTERE concentrate for solution for infusion 20mg/1ml [AVENTIS]
44100 certolizumab pegol injection solution 200mg/1ml
44222 raltitrexed powder for concentrate for solution for infusion 2mg
44273 ENDOXANA injection 200mg [BAXTER ONC]
44309 ENDOXANA injection 1000mg [BAXTER ONC]
44387 etoposide phosphate lyophilised powder for injection 100mg
44388 cisplatin concentrate for solution for infusion 50mg/50ml
44425 docetaxel concentrate for solution for infusion 20mg/1ml
44478 LYSODREN tablets 500mg [LAB HRA]
44529 lenalidomide capsules 10mg
44640 ADOPORT twice daily capsules 500 micrograms [SANDOZ]
44641 ADOPORT twice daily capsules 5mg [SANDOZ]
44740 bortezomib powder for solution for injection 3.5mg
44783 sirolimus tablets 500 micrograms
44804 ADOPORT twice daily capsules 1mg [SANDOZ]
44908 methotrexate injection 30mg/0.6ml
44926 tacrolimus oral suspension 2.5mg/5ml
45026 doxorubicin injection 200mg/100ml
45043 MYFENAX tablets 500mg [TEVA]
45147 paclitaxel concentrate for solution for infusion 150mg/25ml
45165 methotrexate injection 20mg/1ml
45393 ARZIP tablets 500mg [WINTHROP]
45489 MYFENAX capsules 250mg [TEVA]
45558 methotrexate injection 25mg/1.25ml
45647 canakinumab powder for solution for injection 150mg
45820 nilotinib capsules 150mg
46039 methotrexate injection 30mg/1.5ml
46070 everolimus tablets 5mg
46098 METOJECT injection 12.5mg/0.25ml [MEDAC UK]
46129 methotrexate injection 22.5mg/0.45ml
46152 methotrexate injection 12.5mg/0.25ml
46156 methotrexate injection 17.5mg/0.35ml
46197 METOJECT injection 22.5mg/0.45ml [MEDAC UK]
46205 lenalidomide capsules 15mg
46265 METOJECT injection 17.5mg/0.35ml [MEDAC UK]
46324 MODIGRAF granules for oral suspension 200micrograms [ASTELLAS]
46325 MODIGRAF granules for oral suspension 1mg [ASTELLAS]
46348 tocilizumab concentrate for solution for infusion 200mg/10ml
46370 golimumab pre-filled pen injection solution 50mg
46395 CAPIMUNE capsules 100mg [GEN (UK)]
46407 methotrexate injection 1000mg/40ml
46637 CAPIMUNE capsules 25mg [GEN (UK)]
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PHN diagnosis
Medical Code Read Term
1598 Post-herpetic neuralgia
7584 Post-herpetic trigeminal neuralgia
10223 Postherpetic neuralgia




PHN - Neuralgia diagnosis
Medical Code Read Term
2284 Neuralgia unspecified
23839 Neuralgia, neuritis or radiculitis NOS
54992 Neuralgia, neuritis and radiculitis unspecified
348
PHN- Neuropathic pain diagnosis
Medical code Read term
11544 Neuropathic pain
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PHN treatment - anticonvulsants
Product Code Product Name
107 phenytoin capsules 25mg
432 carbamazepine tablets 100mg
584 sodium valproate gastro-resistant tablets 200mg
596 carbamazepine liquid 100mg/5ml
652 carbamazepine tablets 400mg
660 gabapentin capsules 100mg
790 pregabalin capsules 25mg
819 pregabalin capsules 75mg
1158 carbamazepine tablets 200mg
1370 phenytoin capsules 100mg
1398 EPANUTIN capsules 100mg [PFIZER]
1550 sodium valproate syrup 200mg/5ml
1584 gabapentin capsules 300mg
2062 phenytoin sodium tablets 100mg
2079 lamotrigine tablets 25mg
2080 lamotrigine tablets 50mg
2081 lamotrigine dispersible tablet 5mg
2082 EPILIM sugar free liquid 200mg/5ml [SANOFI/AVE]
2085 TEGRETOL tablets 200mg [NOVARTIS]
2128 phenytoin capsules 50mg
2388 carbamazepine modified release tablet 200mg
2782 phenytoin sodium tablets 50mg
2822 EPILIM EC tablets 500mg [SANOFI/AVE]
2823 TEGRETOL RETARD controlled release tablet 200mg [NOVARTIS]
2824 TEGRETOL RETARD controlled release tablet 400mg [NOVARTIS]
3068 phenytoin capsules 300mg
3107 EPILIM CHRONO controlled release tablet 500mg [SANOFI/AVE]
3350 sodium valproate gastro-resistant tablets 500mg
3569 carbamazepine modified release tablet 400mg
3731 EPILIM EC tablets 200mg [SANOFI/AVE]
3733 EPILIM CHRONO controlled release tablet 300mg [SANOFI/AVE]
3734 EPILIM CHRONO controlled release tablet 200mg [SANOFI/AVE]
3845 sodium valproate sugar free liquid 200mg/5ml
3881 EPANUTIN capsules 50mg [PFIZER]
3886 lamotrigine tablets 200mg
4066 TEGRETOL tablets 400mg [NOVARTIS]
4175 EPANUTIN suspension 30mg/5ml [PFIZER]
4195 EPILIM crushable tablets 100mg [SANOFI/AVE]
4490 phenytoin suspension 30mg/5ml
4495 EPILIM syrup 200mg/5ml [SANOFI/AVE]
4502 sodium valproate crushable tablets 100mg
4586 LAMICTAL tablets 25mg [WELLCOME]
4781 gabapentin capsules 400mg
4913 TEGRETOL sugar free liquid 100mg/5ml [NOVARTIS]
4982 carbamazepine chewable tablet 100mg
5076 lamotrigine tablets 100mg
5221 gabapentin tablets 600mg
5449 oxcarbazepine tablets 300mg
5587 phenytoin sodium capsules 50mg
5617 CONVULEX enteric coated soft gelatin capsules 300mg [PHARMACIA]
5658 lamotrigine dispersible tablet 25mg
5722 LAMICTAL dispersible tablet 100mg [WELLCOME]
5848 valproic acid (as semisodium salt) enteric coated tablets 250mg
5907 lamotrigine dispersible tablet 100mg
5977 TEGRETOL tablets 100mg [NOVARTIS]
5997 CONVULEX enteric coated soft gelatin capsules 150mg [PHARMACIA]
6304 NEURONTIN capsules 300mg [PFIZER]
6305 valproic acid (as semisodium salt) enteric coated tablets 500mg
6409 lamotrigine dispersible tablet 2mg
6436 oxcarbazepine tablets 600mg
6504 phenytoin sodium capsules 100mg
6552 oxcarbazepine tablets 150mg
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6560 sodium valproate modified release tablet 500mg
6584 LYRICA capsules 75mg [PFIZER]
6594 phenytoin sodium capsules 300mg
6624 phenytoin sodium capsules 25mg
6631 pregabalin capsules 150mg
6711 sodium valproate modified release tablet 300mg
6936 pregabalin capsules 50mg
6949 pregabalin capsules 200mg
6999 pregabalin capsules 100mg
7005 pregabalin capsules 300mg
7011 sodium valproate with valproic acid modified release tablet 300mg
7020 TRILEPTAL tablets 300mg [NOVARTIS]
7021 TRILEPTAL tablets 150mg [NOVARTIS]
7022 LAMICTAL tablets 50mg [WELLCOME]
7023 LAMICTAL tablets 100mg [WELLCOME]
7064 DEPAKOTE tablets 250mg [SANOFI/AVE]
7208 LYRICA capsules 100mg [PFIZER]
7209 LYRICA capsules 50mg [PFIZER]
7394 LYRICA capsules 200mg [PFIZER]
7498 EPANUTIN capsules 25mg [PFIZER]
7538 gabapentin tablets 800mg
7804 PHENYTOIN SODIUM/ PHENOBARBITONE CAP
8452 PHENYTOIN 150 MG SUS
8885 ORLEPT tablets 500mg [WOCKHARDT]
9168 SOD VALPROATE C/R 200 MG TAB
9281 sodium valproate with valproic acid modified release tablet 200mg
9678 phenytoin sugar-free suspension 90mg/5ml
9759 DEPAKOTE tablets 500mg [SANOFI/AVE]
9979 gabapentin capsules & tablets 300mg + 600mg
10007 NEURONTIN capsules 100mg [PFIZER]
10111 LAMICTAL tablets 200mg [WELLCOME]
10189 LYRICA capsules 300mg [PFIZER]
10263 EPANUTIN capsules 300mg [PFIZER]
11075 sodium valproate with valproic acid modified release tablet 500mg
11445 LAMICTAL dispersible tablet 25mg [WELLCOME]
11696 carbamazepine chewable tablet 200mg
12469 EPANUTIN READY MIXED PARENTERAL injection 250mg/5ml [PFIZER]
12880 TEGRETOL CHEWTAB tablets 200mg [NOVARTIS]
12931 EPIMAZ RETARD tablets 200mg [IVAX]
12932 EPIMAZ tablets 100mg [IVAX]
13112 CARBAGEN SR tablets 200mg [GEN (UK)]
13524 TEGRETOL CHEWTAB tablets 100mg [NOVARTIS]
14199 oxcarbazepine sugar free oral suspension 60mg/ml
15082 TEGRETOL suppository 250mg [NOVARTIS]
15106 PHENYTOIN 30 MG TAB
15126 LAMICTAL dispersible tablet 5mg [WELLCOME]
15650 valproic acid enteric coated soft gelatin capsules 300mg
16021 valproic acid enteric coated soft gelatin capsules 500mg
16149 Herpes zoster with meningitis
16215 NEURONTIN capsules 400mg [PFIZER]
16404 NEURONTIN TITRATION PACK capsules & tablets 300mg + 600mg [PARKE]
16509 LYRICA capsules 150mg [PFIZER]
16542 LYRICA capsules 25mg [PFIZER]
16609 sodium valproate powder for solution for injection 400mg
17152 ORLEPT tablets 200mg [WOCKHARDT]
17177 EPANUTIN INFATAB 50mg [PFIZER]
17428 carbamazepine suppository 250mg
17429 carbamazepine suppository 125mg
17564 NEURONTIN tablets 600mg [PFIZER]
17978 TERIL RETARD modified release tablet 200mg [TARO]
18011 TERIL RETARD modified release tablet 400mg [TARO]
18211 gabapentin oral solution 250mg/5ml
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18567 ZERIDAME SR tablets 150mg [ACTAVIS]
18614 valproic acid enteric coated soft gelatin capsules 150mg
18762 EPIMAZ tablets 200mg [IVAX]
18763 EPIMAZ tablets 400mg [IVAX]
18886 CONVULEX enteric coated soft gelatin capsules 500mg [PHARMACIA]
19296 LAMICTAL dispersible tablet 2mg [WELLCOME]
19326 PHENYTOIN 25 MG SYR
20004 EPILIM powder for solution for injection 400mg [SANOFI/AVE]
21441 TEGRETOL suppository 125mg [NOVARTIS]
21854 PENTRAN tablets 100mg [BERK]
22131 PHENOBARBITONE & PHENYTOIN 60 MG CAP
22286 PHENOBARBITONE 60MG & PHENYTOIN 100MG MG TAB
24153 ORLEPT sugar free liquid 200mg/5ml [WOCKHARDT]
24637 phenytoin sodium injection 250mg/5ml
25815 gabapentin oral suspension 400mg/5ml
25903 fosphenytoin sodium concentrate for solution for infusion 750mg/10ml
26012 CARBAGEN SR tablets 400mg [GEN (UK)]
26902 TRILEPTAL oral suspension 60mg/ml [NOVARTIS]
27113 PHENYTOIN SODIUM tablets 100mg [TEVA]
27221 LAMICTAL NON-VALPROATE ADD-ON START PACK TAB 25 mg
27454 GABAPENTIN capsules 300mg [TEVA]
27541 PHENYTOIN
27881 PHENYTOIN
27967 PRO-EPANUTIN concentrate for solution for infusion 750mg/10ml [PFIZER]
28345 CARBAMAZEPINE tablets 100mg [APS]
28713 NEURONTIN tablets 800mg [PFIZER]
29619 LAMOTRIGINE tablets 25mg [ACTAVIS]
29620 LAMOTRIGINE tablets 100mg [ACTAVIS]
30081 SODIUM VALPROATE CR tablets 500mg [HILLCROSS]
30392 PENTRAN tablets 50mg [BERK]
30509 TIMONIL RETARD modified release tablet 400mg [CP PHARM]
30763 CARBAMAZEPINE tablets 100mg [HILLCROSS]
31634 PHENYTOIN SODIUM/ PHENOBARBITONE SODIUM TAB
32900 CARBAMAZEPINE SR tablets 200mg [IVAX]
32920 LAMOTRIGINE tablets 25mg [GEN (UK)]
32931 CARBAMAZEPINE tablets 400mg [APS]
33058 EPIVAL CR tablets 500mg [CHANELLE]
33106 SODIUM VALPROATE sugar free oral solution 200mg/5ml [IVAX]
34120 SODIUM VALPROATE gastro-resistant tablets 200mg [HILLCROSS]
34144 PHENYTOIN SODIUM tablets 100mg [ACTAVIS]
34150 VALPROATE SODIUM gastro-resistant tablets 200mg [IVAX]
34151 VALPROATE SODIUM gastro-resistant tablets 500mg [IVAX]
34178 SODIUM VALPROATE gastro-resistant tablets 500mg [HILLCROSS]
34370 CARBAMAZEPINE controlled release tablet 200mg [HILLCROSS]
34414 SODIUM VALPROATE tablets 200mg [STERWIN]
34506 GABAPENTIN capsules 100mg [TEVA]
34592 PHENYTOIN SODIUM tablets 100mg [HILLCROSS]
34606 GABAPENTIN capsules 100mg [HILLCROSS]
34626 SODIUM VALPROATE gastro-resistant tablets 200mg [GEN (UK)]
34632 SODIUM VALPROATE gastro-resistant tablets 200mg [TEVA]
34699 PHENYTOIN sugar-free suspension 90mg/5ml [ROSEMONT]
34707 SODIUM VALPROATE gastro-resistant tablets 200mg [IVAX]
34716 GABAPENTIN capsules 300mg [HILLCROSS]
34883 SODIUM VALPROATE sugar free liquid 200mg/5ml [HILLCROSS]
34904 CARBAMAZEPINE tablets 200mg [HILLCROSS]
34946 GABAPENTIN tablets 600mg [TEVA]
34958 CARBAMAZEPINE tablets 100mg [BERK]
35024 sodium valproate modified release capsules 300mg
35471 sodium valproate modified release capsules 150mg
35732 LAMOTRIGINE dispersible tablet 25mg [ARROW]
35747 EPISENTA prolonged release capsules 300mg [BEACON]
35755 sodium valproate modified release granules 500mg
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36318 sodium valproate modified release granules 1000mg
36633 EPISENTA prolonged release capsules 150mg [BEACON]
36634 EPISENTA prolonged release granules 1000mg [BEACON]
37058 carbamazepine oral suspension 500mg/5ml
37306 SODIUM VALPROATE syrup 200mg/5ml [STERWIN]
37584 EPISENTA prolonged release granules 500mg [BEACON]
37611 EPIVAL CR tablets 300mg [CHANELLE]
37800 CARBAMAZEPINE controlled release tablet 200mg [LAGAP]
37801 pregabalin capsules 225mg
38293 LYRICA capsules 225mg [PFIZER]
38507 EPILIM CHRONOSPHERE modified release granules 100mg [SANOFI/AVE]
38508 EPILIM CHRONOSPHERE modified release granules 250mg [SANOFI/AVE]
38939 EPILIM 200 gastro-resistant tablets 200mg [SANOFI/AVE]
38949 EPILIM 500 gastro-resistant tablets 500mg [SANOFI/AVE]
39039 sodium valproate modified release tablet 200mg
39276 sodium valproate with valproic acid modified release granules 250mg
39279 EPILIM CHRONOSPHERE modified release granules 500mg [SANOFI/AVE]
39427 sodium valproate with valproic acid modified release granules 750mg
39452 sodium valproate with valproic acid modified release granules 500mg
39506 LAMOTRIGINE tablets 50mg [ACTAVIS]
39550 EPILIM CHRONOSPHERE modified release granules 750mg [SANOFI/AVE]
39714 LAMOTRIGINE tablets 25mg [TEVA]
39715 LAMOTRIGINE tablets 100mg [TEVA]
39930 EPILIM CHRONOSPHERE modified release granules 50mg [SANOFI/AVE]
40070 sodium valproate injection 300mg/3ml
40395 SODIUM VALPROATE crushable tablets 100mg [GEN (UK)]
40400 SODIUM VALPROATE gastro-resistant tablets 500mg [CP PHARM]
40403 CARBAMAZEPINE controlled release tablet 400mg [LAGAP]
40404 CARBAMAZEPINE controlled release tablet 400mg [HILLCROSS]
41137 sodium valproate with valproic acid modified release granules 100mg
41726 CARBAMAZEPINE tablets 100mg [IVAX]
42038 EPILIM CHRONOSPHERE modified release granules 1000mg [SANOFI/AVE]
42090 SODIUM VALPROATE sugar free liquid 200mg/5ml [WINTHROP]
43178 sodium valproate with valproic acid modified release granules 1000mg
43387 sodium valproate with valproic acid modified release granules 50mg
43417 CARBAMAZEPINE tablets 400mg [HILLCROSS]
43451 CARBAMAZEPINE controlled release tablet 400mg [GEN (UK)]
43648 sodium valproate oral liquid
43742 sodium valproate injection 1000mg/10ml
44022 gabapentin oral suspension 250mg/5ml
44187 GABAPENTIN tablets 600mg [HILLCROSS]
44261 GABAPENTIN oral solution 250mg/5ml [BCM]
44472 sodium valproate modified release granules 100mg
44718 sodium valproate modified release granules 750mg
44903 SODIUM VALPROATE gastro-resistant tablets 500mg [WINTHROP]
45106 sodium valproate modified release granules 250mg
45344 SODIUM VALPROATE solution 200mg/5ml [HILLCROSS]
45419 sodium valproate modified release granules 50mg
45572 lamotrigine suppository 50mg
45903 TEGRETOL PROLONGED RELEASE tablets 400mg [NOVARTIS]
45941 TEGRETOL PROLONGED RELEASE tablets 200mg [NOVARTIS]
46774 SODIUM VALPROATE gastro-resistant tablets 500mg [TEVA]
46775 LAMOTRIGINE tablets 50mg [TEVA]
46888 CARBAMAZEPINE controlled release tablet 200mg [GEN (UK)]
46972 CARBAMAZEPINE tablets 200mg [IVAX]
47014 phenytoin oral suspension 90mg/5ml
47294 CARBAMAZEPINE SR tablets 400mg [IVAX]
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PHN treatment - capaiscin
Product Code Product Name
1808 capsaicin cream 0.075%
7692 AXSAIN cream 0.075% [CEPHALON]
354
PHN treatment - lidocaine
Product Code Product Name
14841 LIDODERM patch 5% [ENDO]
14855 lidocaine medicated plaster 5%
35043 ZERIDAME SR tablets 150mg [ACTAVIS]
38216 lidocaine with tetracaine plaster 70mg + 70mg
38257 RAPYDAN plaster 70mg + 70mg [EUROCEPT]
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Product Code Product Name
7 paracetamol tablets 500mg
15 ibuprofen tablets 400mg
111 ASPIRIN 40 MG CAP
124 DISTALGESIC tablets [CLINIGEN]
139 paracetamol capsules 500mg
175 PARACETAMOL 1 GM SUP
215 IBUPROFEN 200 MG CAP
216 ASPIRIN 70 MG TAB
258 PANADOL tablets 500mg [GLAXSK CON]
262 paracetamol suspension 250mg/5ml
345 IBUPROFEN S/R 300 MG CAP
360 BRUFEN syrup 100mg/5ml [ABBOTT]
383 ASPIRIN 60 MG TAB
392 ibuprofen modified release capsules 200mg
395 ZERIDAME SR tablets 150mg [ACTAVIS]
402 NUROFEN caplets 200mg [CROOKES]
407 BRUFEN granules 600mg [ABBOTT]
416 ibuprofen tablets 200mg
484 EQUAGESIC tablets [WYETH PHAR]
586 ibuprofen capsules 200mg
645 aspirin suppository 300mg
647 ibuprofen syrup 100mg/5ml
685 ASPAV dispersible tablet [ACTAVIS]
784 ibuprofen modified release capsules 300mg
849 IBUMED tablets 400mg [MEDIPHARMA]
899 CALPOL SIX PLUS suspension 250mg/5ml [MCNEIL]
1030 JUNIFEN sugar-free suspension 100mg/5ml [CROOKES]
1086 ibuprofen tablets 600mg
1392 ibuprofen modified release tablet 800mg
1404 PARACETAMOL suspension 120mg/5ml [ROSEMONT]
1468 ibuprofen soluble tablet 200mg
1486 ASPIRIN 75 MG SUP
1609 paracetamol soluble tablet 500mg
1621 BRUFEN tablets 200mg [ABBOTT]
1739 BRUFEN tablets 400mg [ABBOTT]
1762 dextropropoxyphene hcl with paracetamol tablets 32.5mg + 325mg
1862 paracetamol sugar-free suspension 500mg/5ml
1865 PARACETAMOL 1 GM TAB
1946 PARACETAMOL 500 MG SUP
1999 paracetamol suppository 125mg
2034 ALVEDON suppository 125mg [ASTRAZENEC]
2129 BRUFEN retard tablets 800mg [ABBOTT]
2344 paracetamol suppository 120mg
2462 COSALGESIC tablets [ACTAVIS]
2546 PARACETAMOL SOLUBLE TAB
2586 DISPROL sugar-free suspension 120mg/5ml [RECKITT B]
2622 ibuprofen tablets 800mg
2754 ASPIRIN SOLUBLE 150 MG TAB
2800 PANADOL soluble tablet 500mg [GLAXSK CON]
2924 ASPIRIN 150 MG TAB
2938 ibuprofen sugar-free suspension 100mg/5ml
3074 paracetamol soluble tablet 120mg
3313 CALPOL SIX PLUS sugar-free suspension 250mg/5ml [MCNEIL]
3316 DISPROL soluble tablet 120mg [RECKITT B]
3597 NUROFEN soluble tablet 200mg [CROOKES]
3599 ibuprofen granules 600mg
3714 DEXTROPROPOXYPHENE NAPSYLATE/PARACETAMOL MG TAB
4186 paracetamol sugar-free suspension 250mg/5ml
4196 paracetamol suppository 240mg
4203 MEDISED suspension [SSL INT]
4216 BRUFEN tablets 600mg [ABBOTT]
4271 ASPIRIN SOLUBLE 200 MG TAB
4298 NUROFEN tablets 200mg [CROOKES]
4523 ASPIRIN 50 MG CAP
4557 ASPIRIN & PAPAVERUTUM 10 MG TAB
4600 chlormezanone with paracetamol tablets
4911 ibuprofen granules 400mg
5239 paracetamol sachets 1g
5243 paracetamol suppository 500mg
5323 paracetamol suppository 250mg
5648 ibuprofen orodispersible tablet 200mg
6226 papaveretum with aspirin dispersible tablet 7.71mg + 500mg
6571 paracetamol sachets 240mg
6699 paracetamol suppository 60mg
7058 CALPROFEN oral suspension 100mg/5ml [MCNEIL]
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Product Code Product Name
7205 PANADOL capsules 500mg [GLAXSK CON]
7417 ASPIRIN 40 MG TAB
7450 pentazocine with paracetamol tablets 500mg + 15mg
7462 ASPIRIN 325 MG CAP
7486 ASPIRIN 37.5 MG TAB
7535 NUROFEN liquid capsules 200mg [CROOKES]
7621 PARACETAMOL 300 MG TAB
7650 PARACETAMOL 125 MG ELI
7665 ASPIRIN SR 300 MG TAB
7668 PARACETAMOL 250 MG TAB
7769 ASPIRIN/PARACETAMOL TAB
7915 ASPIRIN SR 100 MG TAB
7944 ASPIRIN SOLUBLE 40 MG CAP
8020 PARACETAMOL 125 MG MIX
8091 PARACETAMOL CO TAB
8093 PARACETAMOL SOLUBLE TAB
8259 PARACETAMOL 500 MG ELI
8292 PARACETAMOL 240 MG ELI
8401 MOTRIN tablets 400mg [PHARMACIA]
8700 PARACETAMOL 125 MG TAB
8734 ASPIRIN disp 37.5 MG TAB
8843 ASPIRIN 325 MG TAB
8920 ASPIRIN SOLUBLE 500 MG TAB
9027 ASPIRIN disp 150 MG TAB
9193 paracetamol with sodium bicarbonate effervescent tablet 500mg + 1342mg
9239 paracetamol capsules 120mg
9271 paracetamol syrup 125mg/5ml
9329 paracetamol drops 100mg/ml
9712 paracetamol dissolving tablets 250mg
9914 CALPOL FAST MELTS 6+ dissolving tablets 250mg [MCNEIL]
10149 ibuprofen liquid capsules 200mg
10209 IBUFEM tablets 200mg [GALPHARM]
10325 dexibuprofen tablets 300mg
10509 FORTAGESIC tablets [SANOFI S]
10748 TRAMIL capsules 500mg [WYETH CONS]
10785 FENBID SPANSULE 300mg [GOLDSHIELD]
10901 paracetamol with promethazine hydrochloride suspension 120mg+1.5mg/5ml
11326 meprobamate with ethoheptazine citrate and aspirin tablets
11550 NUROFEN MELTLETS dissolving tablets 200mg [RECKITT B]
11907 dexibuprofen tablets 400mg
11941 ASPIRIN SACHETS 30 MG
11980 CUPROFEN maximum strength tablets 400mg [SSL INT]
12102 ASPIRIN SOLUBLE 100 MG TAB
12332 PARACETAMOL 240 MG SUS
12364 aloxiprin tablets 600mg
12394 LOBAK tablets [SANOFI S]
14333 ibuprofen liquid capsules 400mg
14385 CUPROFEN tablets 200mg [SSL INT]
14551 INFADROPS drops 100mg/ml [GOLDSHIELD]
14560 PARACETAMOL 60 MG SUP
14899 ALVEDON suppository 250mg [ASTRAZENEC]
15044 ASPIRIN disp 500 MG TAB
15068 ARTHROFEN tablets 400mg [ASHBOURNE]
15238 PARACETAMOL tablets 500mg [WINTHROP]
15352 ASPIRIN & PARACETAMOL TAB
15364 aspirin suppository 150mg
15397 ASPIRIN SOLUBLE 50 MG TAB
15439 PARACETAMOL 150 MG SUP
15447 ASPIRIN SOLUBLE 600 MG TAB
15461 PARACETAMOL 100 MG SUP
15517 ASPIRIN 100 MG SUP
16001 IBUPROFEN tablets 200mg [HILLCROSS]
16192 MOTRIN tablets 200mg [PHARMACIA]
16193 MOTRIN tablets 800mg [PHARMACIA]
16205 PALAPRIN FORTE tablets 600mg [NICHOLAS]
17201 MOTRIN tablets 600mg [PHARMACIA]
18261 aspirin with papaveretum dispersible tablet 500mg + 7.71mg
18364 IBULAR tablets 400mg [LAGAP]
18441 ALVEDON suppository 60mg [ASTRAZENEC]
18482 paracetamol with dextropropoxyphene tablets 325mg + 32.5mg
18527 MANDAFEN tablets 400mg [M&A PHARM]
18812 NUROFEN MELTLETS LEMON orodispersible tablet 200mg [RECKITT B]
18820 FENPAED oral suspension 100mg/5ml [PINEWOOD]
19036 ARTHROFEN tablets 200mg [ASHBOURNE]
19046 IBUPROFEN tablets 400mg [HILLCROSS]
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Product Code Product Name
19139 PARACETAMOL suppository 500mg [DISTRIPHAR]





20068 paracetamol sugar-free suspension 250mg/5ml
20194 PARACETAMOL 75 MG SUS
20206 ASPIRIN 50 MG SUP
20650 aspirin with paracetamol dispersible tablet 300mg + 200mg
20840 acetylsalicylic acid mixture
20978 ANADIN ULTRA liquid capsules [WYETH CONS]
21045 IBUMETIN tablets 400mg [BENZON]
21419 SERACTIL tablets 300mg [GENUS]
21421 SERACTIL tablets 400mg [GENUS]
21491 PARACETAMOL 30 MG SUP
21754 PARACETAMOL 20 MG SUP
21770 paracetamol with aspirin dispersible tablet 200mg + 300mg
21811 LIDIFEN tablets 200mg [BERK]
21813 LIDIFEN tablets 400mg [BERK]
21815 ARTHROFEN tablets 600mg [ASHBOURNE]
21821 LIDIFEN F tablets 600mg [BERK]
21932 ETHOHEPTALINE CITRATE/ASPIRIN MG TAB
22014 DISPROL PARACETAMOL sugar-free suspension 120mg/5ml [RECKITT B]
22107 ASPIRIN disp 200 MG TAB
22206 NUROFEN LONG LASTING modified release capsules 300mg [CROOKES]
22236 paracetamol with promethazine hydrochloride colour free sugar-free suspension 120mg+1.5mg/5ml
22288 MEDINOL over 6 sugar free suspension 250mg/5ml [SSL INT]
22305 DISPRIN EXTRA dispersible tablet [RECKITT B]
22380 paracetamol solution for infusion 1g/100ml
22776 aspirin with cyclizine effervescent tablet 500mg+25mg
22824 ASPIRIN disp 600 MG TAB
22863 ASPIRIN S/R 500 MG TAB
23052 promethazine hydrochloride with paracetamol colour free sugar-free suspension 120mg+1.5mg/5ml
23077 PARACETAMOL sugar-free suspension 120mg/5ml [PINEWOOD]
23114 PANALEVE PLUS sugar-free suspension 120mg/5ml [PINEWOOD]
23250 ASPIRIN /ETHOHEPTAZINE CITRATE /MEPROBAM 250 MG TAB
23274 PARACETAMOL
23491 ASPIRIN 500 MG SUP
23495 ASPIRIN
23617 paracetamol powders 50mg
23716 PARACETAMOL caplets 500mg [IVAX]
23840 PANASORB tablets 500mg [SANOFI S]
23841 SAFAPRYN tablets [PFIZER]
24000 MANDANOL tablets 500mg [M&A PHARM]
24075 MANDANOL caplets 500mg [M&A PHARM]
24305 IBUFAC tablets 400mg [DDSA]
24400 PARACETAMOL
24445 paracetamol with promethazine hydrochloride tablets
24534 ANADIN PARACETAMOL tablets [PFIZER]
24803 SALICYLAMIDE/PARACETAMOL MG TAB
24857 ASPIRIN 250 MG SUP
25257 ADVIL tablets 200mg [WYETH CONS]
25619 NUROFEN tablets 400mg [CROOKES]
25794 ISISFEN tablets 400mg [ISIS]
25800 FEVERFEN oral suspension 100mg/5ml [WISE]
25895 HEDEX caplets 500mg [GLAXSK CON]
26099 ASPIRIN 175 MG SUP
26424 ASPIRIN 200 MG SUP
26792 ASPIRIN 125 MG SUP
26970 IBUPROFEN suspension 100mg/5ml [TEVA]
26988 PARACETS tablets 500mg [SUSSEX]
27064 PALDESIC suspension 120mg/5ml [ROSEMONT]
27452 PARACETAMOL soluble tablet 500mg [WINTHROP]
27459 PARACETAMOL caplets 500mg [WINTHROP]
27467 ASPIRIN SOLUBLE 400 MG TAB
27553 PARACETAMOL
27782 IBUPROFEN tablets 400mg [APS]
27783 IBUPROFEN sugar-coated tablets 400mg [ACTAVIS]
27968 APSIFEN tablets 400mg [APS]
28168 NUROFEN RECOVERY orodispersible tablet 200mg [RECKITT B]
28211 PARACETAMOL sugar-free suspension 250mg/5ml [APS]
28344 PARACETAMOL caplets 500mg [WOCKHARDT]
28346 PARACETAMOL caplets 500mg [M&A PHARM]
28348 IBUPROFEN tablets 200mg [APS]
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28479 NUROFEN BACK PAIN SR capsules 300mg [RECKITT B]
28707 ASPIRIN M/F 324 MG TAB
28712 GALPAMOL sugar-free suspension 120mg/5ml [GALPHARM]
28792 MEDISED COLOUR AND SUGAR FREE suspension 120mg+1.5mg/5ml [SSL INT]
28888 GALPROFEN LONG LASTING modified release capsules 200mg [GALPHARM]
28955 PANADOL ACTIFAST tablets 500mg [GLAXSK CON]
29068 NUROFEN EXTRA STRENGTH liquid capsules 400mg [RECKITT B]
29316 CARE IBUPROFEN tablets 400mg [T & R]
29332 IBUPROFEN sugar-free suspension 100mg/5ml [SANDOZ]
29345 IBUPROFEN oral suspension 100mg/5ml [HILLCROSS]
29352 IBUPROFEN sugar-free suspension 100mg/5ml [AAH(VANT)]
29524 IBUMETIN tablets 600mg [BENZON]
29587 EBUFAC tablets 400mg [DDSA]
29704 PAXOFEN tablets 200mg [STEINHARD]
29749 IBUPROFEN tablets 200mg [RANBAXY]
30022 FYNNON CALCIUM ASPIRIN soluble tablet 500mg [SSL INT]
30243 ibuprofen effervescent tablet 200mg
30382 IBUPROFEN tablets 200mg [CP PHARM]
30432 ASPIRIN & DOVERS pwdr TAB
30590 MEDISED tablets [SSL INT]
30695 ASPIRIN 120 MG SUP
30724 GALPROFEN IBUPROFEN sugar-free suspension 100mg/5ml [GALPHARM]
30811 PROFLEX sustained release capsules 300mg [NOVARTIS]
30984 PARACETAMOL suspension 250mg/5ml [HILLCROSS]
31196 PARACETAMOL tablets 500mg [IVAX]
31257 PARACETAMOL caplets 500mg [GALPHARM]
31469 APSIFEN -F tablets 600mg [APS]
31482 APSIFEN tablets 200mg [APS]
31499 paracetamol with aspirin tablets
32093 PARACETAMOL suspension 250mg/5ml [ROSEMONT]
32100 IBUPROFEN tablets 600mg [HILLCROSS]
32136 IBULAR tablets 200mg [LAGAP]
32163 PARACETAMOL tablets 500mg [AAH(VANT)]
32242 IBUPROFEN tablets 400mg [STERWIN]
32365 RELCOFEN sugar-coated tablets 400mg [ACTAVIS]
32366 RELCOFEN sugar-coated tablets 200mg [ACTAVIS]
32509 ANADIN IBUPROFEN tablets 200mg [PFIZER]
32554 PLACIDEX syrup 120mg/5ml [DE WITT]
32626 paracetamol with sodium salicylate tablets 150mg + 100mg
32672 DISPROL PARACETAMOL SF
32766 paracetamol solution for infusion 500mg/50ml
32839 PARACETAMOL tablets 500mg [HILLCROSS]
32862 IBUPROFEN sugar-free suspension 100mg/5ml [T & R]
32875 IBUPROFEN tablets 400mg [SANDOZ]
32970 PARACETS capsules 500mg [SUSSEX]
33075 ASPIRIN 600MG/GLYCINE 300MG 600 MG TAB
33104 PARACLEAR soluble tablet 500mg [ROCHE]
33230 promethazine hydrochloride with paracetamol suspension 120mg+1.5mg/5ml
33357 PACIFENE tablets 200mg [SUSSEX]
33386 PARACETAMOL oral suspension 120mg/5ml [HILLCROSS]
33589 IBUPROFEN tablets 400mg [T & R]
33614 OBIMOL tablets 500mg [AYRTONSAUN]
33666 PARACETAMOL tablets 500mg [ACTAVIS]
33687 PARACETAMOL sugar-free suspension 250mg/5ml [HILLCROSS]
33704 IBUPROFEN sugar-free suspension 100mg/5ml [HILLCROSS]
33710 PARACETAMOL caplets 500mg [HILLCROSS]
33785 GALPROFEN tablets 200mg [GALPHARM]
33826 PARACETAMOL tablets 500mg [TEVA]
33838 Herpes zoster with meningitis
34164 PARACETAMOL soluble tablet 500mg [NEOLAB]
34209 PARACETAMOL sugar-free suspension 500mg/5ml [ROSEMONT]
34235 PARACETAMOL suppository 120mg [PENN]
34266 TIXYMOL sugar-free suspension 120mg/5ml [NOVARTIS]
34305 PARACETAMOL tablets 500mg [M&A PHARM]
34350 PARACETAMOL tablets 500mg [CELLTECH]
34354 IBUPROFEN tablets 200mg [AAH(VANT)]
34359 IBUPROFEN tablets 400mg [AAH(VANT)]
34396 PARACETAMOL tablets 500mg [FAMILY H]
34409 PARACETAMOL tablets 500mg [CO-OPERATI]
34425 IBUPROFEN tablets 400mg [FAMILY H]
34447 IBUPROFEN tablets 200mg [T & R]
34500 PARACETAMOL tablets 500mg [KENT]
34527 IBUPROFEN tablets 200mg [STERWIN]
34536 IBUPROFEN tablets 400mg [IVAX]
34550 IBUPROFEN film coated tablets 400mg [ACTAVIS]
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34621 IBUPROFEN tablets 200mg [NUCARE]
34663 IBUPROFEN oral suspension 100mg/5ml [NEOLAB]
34669 PARACETAMOL capsules 500mg [WINTHROP]
34700 PARACETAMOL sugar-free suspension 250mg/5ml [PINEWOOD]
34718 PARACETAMOL sugar-free suspension 120mg/5ml [APS]
34729 IBUPROFEN tablets 400mg [OBG]
34757 IBUPROFEN tablets 400mg [UNICHEM]
34850 IBUPROFEN tablets 600mg [APS]
34858 PARACETAMOL capsules [CO-OPERATI]
34861 PARACETAMOL suppository 120mg [AURUMPHARM]
34889 IBUPROFEN tablets 400mg [CELLTECH]
34911 IBUPROFEN tablets 200mg [CELLTECH]
34931 IBUPROFEN tablets 200mg [REGENT]
34954 PARACETAMOL tablets 500mg [ASPAR]
34961 IBUPROFEN tablets 600mg [SANDOZ]
34980 IBUPROFEN sugar-coated tablets 200mg [ACTAVIS]
35292 NUROFEN liquid capsules 200mg [RECKITT B]
35679 PARACETAMOL caplets 500mg [NUCARE]
35890 NUROFEN caplets 200mg [RECKITT B]
36472 paracetamol with pentazocine tablets 500mg + 15mg
36597 HEDEX IBUPROFEN tablets 200mg [GLAXSK CON]
36606 MANORFEN tablets 400mg [MANOR]
36650 NUROFEN tablets 200mg [RECKITT B]
36754 PARACETAMOL soluble tablet 500mg [HILLCROSS]
36945 MANDANOL SIX PLUS sugar-free suspension 250mg/5ml [M&A PHARM]
37002 NUROFEN EXPRESS liquid capsules 200mg [RECKITT B]
37053 MIGRAFEN tablets 200mg [CHATFIELD]
37094 CUPROFEN IBUPROFEN tablets 200mg [SSL INT]
37253 ANADIN ULTRA DOUBLE STRENGTH capsules 400mg [WYETH CONS]
37411 PALDESIC suspension 250mg/5ml [ROSEMONT]
37553 IBUCALM tablets 400mg [ASPAR]
37648 NUROFEN EXPRESS liquid capsules 400mg [RECKITT B]
38032 PARACETAMOL capsules 500mg [TEVA]
38332 IBUCALM tablets 200mg [ASPAR]
38493 ANADIN JOINT PAIN tablets 200mg [PFIZER]
38984 PARACETAMOL capsules 500mg [ACTAVIS]
39019 BRUFEN RETARD tablets 800mg [ABBOTT]
39333 PARACETAMOL caplets 500mg [ASPAR]
39481 PANADOL ADVANCE tablets 500mg [GLAXSK CON]
39502 ibuprofen sodium dihydrate tablets 256mg
39647 MEDINOL OVER 6 oral suspension 250mg/5ml [SSL INT]
39758 NUROFEN EXPRESS caplets 256mg [RECKITT B]
39873 CUPROFEN MAXIMUM STRENGTH tablets 400mg [SSL INT]
39934 PARACETAMOL tablets 500mg [ALMUS]
39940 PANADOL ACTIFAST soluble tablet 500mg [GLAXSK CON]
40083 GALPHARM IBUPROFEN caplets 200mg [GALPHARM]
40107 PARACETAMOL soluble tablet 500mg [KENT]
40158 PARACETAMOL capsules 500mg [AAH(VANT)]
40253 IBUPROFEN tablets 600mg [SOVEREIGN]
40394 ADVIL tablets 400mg [WYETH CONS]
40516 ANADIN LIQUIFAST liquid capsules 200mg [PFIZER]
41409 PARACETAMOL suppository 500mg [AURUMPHARM]
41414 PARACETAMOL oral suspension 120mg/5ml [CO-PHARMA]
41513 IBUPROFEN tablets 200mg [IVAX]
41680 PARACETAMOL sugar-free suspension 120mg/5ml [IVAX]
41701 IBUPROFEN tablets 600mg [ACTAVIS]
42061 ASPIRIN 65 MG SUP
42101 PERFALGAN solution for infusion 1g/100ml [BMS]
42108 IBUPROFEN tablets 200mg [OBG]
42125 PARACETAMOL suppository 120mg [DISTRIPHAR]
42201 PARACETAMOL capsules 500mg [HILLCROSS]
42371 paracetamol tablets 1000mg
42397 NUROFEN EXPRESS tablets 256mg [RECKITT B]
42514 paracetamol oral liquid
42834 PANADOL OA tablets 1000mg [GLAXSK CON]
43028 paracetamol powder for oral solution 650mg
43032 INOVEN caplets 200mg [JANSSEN]
43199 PARACETAMOL suspension 6 plus 250mg/5ml [AAH(VANT)]
43233 PARACETAMOL capsules 500mg [KENT]
43252 PARACETAMOL capsules 500mg [ASPAR]
43456 ANADIN LIQUIFAST liquid capsules 400mg [PFIZER]
43479 PARACETAMOL caplets 500mg [ACTAVIS]
43911 IBUPROFEN tablets 600mg [CP PHARM]
44311 DEXTROPROPOXYPHENE NAPSYLATE/ASPIRIN 100 MG TAB
44483 NUROFEN EXPRESS tablets 512mg [RECKITT B]
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44496 sodium salicylate mixture 500mg/5ml
45216 IBUPROFEN tablets 400mg [CP PHARM]
45259 PARACETAMOL tablets 500mg [OBG]
45298 PARACETAMOL tablets 500mg [GALPHARM]
45320 IBUPROFEN tablets 200mg [SANDOZ]
45331 IBUPROFEN tablets 200mg [CO-PHARMA]
45348 PARACETAMOL oral suspension 120mg/5ml [NUCARE]
45349 PARACETAMOL suppository 240mg [AURUMPHARM]
45842 IBUPROFEN tablets 600mg [CELLTECH]
46342 MEDIFEN 3+ MONTHS oral suspension 100mg/5ml [SSL INT]
46544 PARACETAMOL capsules 500mg [WOCKHARDT]
46638 ibuprofen with paracetamol tablets 200mg + 500mg
46763 paracetamol oral suspension 500mg/5ml
46846 paracetamol oral solution 500mg/5ml
46860 ANADIN LIQUIFAST effervescent tablet 200mg [PFIZER]
46904 NUROMOL tablets 200mg + 500mg [RECKITT B]
46921 IBUPROFEN tablets 400mg [RANBAXY]
46942 IBUPROFEN tablets 600mg [IVAX]
47116 PARACETAMOL soluble tablet 500mg [ALMUS]
47211 PARACETAMOL capsules 500mg [FOCUS]
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4 co-proxamol (dextropropoxyphene and paracetamol) tablets 32.5mg + 325mg
11 co-dydramol (dihydrocodeine and paracetamol) tablets 10mg+500mg
19 co-codamol (codeine and paracetamol) tablets 8mg+500mg
53 dihydrocodeine tablets 30mg
57 co-codamol (codeine and paracetamol) effervescent tablet 8mg+500mg
96 co-codamol (codeine and paracetamol) tablets 30mg + 500mg
142 CODEINE SOLUBLE TAB
158 codeine phosphate tablets 30mg
191 dihydrocodeine elixir 10mg/5ml
203 CODEINE CO SOLUBLE TAB
213 codeine phosphate syrup 25mg/5ml
241 CODEINE CO TAB
382 ZERIDAME SR tablets 150mg [ACTAVIS]
462 codeine phosphate injection 60mg/1ml
483 co-proxamol (dextropropoxyphene and paracetamol) sugar-free suspension 32.5mg + 325mg/5ml
539 codeine phosphate tablets 60mg
625 co-codamol (codeine and paracetamol) capsules 8mg+500mg
635 codeine phosphate injection 30mg/1ml
656 TYLEX capsules 500mg + 30mg [UCB]
767 SOLPADOL capsules 500mg + 30mg [SANOFI/AVE]
800 co-codamol (codeine and paracetamol) capsules 30mg + 500mg
810 co-codamol (codeine and paracetamol) effervescent tablet 30mg + 500mg
1261 co-codamol (codeine and paracetamol) sugar free effervescent powder 30mg + 500mg
1640 KAPAKE tablets 30mg + 500mg [GALEN]
1708 CODAFEN CONTINUS modified release tablet 300mg + 20mg [NAPPPHARM]
2040 REMEDEINE tablets 20mg + 500mg [NAPPPHARM]
2041 dihydrocodeine modified release tablet 60mg
2047 co-codaprin (codeine and aspirin) tablets 8mg+400mg
2211 SOLPADOL effervescent tablet 500mg + 30mg [SANOFI/AVE]
2250 CODEINE & PARACETAMOL TAB
2555 dihydrocodeine with paracetamol tablets 10mg + 500mg
2698 CODEINE & PARACETAMOL 8 MG TAB
2794 CO-CODAMOL tablets 30mg + 500mg [WOCKHARDT]
2846 paracetamol with codeine phosphate effervescent tablet 500mg + 30mg
2917 paracetamol with codeine phosphate tablets 500mg + 30mg
2986 co-codaprin (codeine and aspirin) dispersible tablet 8mg+400mg
2988 CODEINE PHOSPHATE 15 MG ELI
2998 PARACETAM/DYHYDROCODEINE(500MG/30MG) MG TAB
3029 CO-CODAMOL EFF 30MG/500MG TAB
3156 SOLPADOL caplets 500mg + 30mg [SANOFI/AVE]
3185 paracetamol with codeine phosphate capsules 500mg + 30mg
3272 PARACETAM/DYHYDROCODEINE(500MG/20MG) TAB
3435 TYLEX effervescent tablet 500mg + 30mg [UCB]
3653 dihydrocodeine injection 50mg/1ml
3698 DF118 forte tablets 40mg [MARTINDALE]
3713 MEDOCODENE tablets [???]
4349 PARACETAMOL & CODEINE TAB
4556 PARAMOL tablets 500mg + 7.46mg [SSL INT]
4607 CO-PROXAMOL tablets (DISTA) 32.5/325 [DISTA]
4671 codeine phosphate with paracetamol capsules 30mg + 500mg
4823 dihydrocodeine tablets 40mg
4950 dihydrocodeine with paracetamol tablets 30mg + 500mg
5955 paracetamol with dihydrocodeine tablets 500mg + 30mg
6234 dihydrocodeine modified release tablet 120mg
6886 codeine phosphate with paracetamol tablets 30mg + 500mg
7063 co-dydramol (dihydrocodeine and paracetamol) sugar-free suspension 10mg + 500mg/5ml
7072 co-codamol (codeine and paracetamol) tablets 15mg + 500mg
7104 KAPAKE effervescent tablet 30mg + 500mg [GALEN]
7469 DF118 elixir 10mg/5ml [MARTINDALE]
7518 aspirin with codeine dispersible tablet 400mg + 8mg
7542 codeine phosphate with paracetamol tablets 8mg + 500mg
7696 PARACETAMOL 500MG/CODEINE 10MG MG TAB
7770 ASPIRIN/CODEINE PHOSPHATE/PARACETAMOL 250 MG TAB
7976 PARACETAMOL 450MG/CODEINE 8.1MG TAB
7989 DIHYDROCODEINE TARTRATE/ASPIRIN 300 MG TAB
8246 codeine phosphate with paracetamol effervescent tablet 8mg + 500mg
8335 PARACODOL capsules [BAYER]
8456 DHC CONTINUS tablets 60mg [NAPPPHARM]
9044 CODIS 500 tablets [RECKITT B]
9129 paracetamol with aspirin and codeine tablets 250mg+250mg+6.8mg
9163 REMEDEINE effervescent tablet 20mg + 500mg [NAPPPHARM]
9209 DHC CONTINUS tablets 90mg [NAPPPHARM]
9275 DHC CONTINUS tablets 120mg [NAPPPHARM]
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Product Code Product Name
9313 dihydrocodeine modified release tablet 90mg
9432 aspirin with codeine soluble tablet 500mg + 8mg
9457 paracetamol with codeine phosphate tablets 500mg + 8mg
9460 paracetamol with codeine phosphate capsules 500mg + 8mg
9462 paracetamol with codeine phosphate effervescent tablet 500mg + 8mg
9516 KAPAKE capsules 30mg + 500mg [GALEN]
9562 REMEDEINE forte effervescent tablets 30mg + 500mg [NAPPPHARM]
9785 REMEDEINE forte tablets 30mg + 500mg [NAPPPHARM]
9855 paracetamol with dihydrocodeine tablets 500mg + 20mg
9917 KAPAKE INSTS sugar free effervescent powder 30mg + 500mg [GALEN]
10023 dihydrocodeine with paracetamol tablets 20mg + 500mg
10122 dihydrocodeine with paracetamol sugar-free suspension 10mg + 500mg/5ml
10176 CODIPAR caplets 500mg + 15mg [GOLDSHIELD]
10309 DF118 injection 50mg/ml [MARTINDALE]
10519 CODEINE PHOS/IBUPROFEN SR (20MG/300MG) TAB
10582 FORMULIX elixir [CILAG]
10602 PARACODOL effervescent tablet [BAYER]
11129 papaveretum injection 15.4mg/ml
11325 paracetamol with codeine phosphate tablets 500mg + 30mg
11461 ibuprofen and codeine modified release tablet 300mg + 20mg
11554 ibuprofen and codeine tablets 200mg + 12.8mg
11665 ZAPAIN caplets 30mg + 500mg [GOLDSHIELD]
11807 paracetamol with codeine tablets 500mg + 12.8mg
11961 VEGANIN tablets [PFIZER]
12709 ibuprofen and codeine tablets 200mg + 12.5mg
12992 co-codaprin (codeine and aspirin) soluble tablet 8mg+500mg
13598 ASPIRIN & CODEINE 500 MG TAB
13893 NUROFEN PLUS tablets [RECKITT B]
14602 co-codamol (codeine and paracetamol) sugar free effervescent powder 60mg + 1000mg
14688 paracetamol with dihydrocodeine tablets 500mg + 10mg
14785 paracetamol with codeine phosphate tablets 500mg + 15mg
14912 codeine phosphate with paracetamol capsules 8mg+500mg
15198 CO-DYDRAMOL tablets 10mg+500mg [CP PHARM]
15353 papaveretum injection 7.7mg/ml
15779 codeine phosphate with aspirin soluble tablet 8mg + 500mg
15831 codeine phosphate with paracetamol sugar free effervescent powder 30mg + 500mg
15871 KAPAKE INSTS  60/1000 sugar free effervescent powder 60mg + 1000mg [GALEN]
16096 codeine phosphate oral liquid 6.75mg/5ml
16112 PARAMOL soluble tablet [SSL INT]
16467 codeine phosphate with paracetamol effervescent tablet 30mg + 500mg
16818 paracetamol with codeine phosphate sugar free effervescent powder 500mg + 30mg
17158 PANADEINE FORTE tablets [SANOFI S]
17563 SOLPADEINE MAX tablets 500mg + 12.8mg [GLAXSK CON]
17808 CO-CODAMOL 30MG/500MG
17917 dihydrocodeine with paracetamol effervescent tablet 20mg + 500mg
17926 aspirin with codeine tablets 400mg + 8mg
17998 MEDOCODENE capsules 30mg + 500mg [UCB]
18221 codeine phosphate with paracetamol tablets 15mg + 500mg
19206 paracetamol with dihydrocodeine tablets 500mg + 7.46mg
19317 OMNOPON tablets 10mg [ROCHE]
19550 CO-PROXAMOL
19764 papaveretum tablets 10mg
20127 codeine phosphate with aspirin dispersible tablet 8mg+400mg
21104 PARACETAMOL/CODEINE PHOSPHATE 500 MG TAB
21113 dihydrocodeine with paracetamol forte effervescent tablets 30mg + 500mg
21229 paracetamol with dihydrocodeine effervescent tablet 500mg + 7.46mg
21703 paracetamol with codeine phosphate sugar free effervescent powder 1000mg + 60mg
21880 ZAPAIN capsules 30mg + 500mg [GOLDSHIELD]
21927 CO-DYDRAMOL
22450 ASPIRIN & CODEINE 75 MG TAB
22627 CODEINE PHOSPHATE 15/PARACETAMOL 500MG TAB
22764 PANADEINE tablets [GLAXSK PHA]
22817 CO-CODAMOL SF EFF POWDER
23420 codeine phosphate with paracetamol sugar free effervescent powder 60mg + 1000mg
23952 PANADEINE SOLUBLE effervescent tablet [SANOFI S]
24209 CO-CODAMOL EFFERVESCENT
24498 ASPIRIN/CODEINE PHOSPHATE/PARACETAMOL 300 MG TAB
24859 CODEINE 8MG & PARACETAMOL 500MG SUP
25330 SOLPAFLEX tablets 200mg + 12.8mg [GLAXSK CON]
25514 paracetamol with codeine phosphate tablets 500mg + 10mg
26653 DIHYDROCODEINE 10mg/PARACETAMOL 500mg
27784 CO-CODAMOL tablets 8mg+500mg [ACTAVIS]
27785 CO-CODAMOL tablets 30mg + 500mg [WINTHROP]
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28253 CO-PROXAMOL sugar-free suspension 32.5/325 [ROSEMONT]
28598 paracetamol with dihydrocodeine sugar-free suspension 500mg +10mg/5ml
28780 CO-DYDRAMOL tablets 10mg+500mg [HILLCROSS]
28784 codeine phosphate with aspirin tablets 8mg+400mg
29342 CO-CODAMOL tablets 8mg+500mg [M&A PHARM]
29488 CO-CODAMOL effervescent tablet 8mg+500mg [WINTHROP]
29828 ACETYLSALICYLIC ACID / CODEINE PHOSPHATE MG TAB
30021 paracetamol with codeine phosphate tablets 500mg + 13.5mg
30123 PANADOL ULTRA tablets 500mg + 12.8mg [GLAXSK CON]
30165 co-dydramol (dihydrocodeine and paracetamol) tablets 7.46mg + 500mg
30295 dihydrocodeine with paracetamol tablets 7.46mg + 500mg
30444 CO-DYDRAMOL tablets 10mg+500mg [GEN (UK)]
30556 CO-CODAMOL effervescent tablet 8mg+500mg [NEOLAB]
30954 CO-PROXAMOL tablets 32.5/325 [ACTAVIS]
30966 CO-PROXAMOL tablets 32.5/325 [DISTA]
31155 PARAKE tablets [GALEN]
31452 CODEINE PHOSPHATE tablets 30mg [CP PHARM]
31577 CO-CODAMOL capsules 30mg + 500mg [HILLCROSS]
31700 CODEINE PHOSPHATE tablets 15mg [ACTAVIS]
31871 paracetamol with codeine phosphate tablets 450mg + 8.1mg
31894 SAFAPRYN -CO tablets [PFIZER]
31943 CODEINE PHOSPHATE tablets 30mg [IVAX]
32692 CO-CODAMOL effervescent tablet 8mg+500mg [HILLCROSS]
32926 CO-DYDRAMOL tablets 10mg+500mg [ACTAVIS]
33340 CO-DYDRAMOL suspension 10mg + 500mg/5ml [ROSEMONT]
33643 CO-CODAMOL tablets 8mg+500mg [FAMILY H]
33647 CO-PROXAMOL tablets 32.5/325 [HILLCROSS]
33653 CO-CODAMOL tablets 8mg+500mg [IVAX]
33654 DIHYDROCODEINE tablets 30mg [WOCKHARDT]
33679 CO-CODAMOL tablets 8mg+500mg [WINTHROP]
33688 CO-CODAMOL effervescent tablet 30mg + 500mg [NEOLAB]
33743 dihydrocodeine with paracetamol effervescent tablet 7.46mg + 500mg
33961 CO-CODAMOL capsules 30mg + 500mg [IVAX]
33995 CO-PROXAMOL tablets 32.5/325 [BERK]
34008 DIHYDROCODEINE tablets 30mg [IVAX]
34022 CO-PROXAMOL tablets 32.5/325 [APS]
34229 CO-CODAMOL dispersible tablet 8mg+500mg [RHONE]
34257 CO-CODAMOL dispersible tablet 8mg+500mg [GEN (UK)]
34264 CO-CODAMOL STRONG tablets 30mg + 500mg [IVAX]
34319 CO-PROXAMOL tablets 32.5/325 [STERWIN]
34348 CODEINE PHOSPHATE tablets 15mg [HILLCROSS]
34349 CO-PROXAMOL tablets 32.5mg + 325mg [IVAX]
34383 CODEINE PHOSPHATE tablets 30mg [HILLCROSS]
34397 CO-PROXAMOL tablets 32.5mg + 325mg [M&A PHARM]
34440 DIHYDROCODEINE tablets 30mg [HILLCROSS]
34444 Herpes zoster with meningitis
34468 CO-PROXAMOL tablets 32.5mg + 325mg [SANDOZ]
34495 CO-CODAMOL tablets 8mg+500mg [GEN (UK)]
34497 CO-CODAMOL tablets 8mg+500mg [BERK]
34518 CO-CODAMOL tablets 8mg+500mg [HILLCROSS]
34546 CO-PROXAMOL tablets 32.5mg + 325mg [NEOLAB]
34552 CODEINE PHOSPHATE tablets 30mg [ACTAVIS]
34554 CO-PROXAMOL tablets 32.5/325 [CP PHARM]
34579 DIHYDROCODEINE tablets 30mg [ACTAVIS]
34597 CO-PROXAMOL tablets 32.5mg + 325mg [KENT]
34662 DIHYDROCODEINE tablets 30mg [GEN (UK)]
34667 CO-CODAMOL tablets 30mg + 500mg [HILLCROSS]
34730 DIHYDROCODEINE tablets 30mg [BERK]
34737 CO-DYDRAMOL tablets 10mg+500mg [TEVA]
34784 CO-CODAMOL effervescent tablet 8mg+500mg [SANDOZ]
34789 CODEINE PHOSPHATE tablets 30mg [KENT]
34815 CO-CODAMOL tablets 8mg+500mg [KENT]
34840 CO-CODAMOL tablets 30mg + 500mg [ALMUS]
34845 CO-CODAMOL effervescent tablet 30mg + 500mg [WINTHROP]
34865 CO-CODAMOL tablets 8mg+500mg [WOCKHARDT]
34920 CO-DYDRAMOL tablets 10mg+500mg [BERK]
34939 CO-DYDRAMOL tablets 10mg+500mg [DF]
34968 CO-CODAMOL tablets 8mg+500mg [TEVA]
35792 CODEINE PHOSPHATE syrup [T & R]
35965 MEDOCODENE effervescent tablet [SCHWARZ]
36019 CO-DYDRAMOL tablets 10mg+500mg [M&A PHARM]
36488 CO-CODAMOL capsules 30mg + 500mg [GEN (UK)]
36608 CO-CODAMOL effervescent tablet [AAH(VANT)]
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36993 CO-CODAMOL capsules 30mg + 500mg [TEVA]
37291 CO-DYDRAMOL tablets 10mg+500mg [RANBAXY]
37816 CUPROFEN PLUS tablets [SSL INT]
37904 co-codamol (codeine and paracetamol) tablets 12.8mg + 500mg
38085 paracetamol with codeine phosphate capsules 500mg + 10mg
38088 paracetamol with codeine phosphate tablets 500mg + 30mg
38363 codeine phosphate with paracetamol tablets 12.8mg + 500mg
38430 CO-DYDRAMOL tablets 10mg+500mg [MERCK-GEN]
38521 DIHYDROCODEINE tablets 30mg [TEVA]
38950 REMEDEINE FORTE tablets 30mg + 500mg [NAPPPHARM]
38970 DF118 FORTE tablets 40mg [MARTINDALE]
39340 CO-CODAMOL caplets 8mg+500mg [AAH(VANT)]
39558 DIHYDROCODEINE tablets 30mg [WINTHROP]
40159 DIHYDROCODEINE elixir 10mg/5ml [MARTINDALE]
40385 CO-CODAMOL effervescent tablet 8mg+500mg [ALMUS]
40422 CO-DYDRAMOL tablets 10mg+500mg [WINTHROP]
40662 CO-CODAMOL effervescent tablet 8mg+500mg [ACTAVIS]
40663 CO-CODAMOL effervescent tablet 30mg + 500mg [ACTAVIS]
41259 CO-CODAMOL effervescent tablet 30mg + 500mg [TEVA]
41275 CO-CODAMOL tablets 8mg+500mg [NUCARE]
41276 CO-CODAMOL tablets 8mg+500mg [ALMUS]
41278 CO-DYDRAMOL tablets 10mg+500mg [IVAX]
41407 CO-PROXAMOL tablets 32.5mg + 325mg [RANBAXY]
41416 CODEINE PHOSPHATE tablets 60mg [CP PHARM]
41535 CODEINE PHOSPHATE tablets 30mg [TEVA]
41599 CODEINE PHOSPHATE tablets 15mg [TEVA]
41682 CO-CODAMOL effervescent tablet 30mg + 500mg [ROCHE]
42208 DF118 tablets 30mg [MARTINDALE]
42213 CO-CODAMOL capsules 8mg+500mg [CUSTOM]
42218 CO-CODAPRIN dispersible tablet 8mg+400mg [HILLCROSS]
42791 CO-CODAMOL FORTE tablets 30mg + 500mg [SANDOZ]
43238 CO-CODAMOL effervescent tablet 30mg + 500mg [GEN (UK)]
43244 CO-CODAMOL effervescent tablet 30mg + 500mg [HILLCROSS]
43414 CO-CODAMOL effervescent tablet 8mg+500mg [BAYER]
43441 CO-DYDRAMOL tablets 10mg+500mg [CELLTECH]
43504 CODEINE PHOSPHATE syrup [RANSOM]
43536 CO-PROXAMOL tablets 32.5/325 [NUMARK]
43550 CODEINE PHOSPHATE tablets 15mg [RANBAXY]
43891 co-proxamol oral liquid
44210 KAPAKE tablets 15mg + 500mg [GALEN]
44924 CO-CODAMOL tablets 30mg + 500mg [TEVA]
45231 CO-PROXAMOL tablets 32.5mg + 325mg [REGENT]
45276 CO-PROXAMOL tablets 32.5mg + 325mg [SIGMA]
46511 co-codamol (codeine and paracetamol) effervescent tablet 15mg + 500mg
46633 CO-CODAMOL capsules 8mg+500mg [HILLCROSS]
46729 co-codamol (codeine and paracetamol) capsules 15mg + 500mg
46898 CODIPAR capsules 15mg + 500mg [GOLDSHIELD]
46906 CO-CODAMOL effervescent tablet 8mg+500mg [NUMARK]
46925 CO-CODAPRIN dispersible tablet 8mg+400mg [ACTAVIS]
46987 CO-CODAMOL tablets 15mg + 500mg [HILLCROSS]
47003 CODEINE PHOSPHATE tablets 60mg [RANBAXY]
47071 co-dydramol (dihydrocodeine and paracetamol) oral suspension 10mg + 500mg/5ml
47072 OMNOPON injection 15.4mg/ml [ROCHE]
47508 CODIPAR effervescent tablet 15mg + 500mg [GOLDSHIELD]
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Product Code Product Name
86 tramadol capsules 50mg
187 ZYDOL capsules 50mg [GRUNENTHAL]
687 TRAMACET film coated tablets 37.5mg + 325mg [GRUNENTHAL]
701 tramadol modified release capsules 50mg
3378 tramadol soluble tablet 50mg
3644 ZYDOL SR tablets 100mg [GRUNENTHAL]
4114 tramadol modified release capsules 100mg
4115 tramadol 12 hour modified release tablets 100mg
4834 tramadol modified release capsules 150mg
4999 tramadol 24 hour modified release tablets 150mg
5028 tramadol 24 hour modified release tablets 200mg
5169 ZYDOL SR tablets 200mg [GRUNENTHAL]
5257 tramadol 12 hour modified release tablets 150mg
6153 ZYDOL SR tablets 150mg [GRUNENTHAL]
6215 tramadol modified release capsules 200mg
6558 tramadol with paracetamol tablets 37.5mg + 325mg
8416 tramadol 12 hour modified release tablets 200mg
9389 ZAMADOL SR modified release capsules 50mg [MEDA]
9396 ZAMADOL SR modified release capsules 100mg [MEDA]
9739 tramadol sachets 100mg
11101 ZYDOL soluble tablet 50mg [GRUNENTHAL]
11275 ZYDOL injection 100mg/2ml [GRUNENTHAL]
11471 tramadol injection 100mg/2ml
11549 tramadol 12 hour modified release tablets 75mg
11559 tramadol sachets 50mg
11734 tramadol orodispersible tablet 50mg
11746 tramadol 24 hour modified release tablets 300mg
11748 tramadol 24 hour modified release tablets 400mg
13813 ZAMADOL capsules 50mg [MEDA]
14490 TRAMAKE capsules 50mg [GALEN]
16076 paracetamol with tramadol tablets 325mg + 37.5mg
16271 ZYDOL XL tablets 300mg [GRUNENTHAL]
16395 ZYDOL XL tablets 200mg [GRUNENTHAL]
19993 DROMADOL SR tablets 100mg [IVAX]
20310 ZAMADOL MELT orodispersible tablet 50mg [MEDA]
21256 TRAMAKE INSTS sachets 50mg [GALEN]
21397 ZYDOL XL tablets 400mg [GRUNENTHAL]
21777 DROMADOL SR tablets 200mg [IVAX]
21797 ZAMADOL SR modified release capsules 200mg [MEDA]
21947 ZYDOL XL tablets 150mg [GRUNENTHAL]
23625 DROMADOL SR tablets 150mg [IVAX]
23981 ZAMADOL SR modified release capsules 150mg [MEDA]
24383 TRAMAKE INSTS sachets 100mg [GALEN]
26336 DROMADOL XL tablets 300mg [IVAX]
26986 ZAMADOL 24 hour modified release tablets 200mg [MEDA]
27591 ZAMADOL 24 hour modified release tablets 150mg [MEDA]
28728 ZAMADOL 24 hour modified release tablets 300mg [MEDA]
29324 DROMADOL SR tablets 75mg [IVAX]
29860 TRAMADOL capsules 50mg [IVAX]
31105 DROMADOL XL tablets 200mg [IVAX]
31107 DROMADOL XL tablets 150mg [IVAX]
31734 DROMADOL XL tablets 400mg [IVAX]
32165 TRAMADOL capsules 50mg [GEN (UK)]
32450 ZAMADOL 24 hour modified release tablets 400mg [MEDA]
34065 TRAMADOL SR modified release tablet 150mg [WINTHROP]
34260 TRAMADOL SR modified release tablet 100mg [WINTHROP]
34281 TRAMADOL SR modified release tablet 200mg [WINTHROP]
34422 TRAMADOL capsules 50mg [ACTAVIS]
34521 TRAMADOL capsules 50mg [HILLCROSS]
34570 TRAMADOL capsules 50mg [TEVA]
34639 TRAMADOL capsules 50mg [GENUS]
34808 TRAMADOL capsules 50mg [PLIVA]
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35347 tramadol 24 hour modified release tablets 100mg
35438 TRAMQUEL SR capsules 100mg [MEDA]
35651 TRADOREC XL tablets 200mg [LABOPHARM]
35656 TRADOREC XL tablets 100mg [LABOPHARM]
35806 LARAPAM SR tablets 100mg [SANDOZ]
36035 TRADOREC XL tablets 300mg [LABOPHARM]
36697 MABRON prolonged release tablet 200mg [MORNINGSID]
36732 tramadol 12 hour modified release tablets 50mg
36873 ZYDOL SR tablets 50mg [GRUNENTHAL]
36949 TRAMQUEL SR capsules 50mg [MEDA]
37020 tramadol modified release tablet 150mg
37021 tramadol modified release tablet 200mg
37831 MABRON prolonged release tablet 100mg [MORNINGSID]
37867 tramadol (roi) tablets 100mg
38196 LARAPAM SR tablets 200mg [SANDOZ]
38528 TRAMADOL capsules 50mg [TILLOMED]
38874 ZAMADOL injection 100mg/2ml [MEDA]
38956 TRAMQUEL SR capsules 200mg [MEDA]
39505 MAROL prolonged release tablet 100mg [MORNINGSID]
39709 MAROL prolonged release tablet 200mg [MORNINGSID]
39750 MAROL prolonged release tablet 150mg [MORNINGSID]
39798 NOBLIGAN RETARD tablets 100mg [GRUNENTHAL]
39811 Herpes zoster with meningitis
40058 TRAMULIEF SR tablets 100mg [SOVEREIGN]
40060 TRAMULIEF SR tablets 200mg [SOVEREIGN]
40061 TRAMULIEF SR tablets 150mg [SOVEREIGN]
40166 TRAMADOL capsules 50mg [NICHE]
40249 MAXITRAM SR modified release capsules 100mg [CHIESI]
40254 MAXITRAM SR modified release capsules 50mg [CHIESI]
40718 TRAMADOL capsules 50mg [ALMUS]
40805 TRAMQUEL SR capsules 150mg [MEDA]
40883 MAXITRAM SR modified release capsules 150mg [CHIESI]
40926 LARAPAM SR tablets 150mg [SANDOZ]
41976 TRAMADOL SR tablets 100mg [HILLCROSS]
42280 tramadol with paracetamol effervescent tablet 37.5mg + 325mg
42332 TRAMACET effervescent tablet 37.5mg + 325mg [GRUNENTHAL]
42798 TRAMADOL SR tablets 150mg [HILLCROSS]
43198 TRAMADOL SR capsules 50mg [HILLCROSS]
43513 TRAMADOL capsules 50mg [WINTHROP]
44371 MABRON prolonged release tablet 150mg [MORNINGSID]
46279 TRAMADOL SR capsules 200mg [HILLCROSS]
46587 tramadol oral drops 100mg/ml
46643 ZERIDAME SR tablets 150mg [ACTAVIS]
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49 amitriptyline hydrochloride tablets 25mg
83 amitriptyline hydrochloride tablets 10mg
182 TRYPTIZOL injection 10mg/ml [M S D]
487 amitriptyline hydrochloride modified release capsules 25mg
873 AMITRIPTYLINE 100 MG TAB
1310 imipramine tablets 10mg
1809 imipramine tablets 25mg
1888 amitriptyline hydrochloride tablets 50mg
2039 trimipramine maleate tablets 25mg
2486 LENTIZOL capsules 25mg [PFIZER]
2525 amitriptyline hydrochloride modified release capsules 75mg
2531 SURMONTIL capsules 50mg [AVENTIS]
2532 SURMONTIL tablets 25mg [AVENTIS]
2533 TRIMIPRAMINE 50 MG TAB
2579 TOFRANIL tablets 10mg [NOVARTIS]
2936 Herpes zoster with meningitis
2985 LENTIZOL capsules 50mg [PFIZER]
3183 nortriptyline tablets 10mg
3196 trimipramine maleate capsules 50mg
3668 IMIPRAMINE 100 MG TAB
3771 AMITRIPTYLINE 75 MG TAB
3777 amitriptyline hydrochloride sugar free oral solution 10mg/5ml
3903 nortriptyline tablets 25mg
4118 nortriptyline capsules 10mg
4310 trimipramine maleate tablets 10mg
4404 TOFRANIL syrup 25mg/5ml [NOVARTIS]
4682 amitriptyline hydrochloride modified release capsules 50mg
4690 amitriptyline hydrochloride sugar free oral solution 50mg/5ml
6312 amitriptyline hydrochloride sugar free oral solution 25mg/5ml
6895 duloxetine gastro-resistant capsules 60mg
7122 ZERIDAME SR tablets 150mg [ACTAVIS]
7147 duloxetine gastro-resistant capsules 40mg
7153 duloxetine gastro-resistant capsules 20mg
7573 IMIPRAMINE 25 MG CAP
7677 ALLEGRON tablets 10mg [KING]
7678 nortriptyline capsules 25mg
7751 TRYPTIZOL tablets 25mg [M S D]
7780 nortriptyline with fluphenazine tablets 10mg + 500micrograms
7784 IMIPRAMINE 50 MG TAB
7910 TOFRANIL tablets 25mg [NOVARTIS]
7979 PERTOFRAN tablets 25mg [NOV/GEIGY]
7981 desipramine tablets 25mg
8055 imipramine syrup 25mg/5ml
8250 AMITRIPTYLINE S/F 25 MG/5ML SYR
8332 TRYPTIZOL tablets 50mg [M S D]
8493 MOTIPRESS tablets 30mg + 1.5mg [SANOFI S]
8640 ALLEGRON tablets 25mg [KING]
8726 TRYPTIZOL tablets 10mg [M S D]
8831 TRYPTIZOL MR capsules 75mg [M S D]
8878 TRYPTIZOL sugar free mixture 10mg/5ml [M S D]
8928 SURMONTIL tablets 10mg [AVENTIS]
10649 IMIPRAMINE 75 MG TAB
11963 LIMBITROL 10 capsules [ROCHE]
12194 NORTRIPTYLINE 10 MG ELI
12353 AVENTYL capsules 25mg [LILLY]
12549 AVENTYL liquid 10mg/5ml [LILLY]
13151 CYMBALTA gastro-resistant capsules 30mg [LILLY]
13496 AMITRIPTYLINE 200 MG TAB
14534 LIMBITROL 5 capsules [ROCHE]
14578 nortriptyline with fluphenazine tablets 30mg + 1.5mg
14803 YENTREVE gastro-resistant capsules 40mg [LILLY]
14849 CYMBALTA gastro-resistant capsules 60mg [LILLY]
16969 YENTREVE gastro-resistant capsules 20mg [LILLY]
17183 AVENTYL capsules 10mg [LILLY]
18342 amitriptyline hydrochloride with chlordiazepoxide capsules 25mg + 10mg
19779 amitriptyline hydrochloride injection 10mg/ml
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20026 DOMICAL tablets 25mg [BERK]
20571 fluphenazine with nortriptyline tablets 500mcg + 10mg
20712 AMITRIPTYLINE S/R
21081 amitriptyline hydrochloride with chlordiazepoxide capsules 12.5mg + 5mg
22070 AMITRIPTYLINE sugar free oral solution 10mg/5ml [ROSEMONT]
23497 AMITRIPTYLINE 300 MG TAB
24134 AMITRIPTYLINE tablets 25mg [KENT]
24141 AMITRIPTYLINE tablets 10mg [ACTAVIS]
24145 AMITRIPTYLINE tablets 25mg [ACTAVIS]
24147 AMITRIPTYLINE tablets 25mg [TEVA]
24152 AMITRIPTYLINE tablets 10mg [TEVA]
24680 ELAVIL tablets 10mg [DDSA]
25045 TRIMIPRAMINE
25085 TRIMIPRAMINE
26213 DOMICAL tablets 10mg [BERK]
27008 DOMICAL tablets 50mg [BERK]
27876 AMITRIPTYLINE
30738 AMITRIPTYLINE S/F
32439 AMITRIPTYLINE tablets 25mg [SUSSEX]
32863 IMIPRAMINE tablets 10mg [TEVA]
33074 PRAMINIL tablets 10mg [DDSA]
33090 AMITRIPTYLINE tablets 10mg [HILLCROSS]
33624 AMITRIPTYLINE tablets 50mg [TEVA]
34107 AMITRIPTYLINE tablets 50mg [WOCKHARDT]
34129 AMITRIPTYLINE tablets 25mg [WOCKHARDT]
34182 AMITRIPTYLINE tablets 50mg [KENT]
34197 AMITRIPTYLINE tablets 25mg [BERK]
34222 IMIPRAMINE tablets 10mg [ACTAVIS]
34224 AMITRIPTYLINE sugar free oral solution 25mg/5ml [ROSEMONT]
34251 AMITRIPTYLINE sugar free oral solution 50mg/5ml [ROSEMONT]
34274 AMITRIPTYLINE tablets 50mg [HILLCROSS]
34355 IMIPRAMINE tablets 25mg [ACTAVIS]
34401 AMITRIPTYLINE tablets 10mg [WOCKHARDT]
34474 AMITRIPTYLINE tablets 25mg [REGENT]
34503 AMITRIPTYLINE tablets 25mg [IVAX]
34634 AMITRIPTYLINE tablets 50mg [ACTAVIS]
34731 AMITRIPTYLINE tablets 10mg [KENT]
34782 AMITRIPTYLINE tablets 25mg [HILLCROSS]
34813 IMIPRAMINE tablets 25mg [HILLCROSS]
34872 IMIPRAMINE tablets 25mg [CP PHARM]
34916 AMITRIPTYLINE tablets 10mg [BERK]
39145 nortriptyline liquid 10mg/5ml
40396 AMITRIPTYLINE tablets 50mg [BERK]
41408 IMIPRAMINE tablets 25mg [TEVA]
41681 IMIPRAMINE tablets 10mg [HILLCROSS]
41729 AMITRIPTYLINE tablets 25mg [CELLTECH]
42078 AMITRIPTYLINE tablets 25mg [ALMUS]
42228 TRIMIPRAMINE tablets 10mg [HILLCROSS]
42247 imipramine oral solution 25mg/5ml
42394 AMITRIPTYLINE tablets 25mg [CROSS-PHAR]
45226 TRIMIPRAMINE tablets 25mg [HILLCROSS]
45233 AMITRIPTYLINE tablets 10mg [IVAX]
45242 AMITRIPTYLINE tablets 10mg [SUSSEX]
46801 amitriptyline hydrochloride oral solution 10mg/5ml
46818 amitriptyline hydrochloride oral suspension 10mg/5ml
46970 AMITRIPTYLINE tablets 50mg [IVAX]
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Rheumatoid arthritis
Medical code Read term
844 Rheumatoid arthritis
4186 Juvenile rheumatoid arthritis - Still's disease
5723 Rheumatoid nodule
6916 Seronegative rheumatoid arthritis
8350 ZERIDAME SR tablets 150mg [ACTAVIS]
9707 Seropositive errosive rheumatoid arthritis
9954 Rheumatoid lung
12019 Seropositive rheumatoid arthritis, unspecified
18155 Rheumatoid bursitis
21358 Rheumatoid arthritis of shoulder
21533 Pauciarticular juvenile rheumatoid arthritis
23552 Felty's syndrome
23834 Adult Still's Disease
27557 Juvenile rheumatoid arthritis NOS
27603 Rheumatoid arthritis and other inflammatory polyarthropathy
28853 Fibrosing alveolitis associated with rheumatoid arthritis
30548 Rheumatoid vasculitis
31054 Herpes zoster with meningitis
31209 Myopathy due to rheumatoid arthritis
31360 Juvenile rheumatoid arthritis
31724 Rheumatoid lung
32001 Adult-onset Still's disease
33264 O/E-hands-rheumatoid spindling
36276 Monarticular juvenile rheumatoid arthritis
37431 Rheumatoid arthropathy + visceral/systemic involvement NOS
41941 Rheumatoid arthritis of PIP joint of finger
42299 Rheumatoid arthritis of MCP joint
43816 Rheumatoid carditis
44203 Other rheumatoid arthritis of spine
44743 Rheumatoid arthritis of cervical spine
46436 Rheumatoid lung disease
47831 Acute polyarticular juvenile rheumatoid arthritis
48832 Rheumatoid arthritis of wrist
49067 Rheumatoid arthritis of hip
49227 Other rheumatoid arthropathy + visceral/systemic involvement
49787 Rheumatoid myocarditis
50644 Juvenile rheumatoid arthropathy unspecified
50863 Rheumatoid arthritis of knee
51238 Rheumatoid arthritis of 1st MTP joint
51239 Rheumatoid arthritis of ankle
53621 Rheumatoid nodule
56202 [X]Seropositive rheumatoid arthritis, unspecified
56838 Caplan's syndrome
59738 Rheumatoid arthritis of elbow
62401 Polyneuropathy in rheumatoid arthritis
63198 Rheumatoid arthritis of DIP joint of finger
63365 Rheumatoid arthritis of distal radio-ulnar joint
70221 [X]Other specified rheumatoid arthritis
70658 Rheumatoid arthritis of talonavicular joint
71784 Rheumatoid arthritis of other tarsal joint
73619 Rheumatoid arthritis of subtalar joint
93715 [X]Other seropositive rheumatoid arthritis
99414 Rheumatoid arthritis of lesser MTP joint
100776 Rheumatoid arthritis of sacro-iliac joint
100914 Rheumatoid arthritis of acromioclavicular joint
102088 Delivery of rehabilitation for rheumatoid arthritis
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Smoking
Medical code Read term Smoking status
33 Never smoked tobacco non-smoker
54 Tobacco consumption current smoker
60 Current non-smoker non-smoker
90 Ex smoker ex-smoker
93 ZERIDAME SR tablets 150mg [ACTAVIS] current smoker
776 Stopped smoking ex-smoker
1822 Very heavy smoker - 40+cigs/d current smoker
1823 Smoker current smoker
1878 Moderate smoker - 10-19 cigs/d current smoker
2111 Health ed. - smoking current smoker
3568 Heavy smoker - 20-39 cigs/day current smoker
6359 Nicotine withdrawal current or ex-smoker
7130 Stop smoking monitoring admin. current or ex-smoker
7622 Smoking cessation advice current or ex-smoker
9045 Advice on smoking current smoker
9833 Nicotine replacement therapy current or ex-smoker
10184 Pregnancy smoking advice current smoker
10211 Herpes zoster with meningitis ex-smoker
10558 Current smoker current smoker
10742 Referral to stop-smoking clinic current or ex-smoker
10898 Smoking free weeks ex-smoker
11356 Seen by smoking cessation advisor current or ex-smoker
11527 DNA - Did not attend smoking cessation clinic current smoker
11713 Pack years current or ex-smoker
11788 Non-smoker non-smoker
12240 Trying to give up smoking current or ex-smoker
12878 Date ceased smoking ex-smoker
12941 Occasional smoker current smoker
12942 Smoker - amount smoked current smoker
12943 Cigar smoker current smoker
12944 Light smoker - 1-9 cigs/day current smoker
12945 Rolls own cigarettes current smoker
12946 Ex-smoker - amount unknown ex-smoker
12947 Pipe smoker current smoker
12951 Smoking restarted current smoker
12952 Smoking started current smoker
12953 Attends stop smoking monitor. current or ex-smoker
12954 [V]Tobacco use current smoker
12955 Ex-moderate smoker (10-19/day) ex-smoker
12956 Ex-heavy smoker (20-39/day) ex-smoker
12957 Ex-light smoker (1-9/day) ex-smoker
12958 Trivial smoker - < 1 cig/day current smoker
12959 Ex-very heavy smoker (40+/day) ex-smoker
12960 Tobacco consumption NOS current smoker
12961 Ex-trivial smoker (<1/day) ex-smoker
12962 Tobacco consumption unknown current smoker
12963 Cigar consumption current smoker
12964 Keeps trying to stop smoking current smoker
12965 Cigarette consumption current smoker
12966 Smoking reduced current smoker
12967 Pipe tobacco consumption current smoker
13351 Passive smoker non-smoker
16717 Smokers' cough current smoker
18573 Referral to smoking cessation advisor current or ex-smoker
18926 Lifestyle advice regarding smoking current smoker
19485 Stop smoking monitor.chck done current or ex-smoker
19488 Ex cigar smoker ex-smoker
21637 Stop smoking monitor admin.NOS current or ex-smoker
24529 Nicotine replacement therapy refused current smoker
25106 Nicotine replacement therapy provided free current or ex-smoker
26096 Smokes drugs current or ex-smoker
26470 Ex pipe smoker ex-smoker
28834 Anti-smoking monitoring admin. current or ex-smoker
30423 Thinking about stopping smoking current smoker
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Medical code Read term Smoking status
30762 Not interested in stopping smoking current smoker
31114 Ready to stop smoking current smoker
32083 Stop smoking clinic admin. current or ex-smoker
32572 Over the counter nicotine replacement therapy current or ex-smoker
32687 Tobacco dependence current smoker
34126 Negotiated date for cessation of smoking current smoker
35055 [V]Tobacco abuse counselling current smoker
38112 Smoking cessation programme start date current smoker
40417 Stop smoking monitor default current or ex-smoker
40418 Refuses stop smoking monitor current smoker
41042 Smoking cessation advice provided by community pharmacist current or ex-smoker
41979 Smoking restarted current smoker
42288 Pack years current or ex-smoker
42722 Stop smoking monitor 1st lettr current or ex-smoker
43433 Toxic effect of tobacco and nicotine current smoker
46300 Cigarette pack-years current or ex-smoker
46321 Reason for restarting smoking current smoker
47273 Motives for smoking scale current smoker
49418 RFS - Reasons for smoking scale current smoker
52503 No smokers in the household non-smoker
53101 Stop smoking monitor verb.inv. current or ex-smoker
56144 [X]Mental and behav dis due to use of tobacco: harmful use current smoker
57639 Bupropion refused current smoker
58597 Stop smoking monitor phone inv current or ex-smoker
59866 Reasons for smoking scale current smoker
60720 Stop smoking monitor 2nd lettr current or ex-smoker
61905 [X]Mental and behavioural disorder due to use of tobacco current smoker
62686 Minutes from waking to first tobacco consumption current smoker
63016 [X]Bupropion causing adverse effects in therapeutic use current or ex-smoker
63299 FTND - Fagerstrom test for nicotine dependence current smoker
63666 Fagerstrom test for nicotine dependence current smoker
63717 Bupropion contraindicated current or ex-smoker
63901 Stop smoking monitoring delete current or ex-smoker
66387 Stop smoking monitor 3rd lettr current or ex-smoker
66409 Nicotine replacement therapy contraindicated current or ex-smoker
67178 Nicotine replacement therapy provided by community pharmacis current or ex-smoker
68658 Tobacco dependence NOS current smoker
70746 Tobacco dependence, continuous current smoker
72700 [V]Personal history of tobacco abuse current or ex-smoker
72706 Tobacco dependence in remission ex-smoker
74907 Smoking cessation therapy current or ex-smoker
81440 Nicotine replacement therapy using nicotine patches current or ex-smoker
85247 Nicotine replacement therapy using nicotine inhalator current or ex-smoker
85975 Nicotine replacement therapy using nicotine gum current or ex-smoker
89464 Nicotine replacement therapy using nicotine lozenges current or ex-smoker
90522 Smoking cessation therapy NOS current or ex-smoker
91513 Occasions for smoking scale current smoker
91708 Other specified smoking cessation therapy current or ex-smoker
94958 Smoking cessation drug therapy current or ex-smoker
95610 Tobacco dependence, unspecified current smoker
96992 Smoking cessation - enhanced services administration current or ex-smoker
97210 Ex-cigarette smoker ex-smoker
97643 Fagerstrom test for nicotine dependence current smoker
97973 Maternal tobacco abuse current smoker
98137 Brief intervention for smoking cessation current or ex-smoker
98154 Referral to NHS stop smoking service current or ex-smoker
98177 Non-smoker annual review - enhanced services administration non-smoker
98245 Stop smoking face to face follow-up current or ex-smoker
98283 COPD structured smoking assessment declined - enh serv admin current or ex-smoker
98284 Refer COPD structured smoking assessment - enhanc serv admin current or ex-smoker
98347 Current smoker annual review - enhanced services admin current smoker
98447 Ex-smoker annual review - enhanced services administration ex-smoker
98493 Smoking cessatn monitor template complet - enhanc serv admin current or ex-smoker
99838 Recently stopped smoking ex-smoker
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100099 Smoking cessation advice declined current smoker
100495 Ex roll-up cigarette smoker ex-smoker
100963 Ex-smoker annual review ex-smoker
101210 Consent given for smoking cessation data sharing current or ex-smoker
101325 Declin cons follow-up evaluation after smoking cess interven current or ex-smoker
101338 Failed attempt to stop smoking current smoker
101385 Consent given for follow-up by smoking cessation team current or ex-smoker
101519 [X]Mental and behav dis due to use tobacco: withdrawal state ex-smoker
101634 Consent given follow-up after smoking cessation intervention current or ex-smoker
101764 Practice based smoking cessation programme start date current or ex-smoker
101851 Declined consent for follow-up by smoking cessation team current or ex-smoker
101854 Declined consent for smoking cessation data sharing current or ex-smoker
101878 Non-smoker annual review non-smoker
102361 Referral for smoking cessation service offered current smoker
102951 Lost to smoking cessation follow-up current or ex-smoker
103760 COPD structured smoking assessment declined current or ex-smoker
103955 Asthma trigger - tobacco smoke current smoker
104310 Current smoker annual review current smoker
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Systemic Lupus Erythematosis
Medical code Read term
4125 Lupus erythematosus
7522 Lupus erythematosus NOS
7871 Systemic lupus erythematosus
11920 Systemic lupus erythematosus with pericarditis
20007 ZERIDAME SR tablets 150mg [ACTAVIS]
22205 Lupus nephritis
25390 Subacute cutaneous lupus erythematosus
29519 Systemic lupus erythematosus with organ or sys involv
31564 Lung disease with systemic lupus erythematosus
33449 Lupus erythematosus chronicus
36942 Drug-induced systemic lupus erythematosus
40797 Lupus erythematosus migrans
42719 Systemic lupus erythematosus NOS
44095 Polyneuropathy in disseminated lupus erythematosus
44984 Lupus erythematosus tumidus
45726 Systemic lupus erythematosus disease activity index
46148 Lupus erythematosus profundus
47672 Herpes zoster with meningitis
51798 Systemic lupus activity measure
58706 [X]Other forms of systemic lupus erythematosus
63955 Lupus erythematosus unguium mutilans
65391 Lupus erythematosus nodularis
99435 Neonatal lupus erythematosus
101433 Cerebral lupus
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